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Abstract 
Charcot-Marie-Tooth (CMT) disease and Brown-Vialetto-Van Laere syndrome 
(BVVL) are two inherited neuropathies. Although most CMT type 1A patients carry 
the same sized duplication containing the peripheral myelin protein 22 (PMP22) 
gene, they present with a wide range of severities both within and between families. 
Some CMT1A patients exhibit chronic inflammatory demyelinating polyneuropathy 
(CIDP)-like features. An association study was performed in a CMT1A and a CIDP 
cohort to identify the genetic factors modifying the CMT1A phenotype. Variants 
associated with CIDP and/or with autoimmune/inflammatory diseases were 
determined to be unlikely to modulate disease severity in CMT1A, or to contribute to 
CMT1A pathogenesis. A susceptibility locus for CIDP was identified in the PXK 
gene. CMT1 genes were screened in CMT1 patients from the UK, Greece and 
Russia, thereby establishing mutation frequencies and expanding phenotype-
genotype correlations. Some cases of CMT1 remain without a genetic diagnosis; two 
potential CMT1 candidate genes were identified by exome sequencing in two 
families. The genetic causes of selected canine neuropathies were investigated and 
several CMT genes were ruled out. 
BVVL is a rare, recessive motor neurone disease (MND) with early onset; a severe 
sensory-motor neuropathy is part of the phenotype. Mutations have been found in 
genes encoding riboflavin transporters, leading to flavin deficiency. To characterise 
the disease and facilitate early access to therapy, the riboflavin transporter genes 
were screened in patients with BVVL-like phenotypes; SLC52A2 mutations were 
most common. A candidate gene for complex axonal neuropathy resembling BVVL 
was uncovered by exome sequencing. Riboflavin and its active metabolites play a 
role in energy metabolism. Three cell models were used to investigate BVVL in 
vitro: patient fibroblasts, as well as a neuroblastoma cell line and mouse motor 
neurones in which one of the riboflavin transporters was knocked down. 
Mitochondrial dysfunction was suggested as a potential pathway leading to neuronal 
damage in BVVL. 
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Chapter 1 Introduction 
1.1 Motor and sensory pathways of the peripheral nervous system 
The nervous system is divided into the central nervous system (CNS) and the 
peripheral nervous system (PNS). The CNS is made up of the brain and spinal cord. 
Nerves in the PNS connect the CNS to the rest of the body by relaying information 
from the brain and spinal cord to the limbs, and then back to the CNS. The basic unit 
of the nervous system is the nerve cell or neurone. Peripheral nerves consist of 
bundles of nerve fibres ensheathed in connective tissue. The PNS is comprised of 12 
pairs of cranial nerves, connecting the brain to the head and neck muscles via skull 
openings, and 31 pairs of spinal nerves, connecting the spinal cord to the trunk and 
limbs. The motor cranial nerves start in the brainstem and end on the muscle, while 
sensory cranial nerves start in the sensory organs and end in the brainstem. Near the 
spinal cord, the spinal nerves separate into dorsal and ventral roots which carry 
sensory and motor fibres, respectively. Sensory pathways include the spinothalamic 
tract (touch, pain, temperature) and the dorsal column-medial lemniscus pathway 
(proprioception, fine touch). Upper motor neurones (UMNs) originate in the motor 
cortex and brainstem, and control the activity of lower motor neurones (LMNs). 
Motor pathways formed by the UMNs include the corticobulbar tract, which controls 
the motor neurones in the cranial nerve nuclei, and the corticospinal tract, which 
regulates the activity of spinal cord motor neurones. LMNs originate in the ventral 
horn of the spinal cord and in the motor cranial nerve nuclei of the brainstem, and 
innervate skeletal muscle (Crossman & Neary, 2010). 
Nerve fibres may or may not be ensheathed with myelin. Early on in the 
development of the PNS, axons larger than 1 μm in diameter become wrapped by 
myelin, which consists of layers of Schwann cell plasma membrane. Schwann cells 
are the glial cells of the PNS. Myelin nourishes the axon and allows for fast saltatory 
conduction of the action potentials at the nodes of Ranvier, which mark the 
separation of individual Schwann cells (Jessen & Mirsky, 1998). In the PNS, the 
myelin membrane is mainly comprised of compact myelin, which is made up of 
cholesterol and other lipids in addition to proteins like myelin protein zero (MPZ) 
and peripheral myelin protein 22 (PMP22). The functions of PMP22 include cell 
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cycle control, proliferation and differentiation of Schwann cells, axonal maintenance, 
and regulation of myelin stability and thickness (Adlkofer et al., 1995; Giambonini-
Brugnoli et al., 2005). Proteins such as connexin-32 and myelin-associated 
glycoprotein are located in the non-compact portion. Mutations in genes encoding 
these and other structural proteins can cause neuropathy of peripheral nerves (Patzkó 
& Shy, 2011). 
1.2 Peripheral neuropathies 
Damage to sensory, motor and/or autonomic nerves may cause peripheral 
neuropathy; the defect may principally involve the axon (axonopathy), cell body 
(neuronopathy), or myelin sheath/Schwann cells (myelinopathy). Demyelinating 
neuropathies, or myelinopathies, result from defects in the development and 
functioning of Schwann cells and the myelin sheath they produce, leading to 
secondary axonal degeneration (Hughes, 2008). 
Single nerves or multiple nerves may be affected in peripheral neuropathies. Carpal 
tunnel syndrome, an acquired cause of neuropathy usually caused by nerve 
compression, is an example of a mononeuropathy as a single peripheral nerve is 
damaged. Rheumatoid arthritis and certain infectious diseases may result in a 
multiple mononeuropathy, which affects two or more nerves in several parts of the 
body. The term polyneuropathy is used to refer to conditions where multiple nerves 
in all limbs are involved; examples include Charcot-Marie-Tooth (CMT) disease and 
chronic inflammatory demyelinating polyneuropathy (CIDP) (Hughes, 2008).  
Approximately 2.4% of the population suffers from symmetrical polyneuropathy; 
elderly individuals are more likely to be affected (Hughes, 2008). A common cause 
of polyneuropathy is diabetic polyneuropathy, which is believed to affect 50% of 
patients with long-standing diabetes (Shakher & Stevens, 2011). 
Peripheral neuropathy is often length-dependent and therefore affects the longest 
nerves first. In humans, this translates to symptoms starting in the feet and 
progressing to the hands and more proximal areas later on in the disease course. 
Interestingly, the laryngeal nerve is the first to suffer damage in horses with 
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peripheral neuropathy, as this is the longest nerve in this animal. Symptoms vary 
depending on the type of nerve which is damaged: sensory loss, neuropathic pain and 
tingling, burning, or numbness sensations result from damage to sensory nerves; 
fasciculations and muscle weakness are caused by impairment to motor nerves; 
autonomic nerve damage involves changes in blood pressure, bladder function and 
sexual function (Asbury & Thomas, 1995). Interestingly, mutations in certain CMT-
associated genes render particular sets of neurones more vulnerable to damage; for 
example, hereditary motor neuropathy due to mutations in glycyl-tRNA synthetase 
(GARS) is characterised by upper limb predominance of symptoms, while heat shock 
27kDa protein 1 (HSPB1) and heat shock 22kDa protein 8 (HSPB8) mutations cause 
length-dependent neuropathy, where the legs are more affected than the arms (Reilly 
& Shy, 2009). 
Severity of disease varies greatly; the range of phenotypes associated with peripheral 
neuropathies will be discussed in detail later on in this Chapter. Indeed, patients with 
peripheral neuropathy may be asymptomatic and disease may be evident only from 
electrophysiological tests. At the other end of the spectrum, some patients may 
require wheelchairs for mobility and ventilatory support, ultimately leading to 
susceptibility to infections such as chest infections that can be fatal. In neuropathies 
such as CIDP, Guillain–Barré Syndrome, hereditary neuropathy with liability to 
pressure palsies (HNPP), porphyria and Refsum’s disease, patients may experience 
periods of disease exacerbation characterised by intermittent relapses. Disease may 
be acute, sub-acute or chronic. A slowly progressive course is usually typical of most 
polyneuropathies (Asbury & Thomas, 1995). 
There is currently no effective treatment to reverse the damage in most peripheral 
neuropathies. Patients suffering from an acquired neuropathy are advised to avoid the 
cause of their neuropathy, such as alcohol, toxins or drugs, and to control their 
diabetes, if appropriate. Corticosteroids, plasmapheresis and/or intravenous 
immunoglobulins (IVIG) may be helpful in CIDP patients and in some CMT cases 
presenting with an overlapping inflammatory neuropathy (Ginsberg et al., 2004). 
Treatment is palliative for most inherited neuropathies; patients may benefit from 
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physical therapy, use of orthotics, orthopaedic interventions, pain management and 
genetic counselling (Reilly et al., 2011). 
Peripheral neuropathy may be the principal manifestation of disease, such as in CMT 
and CIDP, or part of a more generalized disorder as in Brown-Vialetto-Van Laere 
syndrome (BVVL), hereditary spastic paraplegia (HSP), hereditary ataxia, 
neuroaxonal dystrophy (NAD), the genetic forms of porphyrias, metachromatic 
leukodystrophy, Krabbe disease, Tangier disease, Fabry disease, Refsum’s disease 
and others (Reilly & Shy, 2009). Neuropathy may be acquired or inherited. 
1.2.1 Acquired peripheral neuropathies 
Diabetes remains the most common cause of acquired neuropathy in the Western 
world, whilst in developing countries leprosy is responsible for the majority of cases. 
Chronic alcoholism is also frequently associated with acquired neuropathies. Other 
diseases also cause peripheral neuropathy, for example viral or bacterial infections 
such as Lyme disease, Hepatitis B and C, HIV/AIDS and varicella-zoster, and some 
autoimmune diseases including vasculitis due to rheumatoid arthritis, celiac disease, 
CIDP, multifocal motor neuropathy and paraproteinaemia, amongst others (Martyn 
& Hughes, 1997). Other causes include tumours, which may apply excessive 
pressure on a nerve, or traumatic injury to a nerve due to an accident or compression. 
Being exposed to toxic chemicals and heavy metals or taking drugs such as 
vincristine may also lead to neuropathy (Martyn & Hughes, 1997). Nutritional 
deficiencies in vitamin B1, B2, B6, B12 and E, as well as disease of the kidney or liver 
can cause neuropathy (Hughes, 2008). 
1.2.2 Inherited peripheral neuropathies 
Examples of genetic diseases where peripheral neuropathy is part of the phenotype 
include CMT, BVVL, neuroaxonal dystrophy, HSP, hereditary ataxia, Fabry disease, 
Refsum’s disease and others (Reilly & Shy, 2009). This thesis will begin by an 
exploration of CMT disease genetics, a pure neuropathy which may be a 
myelinopathy and/or an axonopathy, and will be followed by a genetic and 
functional investigation of BVVL, a neuronopathy which often presents with a CMT-
like sensory-motor neuropathy as part of a more widespread disorder. 
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1.3 Charcot-Marie-Tooth (CMT) disease: an inherited peripheral neuropathy 
1.3.1 CMT: phenotypes and classification 
Three physicians first described CMT in 1886: Jean-Marie Charcot, Pierre Marie and 
Howard Henry Tooth (Charcot & Marie, 1886; Tooth, 1886). CMT, also known as 
hereditary motor and sensory neuropathy (HMSN), is the most common inherited 
neuromuscular disorder, with a prevalence of 5-40 per 100,000 depending on the 
population studied (Foley et al., 2012; Martyn & Hughes, 1997; Skre, 1974). 
Neurologists recognise it as one of the most phenotypically and genetically 
heterogeneous diseases in neurology. The most common symptoms include distal 
muscle weakness and wasting which is generally symmetrical and becomes proximal 
with disease progression, sensory loss, decreased reflexes and foot deformities (pes 
cavus and hammer toes) (Pareyson & Marchesi, 2009). Inherited neuropathies 
consisting mainly of sensory and autonomic abnormalities are referred to as 
hereditary sensory and autonomic neuropathies (HSAN), and those with only motor 
involvement are termed distal hereditary motor neuropathies (dHMN). There is 
significant phenotypic and genotypic overlap between HSAN, dHMN and CMT 
(Reilly & Shy, 2009). CMT is generally not fatal, and wheelchair use remains rare. 
However, early-onset generally predicts a more severe disease (Reilly et al., 2011).  
The CMT neuropathy score (CMTNS) is used to quantify disability in CMT and is 
divided into mild (CMTNS ≤ 10), moderate (CMTNS 11 to 20) and severe (CMTNS 
≥ 21). The parameters used to calculate the CMTNS include sensory and motor 
symptoms (legs and arms), pin sensibility, vibration, leg and arm strength, compound 
muscle action potentials (CMAPs) and sensory nerve action potentials (SNAPs) (Shy 
et al., 2005). The sensitivity of the CMTNS was recently improved; the second 
version is known as CMTNS2 (Murphy, Herrmann, et al., 2011). 
Before the first genetic cause of CMT was identified, CMT was mainly described by 
neurophysiology and peripheral nerve pathology. CMT was classified using the 
upper limb motor nerve conduction velocity (MNCV), where patients with the 
demyelinating form (CMT1) have MNCVs less than 38 m/s and those with the 
axonal form (CMT2) have MNCVs above 38 m/s (Dyck & Lambert, 1968a; Dyck & 
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Lambert, 1968b; Harding & Thomas, 1980). An intermediate form of CMT (ICMT) 
refers to patients with MNCVs between 25 and 45 m/s (Reilly et al., 2011). 
The demyelinating and axonal forms of CMT may show autosomal dominant (AD), 
recessive (AR), or X-linked inheritance. CMT3, also known as congenital 
hypomyelinating neuropathy (CHN) or Dejerine-Sottas disease (DSD), refers to 
early-onset severe demyelinating or hypomyelinating CMT. CMT4 refers to AR 
demyelinating CMT (Reilly et al., 2011). 
1.3.2 The genetic maze: diagnosis of CMT 
Advances in sequencing technology have allowed for over 60 genes or loci to be 
linked to CMT (Pandraud et al., 2012; Rossor et al., 2013), which have been 
classified according to their axonal or demyelinating nature and inheritance pattern 
(Appendix I Table I-1). Defects in the same gene may be associated with multiple 
phenotypes, while the same phenotype may result from mutations in different genes. 
The significant number of genes known to be associated with CMT as well as the 
phenotypic overlap between CMT subtypes makes diagnosis a challenging task for 
clinicians. In addition to the neurological examination, the diagnosis of CMT is made 
using a combination of family history, neurophysiological studies to assess nerve 
conduction velocities (NCVs), genetic testing, and a nerve biopsy if appropriate, 
although the latter are performed more rarely than they used to be (Pareyson & 
Marchesi, 2009). Mode of inheritance may be difficult to establish due to 
intrafamilial phenotypic variability; additionally, de novo mutations account for a 
non-negligible percentage of patients (Pareyson & Marchesi, 2009). Disease severity, 
age at onset, and the presence of certain rare features such as vocal cord palsy, optic 
atrophy or cranial nerve involvement may help point to the responsible gene. As will 
be discussed further in Chapter 3, the ethnic background of the patient also helps to 
target the genetic tests according to the frequency of CMT subtypes in the population 
of interest (Reilly et al., 2011).  
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1.3.3 Animal models of CMT 
Rodent models of CMT have been instrumental in gaining a deeper understanding of 
the pathomechanisms associated with particular CMT subtypes, as well as for 
identifying drug targets and assessing their therapeutic value (Fledrich, Stassart, et 
al., 2012). Whether naturally occurring or generated in the laboratory, rodent models 
are available for several CMT subtypes such as CMT associated with mutations 
and/or gene dosage alterations in PMP22, MPZ, gap junction protein, beta 1 (GJB1), 
early growth response 2 (EGR2), mitofusin 2 (MFN2), periaxin (PRX), myotubularin 
related protein 2 (MTMR2), myotubularin related protein 13 (MTMR13), 
neurofilament, light polypeptide (NEFL), HSPB1, leucine rich repeat and sterile 
alpha motif containing 1 (LRSAM1), GARS and lamin A/C (LMNA) (Bouhy & 
Timmerman, 2013; Cartoni et al., 2010; Fledrich, Stassart, et al., 2012; Meyer Zu 
Hörste & Nave, 2006; Seo et al., 2014).  
Naturally occurring animal models of peripheral neuropathies have been described in 
many species, including canines, which are of particular interest in this study. 
Peripheral neuropathies in canines may be part of a generalised disorder involving 
both the CNS and PNS, or may be “non-syndromic” and involve a peripheral 
neuropathy alone (Granger, 2011). Similar to CMT in humans, non-syndromic 
canine peripheral neuropathies may be motor, sensory and/or autonomic, and may be 
demyelinating or axonal with early or late-onset; in contrast to humans, only AR 
inheritance has been described in dogs, however sporadic forms exist as well 
(Granger, 2011). Axonal neuropathies tend to be more common than the 
demyelinating form in canines (Coates & O’Brien, 2004; Granger, 2011; 
Vanhaesebrouck et al., 2008). Animals affected by peripheral neuropathies 
resembling CMT or canines with mutations in known CMT genes may serve as 
disease models (Matiasek & Drögemüller, 2011); this topic will be investigated in 
Chapter 3. Determining the genetic cause of disease in canines may lead to a greater 
understanding of disease pathogenesis in humans, as well as to the identification of 
new candidate genes (Vanhaesebrouck et al., 2008). 
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1.4 CMT type 1A as an example of phenotypic heterogeneity in CMT 
1.4.1 The CMT1A phenotype 
CMT1A patients with the chromosome 17 (Chr17) p11.2 duplication usually have 
disease onset in childhood and a classic phenotype of progressive muscle weakness 
and atrophy with predominance in the lower limbs, sensory loss, walking difficulties, 
loss of reflexes, and foot deformities. Breathing difficulties may also be present; 
cerebellar or bulbar involvement is rare (Birouk et al., 1997; Thomas et al., 1997). 
CMT1A is very slowly progressive (Marques et al., 2005; Shy et al., 2008). Motor 
and sensory nerve conduction studies (NCS) usually show a uniform slowing with 
velocities of 15-30 m/s and onion bulb formations on nerve biopsy (Birouk et al., 
1997; Marques et al., 2005; Thomas et al., 1997). Disease severity may be mild or 
moderate, and is not influenced by gender or pregnancy (Birouk et al., 1997; Swan et 
al., 2007). Motor nerve conduction slowing does not correlate with muscle wasting 
and extent of sensory involvement; however, severity is correlated with CMAP and 
SNAP decrease, since disease symptoms are due to axonal damage rather than 
damage to the myelin sheath in CMT1A (Kim et al., 2012; Shy et al., 2008). CMAPs 
correlate with disease duration but not age at onset, although an earlier age of onset 
had previously been found to predict a more severe disease course (Birouk et al., 
1997; Kim et al., 2012). NCVs are a marker of disease but not of severity because 
they do not show significant change over time after the conduction velocities are 
established at three to five years of age (Kaku et al., 1993).  
1.4.2 Coexistent inflammatory neuropathy in CMT 
CIDP is a chronic acquired autoimmune inflammatory neuropathy associated with 
multifocal demyelination in the spinal root, plexuses and proximal nerve trunks. 
There are multiple forms of CIDP: motor and sensory, solely motor, solely sensory, 
or entirely distal. The neurophysiological profile includes decreased NCV, 
conduction block with features such as dispersion, and evidence of loss of axons and 
denervation (Dalakas, 2011). Compared to CMT1, CIDP is later onset, acquired, 
asymmetric, has a relapsing or subacute disease course, does not cause skeletal 
deformities, and leads to multi-focal demyelination (Latov, 2011).  
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Various cases of CMT (including CMT1A) with coexistent inflammatory features 
such as those seen in CIDP have been documented. CIDP-like features which have 
been found in some CMT patients include acute worsening of symptoms, 
asymmetrical symptoms, positive sensory symptoms, neuropathic pain, increased 
cerebrospinal fluid (CSF) protein, atypical NCS findings, positive response to IVIG, 
corticosteroids or plasma exchange, evidence of macrophage-associated 
demyelination, and inflammatory infiltrates on biopsy (Ben Youssef-Turki et al., 
2011; Carvalho et al., 2005; Desurkar et al., 2009; Dyck et al., 1982; Gabriel et al., 
2000; Ginsberg et al., 2004; Houlden et al., 2009; Latov, 2011; Malandrini et al., 
1999; Mazzeo et al., 2012; Miki et al., 2013; Pál et al., 2009; Thomas et al., 1997; 
Vital et al., 1992; Vital et al., 2003; Williams & Penn, 1979). It should be noted that 
some of these features may be seen exclusively in CMT without overlap of an 
inflammatory neuropathy (Ginsberg et al., 2004). Of note, a superimposed acquired 
neuropathy associated with anti-myelin associated glycoprotein activity was 
documented in a CMT1A patient (Piscosquito et al., 2013). CMT patients were also 
found to be more likely than controls to have IgA deficiency (Williams & Penn, 
1979). 
This association of CMT with CIDP is thought to occur more often than expected by 
chance; as calculated by Ginsberg et al. (2004), we would expect about 1 in 250 
cases of CMT to have coexistent inflammation, while the prevalence of CIDP in the 
general population is approximately 1 in 100,000. In fact, it has been proposed that 
CMT may increase the chances of developing CIDP (Ginsberg et al., 2004). 
Numerous animal models of CMT1 have noted an implication of immune cells in 
disease pathogenesis and an amelioration of disease in immune-deficient conditions, 
suggesting that the immune system may participate in the demyelination process 
(Carenini et al., 2001; Ip et al., 2006; Kobsar et al., 2005; Kohl et al., 2010; Mäurer 
et al., 2002; Schmid et al., 2000; Stoll et al., 1998; Williams et al., 1993). It is 
possible that an inflammatory component is always part of the pathogenic 
mechanism in CMT1, but is subclinical in most patients, although this is less likely 
as most patients do not respond to immunosuppressant therapy (Ginsberg et al., 
2004; Martini & Toyka, 2004). Nevertheless, it remains unclear whether 
autoimmune involvement occurs in most CMT1 patients, or a subset of patients who 
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develop a secondary acquired autoimmune-mediated neuropathy (Martini & Toyka, 
2004). Immune-mediated components of CMT disease pathogenesis and their 
possible involvement in modifying the CMT1A phenotype will be discussed in more 
detail in Chapter 4. 
1.4.3 The chromosome 17 (Chr17) duplication in CMT1A 
The genetic cause of disease in several CMT1 kindreds was linked to Chr17 in 1989 
(Raeymaekers et al., 1989; Vance et al., 1989). A 1.5 megabase (Mb) duplication 
was subsequently found in the Chr17p11.2 region (Lupski et al., 1991; Raeymaekers 
et al., 1991). CMT1A is the most common type of CMT, accounting for 
approximately 55% of CMT and 66.8% of CMT1 cases (Saporta et al., 2011). About 
10% of CMT1A cases are sporadic (Blair et al., 1996; Reilly et al., 2011). The 
duplication is usually of paternal origin (Blair et al., 1996; Lopes et al., 1997; Palau 
et al., 1993). The discovery of the CMT1A-linked duplication is still the most 
significant event in the history of CMT genetics. The duplication results from non-
allelic homologous recombination (NAHR) between two highly homologous 24 
kilobase (Kb) low-copy repeat sequences called Charcot-Marie-Tooth disease Type 
1A repeat sequences (CMT1A-REPs) located at either end of the duplicated region 
(Chance et al., 1994; Pentao et al., 1992; Reiter et al., 1996). The duplication of the 
CMT1A–REP sequence arose during speciation from the gorilla to the chimpanzee 
(Boerkoel et al., 1999; Kiyosawa & Chance, 1996). The proximal copy of the 
CMT1A-REP misaligns and pairs with the distal copy from the other chromosome 
homologue during meiosis (Chance et al., 1994; Palau et al., 1993; Pentao et al., 
1992). A reciprocal deletion of the same segment of deoxyribonucleic acid (DNA) 
was linked to HNPP, an AD condition of focal motor sensory neuropathy with 
recurrent pressure palsies (Chance et al., 1993). Shortly thereafter, the PMP22 gene 
was mapped within the duplication and the encoded protein was found to be highly 
expressed in Schwann cells (Matsunami et al., 1992; Patel et al., 1992; Timmerman 
et al., 1992; Valentijn, Bolhuis, et al., 1992). The unequal crossing over results in 
three copies of PMP22 instead of two (Figure 1-1) (Valentijn, Bolhuis, et al., 1992). 
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Figure 1-1 CMT1A and HNPP duplication/deletion mechanisms; Cen: centromere; 
Tel: telomere (adapted from Reiter et al., 1997). 
The CMT1A-like demyelinating pathology found in the Trembler (p.Gly150Asp) 
and Trembler-J (p.Leu16Pro) mice carrying spontaneous Pmp22 point mutations 
provided further evidence for the involvement of this gene in disease pathogenesis 
(Suter, Moskow, et al., 1992; Suter, Welcher, et al., 1992). PMP22 point mutations, 
including the same point mutations as those found in the Trembler-J and Trembler 
mice were subsequently found in CMT1 and DSD patients not carrying the 
duplication, providing additional proof that this is the causative gene within the 
duplicated region (Ionasescu, Searby, Ionasescu, Chatkupt, et al., 1997; Ionasescu, 
Searby, Ionasescu, Reisin, et al., 1997; Roa, Garcia, Pentao, et al., 1993; Roa, 
Garcia, Suter, et al., 1993; Suter, Moskow, et al., 1992; Valentijn, Baas, et al., 1992). 
Point mutations in PMP22 usually cause a rare, more severe form of CMT (Reilly et 
al., 2011; Valentijn, Baas, et al., 1992). In addition, when smaller duplications 
(Huang et al., 2010; Ionasescu et al., 1993; Palau et al., 1993; Valentijn et al., 1993) 
or deletions (Chapon et al., 1996) were discovered, PMP22 was always found within 
the affected segment of DNA. Similarly, patients with a partial trisomy of Chr17p 
encompassing PMP22 have a demyelinating neuropathy (Lupski et al., 1992; Roa et 
al., 1996). These findings, in addition to the observation that messenger ribonucleic 
acid (mRNA) levels of PMP22 are increased in CMT1A patient nerve biopsies 
suggest that disease occurs via an increased gene dosage mechanism rather than by 
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gene disruption or mutation in another gene within the duplication (Boerkoel et al., 
1999; Lupski et al., 1992; Yoshikawa et al., 1994). Recently, shorter duplications 
upstream of and not including PMP22 were found to be associated with CMT1A. It 
is postulated that these smaller duplications affect PMP22 expression via an as-of-
yet undetermined mechanism (Weterman et al., 2010, Zhang et al., 2010). 
1.4.4 Phenotypic variability in CMT1A: a role for genetic modifiers? 
CMT1A patients with the same size duplication display high intra- and interfamilial 
phenotypic variability in terms of age of onset, extent of weakness and wasting, 
sensory signs and NCVs, even between monozygotic twins (Birouk et al., 1997; 
Garcia et al., 1995; Kaku et al., 1993; Thomas et al., 1997). While some patients may 
have serious skeletal deformities with severe proximal weakness and may be 
wheelchair-bound, others may remain asymptomatic and unaware they are affected 
(Pareyson & Marchesi 2009). A mildly affected father of a CMT1A patient was 
found to be a mosaic for the duplication therefore mosaicism may be a rare source of 
phenotypic variability in CMT1A (Sorour et al., 1995). In a study of 119 CMT1A 
patients, 25% were found to be asymptomatic, however patients will always have 
decreased NCV if they carry the duplication (Kaku et al., 1993; Birouk et al., 1997). 
A CMT1A patient was asymptomatic late in life with a mild phenotype on 
examination, while his son was severely affected (Berciano et al., 2012). 
Anticipation, or increase in disease severity over generations, has been described in 
CMT1A, with significantly earlier age of onset and more severe phenotype in some 
children of affected parents (Steiner et al., 2008).  
Consistent with the predicted dosage effect mechanism of CMT1A, some rare 
CMT1A cases with four copies of PMP22 have a more severe phenotype, although 
this is not always the case. In fact, levels of PMP22 mRNA or protein were not 
found to correlate with disease severity. It follows that the expression level of 
PMP22 does not completely determine the phenotype (Boerkoel et al., 1999; 
Hanemann et al., 1994; Huang et al., 2010; Kaku et al., 1993; Katona et al., 2009; 
LeGuern et al., 1997, Lupski et al., 1991).  
A phenotype modifier effect of the environment as well as stochastic or epigenetic 
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effects would be predicted on the basis that identical twins show variable disease 
severity (Boerkoel et al., 1999; Fraga et al., 2005; Garcia et al. 1995). 
Hypothyroidism, obesity and exposure to toxins have been found to cause a mild 
increase in CMTNS scores and decrease in ambulation ability of CMT1A patients 
(Ursino et al., 2013). Diabetes is also usually associated with more severe sensory 
and motor impairment in patients with CMT1A. Diabetes may lead to deficient 
action potential propagation in motor nerve terminals, impaired axonal transport or 
mitochondrial function; therefore, the compound effect of CMT and diabetes 
pathologies would be expected to worsen the phenotype (Sheth et al., 2008; Ursino et 
al., 2013). However, it is unlikely that environmental factors and co-morbidities 
account for all of the disease variability. Therefore, epigenetics and genetic modifiers 
probably also play a role in influencing disease severity (Pareyson & Marchesi, 
2009). As discussed in Section 1.4.2, it is possible that some of the phenotypic 
variability may be explained by immunological mechanisms in CMT1A (Ginsberg et 
al., 2004). 
1.5 Novel disease genes in undiagnosed CMT patients 
Despite the large number of genes already known to cause CMT, a genetic diagnosis 
is only reached in 70% of patients, therefore many patients remain undiagnosed, 
especially in CMT2 (Saporta et al., 2011). Obtaining a genetic diagnosis is crucial as 
it enables patients to receive more accurate counselling for family planning and rules 
out potentially treatable, acquired causes of neuropathy (Reilly et al., 2011). 
Identifying novel CMT-causing genes expands the list of pathomechanisms involved 
in CMT, allowing a better understanding of disease and the discovery of novel 
possible drug targets. Exome sequencing, or targeted sequencing of the protein-
coding portion of the genome, has already been used successfully numerous times to 
identify new CMT genes or novel mutations in known CMT genes (Lupski et al., 
2010; Montenegro et al., 2011; Weedon et al., 2011). This method is particularly 
time and cost-effective in genetically heterogeneous diseases such as CMT 
(Montenegro et al., 2011).  
The many pathways involved in peripheral nerve degeneration render it difficult to 
identify the causative variant within the exome sequencing data. CMT genes encode 
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proteins with a variety of functions, including myelin structural components 
(PMP22, MPZ, GJB1, PRX), mitochondrial fusion and fission (MFN2, ganglioside 
induced differentiation associated protein 1 (GDAP1)), endocytosis, intracellular 
protein sorting and quality control (HSPB1, HSPB8, SH3 domain and 
tetratricopeptide repeats 2 (SH3TC2), dynamin 2 (DNM2), LRSAM1, MTMR2, 
MTMR13, SAC1 lipid phosphatase domain containing (FIG4), rab7 member RAS 
oncogene family (RAB7), lipopolysaccharide-induced TNF factor (LITAF)), 
transcription factors and regulation of gene expression (EGR2, LMNA, mediator 
complex subunit 25 (MED25), CTD (carboxy-terminal domain, RNA polymerase II, 
polypeptide A) phosphatase, subunit 1 (CTDP1)), ion channels (transient receptor 
potential cation channel, subfamily V, member 4 (TRPV4)), protein synthesis (GARS, 
tyrosyl-tRNA synthetase (YARS), alanyl-tRNA synthetase (AARS), lysyl-tRNA 
synthetase (KARS), methionyl-tRNA synthetase (MARS)), as well as cytoskeletal 
dynamics, axonal transport, and vesicular motility (NEFL, inverted formin, FH2 and 
WH2 domain containing (INF2), FYVE, RhoGEF and PH domain containing 4 
(FGD4), kinesin family member 1B (KIF1B), dynein, cytoplasmic 1, heavy chain 1 
(DYNC1H1)) (Pandraud, in press; Patzkó & Shy, 2011). The protein functions of the 
CMT-associated genes are summarized in Appendix I Table I-2. It remains unknown 
whether mutations in all CMT genes act via a small number of shared 
pathomechanisms, or if the mechanism of neurodegeneration is unique for each 
mutation; elucidating this issue will be important for the development of treatment 
strategies in CMT (Roberts, 2012). 
The genes causing demyelinating neuropathy are all expressed in Schwann cells. 
However, many of these genes such as LITAF, GJB1, MTMR2, SH3TC2, FGD4 and 
FIG4 are also expressed in other cell types (Scherer & Wrabetz, 2008). While it is 
fascinating that mutations in ubiquitously-expressed genes may exclusively cause a 
peripheral neuropathy, and that proteins involved in CMT have many different cell 
functions, it renders novel gene finding very complicated. The intricacies of exome 
sequencing in CMT will be highlighted in Chapter 5. 
Exome sequencing was recently successfully used to identify a mutation in a novel 
gene causing another related neuropathy, BVVL (Green et al., 2010; Johnson, Gibbs, 
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et al., 2010). A severe sensory-motor neuropathy is present in BVVL as part of a 
more complex disorder. This discovery has identified a new pathway leading to 
neuropathy along with a potential treatment. 
1.6 Brown-Vialetto-Van Laere (BVVL) syndrome: a severe neuronopathy 
1.6.1 The BVVL phenotype 
BVVL, a rare condition characterised by progressive pontobulbar palsy with 
deafness is named after the physicians who described it initially. Charles Brown first 
defined this condition as an Amyotrophic Lateral Sclerosis (ALS)-like disease with 
infantile-onset and hearing loss (Brown, 1894). The index case was a 15-year old 
German boy with severe deafness, respiratory insufficiency and bulbar weakness 
with labio-glosso laryngeal paralysis and atrophy of the hand and arm muscles 
(Brown, 1894). According to Brown (1894), five such cases of progressive bulbar 
paralysis had been described since 1889. In 1936, Vialetto reported three siblings 
with hearing loss and pontobulbar palsy; a similar phenotype was described in four 
sisters by M. J. Van Laere in 1966 (Van Laere, 1966; Vialetto, 1936). 
Disease onset ranges from infancy to early on in the third decade of life, however the 
age of onset may be variable, even within families (Dipti et al., 2005; Gallai et al., 
1981; Johnson, Gibbs, et al., 2010; Sathasivam, 2008). The disease is most 
frequently diagnosed in the second decade. Patients may present with pontobulbar 
palsy, bilateral sensorineural hearing loss (usually the presenting symptom), 
diaphragmatic paralysis, LMN signs in the limbs and severe sensory-motor 
neuropathy (Sathasivam, 2008). There is often upper and lower limb wasting and 
weakness (Dipti et al., 2005; Gallai et al., 1981; Mégarbané et al., 2000; Sathasivam, 
2008). Some patients may have less bulbar involvement but these patients often have 
significant weakness of the trunk and limbs. UMNs are less frequently affected 
(Dipti et al., 2005; Sathasivam, 2008). Two main phenotypes have been described. 
The type with onset in infancy is more severe and includes hypotonia, respiratory 
insufficiency, rapid progression and early death. An early-onset BVVL phenotype 
may also involve ptosis, stridor caused by vocal cord paresis, and facial and upper 
limb weakness. Later onset cases display deafness, cranial nerve palsies and 
neuronopathy. Hearing loss may not always be clinically obvious, and may need to 
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be confirmed with brainstem auditory evoked potentials, especially in younger cases 
(Voudris et al., 2002).  
In a recent review of 74 patients described in a total of 35 reports in the literature, the 
mean age of presentation was 8.2 years. The most common symptoms for all age 
groups were: bulbar palsy (92%), hearing loss (81%), facial weakness (77%) and 
respiratory compromise (64%) (Bosch et al., 2012). Features such as retinitis 
pigmentosa, epilepsy, optic atrophy, autonomic dysfunction, cerebellar ataxia and 
cognitive impairment may also be present, albeit these remain rare (Bosch et al., 
2012; Sathasivam et al., 2008). 
The course of disease is variable (Sathasivam et al., 2008). It may be fatal with a 
short disease course; infants with BVVL become dependent on ventilation early on 
in the disease, with most dying before the age of 10 years old. Alternatively, BVVL 
patients may stay stable or improve over time, but events such as viral infection, 
fever, surgery, or pregnancy during which riboflavin is in higher demand may trigger 
the onset of disease or cause a worsening of symptoms (Bandettini Di Poggio et al., 
2014; De Grandis et al., 2005; Dipti et al., 2005; Francis et al., 1993; Gallai et al., 
1981; Heller et al., 1974; Powers, 2003; Vialetto, 1936). Cardiac complications have 
been reported in BVVL patients (Descatha et al., 2006), including one patient who 
developed cor pulmonale likely due to hypoventilation (Da Silva-Júnior et al., 2011). 
Sleep-disordered breathing due to central sleep apnoea has also been reported (Miao 
et al., 2007). 
Approximately half of cases are sporadic; inheritance is mostly AR although some 
rare cases with AD or X-linked inheritance have been reported (De Grandis et al., 
2005; Hawkins et al., 1990; Sathasivam, 2008). Incomplete penetrance and variable 
phenotypes among affected family members have been described (Hawkins et al., 
1990; Lombaert et al., 1976). Males are more severely affected and die at a younger 
age, which may explain the female to male ratio of 3:1 (Gallai et al., 1981; 
Sathasivam, 2008). 
CMAPs may be reduced (De Grandis et al., 2005) but NCVs are often normal 
(Sathasivam, 2008; Yiu & Ryan, 2012). Magnetic resonance imaging (MRI) is 
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usually normal in BVVL, although brainstem and cerebellar atrophy, and/or 
hyperintensity of basal ganglia, brainstem nuclei, cerebellar peduncles or subcortical 
white matter have been described in some cases (Ciccolella et al., 2012; Dakhil et al., 
2010; Francis et al., 1993; Koul et al., 2006; Koy et al., 2012; Malheiros et al., 2007; 
Sathasivam, 2008). BVVL often results in degeneration of the cranial nerve nuclei of 
the brainstem with chromatolysis and gliosis (Sathasivam, 2008; Spagnoli & De 
Sousa, 2011). The cranial nerves VII to XII
 
are most commonly affected; it is less 
common for the II to VI cranial nerves to become involved as the disease progresses 
(Bosch et al., 2012; Gallai et al., 1981; Koul et al., 2006; Sathasivam, 2008). Reports 
have also described anterior horn cell degeneration and loss of myelinated fibres in 
the ventral roots of the spinal cord, as well as axon loss in the peripheral nerve 
(Francis et al., 1993; Gallai et al., 1981; McShane et al., 1992; Spagnoli & De Sousa, 
2011). Muscle biopsies are either normal or show myopathic changes or grouped 
atrophic fibres (Sathasivam, 2008). Signs of reinnervation in the limbs and facial 
muscles have been reported (De Grandis et al., 2005). 
BVVL is therefore an early-onset motor neurone disease (MND), with bulbar and 
corticospinal tract involvement (De Grandis et al., 2005; Dipti et al., 2005). 
However, given the presence of a CMT-like sensory or sensory-motor 
polyneuropathy in many BVVL cases, with damage to primary sensory neurones and 
many times absence of sensory responses, it has been suggested to consider BVVL a 
severe sensory-motor neuropathy and not just a pure anterior horn disease or motor 
neuronopathy (Gallai et al., 1981; Mégarbané et al., 2000; Sathasivam et al., 2000). 
In contrast to demyelinating neuropathies, there is usually more CNS involvement in 
early-onset motor neuronopathies and early-onset axonal neuropathies. Axonal 
sensory-motor neuropathies with early-onset are not always easy to distinguish from 
motor neuronopathies, both clinically and on NCS (Yiu & Ryan, 2012). 
Fazio-Londe (FL) syndrome is now considered to be an allelic condition and part of 
a clinical spectrum with BVVL; it has the same clinical presentation but without the 
deafness (Dipti et al., 2005; Fazio, 1892; Londe, 1893; Londe, 1894; McShane et al., 
1992). Other diseases closely resembling BVVL include Madras MND, Boltshauser 
syndrome and Nathalie Syndrome. Madras MND is predominantly seen in India; 
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patients exhibit muscle weakness and wasting in the limbs, deafness, and palsies of 
the VII, IX and XII cranial nerves. Most cases are sporadic. Boltshauser syndrome 
has AD inheritance and is characterized by deafness, distal muscular atrophy and 
vocal cord paralysis without LMN limb signs. Patients with Nathalie syndrome have 
no lower cranial nerve signs but have deafness and weakness in addition to spinal 
muscular atrophy (SMA), cataracts, hypogonadism and cardiac conduction defects 
(Sathasivam, 2008). 
The phenotypes of both ALS and SMA may overlap with the complex BVVL 
phenotype (Horvath, 2012; Sathasivam, 2008). Although spinal muscular atrophy 
type 1 mostly involves motor neurones of the anterior horns, patients with 
homozygous gene defects in survival motor neuron 1 (SMN1) may have peripheral 
motor and sensory nerve involvement (Yiu & Ryan, 2012). Spinal muscular atrophy 
with respiratory distress type 1 (SMARD1) is an “SMA plus” syndrome caused by 
AR mutations in immunoglobulin mu binding protein 2 (IGHMBP2), usually leading 
to early-onset severe axonal polyneuropathy with distal muscle and lower limb 
weakness and respiratory failure due to diaphragmatic paralysis. Infantile-onset is 
most common. There may also be autonomic involvement, pneumonia and hypotonia 
but no deafness has been described (Yiu & Ryan, 2012). ALS is characterised by 
adult-onset degeneration of motor neurones in the corticospinal tract, brainstem and 
anterior horn cells of the spinal cord. Patients have UMN and LMN limb signs with 
progressive muscle weakness and wasting, fasciculations and spasticity. Patients 
often die of respiratory paralysis (Hardiman et al., 2011). BVVL has been described 
as an AR juvenile form of ALS since both BVVL and ALS have bulbar and LMN 
involvement (Brown, 1894; De Grandis et al., 2005; Gallai et al., 1981; Sathasivam, 
2008). BVVL differs from ALS in that BVVL patients have deafness, an earlier age 
of onset, a more irregular disease course, and UMN limb signs are not invariably 
present (De Grandis et al., 2005; Gallai et al., 1981; Sathasivam, 2008). Of note, 
ubiquilin 2 (UBQLN2) mutations have been identified as a rare cause of ALS; a 
recent study has identified a heterozygous mutation in a related gene previously 
linked to neurodegeneration, ubiquilin 1 (UBQLN1), in a BVVL patient with atypical 
early-onset ALS with bulbar palsy and hearing loss. Although the pathogenicity of 
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this mutation remains uncertain, this finding highlights the overlap of BVVL and 
ALS phenotypes (González-Pérez et al., 2012). 
1.6.2 Biochemical profile of BVVL: clue to new mechanism of neuropathy 
The first clue into the genetic cause of BVVL came from results of fatty acid β-
oxidation analyses. In the matrix of mitochondria, fatty acid β-oxidation breaks down 
long chains of acyl-Coenzyme A (acyl-CoA) fatty acids into acetyl-Coenzyme A 
(acetyl-CoA) molecules, which are needed for adenosine 5’-triphosphate (ATP) 
production via the Krebs cycle. During the first step of fatty acid metabolism, the 
fatty acid moiety of acyl-CoA esters is oxidised by either short-chain, medium-chain 
or long-chain acyl-CoA dehydrogenases. The next two enzymes involved, electron 
transfer flavoprotein (ETF) and electron transfer flavoprotein ubiquinone 
oxidoreductase (ETF:QO) carry reducing equivalents to Coenzyme Q (CoQ) in the 
mitochondrial electron transport chain. CoQ transfers these electrons to oxygen in an 
ATP-producing process (Henriques et al., 2010). 
Metabolic studies of BVVL patients reveal accumulating acyl-CoA and carnitine 
esters in the plasma, as well as a urine organic acid profile which both mimic the 
fatty acid β-oxidation defect seen in patients with mild multiple acyl-CoA 
dehydrogenase deficiency (MADD). BVVL patients showed evidence of elevated 
short and medium-chain acylcarnitines. Long-chain acylcarnitines were elevated in 
only one of the patients (Anand et al., 2012; Bosch et al., 2011; Haack et al., 2012; 
Johnson et al., 2012). 
MADD may be early-onset with a severe, often fatal disease course and hypoketotic 
hypoglycaemia, or late-onset with a mild phenotype of lipid storage myopathy. 
MADD results in impaired flavin adenine dinucleotide (FAD)-dependent 
dehydrogenation reactions during mitochondrial fatty acid β-oxidation and amino 
acid metabolism as a result of mutations in electron transfer flavoprotein alpha/beta 
subunit (ETFA/ETFB), which encodes ETF, or electron transfer flavoprotein 
dehydrogenase (ETFDH), which encodes ETF:QO, leading to accumulation of 
metabolic intermediates (Bosch et al., 2011; Gregersen et al., 2008; Olsen et al., 
2007; Powers, 2003). FAD, one of the active co-enzyme forms of riboflavin, is an 
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essential cofactor for acyl-CoA dehydrogenases, as well as ETF and EFT:QO, 
functioning as an electron carrier in fatty acid β-oxidation (Depeint et al., 2006; 
Gregersen, 1985; Henriques et al., 2009; Massey, 2000). Interestingly, studies of 
riboflavin-deficient rats have shown that moderate riboflavin deficiency results in an 
MADD-like metabolic profile (Brady & Hoppel, 1985; Goodman, 1981). In fact, as 
will be discussed in Chapter 7, some forms of MADD are responsive to riboflavin 
treatment.  
Another important insight into the genetic basis of BVVL was that BVVL patients 
had decreased plasma levels of riboflavin and its active coenzyme forms, FAD and 
flavin mononucleotide (FMN), which were not due to nutritional riboflavin 
deficiency (Bosch et al., 2011). 
1.6.3 Riboflavin transporter mutations: a novel cause of motor and sensory 
neuropathy 
As of 2008, 58 cases of BVVL with no known genetic cause had been described in 
the literature since the first report in 1894 (Sathasivam, 2008). Since then, the genetic 
cause of over 20 BVVL cases has been found. The decrease in plasma flavin levels 
and MADD-like profile suggested that riboflavin transporters may play a role in 
BVVL disease pathogenesis (Bosch et al., 2011). Indeed, Green et al. (2010) were 
the first to report mutations in solute carrier family 52, riboflavin transporter, 
member 3 (SLC52A3) (previously chromosome 20 open reading frame 54 
(C20orf54)) as the cause of disease in a consanguineous family with BVVL, and 
later in other unrelated families (Green et al., 2010). SLC52A3 was found to produce 
the intestinal human riboflavin transporter 3 (RFVT3) (previously human riboflavin 
transporter 2 (hRFT2)), a protein necessary for riboflavin absorption. As described 
by Bosch et al. (2011) a block in the riboflavin transport due to a mutation in 
SLC52A3 leads to decreased availability of riboflavin, FAD and FMN (as evidenced 
by reduced plasma levels of all three); this causes metabolic dysfunction via an 
increase in the levels of acylcarnitines resulting from impaired dehydrogenation 
reactions in fatty acid β-oxidation, thus explaining the MADD-like biochemical 
profile. Almost simultaneously, Johnson, Gibbs, and colleagues (2010) described 
additional families with mutations in SLC52A3. Bosch et al. (2011) also found a 
defect in the same gene in a BVVL patient and two siblings with FL syndrome with 
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early-onset progressive muscle weakness, respiratory insufficiency, cranial nerve 
palsies and diaphragmatic paralysis (Bosch et al., 2011). Additional reports 
confirmed the association of SLC52A3 mutations and the BVVL phenotype (Anand 
et al., 2012; Bandettini Di Poggio et al., 2013; Ciccolella et al., 2012; Dezfouli et al., 
2012; Johnson et al., 2012; Koy et al., 2012). 
Solute carrier family 52, riboflavin transporter member 1 (SLC52A1) (previously G 
protein-coupled receptor 172B (GPR172B)) encodes another human riboflavin 
transporter, human riboflavin transporter 1 (RFVT1) (previously human riboflavin 
transporter 1 (hRFT1)) (Yonezawa et al., 2008). Haploinsufficiency in SLC52A1 
caused by a heterozygous deletion of exons 2 and 3 can cause mild maternal 
riboflavin deficiency (Chiong et al., 2007; Ho et al., 2010). While the 
haploinsufficient mother showed no symptoms, she had an MADD-like biochemical 
profile and plasma flavin deficiency. In her infant however, the heterozygous 
deletion of two exons in the mother in addition to the nutritional riboflavin 
deficiency during pregnancy resulted in a transient riboflavin-responsive disorder 
with an MADD-like clinical and biochemical profile at birth (Ho et al., 2010). As 
only one patient with a genetic defect in SLC52A1 has been reported and the clinical 
picture was MADD-like, it remains unclear if mutations in SLC52A1 may be 
associated with BVVL. Interestingly, a report has previously described a pregnant 
mother with MADD with an unknown defect in riboflavin metabolism; the mother 
had several floppy or stillborn babies, but the syndrome could be prevented in further 
pregnancies by supplementation with riboflavin. A defect in FAD transport or 
synthesis was suggested to cause the disease (Harpey et al., 1983). 
Johnson et al. (2012) performed exome sequencing in a cohort of BVVL patients 
negative for SLC52A3 mutations and found a homozygous mutation in solute carrier 
family 52, riboflavin transporter member 2 (SLC52A2) in a Lebanese kindred with 
childhood MND and BVVL features (Johnson et al., 2012). SLC52A2 (previously G 
protein-coupled receptor 172A (GPR172A)) encodes a third riboflavin transporter, 
human riboflavin transporter 2 (RFVT2) (previously human riboflavin transporter 3 
(hRFT3)) (Yao et al., 2010). The same mutation was found in another family on a 
different haplotype; BVVL patients in both families shared a similar phenotype as 
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well as an MADD-like biochemical profile (Johnson et al., 2012). Additional patients 
with compound heterozygous or homozygous SLC52A2 mutations were soon 
described (Ciccolella et al. 2013; Haack et al., 2012). In contrast to patients with 
SLC52A3 mutations, plasma flavin levels are often normal in patients with SLC52A2 
mutations, most likely because the SLC52A3 encoded-transporter RFVT3 is 
responsible for riboflavin uptake from food while the SLC52A2-encoded transporter 
RFVT2 transports riboflavin from the blood into target cells (Haack et al., 2012). It 
should be noted that the metabolic profile may also be normal in both SLC52A2 and 
SLC52A3 mutated patients (Bosch et al., 2012; Ciccolella et al., 2012; Ciccolella et 
al., 2013; Koy et al., 2012). Furthermore, acylcarnitines profiles of the newborn 
bloodspots of BVVL patients were normal and patients did not show a phenotype at 
birth, likely due to the riboflavin available from the baby’s mother (Bosch et al., 
2011). Therefore, acylcarnitine profiles cannot be used as a diagnostic tool at birth 
(Bosch et al., 2012). 
Although there have been significant advances in the genetic diagnosis of BVVL in 
the past few years, many cases remain unresolved, suggesting genetic heterogeneity 
in this disease. Chapter 6 will investigate the genetics of BVVL by performing a 
genetic screening of SLC52A1, SLC52A2 and SLC52A3 in BVVL and BVVL-like 
patients, and by searching for novel causative genes in BVVL and related 
neuropathies using exome sequencing. 
1.6.4 Phenotype of nutritional riboflavin deficiency  
Riboflavin deficiency (ariboflavinosis) is common in many parts of the world, 
especially amongst individuals whose diets lack meat and dairy products. The 
recommended daily intake is 1.1 mg and 1.3 mg for adult females and males, 
respectively (Lienhart et al., 2013; Powers, 2003). In developed countries, riboflavin 
deficiency usually remains subclinical and its effects are usually only seen at the 
biochemical level (Foraker et al., 2003). In contrast to the phenotype of BVVL, the 
symptoms associated with riboflavin deficiency are usually dermatological in nature 
and usually include anaemia, inflammation of the tongue and mouth, cracked and red 
lips, mouth ulcers, cheilosis, sore throat but also neuropathy (Depeint et al., 2006; 
Powers, 2003; Spagnoli & De Sousa, 2011). In animals, riboflavin deficiency can be 
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associated with foetal development abnormalities (Powers, 2003). Biochemical 
indications of deficiency generally appear after a few days of following a riboflavin-
free diet (Powers, 2003). A rare case of neurodegeneration with progressive 
deafness, vision loss, anaemia, gait ataxia and sensory-motor polyneuropathy has 
been described in a patient with moderate riboflavin deficiency; most of the 
symptoms resolved upon riboflavin treatment (Leshner et al., 1981). A 
demyelinating peripheral neuropathy characterized by hypertrophic Schwann cells, 
tomaculae and onion bulb formation was also observed in young chickens with 
riboflavin deficiency, with remyelination taking place when riboflavin levels were 
restored (Cai et al., 2009). Demyelination has also been noted in pigeons and rats fed 
a riboflavin-deficient diet (Powers, 2003). Riboflavin deficiency may increase the 
risk of certain cancers, although this is a matter of debate (Powers, 2003). Riboflavin 
is also necessary for the proper functioning of the endocrine, cardiovascular and 
immune systems, and deficiency may therefore negatively impact these systems as 
well (Mazur-Bialy et al., 2013; Powers, 2003). 
1.6.5 Response to high-dose riboflavin treatment in BVVL patients 
Before the identification of riboflavin transporter mutations in BVVL patients, 
treatment was palliative and involved gastrostomy and assisted ventilation; patients 
usually died of respiratory failure (Sathasivam, 2008). Treatment with steroids and 
immunoglobulins was usually not successful or allowed only temporary stabilization 
or improvement of only some of the symptoms (Ciccolella et al., 2012; Dakhil et al., 
2010; Gallai et al., 1981; Hawkins et al., 1990; Koy et al., 2012; Sathasivam, 2008). 
Given the role of the causative genes in riboflavin transport, a treatment of 
intravenous or oral riboflavin at 10 mg/kg body weight/day was initiated in some 
patients. In a review of BVVL patients treated with riboflavin, the mean age at the 
start of treatment was 6.9 years, with the first improvements seen within days for 
some and gradually over a few months for other patients (Bosch et al., 2012). Eight 
patients among the 13 treated showed very good clinical improvement (Bosch et al., 
2012). Indeed, most BVVL and FL patients carrying SLC52A3 mutations improved 
from a clinical and biochemical point of view when administered high-dose 
riboflavin therapy early on in the disease course (Anand et al., 2012; Bosch et al., 
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2011). In the SLC52A3 patients described in the Ciccolella et al. (2012) study, one 
patient with a severe phenotype showed a halt in disease progression after eight 
months of treatment, but there was no improvement in the other patient. Another 
case with a normal metabolic profile and SLC52A3 mutations did not improve on 
high-dose riboflavin (Koy et al., 2012). In SLC52A2 mutated patients, there was 
either moderate improvement of symptoms (Haack et al., 2012) or good clinical 
improvement with normalization of the biochemical profile (Johnson et al., 2012). 
Overall, most BVVL patients treated with riboflavin had less need for ventilation, 
and some showed full recovery. In all cases, riboflavin restored acylcarnitine profiles 
and plasma flavin levels to normal. Importantly, improvements were also seen in 
patients with normal plasma acylcarnitine profiles and flavin levels. Symptoms often 
came back if supplementation was stopped and in the long-term, the effect of the 
riboflavin treatment sometimes decreased (Bosch et al., 2012). The patients who did 
not respond to riboflavin were either not treated for very long, or received prolonged 
treatment but remained stable with no improvement; three out of the five 
unresponsive patients did not have mutations in SLC52A1, SLC52A2 or SLC52A3. In 
the untreated patients that died, the mean age of death was 11.6 years with a mean 
time span between presentation and death of five years. The most common cause of 
death was respiratory insufficiency (Bosch et al., 2012). Given the promising results 
of riboflavin therapy, Bosch and colleagues (2012) suggest not to wait for results of 
genetic tests to start treatment. This treatment needs to be administered early on in 
the disease course because diaphragmatic paralysis is probably not reversible (Bosch 
et al., 2012; Spagnoli & De Sousa, 2011). Riboflavin supplementation may only 
delay disease progression and may be ineffective if too much damage has already 
occurred in the early disease stages (Bosch et al., 2012; Spagnoli & De Sousa, 2011). 
The identification of riboflavin transporter mutations as a novel genetic cause of 
neuropathy has uncovered yet another new disease pathway leading to damage of 
peripheral nerves. Importantly, this exciting discovery has made BVVL the first 
treatable inherited neuropathy. Riboflavin may also be a potential therapy in other 
MNDs. 
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1.6.6 Biological functions of riboflavin, flavin adenine dinucleotide (FAD) and 
flavin mononucleotide (FMN) 
An understanding of the biological functions of riboflavin and its cofactors is 
essential for elucidating the disease mechanisms leading to the BVVL phenotype, 
which is the principal aim of Chapter 7. Riboflavin (7,8-dimethyl-10-ribityl-
isoalloxazine, C17H20N4O6, vitamin B2), one of the eight B vitamins, is a yellow 
fluorescent water-soluble vitamin which was first observed in 1872 and recognized 
to be riboflavin in the early 1930s when it was still known as the “old yellow 
enzyme” (Massey, 2000; McCormick, 1989; Northrop-Clewes & Thurnham, 2012). 
Riboflavin is sensitive to sunlight and ultraviolet (UV) rays. Unlike prokaryotes, 
humans cannot synthesize riboflavin and therefore need to obtain it from food via 
intestinal absorption as it is continually excreted through the urine (Depeint et al., 
2006; Northrop-Clewes & Thurnham, 2012). Riboflavin is necessary for normal 
cellular function, growth and development. In our diet, riboflavin is found in the 
highest quantities in eggs, milk, cheese, leafy green vegetables, meat, almonds and 
yeast (Depeint et al., 2006; Powers, 2003). A small amount of riboflavin is also 
obtained from a bacterial source as it is synthesized by the microflora of the large 
intestine in humans (Powers, 2003). 
Riboflavin is a precursor of FAD (riboflavin 5' adenosine diphosphate) and FMN 
(riboflavin-5′-phosphate), its biologically active forms (Depeint et al., 2006; 
Northrop-Clewes & Thurnham, 2012). In addition to the isoalloxazine tricyclic ring 
and ribityl side chain of riboflavin, FMN contains an additional phosphate group at 
the 5’ hydroxyl side chain terminus of riboflavin, and FAD contains the FMN 
structure with an added AMP moiety (Figure 1-2). Riboflavin is converted to FMN 
by riboflavin kinase and FAD synthetase converts FMN to FAD (Henriques et al., 
2010; McCormick, 1989).  
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Figure 1-2 Structure of riboflavin and its cofactor forms, FAD and FMN 
(reproduced from Johnson et al., 2012). 
FMN and FAD are prosthetic groups of flavoenzymes, which may be flavin 
oxidases, flavin reductases, or flavin dehydrogenases (Depeint et al., 2006; Massey, 
2000). Due to the aromatic ring structure of the FAD and FMN cofactors, flavins are 
able to donate or accept one or two electrons in oxidation, reduction and 
dehydrogenation reactions. Most flavoenzymes (84%) use FAD as a prosthetic group 
and most are non-covalently bound to either FAD or FMN (Henriques et al., 2010; 
Lienhart et al., 2013; Powers, 2003). Over 90 genes encode flavin-dependent 
proteins, and mutations in about 60% of them are involved in causing human disease, 
many of which are mitochondrial since most flavins in the cell are located in the 
mitochondria (Lienhart et al., 2013; Rhead et al., 1993).  
Flavoenzymes and flavoproteins are involved in a large number of biochemical 
reactions therefore riboflavin, FAD and FMN are extremely important for a wide 
range of cellular functions. In the case of a riboflavin deficiency or error in riboflavin 
metabolism or transport, activity of many of these enzymes and proteins is affected 
(Henriques et al., 2010; Massey, 2000). Some functions of flavoenzymes include but 
are not limited to: metabolism of lipids, proteins and carbohydrates, iron metabolism, 
conversion of vitamin A to retinoic acid, conversion of tryptophan to vitamin B3, 
activation of vitamin B6 and folate, choline metabolism, biosynthesis of Coenzyme 
A, CoQ, steroid and thyroxine, phospholipid metabolism, neurotransmitter 
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metabolism, synthesis of sphingosine, production of superoxide, reduction of 
hydroperoxides and light production in bioluminescent bacteria (Lienhart et al., 
2013; Massey, 2000). Flavoproteins have signal transduction roles in DNA repair 
(Schuman Jorns et al., 1987) and apoptosis (Susin et al., 1999). Riboflavin has also 
been found to have anti-inflammatory and anti-nociceptive properties (Mazur-Bialy 
et al., 2013). 
As mentioned in Section 1.6.2, riboflavin and its cofactors are important for energy 
metabolism due to the role of FAD as a coenzyme for acyl-CoA dehydrogenase, ETF 
and ETF:QO during fatty acid β-oxidation. However, FMN and FAD are also needed 
for cellular respiration in the mitochondrial respiratory chain (MRC). Complexes I 
and II are two flavin-dependent complexes of the MRC. FMN is the primary electron 
acceptor for complex I. FAD is the initial electron acceptor in complex II, a second 
point of entry into the MRC. Mitochondrial diseases, which may include 
neuropathies, are associated with suboptimal oxidative phosphorylation and ATP 
production (Marriage et al., 2003). Interestingly and as will be discussed further in 
Chapter 7, riboflavin has proven an effective therapy in patients with mitochondrial 
diseases associated with complex I and/or complex II deficiencies (Bernsen et al., 
1993; Bugiani et al., 2006; Gerards et al., 2011; Gianazza et al., 2006; Marriage et 
al., 2003; Olsen et al., 2007; Scholte et al., 1995; Vergani et al., 1999). The functions 
of FAD and FMN in energy metabolism, as well as their possible involvement in the 
pathogenesis of BVVL will be discussed extensively in Chapter 7. 
In addition to its role in energy metabolism, riboflavin also acts indirectly as an 
antioxidant: FAD is needed for the recycling of glutathione as it is a cofactor for 
glutathione reductase. Glutathione reductase converts oxidised glutathione (GSSG) 
to reduced glutathione (GSH). Therefore, FAD is indirectly necessary for protection 
against oxygen-derived free radicals since GSH is a scavenger of free radical and 
reactive oxygen species (ROS) (Depeint et al., 2006; Henriques et al., 2010). In fact, 
the erythrocyte glutathione reductase (EGR) test, which assesses the activity of EGR 
with and without FAD, is commonly performed to test for riboflavin nutritional 
status (Northrop-Clewes & Thurnham, 2012). 
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1.7 Thesis aims 
This Thesis focuses on several aspects of two inherited peripheral neuropathies, 
CMT and BVVL, and utilises both genetic and molecular biology-based methods 
with the following aims: 
 Chapter 3: To provide frequency data of mutations in CMT1 genes in 
selected populations (United Kingdom, Greece and Russia), and to expand 
phenotype-genotype correlations in CMT1. It is hoped that this work will 
help clinicians target genetic tests in CMT. Canines with peripheral 
neuropathies will also be screened for CMT genes in the hope that they may 
serve as animal models of CMT. 
 Chapter 4: To elucidate the pathogenesis of CMT1A by identifying the 
genetic factors modulating the disease phenotype. This work may lead to the 
identification of targets for drug treatment, and allow for more accurate 
prediction of the phenotype in patient counselling. 
 Chapter 5: To identify novel causes of CMT in undiagnosed families using 
exome sequencing. 
 Chapter 6: To detect unrecognized cases of BVVL and allow for early 
treatment by screening cases with a BVVL-like phenotype for mutations in 
riboflavin transporter genes, a novel genetic cause of severe but treatable 
infantile neuropathy. This Chapter also aims to identify the genetic cause of 
disease in patients with BVVL-like phenotypes and in patients with AR 
polyneuropathy with a predominant motor component. 
 Chapter 7: To elucidate the pathogenesis of riboflavin transporter mutations 
in BVVL, a novel neuropathy-associated disease pathway. 
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Chapter 2 Materials and methods 
2.1 Genetic studies 
2.1.1 Ethics approval and consent  
This study has been granted ethical approval by the National Research Ethics Service 
Committee of the National Hospital for Neurology and Neurosurgery (NHNN) in 
Queen Square, London, UK. The University College London Hospital (UCLH) REC 
numbers are 09/H0716/61 for the CMT genetic study and 99/N103 for the BVVL 
genetic study and any disorder of the peripheral nerve and spinal cord. Written 
informed consent was obtained from all patients, parental guardians and/or included 
family members.  
2.1.2 Control deoxyribonucleic acid (DNA) samples 
DNA of British controls for CMT sequencing studies was obtained from the 
Wellcome Trust Case Control Consortium (WTCCC) 1958 British Birth Cohort 
(http://www.wtccc.org.uk). DNA of controls of Northern European origin for the 
CMT Immunochip association study was obtained from the WTCCC2 
(http://www.wtccc.org.uk/ccc2/). The WTCCC is a collaborative study composed of 
over 50 research groups from the UK designed to look at genetic variation in the 
human population and its role in disease. 
2.1.3 DNA extraction from blood, snap-frozen muscle and saliva 
The QIAamp DNA blood Midi kit (spin protocol; Qiagen, Germany) was used to 
extract total DNA from 700 μl ethylenediaminetetraacetic acid (EDTA) blood of 
some canines with peripheral neuropathies according to the manufacturer’s 
instructions. The DNeasy Blood & Tissue kit (Qiagen) was used to extract total DNA 
from snap-frozen muscle of additional canines. Briefly, for both DNA extraction kits, 
the lysate was added to the spin column following enzymatic lysis. DNA remained 
bound to the silica membrane column, and impurities were washed away. Finally, 
DNA was eluted in autoclaved deionised water (dH2O). 
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The Oragene kit (OraSure technologies, USA) was used to extract total DNA from 
human saliva of one BVVL patient following the manufacturer’s instructions (details 
of standard protocol in Appendix II).  
2.1.4 Whole-genome DNA amplification 
Due to the low amount of DNA available for Sanger sequencing, a whole-genome 
amplification of genomic DNA (gDNA) samples (10 ng) from the Russian CMT 
cohort was performed using the GenomePlex Complete Whole-Genome 
Amplification kit according to the manufacturer’s instructions (Sigma, USA). This 
kit enables 500-fold amplification of gDNA. It is based upon 1) random 
fragmentation of gDNA 2) library preparation by converting the resulting small 
fragments to polymerase chain reaction (PCR)-amplifiable OmniPlex Library 
molecules flanked by universal priming sites, and 3) PCR amplification of library 
using universal oligonucleotide primers. Following this procedure, the whole-
genome amplification product was purified using Millipore Multiscreen HTS filter 
plates (Merck-Millipore, Germany). For quality control, products were run on a 1.3% 
w/v agarose (Roche, Switzerland) gel. DNA concentration and purity were assessed 
using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, USA) 
(Section 2.1.5). 
2.1.5 DNA concentration and purity  
DNA concentration and purity were assessed using the NanoDrop ND-1000 
spectrophotometer as per the manufacturer’s instructions (NanoDrop Technologies). 
The DNA concentration was assayed at 260 nm. Nucleic acids and proteins have 
absorbance maxima at 260 and 280 nm, respectively. Absorbance at 230 nm reflects 
the presence of other contaminants. The 260/280 and 260/230 absorbance ratios are 
used to evaluate contamination with protein, phenol or other compounds. For DNA, 
a 260/280 absorbance ratio of approximately 1.8 and a 260/230 absorbance ratio of 
1.8-2.2 are considered acceptable. 
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2.1.6 Quantitative polymerase chain reaction for confirmation of the 
Chr17p11.2 duplication  
Quantitative polymerase chain reaction (qPCR) for confirmation of the Chr17p11.2 
duplication in selected CMT1A cases was carried out by assessing gene dosage of 
PMP22 exon 4 using SYBR
 
Green I chemistry (Applied Biosystems, USA). The 
SYBR Green dye binds to all double-stranded DNA non-specifically therefore the 
fluorescence signal represents the amount of double-stranded DNA product 
generated during the PCR reaction. Primer sequences for PMP22 exon 4 (obtained 
from Kim et al., 2003) and the housekeeping gene actin, beta-like 2 (ACTBL2) are 
found in Appendix IV Table IV-1. qPCR was performed according to the standard 
SYBR Green I protocol (see Appendix II). The comparative delta-delta threshold 
cycle (Ct) method was used for relative quantification of PMP22 gene dosage since 
both the target and housekeeping genes amplified at similar efficiencies. The Ct, or 
threshold cycle in the log phase of PCR, is the number of cycles needed for the 
fluorescent signal to exceed background signal; it is inversely proportional to the 
amount of DNA in the sample (Livak & Schmittgen, 2001). Samples with relative 
quantification values (RQ) between 0.8 and 1.2 did not carry the duplication and 
those with RQ between 1.3 and 1.7 were considered to carry the PMP22 duplication. 
2.1.7 Transcriptional analysis of a small duplication and deletion in the Greek 
CMT cohort  
For the transcriptional analysis of the small duplication and deletion in the Greek 
CMT cohort, ribonucleic acid (RNA) was obtained from peripheral blood using the 
PreAnalytiX PAXgene blood RNA system as per the manufacturer’s instructions 
(Qiagen). Complementary DNA (cDNA) was synthesized using the High capacity 
cDNA reverse transcription (RT) kit following the manufacturer’s instructions 
(Applied Biosystems). This work was carried out entirely by Dr George Koutsis 
from Eginitio Hospital, Athens, Greece. 
2.1.8 Fragment analysis of a small duplication and deletion in the Greek CMT 
cohort 
The small duplication and deletion in the Greek CMT cohort were further analysed 
by fluorescent PCR amplification and subsequent capillary electrophoresis using a 
Hi-Di Formamide mix (Life Technologies, USA). Fragment analysis was analysed 
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with GeneMapper software (Applied Biosystems) after running fragments on the 
3730XL capillary sequencer (Applied Biosystems) with a GeneScan 500 LIZ dye 
size standard (Applied Biosystems). This work was carried out entirely by Dr George 
Koutsis. 
2.1.9 Polymerase chain reaction (PCR) 
The PCR technique to select and amplify specific DNA fragments was originally 
developed by Kary Mullis in the 1980s (Mullis et al., 1986). PCR uses a DNA 
polymerase to synthesize DNA strands complementary to the template strands using 
primers, a DNA template, and nucleotides or deoxyribonucleotide triphosphates 
(dNTPs). 
For PCR amplification prior to DNA se uencing, primers were designed using 
Primer3Plus software (www.bioinformatics.nl primer3plus  ; Rozen & Skaletsky, 
2000) to cover coding exons and at least 20 base pairs (bp) of flanking intronic 
sequences. Gene sequences were retrieved from Ensembl (www.ensembl.org). 
Primers were checked for specificity using the basic local alignment search tool 
(BLAST) feature in Ensembl (http://www.ensembl.org/Multi/blastview). Primers 
were purchased from Sigma. Optimal annealing temperatures were determined using 
a gradient block, ranging from 50°C to 65°C or, for touchdown PCRs, by testing 
multiple touchdown temperatures on individual thermalcyclers. Touchdown PCR, 
where the annealing temperature is decreased in increments over subsequent cycles, 
allows for increased binding specificity at the higher annealing temperatures. These 
specific fragments are amplified at lower annealing temperatures as well, but will be 
present in a higher proportion compared to the nonspecific sequences which may 
arise from low annealing temperatures (Don et al., 1991). 
For the PCR reaction, DNA was used at 50-100 ng μl. The PCR reactions included 
0.75 μl of both forward and reverse primers (each at 10 μM), 12.5 μl of 2X PCR 
Master Mix (Roche), 10 μl of autoclaved dH2O and 1 μl DNA. When required for 
particular primer pairs, the following PCR reaction mix was used: 2.5 μl of 10X 
TopTaq PCR buffer (Qiagen), 0.5 μl of dNTP mix (10 nM of each) (Qiagen), 5 μl of 
5X Q-Solution (Qiagen), 1 μl of both forward and reverse primers (each at 10 μM), 
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0.25 μl of TopTaq DNA Polymerase (Qiagen), 13.75 μl of autoclaved dH2O and 1 μl 
of DNA. One well per plate served as a negative control, where autoclaved dH2O 
was used instead of DNA. Plates were sealed with heat-resistant covers, centrifuged, 
and run on a GeneAmp PCR System PerkinElmer 9700 Thermalcycler (PerkinElmer, 
USA). PCR thermalcycling conditions were as follows: 15 min at 95°C (initialization 
stage), followed by 35 cycles of 30 s at 95°C (denaturation stage), 30 s at specified 
annealing temperature (annealing stage), and 45 s at 72°C (elongation stage) before a 
final 10 min elongation stage at 72°C. For touchdown PCR, the starting annealing 
temperature is decreased in 0.4°C increments to a final annealing temperature for 
every successive set of cycles. Transcript references used for primer design, gene-
specific primers sequences, and fragment-specific PCR cycling conditions are 
detailed in Appendix III Tables III-1 to III-3, Appendix IV Table IV-2, Appendix V 
Table V-1, Appendix VI Tables VI-3, VI-4, and VI-5, and Appendix VII Tables VII-
4, VII-6, VII-9, and VII-10. 
2.1.10 Agarose gel electrophoresis of PCR products 
After PCR amplification, the length of PCR products was verified by agarose gel 
electrophoresis, in which 5 μl of the PCR product was mixed with 3 μl Orange G 
loading dye (Sigma) and run on a 1.3% w/v agarose gel with a 1 Kb DNA ladder 
(Promega, USA). Samples were electrophoresed for 25 min at 60 V and visualized 
under a UV transilluminator. Digital photographs were obtained using the Syngene 
GeneGenius image acquisition system and GeneSnap software (Synoptics, UK). The 
recipes for the Orange G loading dye, agarose gel, and 10X Tris/borate/EDTA (TBE) 
are provided in Appendix II. 
2.1.11 PCR product purification 
The PCR products were purified using either of two methods. For the first method, 
80 μl of autoclaved dH2O was added to each PCR product. The diluted PCR products 
were transferred to a Multiscreen HTS filter plate (Merck-Millipore) and vacuumed 
at 25 inches Hg for 5 min until dry. 80 μl of autoclaved dH2O was once again added 
to the filter plate, and placed on the vacuum at 25 inches Hg for 5 min. 50 μl of 
autoclaved dH2O was added to each well and placed on a shaker for 30 min. The 50 
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μl of resuspended PCR product was added to a storage plate to serve as a template 
for future sequencing. 
For the second method, 5 μl of PCR product was transferred to a fresh PCR plate. 
Exo-Fast mix was prepared by combining 50 μl Exonuclease I (Thermo Fisher 
Scientific, USA), 200 μl of FastAP alkaline phosphatase (Thermo Fisher Scientific) 
and 750 μl autoclaved dH2O. FastAP and Exonuclease I remove unincorporated 
dNTPs and single-stranded DNA from PCR products. 2 μl of Exo-Fast mix was 
added to each well and was pipette-mixed with the PCR product. The PCR plate was 
sealed with a heat-resistant cover, centrifuged, and run on a PerkinElmer 9700 
thermalcycler at 37°C for 30 min and 80°C for 15 min. 
2.1.12 Sanger sequencing  
The Sanger (or dideoxy-chain-termination) method of sequencing was developed in 
the 1970s by Frederick Sanger (Sanger & Coulson, 1975). The Sanger method 
consists in synthesising DNA complementary to the PCR product using dNTPs and 
fluorescently labelled dideoxynucleotides (ddNTPs), DNA polymerase, primers and 
a template. When a ddNTP is incorporated in place of a normal nucleotide (a dNTP), 
this terminates DNA synthesis. This results in a series of fragments terminating with 
a ddNTP at different positions along the DNA sequence. In automated sequencing, 
the fluorescence of each fragment depends on which ddNTP is incorporated. 
Sanger sequencing was carried out bi-directionally using BigDye Terminator v3.1 
Cycle Sequencing kit (Life Technologies). Primers used were the same as those used 
for PCR. Each sequencing reaction contained 1 μl forward or reverse primer at 3.2 
μM, 3.5 μl of purified PCR product, 2 μl of 5X BigDye Terminator v3.1 sequencing 
buffer (Life Technologies), 3.25 μl of autoclaved dH2O and 0.25 μl BigDye 
Terminator v3.1 reaction mix (Life Technologies). The plates were sealed with a 
heat-resistant cover, centrifuged briefly and placed on the PerkinElmer 9700 
Thermalcycler. Thermalcycling conditions were as follows: 10 s at 96°C, 5 s at 
50°C, and 4 min at 60°C for a total of 25 cycles. 
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Dye removal was carried out to remove excess fluorescently labelled ddNTPs and 
salts from the sequencing reactions. Dye removal was performed by one of three 
methods. The first method utilised the Dye Terminator Removal kit (Thermo Fisher 
Scientific) as per the manufacturer’s instructions. Briefly, the Dye Terminator 
Removal plate was centrifuged at 2,150 revolutions per minute (rpm) for 3 min, and 
then placed over a fresh PCR plate. 10 μl of autoclaved dH2O was added to each 
sequencing reaction, and the diluted sequencing reaction was added to the Dye 
Terminator Removal plate. Both the Dye Terminator Removal plate and the PCR 
plate were centrifuged at 2,150 rpm for 3 min. The second method utilised the 
Multiscreen HTS filter plates (Merck-Millipore). The same protocol as for PCR 
product purification was followed, except that sequencing reactions were 
resuspended in 20 μl of autoclaved dH2O. The third method utilised the Sephadex
 
G-
50 BioReagent (Sigma). To prepare the Sephadex mix for each sequencing plate, 2.9 
g of Sephadex was diluted in 40 ml of autoclaved dH2O. The mix was left to hydrate 
for 30 min at room temperature. The purification plate was prepared by adding 350 
μl of Sephadex mix to each well of a Corning FiltrEX filter plate (Corning, USA). 
The filter plate was placed on an empty collection plate and centrifuged at 700 g for 
3 min. The filter plate was placed on a fresh sequencing plate and the entire volume 
of the sequencing reaction was pipetted onto the Sephadex purification column. The 
plate was centrifuged at 910 g for 5 min. Following dye removal, plates were 
resolved on a 3730XL capillary sequencer (Applied Biosystems). Sequences were 
aligned and analysed using the Sequencher v4.10 software (Gene Codes, USA). PCR 
and sequencing were repeated at least twice to reconfirm variants.  
2.1.13 HumanCytoSNP-12 v.2.1 BeadChip analysis 
The HumanCytoSNP-12 v.2.1 BeadChip (Illumina, USA) is a whole-genome 
scanning panel allowing detection of duplications and deletions with better resolution 
than comparative genomic hybridisation arrays. The BeadChip contains 220,000 
genome-wide tag single nucleotide polymorphisms (SNPs). In a BVVL patient with 
a homozygous SLC52A2 mutation, the BeadChip was used to exclude a large 
deletion on the other allele and to establish the likelihood of the mutation actually 
being homozygous by evaluating the frequency of homozygous genotypes in the 
surrounding genomic region. The BeadChip was run by Kerra Pearce at University 
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College London (UCL) Genomics as per the manufacturer’s instructions. The 
genotyping module within GenomeStudio
 
(v. 2010.1, Illumina) was used to visualise 
the array data. Each allele is labelled with a different fluorophore; the genotypes are 
assigned based on the intensities of the A and B alleles. The B allele frequency is the 
proportion of the hybridized sample which carries the B allele as opposed to the A 
allele, therefore the genotypes BB, BA and AA have B allele frequencies of 1, 0.5, 
and 0, respectively, where B allele is the less frequent allele. The plot of B allele 
frequencies can therefore be used to detect regions of homozygosity. The log R ratio 
is the log of the ratio of observed probe intensity to expected probe intensity, and 
reflects copy number changes when it deviates from zero; deletions are represented 
by a decrease in intensity (i.e. decrease in the log R ratio). The Illumina Genome 
Viewer was used to examine the plots of B allele frequencies and log R ratio at SNPs 
surrounding SLC52A2. 
2.1.14 Human Immuno BeadChip genotyping 
The genotyping on the Illumina Infinium HD Human Immuno BeadChip (Illumina) 
was performed entirely by Kerra Pearce using the Infinium HD Ultra Assay 
according to the manufacturer’s protocol (Rev B, 2010, Illumina) (details of standard 
protocol in Appendix II).  
2.1.15 Exome sequencing 
Briefly, exome capture involves randomly shearing gDNA into short fragments of a 
few hundred bp, ligating DNA to sequencing adapters, enriching for exons by 
hybridising the library to baits specific for the exome via immobilisation on a solid 
support, washing off non-targeted fragments, eluting selected fragments to create a 
library composed mainly of protein-coding regions, and PCR amplification of the 
library. Exome capture is followed by massively parallel sequencing of the library. 
Data processing involves alignment to a reference sequence, quality control, variant 
calling, and data filtering (Bamshad et al., 2011). In this PhD, the steps prior to data 
filtering were performed by several exome sequencing facilities, and I performed the 
data filtering. The commercial platforms for exome capture and sequencing used by 
each facility are specified in the appropriate Chapters. Details of the data processing 
are available in Appendix II. 
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2.1.16 Exome sequencing: gene coverage and read depth 
Some genes, exons or genomic areas with certain characteristics may not be covered 
by the hybridization probe design as the efficiency of capture probes varies greatly. 
Furthermore, read depth, which is defined as the number of independent reads at a 
particular base pair, is often quite variable from gene to gene and may not always be 
sufficient to ensure accuracy of data (Bamshad et al., 2011). Therefore, gene 
coverage and read depths of known disease-associated genes and candidates genes 
were determined by exploring BAM files using the GenomeBrowse software 
(Golden Helix, USA). A base was considered poorly covered if it had less than 15-
20X coverage. The values for overall mean target coverage and total number of reads 
were obtained from the data processing. The mean target coverage is defined as “the 
mean coverage of targets that received at least coverage depth=2 at one base” 
(http://picard.sourceforge.net). 
2.1.17 Exome sequencing: variant filtering 
All genes known to be involved in CMT/BVVL or related diseases were checked for 
variants, as were genes which were considered potential candidates. Variants were 
filtered so as to fit with the predicted inheritance pattern. All synonymous variants 
were removed as these do not alter the amino acid sequence and are less likely to be 
deleterious. Variants found in the general population were excluded (see Section 2.6 
for control databases used). The cut-off point of the minor allele frequency (MAF) 
was adapted to the predicted mode of inheritance, as will be described in the 
appropriate Chapters. Any remaining variants with a low quality score (below 20) 
were excluded. Any variant within a segmental duplication region with identity 
≥96% was removed; variants within these regions are fre uently false positive calls 
(Bamshad et al., 2011). The coverage depth of all variants of interest was also 
verified, as described in Section 2.1.16. In-silico predictions of pathogenicity and 
conservation between species were assessed for all variants of interest as described in 
Section 2.6. Details of gene expression in various tissues and location of the mutated 
amino acid within the protein were obtained as described in Section 2.6. The 
GEM.app (https://genomics.med.miami.edu), described in Section 2.6, was used for 
CMT exome data. 
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2.2 Cellular model: solute carrier family 52, riboflavin transporter member 2 
(SLC52A2) patient fibroblasts 
2.2.1 Ethics approval and consent  
This study has been granted ethical approval by the National Research Ethics Service 
Committee of the NHNN (UCLH REC number 99/N103). Written informed consent 
to perform a skin biopsy and obtain fibroblasts was obtained from all patients and/or 
parental guardians.  
2.2.2 Generation of human fibroblast cultures and details of control fibroblast 
lines 
The 6 mm punch skin biopsies were taken under local anaesthetic at the 
NHNN/Great Ormond Street Hospital (GOSH). Fibroblasts of BVVL patients with 
SLC52A2 mutations were generated at the Medical Research Council (MRC) Centre 
for Neuromuscular Diseases Biobank, Dubowitz Centre, UCL Institute of Child 
Health (ICH) by Dr Diana Johnson, or were sent to us in culture by our collaborators. 
Three age-matched controls were obtained from the ICH Biobank: control-1 (age at 
biopsy: 14 years; female); control-2 (age at biopsy: nine years; male); control-3 (age 
at biopsy: five years; male). A neuromuscular cause of disease was excluded for all 
control fibroblast lines. 
2.2.3 Cell culture 
Fibroblasts were grown at 37°C in 95% air and 5% CO2. Unless otherwise specified, 
cells were maintained in Dulbecco’s modified eagle medium (DMEM)-GlutaMAX 
(high glucose and pyruvate; Life Technologies) with 10% v/v foetal bovine serum 
(FBS; heat-inactivated, non-USA origin; Life Technologies) and 1% v/v 
Penicillin/Streptomycin (P/S; 5000 U/5000 μg per ml; Gibco, UK) in 75 cm2 tissue 
culture flasks. This fibroblast cell medium is referred to as “regular DMEM” 
throughout the Thesis. The medium was changed every four days. Cultures were 
passaged when cells reached 70-80% confluence. To split or freeze cells, the medium 
was removed from the flask. Cells were washed in 7 ml of 1X Dulbecco’s phosphate 
buffered saline (DPBS; Life Technologies). 1.5 ml of 0.05% 1X trypsin-EDTA (Life 
Technologies) was added and cells were placed back in the incubator at 37°C for 5 
min. The flask was swirled and tapped to detach the fibroblasts. 5 ml of medium was 
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added to the flask to quench the trypsin, and cells were collected and centrifuged at 
1,200 rpm for 5 min. The supernatant was discarded. To split cells, the cell pellet 
was resuspended in medium and split into new flasks as appropriate. To freeze cells, 
the cell pellet was resuspended in ½ final volume FBS and ½ final volume freezing 
medium (recipe in Appendix II) and placed in labelled cryovials (1 ml per cryovial; 
two cryovials per 80% confluent 75 cm
2
 flask). Cells were first frozen at -80°C for 
24 h in a tightly sealed Polystyrene box, and then were transferred to liquid nitrogen 
for long-term storage. Cells were defrosted quickly in a 37°C water bath and seeded 
at a density of 5 x 10
3
 cells/cm
2
 into 75 cm
2
 tissue culture flasks. To obtain 
reproducible results, only fibroblasts of passage number 2 to 12 were used in 
experiments. 
2.2.4 Cell counting 
To establish the number of fibroblast cells in 1 ml of cell suspension prior to cell 
seeding, a 10 μl sample of suspension was added to 10 μl of 0.4% trypan blue 
(Sigma). The solution was pipetted onto a haemocytometer and the number of live 
cells (colourless and bright) in 4 sets of 16 corner squares of the grid was counted 
under a light microscope. The total count was divided by four and multiplied by two 
to adjust for the 1:2 dilution in trypan blue. The resulting value x 10
4
 is equivalent to 
the number of cells per ml of suspension. 
2.2.5 Cell harvesting for biochemical analysis 
For the FMN/FAD assay, the measurement of activities of MRC complexes I and II 
and citrate synthase (CS), and for the Coenzyme Q10 (CoQ10) assay, fibroblasts were 
harvested from confluent 75 cm
2 
flasks. The medium was removed, and cells were 
washed once with DPBS and then detached with trypsin-EDTA as described in 
Section 2.2.3. Cell medium was added to the flask and cells were collected and 
centrifuged at 1,200 rpm for 5 min. The cell pellet was washed in DPBS. Cells were 
centrifuged again at 1200 rpm for 5 min. The cell pellet was resuspended in DPBS, 
aliquoted into Eppendorfs and stored at -80°C. For the FMN/FAD assay, the pellet 
was resuspended in 150 μl DPBS (25 μl for protein determination, 125 μl for the 
FMN/ FAD assay). For the MRC complex activities, the pellet was resuspended in 
160 μl DPBS (10 μl for protein determination, 60 μl for complex I, 60 μl for complex 
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II, and 30 μl for CS measurements). For the CoQ10 assay, the pellet was resuspended 
in 175 μl DPBS (25 μl for protein determination, 50 μl for CoQ10 assay). 
2.2.6 Cell harvesting for Western blot 
For Western blot analysis, fibroblasts were harvested from confluent 75 cm
2 
flasks. 
The medium was removed, and cells were washed once with DPBS and then 
detached with trypsin-EDTA as described in Section 2.2.3. Cell medium was added 
to the flask and cells were collected and centrifuged at 1,200 rpm for 5 min. The 
resulting cell pellet was washed in DPBS. Cells were centrifuged again at 1,200 rpm 
for 5 min. The cell pellet was resuspended in 50 µl of cold lysis buffer (recipe in 
Appendix II) and the sample was transferred to a new, cold Eppendorf and stored at -
80°C. 
2.2.7 Total protein determination 
For all biochemical and Western blot experiments, the Bio-Rad DC protein assay 
(Bio-Rad Laboratories, USA) was used to normalise for protein concentration. The 
assay was performed as per the manufacturer’s instructions with all samples and 
bovine serum albumin (BSA) standards plated in triplicate on a 96-well plate. 
Briefly, a 6-point standard line was prepared with BSA in DPBS from 0 to 1 mg/ml. 
All samples were diluted in DPBS as necessary for the sample concentrations to fall 
within the standard curve. 2 μl of each sample was added per well. 25 μl of “S+A” 
reagent mix (30 μl reagent “S” + 970 μl reagent “A”) and 200 μl of reagent “B” were 
then added to each well. The plate was incubated for 15 min in the dark at room 
temperature. The relative absorbance at an excitatory wavelength of 750 nm was 
obtained using a FLUOstar omega plate reader (BMG Labtech Ltd, Germany). The 
relative concentration of each sample was determined relative to the absorbance of 
the BSA standards. 
2.2.8 Optimisation of riboflavin concentration in cell medium 
As discussed in Sections 7.1.5 and 7.3.4, studies using fibroblasts of patients with 
riboflavin-responsive diseases have indicated that high concentrations of the vitamin 
in cell medium may mask metabolic defects in vitro. As many BVVL patients 
improve clinically and biochemically as a result of riboflavin therapy (Section 1.6.5), 
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and as DMEM typically contains supra-physiological concentrations of riboflavin 
(1.06 M), the minimum amount of riboflavin required in the medium which would 
support a healthy metabolism in controls (see Section 7.1.5 for effects of riboflavin 
deprivation in vitro) but expose any metabolic defects in the BVVL patient 
fibroblasts was determined. Custom-made DMEM without riboflavin was purchased 
from Merck-Millipore. As regular FBS contains high levels of riboflavin, it was 
replaced with dialysed FBS (heat-inactivated, non-USA origin; Life Technologies) 
which was determined to contain 6.6 nM riboflavin by high-performance liquid 
chromatography (HPLC) (Section 2.2.14) by Marcus Oppenheim in the 
Neurometabolic Unit, NHNN. FMN and FAD were below limits of detection. The 
remaining riboflavin in the dialysed FBS is likely bound to larger molecular weight 
proteins which escaped the process of dialysis. As dialysed FBS was used at 10% in 
the medium, it contributed 0.66 nM riboflavin. 1% P/S was added to the medium as 
before. (-)-Riboflavin in powder form (≥98%; Sigma) was diluted to 0.1 g/L in 
sterile H2O (riboflavin solubility: 1 g per 3-15 L H2O), sterile-filtered, and kept 
frozen in small light-protected aliquots. All tissue culture work involving added 
riboflavin was performed in the dark as riboflavin is sensitive to light (Depeint et al., 
2006; Rhead et al., 1993). 
MRC complex I and II activities (Sections 2.2.15-2.2.17) were used as a measure in 
controls to establish the lower threshold at which function became compromised. 
Riboflavin was added to the medium to obtain the following final concentrations 
(including the dialysed FBS): 0.85 nM (0.32 μg L; severely deficient), 3.1 nM (1.17 
μg L; moderately deficient or “low riboflavin”), 12.6 nM (4.7 μg L; physiologic), 
and 300.6 nM (113 μg L; pharmacological or “riboflavin-supplemented”). The 
concentration of riboflavin was reduced until complex I and II activities in controls 
were determined to be at the lower limit of normal (controls grown in riboflavin-
supplemented medium). These concentrations were chosen based on this logic: 300.6 
nM is the riboflavin concentration in plasma of riboflavin-supplemented adults; 12.6 
nM is the concentration in normal human plasma; 3.1 nM is the concentration in 
plasma of moderately deficient pregnant women; 0.85 nM is the concentration in 
plasma of severely deficient patients with cystic fibrosis or in pre-term infants treated 
with phototherapy (Camporeale & Zempleni, 2003). 
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For the first trial, control fibroblasts were first grown for four days in medium with 
physiological (12.6 nM) concentrations of riboflavin to adjust the cells to this 
medium (Camporeale & Zempleni, 2003). For the subsequent four days, one half of 
the cells was grown in severely deficient medium (0.85 nM) and the other in 
riboflavin-supplemented medium (300.6 nM) (see Appendix VII Table VII-1 for 
complex I and II activity data; n=1). MRC complex I and II activities were severely 
reduced in controls grown in 0.85 nM riboflavin. Complex I and II activities for the 
severely riboflavin-deficient (0.85 nM) control fibroblasts were on average 24% and 
38% of those grown in riboflavin-supplemented medium. In the second trial, control 
fibroblasts were again grown for four days in physiological concentrations, and were 
then grown for an additional four days in 3.1 nM, 12.6 nM or 300.6 nM riboflavin 
(see Appendix VII Table VII-2 for complex I and II activity data; n=1). Although 
complex activities had a mild tendency to decrease as riboflavin concentration was 
reduced from 300.6 nM to 3.1 nM, the reduction was much less drastic than that seen 
with 0.85 nM riboflavin. Therefore, the minimum amount of riboflavin required by 
control human fibroblasts (as determined by a single parameter, i.e. MRC complex I 
and II activities) when grown under these conditions lies between 0.85 nM and 3.1 
nM. The latter concentration was therefore trialled in BVVL patient fibroblasts. 
Unless otherwise specified, for all experiments, patient and control fibroblasts were 
grown for four days in medium containing physiological (12.6 nM) concentrations of 
riboflavin. After this time, cells were 60-70% confluent and cultures were split 1:2: 
half was transferred to riboflavin-supplemented (300.6 nM) medium, and the other 
was transferred to low riboflavin (3.1 nM) medium. Cells were cultured in these 
media for an additional four days before harvesting or using in experiments. 
Fibroblasts were not kept in the low riboflavin medium longer as a previous study 
had shown that culturing control fibroblasts in medium with <3.72 nM riboflavin for 
two weeks caused a reduction of more than 85% in the cellular FAD content (Rhead 
et al., 1993). Cells grown in low riboflavin medium were never exposed to medium 
containing higher concentrations of riboflavin throughout the tissue culture 
procedures. 
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Fibroblasts for RNA extraction and subsequent real-time reverse transcription 
polymerase chain reaction (RT-qPCR) analysis were grown in regular DMEM to 
minimize the potential confounding effect of riboflavin deprivation on SLC52A2 
transcript levels. Fibroblasts for immunocytochemistry were also cultured in regular 
DMEM. Fibroblasts for HPLC (FMN and FAD), spectrophotometry (complex I, 
complex II and CS activities), mitochondrial membrane potential (∆Ψm), reduced 
nicotinamide adenine dinucleotide (NADH) assay, lactate/pyruvate assay, and CoQ10 
assay were cultured in low riboflavin and riboflavin-supplemented medium as 
described above. All Western blot experiments were performed using physiological 
medium followed by low riboflavin medium only. 
2.2.9 Ribonucleic acid (RNA) extraction 
Prior to RNA extraction, fibroblasts were grown to confluence in 6-well plates. Total 
RNA was isolated from fibroblasts using the MiRNeasy Mini kit (Qiagen) following 
the manufacturer’s instructions. The RNase-Free DNase Set (Qiagen) was also used 
during the RNA extraction procedure to ensure complete DNA removal. RNA 
concentration and purity were assessed using the NanoDrop ND-1000 
spectrophotometer as per the manufacturer’s instructions (NanoDrop Technologies). 
A 260/280 absorbance ratio of approximately 2.0 is generally acceptable for RNA 
(Section 2.1.5). 
2.2.10 Complementary deoxyribonucleic acid (cDNA) synthesis 
Following RNA extraction, cDNA was synthesized from total RNA using the First-
Strand cDNA SuperScript II Reverse Transcriptase kit (Life Technologies) as per the 
manufacturer’s instructions (details in Appendix II). To assess the efficiency of 
cDNA synthesis and to test for DNA contamination, a PCR (60°C annealing 
temperature) and agarose gel electrophoresis were performed (Sections 2.1.9 and 
2.1.10) with cDNA primers and exon/intron boundary-spanning gDNA primers, 
respectively. A PCR reaction using SLC52A2 primers and subsequent agarose gel 
electrophoresis also served to confirm that SLC52A2 is expressed in human 
fibroblasts as seen by a strong, single band on the gel. 
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2.2.11 Real-time reverse transcription polymerase chain reaction (RT-qPCR) 
RT-qPCR was carried out using a Taqman probe-based gene expression assay 
(Applied Biosystems) to assess levels of SLC52A2 mRNA in the fibroblasts. In 
Taqman-based qPCR assays, a Taq DNA polymerase cleaves a labelled Taqman
 
probe during hybridization to the target complimentary sequence, and the resulting 
fluorescence signal allows for quantitative measurements of the PCR product 
accumulated during the exponential stage. The Taqman gene expression assay is a 
20X mix of forward primer, reverse primer, and a FAM or VIC dye-labelled probe. 
Taqman probes for SLC52A2 (Assay ID: Hs04194586_s1; FAM-labelled) and the 
housekeeping gene actin, beta (ACTB) (Reference sequence: NM_001101.2; VIC-
labelled) were purchased from Applied Biosystems. Each RT-qPCR reaction 
contained 1 μl of template cDNA diluted 1:10 v/v with nuclease-free H2O, 0.5 μl of 
20X Taqman SLC52A2 gene expression assay, 0.5 μl of 20X Taqman ACTB gene 
expression assay, 5 μl of 2X Rotor-Gene Multiplex PCR Master Mix (Qiagen) and 3 
μl nuclease-free H2O. A 6–point standard curve with serial fivefold dilutions of a 
cDNA sample from a control fibroblast line was constructed; the same control 
fibroblast line was used to construct the standard curve for all replicate experiments. 
Samples and standards were run in triplicates in a 100-well circular plate. A “no 
template” control was used to assess possible well-to-well contamination; a “no RT” 
control was used to control for DNA contamination in the RNA samples. Cycling 
conditions were as follows: 95°C for 5 min, followed by 45 cycles of 95°C for 15 s 
and 60°C for 15 s with fluorescence acquisition in the green and yellow channels 
(Figure 2-1). 
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Figure 2-1 Sample plot of amplification curves of an RT-qPCR experiment in 
fibroblasts. The black-coloured curves not reaching the threshold of detection 
represent the “no template” controls. 
As the amplification efficiencies of SLC52A2 and ACTB were not comparable, 
standard curves for both the target and housekeeping genes were constructed by 
plotting the Ct values (Section 2.1.6) (y-axis) against the log of template amount (x-
axis). The amount of target and reference in the samples were calculated using the Ct 
values and the corresponding standard curve. To calculate the normalised amount of 
target, the amount of target was divided by the amount of reference. The relative 
expression level of the target gene in the patient and carrier fibroblasts was 
determined by dividing the normalised target amounts by the average value of the 
calibrators (i.e. average of the normalised target amounts in the three control 
fibroblast lines). 
2.2.12 [3H]-Riboflavin uptake assay 
For the [
3
H]-Riboflavin uptake trial assays, control fibroblasts were seeded in 12-
well plates and cultured for four days in either riboflavin-supplemented (300.6 nM) 
or low riboflavin (3.1 nM) medium (Section 2.2.8). In another trial, control 
fibroblasts were grown in 12-well plates for 48 h; 24 h before the experiment, the 
medium was changed to either riboflavin-supplemented (300.6 nM) or medium with 
0.4 nM riboflavin. Fibroblasts reached 80-90% confluence and were used for 
experiments immediately following these time periods.  
The [
3
H]-Riboflavin uptake assay protocol was based on the method used by 
Ciccolella et al. (2013). The protocol and various modifications trialled are detailed 
in Appendix II. Overall, the disintegrations per minute (dpm) values (measure of the 
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intensity of the radioactivity) were not sufficiently higher than basal levels to allow 
for accurate determination of [
3
H]-Riboflavin uptake; the experiment could not be 
optimised. 
2.2.13 Immunocytochemistry 
To determine the subcellular localisation of endogenous RFVT2 in the fibroblasts, 2 
x 10
4 
fibroblast cells were seeded per well of a 24-well plate and grown overnight on 
13 mm glass round coverslips (VWR, USA) previously coated with Poly-D-lysine 
hydrobromide (0.025 mg/ml) (Sigma). Cells were washed in 1X phosphate buffered 
saline (PBS), fixed in 4% w/v paraformaldehyde (PFA) for 20 min, washed and 
permeabilised in PBS-0.05% Triton X-100 for 10 min. Cells were then washed three 
times with 1X PBS and blocked with 10% FBS in 1X PBS (Life Technologies) for 
1.5 h. Coverslips were incubated with 40 μl of primary antibody for 60 min, washed 
three times with 1X PBS, and incubated with secondary antibody for 60 min. 
Coverslips were washed three times with 1X PBS, mounted on microscope slides 
(VWR) with ProLong Gold Antifade reagent with 4’,6-diamidino-2-phenylindole 
(DAPI) (Life Technologies), and imaged using a Zeiss LSM 710 confocal 
microscope (Carl Zeiss AG, Germany) and 40X and 63X oil immersion objectives. 
For all experiments, a negative control (incubated overnight in blocking solution 
only, with no primary antibody) was included to assess the specificity of the 
secondary antibody. The primary antibody used was rabbit polyclonal anti-human 
SLC52A2 (1:200 and 1:500; Sigma). The secondary antibody used was Alexa Fluor 
488 Goat Anti-Rabbit IgG (1:2,000 in 10% FBS or 1% w/v BSA in PBS-Tween; Life 
Technologies). 
Despite extensive optimisation of the immunocytochemistry protocol (including 
modifications of antibody concentration/incubation time, blocking agent and 
blocking time, and number of PBS washes), the endogenous RFVT2 staining in both 
the control and patient fibroblasts showed very diffuse staining which was not 
specific for the plasma membrane. No conclusions could be drawn from the RFVT2 
localization experiments in the fibroblasts given the poor quality of the commercial 
antibodies. Yonezawa et al. (2008) had previously reported on the difficulty of 
producing an antibody against RFVT1 as it is a multi-membrane spanning protein 
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and its amino acid sequence is similar to that of a G protein-coupled receptor family 
member.  
2.2.14 Intracellular levels of FMN and FAD by high-performance liquid 
chromatography (HPLC) 
HPLC is a technique to separate and identify compounds in a sample by 
chromatography, and to quantify the amount of each compound in the mixture. As 
riboflavin is naturally fluorescent, fluorescent tags are not necessary. During reverse-
phase HPLC, a high-pressure pump generates a flow rate of polar mobile phase. The 
sample is introduced into the mobile phase by an injector and is driven through the 
HPLC column for compound separation. The column is made of hydrophobic, non-
polar silica-based chromatographic packing material (the stationary phase). A 
detector records the electrical signal as the compound passes through the detector 
flow cell, and generates a chromatogram (Figure 2-2). Each compound passing 
through the column has to “choose” between interacting with the mobile phase and 
the column. Hydrophilic, polar compounds move faster through the hydrophobic 
column, and generate a peak earlier on the chromatogram. In this case, the retention 
time, or time taken for a compound to travel through the column, is shorter. Reverse-
phase HPLC with fluorescence detection was used to determine the total intracellular 
FMN and FAD levels in the fibroblasts using the Whole Blood Chromsystems 
vitamins B1/B2 kit (Chromsystems, Germany) as per the manufacturer’s protocol. 
The levels of riboflavin were not reported as the levels frequently fell below the 
threshold of detection for cells grown in the low riboflavin medium (riboflavin 
threshold of detection: 5.31-664.25 nM). 
Cell aliquots for the FMN and FAD assay were obtained as described in Section 
2.2.5. Briefly, test samples were kept frozen and protected from light until needed. 
The calibration standard was reconstituted in 1 ml ultra-pure H2O, and two quality 
control samples were reconstituted in 2 ml ultra-pure H2O. Samples were thawed and 
50 μl of standard, two  uality controls samples, and all test samples were aliquoted 
into labelled, light-protected Eppendorf tubes. 50 μl of extraction buffer was added 
and tubes were incubated for 5 min at room temperature. 100 μl of cooled 
precipitation reagent was added to each tube. Tubes were mixed and incubated for 10 
min at 4°C. 100 μl of stabilisation buffer was added to each tube. Samples were 
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mixed and centrifuged at 14,000 rpm for 10 min. 100 μl of the supernatant was 
aliquoted into capped, labelled autosampler vials. The reverse-phase HPLC 
components included a Jasco AS-950 intelligent autosampler (SpectraLab Scientific, 
Canada), a Jasco PU-980 intelligent pump (SpectraLab Scientific), a Chromsystems 
HPLC column for vitamin B2 analysis (Chromsystems), and a Jasco FP-920 
intelligent fluorescence detector (SpectraLab Scientific). The autosampler was 
programmed to inject 50 μl of each sample onto the column, allowing a run time of 
14 min with five flushes between each injection. Riboflavin, FMN and FAD were 
detected using the fluorimetric detector (excitation 465 nm, emission 525 nm). Peak 
integration and data analysis on the HPLC were performed by Marcus Oppenheim. 
The height of the peak is proportional to the amount of a particular compound which 
has passed through the detector. Peaks were integrated and peaks of interest were 
identified and quantified using the Azur data capture system (Kromatek, UK) as per 
the manufacturer’s instructions. The concentration of each analyte expressed in 
nmol/L was calculated by relating the height of the peak in the chromatogram of the 
sample to the height of the peak in the chromatogram of the standard (Figure 2-2): 
 [analyte] = peak height in sample          x          [standard] nmol/L 
                   peak height in standard 
The concentration in nmol/L was converted to nmol/g using the protein 
concentration of the original sample (Section 2.2.7). All FMN and FAD levels were 
compared to the mean levels in controls separately for each experimental day and 
each medium condition (low versus high riboflavin).  
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Figure 2-2 Sample chromatogram of HPLC retention time (x-axis) and fluorescence 
(y-axis) for FAD, FMN and riboflavin resulting from chromatographic separation by 
the HPLC system and detection of the analyte by the detector flow cell, with each 
peak corresponding to a different compound. FAD moves at a speed closer to the 
mobile phase than to the stationary phase; it moves fastest through the 
chromatographic packing material particles and elutes first from the column, 
followed by FMN and lastly riboflavin, reflecting the relative polarity of these 
compounds (FAD>FMN>riboflavin). 
2.2.15 Mitochondrial respiratory chain (MRC) complex I assay 
NADH: ubiquinone oxidoreductase (complex I) activity was measured 
spectrophotometrically by measuring the decrease of UV absorbance at 340 nm 
associated with the oxidation of NADH by electron transfer to ubiquinone in the 
MRC. This assay was performed according to the method of Reed and Ragan (1987). 
Rotenone, a complex I inhibitor, was used to assess the level of complex I-
independent NADH oxidation. Prior to the assay, cell aliquots obtained as described 
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in Section 2.2.5 were thawed on ice, vortexed, and refrozen in liquid nitrogen three 
times before being thawed and used in the assay. This procedure helps to rupture the 
cell and mitochondrial membranes so the substrates in the assay may reach the active 
sites. 
20 μl of each sample (diluted 1:2 or 1:5 as necessary) was added to two 
microcuvettes (Sigma) in parallel containing at final concentration: 2.5 mg/ml BSA 
(≥96%; Sigma), 0.2 mM β-NADH disodium salt hydrate (≥97%; Sigma), 1 mM 
potassium cyanide (KCN) (VWR) in a 20 mM potassium phosphate (VWR) buffer 
with 8 mM magnesium chloride (VWR) (pH 7.2). The final volume in each cuvette 
was 1 ml. Samples were mixed by double inversion and loaded onto the Uvikon 941 
spectrophotometer (Northstar Scientific, UK). Duplicate cuvettes were placed into 
the reference or sample compartment. The reaction was primed by adding 10 μl of 5 
mM Coenzyme Q1 (CoQ1) (~95%; Sigma) into the sample cuvette and subsequent 
mixing. The reaction was monitored at an absorbance of 340 nm at 30 s intervals for 
6 min at 30˚C. 20 μl of 1 mM rotenone (≥95%; Sigma) was added to each sample 
cuvette and measurement was continued for an additional 5 min. Rotenone-
insensitive complex I activities (activities after addition of rotenone) were subtracted 
from total complex I activities thus providing a value for rotenone-sensitive complex 
I NADH oxidation. The Beer-Lambert law was used to convert absorbance to molar 
concentration: 
ΔA x l = c 
______ 
                          ε 
 
where ΔA is the specific change in absorbance, ε is the extinction coefficient (6.81 x 
10
3
 M
-1
 cm
-1
), l is the path length (1 cm) and c is the concentration in mole/min/ml. 
Results were expressed both as nmol/min/mg of protein (as determined in Section 
2.2.7) and as a ratio to activity of CS, a mitochondrial marker enzyme, to normalise 
for mitochondrial enrichment (Hargreaves et al., 1999) (see Section 2.2.17 for 
description of CS activity assay). All complex I activities were compared to the mean 
activity in controls for each experimental day and each medium condition (low 
versus high riboflavin) separately. 
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2.2.16 MRC complex II assay 
Succinate: ubiquinone oxidoreductase (complex II) activity was measured 
spectrophotometrically by measuring the decrease of UV absorbance at 600 nm 
associated with the secondary 2-thenoyltrifluoroacetone (TTFA)-sensitive reduction 
of the 2,6-dichlorophenol-indophenol (DCPIP; Sigma) dye by the ubiquinol formed 
during the oxidation of succinate in complex II. This assay was performed according 
to the method of Birch-Machin et al. (1994). Prior to the assay, cell aliquots obtained 
as described in Section 2.2.5 were thawed on ice, vortexed, and refrozen in liquid 
nitrogen three times before being thawed and used in the assay. 
20 μl of each sample (diluted 1:2 or 1:5 as necessary) was added to two 
microcuvettes (Sigma) in parallel containing at final concentration: 0.1 mM EDTA 
(VWR), 0.12 mM DCPIP, 20 mM succinate (Sigma), 1 mM KCN (Sigma), 0.01 mM 
rotenone (≥95%; Sigma), in a 50 mM potassium phosphate (VWR) buffer (pH 7.4). 1 
mM final concentration of TTFA (VWR) was added to the reference sample. The 
final volume in each cuvette was 1 ml. Samples were mixed by double inversion and 
loaded onto the Uvikon 941 spectrophotometer (Northstar Scientific). Duplicate 
cuvettes were placed into the reference or sample compartment. The reaction was 
initiated by the addition of 10 μl 5 mM CoQ1 (Sigma) into the sample cuvette and 
subsequent mixing. The reaction was monitored at an absorbance of 600 nm at 30 s 
intervals for 6 min at 30˚C. 20 μl 1 mM TTFA was added to each sample cuvette to 
block complex II activity and measurement was continued for an additional 7 min. 
Subtraction of the decrease before and after TTFA addition produced a specific value 
for complex II reduction of DCPIP. The Beer-Lambert law was used to convert 
absorbance to molar concentration as described in Section 2.2.15 (extinction 
coefficient=9.1 x 10
3
 M
-1
 cm
-1
). Results were expressed both as nmol/min/mg of 
protein (as determined in Section 2.2.7) and as a ratio to CS activity. All complex II 
activities were compared to the mean activity in controls for each experimental day 
and each medium condition (low versus high riboflavin) separately. 
2.2.17 Citrate synthase (CS) assay 
CS, an enzyme in the Krebs cycle, catalyses the condensation of oxaloacetate and 
acetyl-CoA to citric acid and Coenzyme A. CS activities provide an estimate of 
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mitochondrial content and were therefore used to normalise complex I and II 
activities for mitochondrial enrichment (Hargreaves et al., 1999). The CS activity is 
quantified by measuring the reaction of free Coenzyme A with 5,5’-dithio-bis(2-
nitrobenzoic acid) (DTNB; ≥98%; Sigma). This assay was performed according to 
the method of Shepherd and Garland (1969). Prior to the assay, cell aliquots obtained 
as described in Section 2.2.5 were thawed on ice, vortexed, and refrozen in liquid 
nitrogen three times before being thawed and used in the assay. 
10 μl of each sample (diluted 1:2 or 1:5 as necessary) was added to two 
microcuvettes (Sigma) in parallel containing at final concentration 0.1 mM acetyl-
CoA (≥ 93%; Sigma), 0.2 mM DNTB (Sigma) in 100 mM Tris (Sigma) and 0.1% v/v 
Triton X-100 (≥99.5%; Sigma) buffer (pH 8.0). The final volume in each cuvette was 
1 ml. Samples were mixed by double inversion and loaded onto the Uvikon 941 
spectrophotometer (Northstar Scientific). Duplicate cuvettes were placed into the 
reference or sample compartment. The reaction was initiated by the addition of 10 μl 
20 mM oxaloacetate (≥97%; Sigma) into the sample cuvette and subsequent mixing. 
The reaction was monitored at an absorbance of 412 nm at 30 s intervals for 6 min at 
30˚C. The Beer-Lambert law was used to convert absorbance to molar concentration 
as described in Section 2.2.15 (extinction coefficient=13.6 x 10
3
 M
-1
 cm
-1
). In 
addition to using CS activities to normalize for mitochondrial enrichment, results 
were also expressed as nmol/min/mg of protein (as determined in Section 2.2.7). 
After correcting CS activity for protein content, it was important to check that the CS 
activity per se was not affected by the SLC52A2 mutations as it was used as a marker 
enzyme in our assay. An increase or decrease in CS activity may indicate an increase 
or decrease in mitochondrial number; the former may suggest a compensation effect 
whereby the cell attempts to increase its energy-making capacity. CS activity was not 
affected by SLC52A2 status or by concentration of riboflavin in the culture medium. 
2.2.18 Confocal microscopy: mitochondrial membrane potential (∆Ψm) 
For live-cell confocal microscopy, fibroblasts needed to be alive and adherent to 25 
mm glass coverslips. Autoclaved coverslips were placed into 6-well plates and 
sterilized under the UV light for 60 min. After growing the fibroblasts for four days 
in physiological concentrations of riboflavin (Section 2.2.8), fibroblasts were seeded 
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into 6-well plates containing low riboflavin or riboflavin-supplemented medium and 
were cultured for another four days at which point they reached 70-80% confluence. 
The experiment was performed immediately following this time period.  
The ∆Ψm, the difference in electrochemical potential between the cytoplasm and the 
matrix generated by the MRC during cellular respiration, is the driving force for ATP 
synthesis and is a key function of mitochondria. Thus, the ΔΨm is an indicator of 
mitochondrial health and cellular metabolism (Brand & Nicholls, 2011; Cecchini, 
2003). The tetramethylrhodamine methyl ester (TMRM) dye used in this experiment 
is a membrane-permeable cationic dye with a single delocalized positive charge, 
which is sequestered in the mitochondria due to the electrochemical potential 
gradient between the mitochondria and the cytosol; the resulting fluorescence 
intensity is representative of the ΔΨm. The dye is released into the cytosol upon 
depolarization of the mitochondria, leading to a decrease in signal intensity in the 
mitochondria, and an increase in signal in the cytosol (Brand & Nicholls, 2011; 
Burchell et al., 2010; Duchen, 2004).  
The cell medium was removed and cells were loaded with 25 nM TMRM (Life 
Technologies) in 500 μl 1X Hank’s balanced salt solution (HBSS) (with Ca2+ and 
Mg
2+
, without phenol red; Gibco) or glucose-free HBSS where glucose is replaced 
with 2-deoxy-D-glucose (recipe in Appendix II) to block glycolysis and increase 
dependence on oxidative phosphorylation for energy production, as described in 
Section 7.8.4. Cells were incubated in the dark at room temperature for 40 min-1 h 
for the cells to reach equilibrium. The dye was present in the chamber throughout the 
experiment for use in redistribution mode (Abramov et al., 2010). 
Images were obtained using a Zeiss LSM 710 confocal microscope (Carl Zeiss AG), 
40X oil immersion objective, and fixed laser power and detector sensitivity (Figure 
2-3). TMRM was excited using the 560 nm laser line and the emission fluorescence 
was measured above 580 nm. The pinhole was set to 1 airy unit for optimal 
resolution and laser intensity was kept as low as possible to minimize phototoxicity. 
For the basal ΔΨm measurements, three to four “z-stack” scans were obtained per 
coverslip.  
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Figure 2-3 Fibroblasts incubated with 25 nM TMRM. 
For assessing the response of the ΔΨm to the mitochondrial toxins oligomycin, 
rotenone, and carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone (FCCP) 
(described in Chapter 7 and in Gandhi et al., 2009), images were obtained at 10 s 
intervals from a single focal plane. After measuring baseline TMRM intensity for 2-3 
min, oligomycin from Streptomyces diastatochromogenes (2 g/ml; Sigma) was 
added to the chamber and fluorescence measured for another 4-5 min (until a plateau 
was reached), following which rotenone (10 M; Sigma) was added. After 4-5 min, 
1 M FCCP (≥98%; Sigma) was added and recordings were stopped after 2-3 min 
when the mitochondria had fully depolarised. One such time-series experiment was 
performed per coverslip. 
Basal ΔΨm measurements were analysed using the Volocity image analysis software 
(PerkinElmer). To control for mitochondrial mass, TMRM fluorescence intensity 
from background signals (below a defined threshold) was removed for the analysis, 
and the mean TMRM fluorescence intensity across the pixels containing 
mitochondria was measured. All measurements were compared to the mean intensity 
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in controls for each experimental day and each medium condition (low versus high 
riboflavin) separately. 
Time-series data were analysed using the Zeiss Zen software (Carl Zeiss AG). A 
total of 10-20 areas were selected for analysis and the average dye intensity across 
these areas was plotted on the y-axis against time on the x-axis. The change in 
TMRM intensity after addition of each toxin was expressed as a percentage of basal 
intensity (basal=baseline Δψm - Δψm after FCCP). Because mitochondrial 
movement may affect measurement accuracy, it was sometimes necessary to express 
the dye intensity in the mitochondria as a ratio of that in the cytosol to establish the 
extent of dye redistribution (Figure 2-4). The top graph in Figure 2-4 shows that in 
this instance, measuring the change in dye intensity in the mitochondria alone does 
not adequately reflect the extent of depolarization following oligomycin addition. 
This depolarization is more accurately represented when the increase in dye intensity 
within the cytosol is accounted for (bottom graph).  
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Figure 2-4 TMRM time-series experiment requiring the dye intensity in the 
mitochondria to be expressed as a ratio of the intensity in the cytosol. 
2.2.19 Charge-coupled device (CCD) camera: reduced nicotinamide adenine 
dinucleotide (NADH) 
For the NADH assay, fibroblasts needed to be alive and adherent to 25 mm glass 
coverslips in 6-well plates. Coverslips were sterilised as described in Section 2.2.18. 
Fibroblasts were cultured for four days in physiological concentrations of riboflavin 
(Section 2.2.8), seeded into 6-well plates containing low riboflavin or riboflavin-
supplemented medium, and cultured for an additional four days at the end of which 
they reached 70-80% confluence. The experiment was performed immediately 
following this time period.  
The cell medium was removed and cells were washed once in HBSS (with Ca
2+
 and 
Mg
2+
, without phenol red; Life Technologies) at room temperature. The coverslip 
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was placed in a chamber with 500 μl of HBSS. NADH is intrinsically 
autofluorescent therefore no indicators need to be artificially introduced to measure 
NADH levels. The oxidised nicotinamide adenine dinucleotide (NAD
+
) is not 
fluorescent (Duchen, 2004). The resting level of NADH autofluorescence was 
measured in fibroblasts using an epifluorescence inverted microscope with a X20 
fluorite objective as described in Bartolome et al. (2013). Excitation light at 350 nm 
from a Xenon arc lamp passed through a monochromator (Cairn Research, UK). 
Emitted fluorescence light passed through a 455 nm long-pass filter to a cooled 
charge-coupled device (CCD) camera (Retiga, QImaging, Canada). Illumination 
intensity was minimised to prevent phototoxicity. The pinhole was set to produce a 
~2 μm optical slice. The NADH redox index was determined by calibration of the 
NADH fluorescence signal with the mitochondrial inhibitors sodium cyanide 
(NaCN) and FCCP. After acquiring the basal NADH autofluorescence for 2 min, 2 
µM final concentration of FCCP (Sigma) was added, and 3-4 min later, 2 mM final 
concentration of NaCN (Sigma) was added to the chamber.  
The Andor IQ software (Andor, UK) was used to collect and analyse imaging data. 
For data analysis, 30-50 regions were selected within the field (one per coverslip). 
The average autofluorescence intensity across these areas was plotted on the y-axis 
against time on the x-axis. The redox index was calculated by expressing the basal 
NADH levels as a percentage of the range, i.e. the difference between the maximally 
oxidised (response to the uncoupler FCCP, which maximises respiration (0% 
NADH)) and maximally reduced signals (response to NaCN, a complex IV inhibitor 
which fully inhibits respiration (100% NADH)) (Duchen, 2004; Gandhi et al., 2009). 
The NADH pool was calculated by subtracting the NADH autofluorescence after 
addition of FCCP from the fluorescence after addition of NaCN. All measurements 
were compared to the mean intensity in controls for each experimental day and each 
medium condition (low versus high riboflavin) separately. 
2.2.20 Lactate/pyruvate ratio 
For the lactate/pyruvate ratio assessment, cells were grown to confluence in 75 cm
2 
flasks. The flasks were gently shaken and a 400 μl ali uot of the medium was 
collected. The cell medium was mixed with 400 μl of 0.8 M perchloric acid (VWR) 
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and immediately stored at -80°C. Perchloric acid is used to stabilise pyruvate. The 
pyruvate concentration was determined according to the method described by 
Harrison et al. (1988) by monitoring the decrease in NADH fluorometrically in the 
presence of excess lactate dehydrogenase. The lactate concentration was assessed as 
described by Gutman & Wahlefeld (1974) by monitoring the increase in NADH 
fluorometrically in the presence of excess lactate dehydrogenase at pH 9. The 
background level of lactate and pyruvate in fresh, unused medium was subtracted 
from the concentration of lactate and pyruvate in the samples. This assay was 
performed by the Neurometabolic Unit at the NHNN. All lactate/pyruvate ratios 
were compared to the ratios in controls for each experimental day and each medium 
condition (low versus high riboflavin) separately. 
2.2.21 Coenzyme Q10 (CoQ10) status 
Cell lysates for the CoQ10 assays were prepared as described in Section 2.2.5. CoQ10 
status was assessed by both reversed-phase HPLC with UV detection and tandem 
mass spectrometry. Briefly, after addition of an internal standard (IS) to samples, 
samples were freeze-thawed three times and CoQ10 was extracted using a 5:2 v/v 
hexane/ethanol solution. Samples were centrifuged at 15,000 rpm for 3 min at room 
temperature, and the top layer (hexane) was collected and stored on ice. The bottom 
layer was re-extracted two more times. Samples were evaporated using a rotary 
evaporator, resuspended in 300 µl ethanol and filtered.  
The HPLC method was based on that described by Boitier et al. (1998) and was 
carried out using the following equipment: PU-980 intelligent pump (SpectraLab 
Scientific), AS-950 intelligent autosampler (SpectraLab Scientific), Techsphere ODS 
5 µm 150 x 4.6 mm column, TSPChromojet SP4400 series integrator, and PG-975-
50 UV/VIS detector (SpectraLab Scientific). 50 µl of sample was injected and the 
absorbance of CoQ10 was measured at 275 nm. The CoQ10 concentration in pmol/ml 
was quantified by relating the sample peak height to the IS peak height, and was 
divided by the protein concentration (Section 2.2.7) to obtain the concentration in 
pmol/mg. CoQ10 quantification by tandem mass spectrometry was carried out as 
described in Duberley et al. (2013). This work was entirely carried out by Dr Kate 
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Duberley at the Institute of Neurology (ION), although I assisted with the extraction 
of CoQ10. 
2.2.22 Western blot 
Cell lysates for Western blot prepared as described in Section 2.2.6 were thawed on 
ice and centrifuged at 4°C at 13.2 rpm for 10 min. The supernatant was transferred to 
a cold Eppendorf on ice. The protein concentration of the supernatant was assayed as 
described in Section 2.2.7. Samples were prepared using 25 μl 4X sodium dodecyl 
sulphate (SDS) buffer (Life Technologies), 1 μl 1 M dithiothreitol (DTT) (Sigma), 
sample at 2 mg/ml, made up to 100 μl with lysis buffer (recipe in Appendix II). 
Samples were mixed, heated at 70°C for 10 min, and spun down briefly. 40 μg of 
each sample was loaded per well along with one well containing 3 μl pre-stained 
protein standard molecular weight marker (Life Technologies). Samples were 
electrophoresed on a NuPAGE Novex 4-12% Bis-Tris Gel (Life Technologies) in 
SDS running buffer (recipe in Appendix II) at 180 V for 1 h or until the samples had 
run to the bottom of the gel. Proteins were transferred to an Amersham Hybond 
electrochemiluminescence (ECL) nitrocellulose membrane (GE Healthcare, UK) in a 
cassette containing sponge and blotting paper at 35 V for 2 h in Tris transfer buffer 
(recipe in Appendix II). The membranes were removed and soaked in Ponceau 
solution (Sigma) for 2 min to confirm the protein transfer. The membranes were 
washed in PBS-Tween and blocked in 5% milk in PBS-Tween or in 5% w/v BSA in 
PBS-Tween for 1 h at room temperature with gentle agitation. Membranes were 
washed once with PBS-Tween, and incubated in primary antibody overnight at 4°C. 
The following morning, membranes were washed three times with PBS-Tween and 
incubated with secondary antibody for 1 h. Membranes were washed three times 
with PBS-Tween. The primary antibodies used were horseradish peroxidase (HRP)-
conjugated rabbit polyclonal anti-glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) (1:1,000 in 1% BSA; Abcam, UK), mouse monoclonal anti-ATP-synthase 
β subunit (ATP5β) (1:1,000; Abcam), and mouse monoclonal anti-β-Actin (1:10,000; 
Sigma). The secondary antibodies used were goat anti-mouse IgG-HRP (1:5,000; 
Santa Cruz Biotechnology, USA) and goat anti-rabbit IgG-HRP (1:5,000; Santa Cruz 
Biotechnology). Primary and secondary antibodies were diluted in 1% milk in PBS-
Tween unless stated otherwise. β-Actin was used as the loading control. Antibody 
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binding was detected in a dark room on Super Rx X-ray film (Fujifilm, Japan) in an 
Amersham autoradiography cassette (GE Healthcare) using an ECL kit with each 
ECL reagent at a 1:1 ratio (Thermo Fisher Scientific). 
Optimisation of the Western blot protocol for measurement of expression levels of 
endogenous RFVT2 is found in Appendix II. This experiment could not be 
successfully optimised due to the poor quality of the commercially available 
antibodies. 
2.3 Cellular model: SLC52A2-short hairpin ribonucleic acid (shRNA) 
knockdown (KD) SH-SY5Y neuroblastoma cells 
2.3.1 Cell line 
Human neuroblastoma (SH-SY5Y) cells were kindly provided by Dr Kate Duberley; 
these cells were originally acquired from the European Collection of Cell Cultures 
(Health Protection Agency, Salisbury, UK). The SK-N-SH cell line had initially been 
grown from a bone-marrow biopsy of a female patient with a chest neuroblastoma 
(Biedler et al., 1973). The neuroblast-like cells from this biopsy were sub-cloned 
three times as SH-SY, SHSY5 and SH-SY5Y (Biedler et al., 1978). The SK-N-SH 
cell line had been determined to have dopaminergic, acetylcholinergic and 
adenosinergic neurotransmitter activity (Biedler et al., 1978). 
2.3.2 Cell culture 
SH-SY5Y cells were grown at 37°C in 95% air and 5% CO2. Unless otherwise 
specified, cells were maintained in DMEM (high glucose and pyruvate; Life 
Technologies) with 10% v/v FBS (heat-inactivated, non-USA origin; Life 
Technologies) and 1% v/v P/S (5,000 U/5,000 μg per ml; Gibco) in 75 cm2 tissue 
culture flasks. The medium was changed every four days. Cultures were passaged 
when cells reached 70-80% confluence. To split or freeze cells, the medium was 
removed from the flask. Cells were washed in 7 ml of 1X DPBS (Life Technologies). 
1.5 ml of 0.25% 1X trypsin-EDTA (Life Technologies) was added and cells were 
placed back in the incubator at 37°C for 3 min. The flask was swirled and tapped to 
detach the cells. 5 ml of medium was added to the flask to quench the trypsin, and 
cells were collected and centrifuged at 1,200 rpm for 5 min. The supernatant was 
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discarded. To split cells, the cell pellet was resuspended in medium and split into 
new flasks as appropriate. To freeze cells, the cell pellet was resuspended in 40% 
FBS, 10% dimethyl sulfoxide (DMSO) (Sigma) and 50% cell medium and placed in 
labelled cryovials (1 ml per cryovial) at a density of 1 x 10
6
 cells/ml. Cells were first 
frozen at -80°C for 24 h in a tightly sealed Polystyrene box, and then transferred to 
liquid nitrogen for long-term storage. Cells were defrosted quickly in a 37°C water 
bath and seeded at a density of 4 x 10
4
 cells/cm
2
 into 75 cm
2
 tissue culture flasks. To 
obtain reproducible results, only SH-SY5Y cells of passage number 19-25 were used 
in experiments. 
2.3.3 Cell counting 
Cell counting was performed as described in Section 2.2.4. 
2.3.4 pGIPZ lentiviral SLC52A2 shRNAmir vectors: description 
Two human pGIPZ lentiviral microRNA-adapted short hairpin ribonucleic acid 
(shRNAmir) vectors containing hairpin sequences uniquely targeting SLC52A2 
(SLC52A2-short hairpin ribonucleic acid (shRNA) 1 and SLC52A2-shRNA2) were 
purchased as bacterial agar stab cultures from Open Biosystems (Thermo Fisher 
Scientific) (see Appendix VII Table VII-3 for clone IDs and hairpin sequences). The 
pGIPZ lentiviral shRNAmir empty vector (no shRNAmir insert) and non-targeting 
(non-silencing) shRNAmir vector (referred to as scrambled shRNA herein) were 
used as controls and were kindly provided by Dr Klaus Wanisch at the ION. The 
pGIPZ lentiviral vector contains a microRNA-adapted shRNA insert for RNA 
interference via Drosha and Dicer processing of the expressed hairpin. Some other 
features of the pGIPZ lentiviral vector include a CMV promoter, Turbo-green 
fluorescent protein (GFP) reporter, and ampicillin and puromycin antibiotic 
resistance markers. The 5’ LTR is a hybrid promoter re uired for high expression of 
viral transcripts in the target cells. The pUC origin is required for high-copy 
replication in Escherichia coli cells (Figure 2-5). 
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Figure 2-5 Map of the pGIPZ lentiviral shRNAmir vector (reproduced from Thermo 
Fisher Scientific website). 
2.3.5 Transformation of chemically competent cells 
Bacteria from the surface of the agar stab cultures corresponding to each of two 
SLC52A2 pGIPZ shRNAmir vectors (SLC52A2-shRNA1 and SLC52A2-shRNA2) 
were streaked on pre-warmed Luria-Bertani (LB) agar plates (recipe in Appendix II) 
containing 50 μg ml ampicillin and incubated upside down overnight at 37°C. The 
following day, single colonies were picked aseptically and inoculated into a tube 
containing 2 ml of LB broth (recipe in Appendix II) with 50 μg ml ampicillin. These 
starter cultures were grown for 7 h on a shaking (225 rpm) incubator at 37°C. 300 μl 
of starter culture was aseptically added to a 500 ml flask containing 150 ml of LB 
broth  (1:500 dilution) with 50 μg ml ampicillin and grown overnight at 37°C in a 
shaking (225 rpm) incubator. Glycerol stocks of all clones were prepared by mixing 
500 μl of the overnight culture with 500 μl glycerol at 50% v v and freezing at -
80°C. Overnight cultures were harvested by centrifugation at 4°C at 3,000 rpm for 20 
min; the pellet was frozen at -80°C. 
2.3.6 Maxiprep isolation of plasmid DNA and quality control 
To obtain high-quality plasmid DNA for mammalian cell transfection, plasmid DNA 
for human pGIPZ lentiviral shRNAmir clones with empty control, scrambled control, 
and SLC52A2-targeting (SLC52A2-shRNA1 and SLC52A2-shRNA2) hairpin 
sequences was purified from the cell pellets obtained from overnight bacterial 
cultures (Section 2.3.5) using the Qiafilter Maxiprep kit (Qiagen) as per the 
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manufacturer’s instructions. Plasmid DNA purity and concentration were determined 
as described in Section 2.1.5. 
All pGIPZ vectors were sequenced by the UCL DNA sequencing service to confirm 
that the hairpin sequences were correct (see Appendix VII Table VII-4 for sequence 
of pGIPZ vector sequencing primer). A restriction digest was performed on all 
clones to ensure no recombination had occurred. The digest reaction contained: 2 μl 
10X restriction enzyme buffer 4 (New England Biolabs (NEB), USA), 0.5 μl 
restriction enzyme SacII (20 U; NEB), 300 ng plasmid DNA, made up to 20 μl final 
volume with dH2O. The reaction was mixed and incubated at 37°C for 2 h. 10 μl of 
the digested samples were loaded with 2 μl 5X loading dye (Qiagen) onto a 1% w v 
agarose gel with 1 Kb DNA ladder (NEB). Uncut samples were run alongside the 
digested samples for comparison. Three bands of the expected size were obtained, 
confirming that no recombination had occurred. 
2.3.7 Stable transfection 
The night before transfection, cells were plated at approximately 50% confluence in 
6-well plates and incubated under normal conditions. The following morning, SH-
SY5Y cells were transfected with empty control, scrambled control, and SLC52A2-
shRNA using the Effectene transfection reagent following the manufacturer’s 
protocol with minor modifications (Qiagen). A control well of untransfected cells 
was also prepared. For each well, 2 μg of DNA was diluted with 100 μl DNA-
condensation buffer in an Eppendorf tube, followed by gentle mixing. DNA for the 
two SLC52A2-shRNAs were either pooled or transfected as individual shRNAs. 3.2 
μl of enhancer was added and the tube was mixed briefly. 10 μl of Effectene 
transfection reagent was added to the DNA-enhancer mixture, followed by brief 
mixing. Tubes were incubated for 20 min at room temperature. In the meantime, the 
growth medium was replaced with fresh medium. The entire content of each tube 
was added drop-wise to the appropriate well, following by gentle swirling. Cells 
were placed back into the incubator. The day after transfection, transfection 
efficiency was assessed microscopically by visualising Turbo-GFP expression. For 
stable knockdown (KD) of SLC52A2, the polyclonal SH-SY5Y cells were 
maintained in selective medium containing 2 g/ml puromycin dihydrochloride from 
 94 
Streptomyces alboniger (Sigma) from 48 h after transfection to eliminate cells not 
expressing Turbo-GFP. The well of non-transfected cells was also treated with 
puromycin; when all cells in this well were dead, it could be presumed that the cells 
which did not take up the vector in the transfected wells would also be dead. The 
puromycin concentration was reduced to 1 g/ml after two weeks. 
2.3.8 RNA extraction 
Prior to RNA extraction, SH-SY5Y cells were grown to confluence in 6-well plates. 
To assess KD efficiency of SLC52A2-shRNA, total RNA was extracted from purely 
transfected cells using the MiRNeasy Mini kit (Qiagen) and the RNase-free DNase 
set (Qiagen) as described in Section 2.2.9.  
2.3.9 cDNA synthesis 
Following RNA extraction, cDNA was synthesized from total RNA using the First-
Strand cDNA SuperScript II Reverse Transcriptase kit (Life Technologies) as 
described in Section 2.2.10. The efficiency of cDNA synthesis and the possibility of 
DNA contamination were assessed as described in Section 2.2.10. A PCR reaction 
using SLC52A2 primers and subsequent agarose gel electrophoresis also served to 
confirm that SLC52A2 is expressed in SH-SY5Y cells as evidenced by a strong, 
single band on the gel. 
2.3.10 RT-qPCR 
To assess KD efficiency of the SLC52A2 shRNAs in the SH-SY5Y cells, RT-qPCR 
was performed as described in Section 2.2.11 with minor modifications. The 
standard curve was constructed using a cDNA sample corresponding to the 
scrambled shRNA. For relative quantification, the scrambled shRNA was used as the 
calibrator. 
2.3.11 Optimisation of riboflavin concentration in SH-SY5Y cell medium 
As was done for the fibroblast medium, the riboflavin concentration in the SH-SY5Y 
cell medium was optimised, as an effect of high riboflavin levels in the medium on 
the parameters of interest could not be discarded. It is expected that the threshold of 
riboflavin concentration for demonstrating biochemical defects would vary between 
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cell lines (S. Olpin, personal communication). Complex I and II activities (see 
Sections 2.3.12-2.3.16 for methods) were again used as a measure of cell health for 
medium optimisation in the empty control, scrambled control, and SLC52A2-KD 
shRNA (clones 1, 2 and 1+2 combined) SH-SY5Y cells. Five independent 
optimisation trials were carried out using a total of seven different concentrations of 
riboflavin ranging from 0.66 nM to 300.6 nM, leaving cells to grow in the medium 
from one to eight days, and using either dialysed or regular FBS. Unfortunately, no 
condition revealed a specific defect in SLC52A2-KD shRNA cells compared to 
empty and scrambled control shRNA cells. Details and results of all optimisation 
trials are available in Appendix VII Table VII-5 and in Section 7.9. 
2.3.12 Cell harvesting for biochemical analysis 
For the MRC complex I and II activities assay, SH-SY5Y cells were grown in 
variable concentrations of riboflavin for varying lengths of time (see Appendix VII 
Table VII-5), and were harvested from confluent 75 cm
2 
flasks. The medium was 
removed, and cells were washed once with DPBS and then detached with trypsin-
EDTA as described in Section 2.3.2. Cell medium was added to the flask and cells 
were collected and centrifuged at 1,200 rpm for 5 min. The cell pellet was washed in 
DPBS. Cells were centrifuged again at 1,200 rpm for 5 min. The pellet was 
resuspended in 160 μl DPBS in ali uots (10 μl for protein determination, 60 μl for 
complex I, 60 μl for complex II, and 30 μl for CS measurements). Samples were 
stored at -80°C. 
2.3.13 Total protein determination 
The total protein content of the SH-SY5Y cell lysates was determined using the Bio-
Rad DC protein assay (Bio-Rad Laboratories) as described in Section 2.2.7.  
2.3.14 MRC complex I assay 
The MRC complex I assay was performed as described in Section 2.2.15. 
2.3.15 MRC complex II assay 
The MRC complex II assay was performed as described in Section 2.2.16. 
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2.3.16 CS assay 
The CS assay was performed as described in Section 2.2.17. 
2.4 Cellular model: embryonic mouse mixed ventral horn cultures 
2.4.1 Ethics approval  
BL6/SJL hybrid wild-type (WT) female mice (Harlan Laboratories, UK) were 
examined in the experiments performed in this Thesis. All procedures and 
experiments using mice were performed under License from the UK Home Office in 
accordance with the Animals (Scientific Procedures) Act of 1986 and following 
ethical approval from the Ethical Review Panel of the ION. All work involving mice 
prior to culturing was performed entirely by Dr Bernadett Kalmar at the ION. 
2.4.2 Cell culture of mixed ventral horn cultures 
6-well plates, 12-well plates, 35 mm glass-bottomed microscope MatTek dishes 
(MatTek Corporation, USA), or previously autoclaved 13 mm round glass coverslips 
in 24-well plates (Beckton Dickinson, USA) were coated with 1.5 mg/ml 
polyornithine (Sigma) diluted 1:1,000 in sterile H2O (Baxter Healthcare, USA) and 
left overnight at 37°C. In the morning, the polyornithine was aspirated and dishes 
were coated with 1 mg/ml laminin (Sigma) at 1:200 in L-15 medium (Sigma) for 2 h 
at 37°C. Laminin was removed prior to cell seeding.  
Following euthanisation by cervical dissection, day 12-13 (E12-E13) embryos were 
harvested from pregnant WT female mice by hysterectomy and placed in a petri dish 
with chilled HBSS (Ca
2+
, Mg
2+
 free, without phenol red; Sigma) with 2% v/v P/S 
(Gibco). Single embryos were placed in a 2 cm petri dish with HBSS and 2% P/S 
under a dissecting light microscope and the yolk sack was removed. The ventral horn 
of the spinal cord was dissected and mixed ventral horn cultures were prepared as 
described in Camu & Henderson (1994). Using this technique, on average 30-50% of 
mixed ventral horn cultures are primary motor neurones, the remaining cells being 
fibroblasts and astroglia. Purifying cultures to increase the proportion of motor 
neurones results in decreased viability as glia and fibroblasts promote motor neurone 
survival.  
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First, the head, liver, intestines and stomach of the embryos were removed and the 
embryo was laid down flat with the spinal cord on top. The skin covering the neural 
tube was carefully removed using forceps and the spinal cord was teased away from 
the body. The meninges were peeled off and the dorsal column removed with a 
scalpel. Ventral columns were placed in fresh chilled HBSS with 2% P/S for 
subsequent dissociation and seeding. 
At most four dissected spinal cords were pooled (all WT genotype) and placed in 1 
ml HBSS (Ca
2+
, Mg
2+
 free; Sigma) with 10 μl of 2.5% w v trypsin in PBS (final 
concentration 0.025%; Sigma) at 37°C for 9 min. The resultant clump of tissue was 
transferred to a tube containing 800 μl L-15 medium, 100 μl BSA (4% w v in L-15; 
Sigma) and 100 μl DNAse (1 mg/ml in L-15) and gently triturated twice with a 1 ml 
pipette. After allowing the cord to settle, the supernatant (containing the motor 
neurones) was transferred to a new 15 ml tube. 900 μl L-15, 100 μl BSA and 20 μl 
DNAse were added to the remaining pellet and the solution was gently triturated six 
times. After allowing the solution to settle again, the supernatant was collected and 
pooled with the first supernatant. 1 ml of BSA was layered at the bottom of the tube 
containing the supernatants, and the tube was centrifuged at 380 g for 5 min at room 
temperature. The supernatant was discarded and the pellet was resuspended in 1 ml 
complete Neurobasal (CNB) medium (see Appendix II for recipe). Cells were 
counted as described in Section 2.2.4 and plated at the appropriate density depending 
on the experiment. For biochemical measurements (complex I, complex II and CS 
activities), cells were plated on 6-well plates at a density of 2-2.5 x 10
5
 cells per well. 
For RNA extraction, cells were plated on 12-well plates at a density of 1.5 x 10
5
 cells 
per well. For confocal microscopy experiments, 1 x 10
5
 cells were plated per 
MatTek. For determination of viral titre by immunocytochemistry, cells were seeded 
in 24-well plates at a density of 2.5-5 x 10
4
 cells per well on glass coverslips. Cells 
were maintained in a 37°C incubator with 5% CO2 and were examined daily. This 
work was performed with the help of Dr Bernadett Kalmar. 
For riboflavin deprivation experiments in the mixed ventral horn cultures, the 
concentration of riboflavin in the CNB medium was first determined. The horse 
serum (non-USA origin; Life Technologies) contained 49 nM (18.4 μg L) riboflavin 
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as determined by HPLC performed by Marcus Oppenheim; therefore the serum 
contributes 0.98 nM (0.369 μg L) riboflavin to the medium as it represents 2% of the 
CNB medium. The 1X Neurobasal medium (Life Technologies) contains 1,060 nM 
(400 μg/L) riboflavin (according to the Life Technologies specifications) and 
contributes approximately 1,004 nM (378.9 μg L) riboflavin to the CNB medium. 
All other components of the CNB medium are riboflavin-free (according to company 
specifications) therefore the total concentration of riboflavin in prepared CNB 
medium (termed “regular CNB medium”) is approximately 1,005 nM (379.3 μg L). 
To prepare the medium for riboflavin deprivation experiments, the Neurobasal 
medium in the regular CNB medium was replaced with an equivalent volume of 
custom-made DMEM without riboflavin (Merck-Millipore); no other components 
were changed therefore the riboflavin concentration was 0.98 nM riboflavin (from 
the horse serum) in this “modified DMEM”. Riboflavin was diluted and prepared as 
described in Section 2.2.8. For the riboflavin-supplemented modified DMEM (no 
deprivation), riboflavin was added to match the concentration in the regular CNB 
medium (1,005 nM). For the 50% riboflavin-deficient modified DMEM, the final 
concentration of riboflavin was 502.5 nM (189.7 μg L). For the modified DMEM 
with 99% deprivation (0.98 nM), no riboflavin was added to the medium. For the 
biochemical and confocal microscopy experiments, the day following seeding, the 
medium was changed from regular CNB medium to one of the riboflavin-defined 
media described above; the mixed ventral horn cultures were maintained for a further 
nine days in vitro (DIV) in riboflavin-defined medium. 
2.4.3 Cell counting 
Cell counting was performed as described in Section 2.2.4. 
2.4.4 pGIPZ lentiviral Slc52a2 and solute carrier family 52, riboflavin 
transporter member 3 (Slc52a3) microRNA-adapted short hairpin RNA 
(shRNAmir) vectors 
Two pGIPZ lentiviral shRNAmir vectors containing hairpin sequences uniquely 
targeting the mouse Slc52a2 (Slc52a2-1) or Slc52a3 (Slc52a3-1 and Slc52a3-2) 
genes were purchased as bacterial agar stab cultures from Open Biosystems (Thermo 
Fisher Scientific) (see Appendix VII Table VII-8 for clone IDs and hairpin 
sequences). The pGIPZ lentiviral shRNAmir empty vector (no shRNAmir insert) and 
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non-targeting (non-silencing) shRNAmir vector (referred to as scrambled shRNA) 
were used as controls and were kindly provided by Dr Klaus Wanisch. The pGIPZ 
lentiviral vector was previously described in Section 2.3.4. This vector is also 
suitable for transductions using the replication-incompetent HIV-based lentivirus. 
2.4.5 Transformation of chemically competent cells 
Transformation of chemically competent cells from bacterial agar stab cultures of the 
pGIPZ lentiviral Slc52a2 and Slc52a3 shRNAmir vectors as well as the empty and 
scrambled control vectors was performed as described in Section 2.3.5. 
2.4.6 Maxiprep isolation of plasmid DNA and quality control 
To obtain high-quality plasmid DNA for transduction, DNA for the empty control, 
scrambled control, Slc52a2-targeting (Slc52a2-1) and Slc52a3-targeting (Slc52a3-1 
and Slc52a3-2) hairpin sequences was purified from the cell pellets obtained from 
overnight bacterial cultures (Section 2.4.5) using the Qiagen HiSpeed Maxi kit 
(Qiagen) or EndoFree Plasmid Maxi kit (Qiagen) as per the manufacturer’s 
instructions. Plasmid DNA purity and concentration were determined as described in 
Section 2.1.5. All pGIPZ vectors were sequenced by the UCL DNA sequencing 
service to confirm that the hairpin sequences were correct (see Appendix VII Table 
VII-4 for sequence of pGIPZ vector sequencing primer). 
2.4.7 Second generation lentivirus preparation 
Second generation lentiviral particles for empty control, scrambled control, Slc52a2-
targeting (Slc52a2-1) and Slc52a3-targeting (Slc52a3-1 and Slc52a3-2) hairpin 
sequences were prepared by packaging in human embryonic kidney 293T 
(HEK293T) cells. Three components are required to produce a 2
nd
 generation 
lentivirus: a packaging plasmid, an envelope plasmid, and the shRNA (or cDNA)-
containing transfer plasmid (Figure 2-6). The pGIPZ transfer plasmid was described 
in Section 2.3.4. The envelope plasmid used here is the pMD2.g plasmid coding for 
the vesicular stomatitis virus (VSV-G) envelope gene (Figure 2-7; Addgene, USA). 
The packaging plasmid used here, p8.91 (Addgene), encodes the HIV gag, pol, rev 
and tat genes. 
 100 
 
Figure 2-6 Components required for 2
nd
 generation virus: a transfer plasmid, a 
packaging plasmid, and an envelope plasmid (image obtained from 
http://www.addgene.org/ lentiviral/packaging/). 
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Figure 2-7 Vector map of the envelope plasmid pMD2.g coding for the VSV-G gene 
(image obtained from http://www.addgene.org/12259/). 
HEK293T cells required for 2
nd
 generation lentivirus preparation and viral titre 
determination were kindly provided by Dr Klaus Wanisch. On day 0, 1 x 10
6 
HEK293T cells were seeded on 100 mm round dishes (Corning) with 15 ml HEK 
cell medium (DMEM High glucose (Gibco) + 10% foetal calf serum (FCS) (Gibco) 
+ 1% P/S (Gibco)). Four dishes were used per virus. On day 3, the medium was 
replaced with 10 ml of Optimem-I (without serum and P/S; Gibco). The 
Lipofectamine mix “A” was prepared by mixing 2 ml Optimem-I with 60 μl 
Lipofectamine 2000 (Life Technologies) per dish. The DNA mix “B” was prepared 
by mixing (per dish) 12 μg p8.91 packaging plasmid, 7 μg ENV envelope plasmid, 
25 μg of transfer plasmid (lentiviral vector containing shRNA), made up to 2 ml with 
Optimem-I. Mix “A” and “B” were incubated separately for 5 min and then 
combined and incubated for 20 min with several inversions during incubation. The 
mixture was added to the dish of HEK293T cells in Optimem-I medium. The 
morning of day 4, the medium was changed to HEK cell medium and transfection 
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efficiency was assessed by visualising GFP fluorescence. On day 5, the virus was 
collected by removing the cell medium (lentiviral particle-containing supernatant), 
placing it in a 50 ml tube, spinning at 4,500 rpm for 15 min, passing the supernatant 
through a 0.4 μm filter, and storing at 4˚C. The dish with the HEK293T cells was 
replenished with 15 ml fresh HEK cell medium. On day 6, the virus was again 
collected as before and combined with the supernatant from day 5 into a 50 ml 
Oakridge top ultracentrifuge tube (Nalgene- Thermo Fisher Scientific). The 
combined supernatants were spun in a refrigerated ultracentrifuge at 47,000 g for 2.5 
h. The supernatant was removed and the viral pellet resuspended in 200 μl PBS 
(Sigma). 20 μl ali uots were prepared and stored at -80˚C. Empty control, scrambled 
control, Slc52a2-KD (Slc52a2-1) and Slc52a3-KD (Slc52a3-1 and Slc52a3-2) 
shRNA mixed ventral horn cultures, mouse embryonic fibroblasts (MEFs), and 
HEK293T cells were generated by lentiviral infection with variable concentrations of 
these viruses. 
2.4.8 Immunocytochemistry for viral titre determination in human embryonic 
kidney 293T (HEK293T) cells and mixed ventral horn cultures 
Immunocytochemistry was used to determine the viral titres (number of transducing 
units (TU) per ml) for the empty control, scrambled control, Slc52a2-KD (Slc52a2-
1) and Slc52a3-KD (Slc52a3-1 and Slc52a3-2) shRNAs transduced into HEK293T 
cells and mixed ventral horn cultures. 
On day 0, HEK293T cells were seeded on 13 mm glass coverslips in a 24-well plate 
with 500 μl well HEK cell medium at a density of 5 x 103 cells per well. On day 1, 
the HEK293T cells were infected with 5 μl (1:100), 1 μl (1:500) or 0.5 μl (1:1,000) 
of empty control, scrambled control, Slc52a2-KD (Slc52a2-1) or Slc52a3-KD 
(Slc52a3-1 or Slc52a3-2) lentivirus. Un-transduced control wells were also used to 
assess the effect of the virus on cell death. After 48 h, immunocytochemistry was 
performed. The medium was removed and cells were washed once in 1X PBS (Life 
Technologies). All PBS washes lasted 5 min. Cells were fixed for 20 min in 4% w/v 
PFA (10% Ultra pure EM grade; Polysciences Inc., USA) diluted in 1X PBS, 
followed by two washes with 1X PBS. The coverslips were mounted on polylysine 
slides (VWR) using fluorescent mounting medium (Dako, UK). 
 103 
Mixed ventral horn cultures were seeded on day 0 on glass coverslips in a 24-well 
plate with 300 μl CNB medium per well as described in Section 2.4.2. On day 1, 
mixed ventral horn cultures were infected with 3 μl (1:100) or 0.6 μl (1:500) of 
empty control, scrambled control, Slc52a2-KD (Slc52a2-1) or Slc52a3-KD (Slc52a3-
1 or Slc52a3-2) lentivirus. Un-transduced control wells were also used. After 18 h, 
the virus was replaced with fresh CNB medium. On day 5, the medium was removed 
and cells were washed once in 1X PBS (Life Technologies). Cells were fixed for 20 
min in 4% w/v PFA diluted in 1X PBS, followed by two washes with 1X PBS. Cells 
were blocked at room temperature in PBS-0.1% Triton X-100 (Sigma) with 5% goat 
serum for 40 min. The blocking solution was aspirated and a mouse monoclonal 
primary antibody for the neuronal marker β-III tubulin (1:500; Covance, USA) 
diluted in blocking solution was applied for 2 h. Cells were washed three times in 1X 
PBS. Cells were incubated with a goat anti-mouse Alexa Fluor 568 secondary 
antibody (1:1,000; Life Technologies) diluted in blocking solution for 1.5 h in the 
dark. The secondary antibody was removed and cells were washed once with nuclear 
stain DAPI (1:1,000 in 1X PBS; Sigma) for 10 min in the dark. Cells were washed 
twice with 1X PBS before mounting the coverslips on polylysine slides (VWR) using 
fluorescent mounting medium (Dako).  
Coverslips were imaged using a Leica DFC420C fluorescence microscope (Leica 
Microsystems- Danaher, USA), the Leica Application Suite software (Leica 
Microsystems- Danaher), and a 20X objective lens. The coverslip with the infection 
ratio giving approximately 10% GFP-positive cells was selected. Three to four fields 
were randomly selected so that a total of 300-400 DAPI-positive cells were counted. 
For the titre determination in HEK293T cells, the total number of GFP-positive cells 
and total number of DAPI-stained cells were counted. For the motor neurones, the 
total number of GFP-positive motor neurones and the total number of DAPI-positive 
cells (which includes other cell types besides motor neurones) were counted. Motor 
neurones were identified according to their morphology (Section 2.4.17) and positive 
staining for β-III tubulin and DAPI. The data was analysed using the Image J web-
based software (http://rsb.info.nih.gov/ij/). As an example of titre calculation, let us 
presume that 40 GFP and DAPI-positive HEK293T cells were counted out of a total 
of 400 DAPI-positive HEK293T cells for all fields counted on a single coverslip. 
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The number of TU (40 GFP and DAPI-positive cells) was then calculated to the 
original number of cells seeded (500 TU for 5000 cells seeded). If the coverslip 
corresponding to the 1:500 dilution (1 μl virus per 500 μl medium) was used for 
counting, the viral titre would be 5 x 10
5
 TU/ml (=500 TU x 1,000). The viral titres 
in HEK293T cells and mixed ventral horn cultures are provided in Section 7.11.1. 
2.4.9 RNA extraction 
To establish the mRNA expression levels of Slc52a2 and Slc52a3 in WT mixed 
ventral horn cultures, cells were seeded in 12-well plates as described in Section 
2.4.2 and were grown for five DIV in regular CNB medium. To assess KD efficiency 
of Slc52a2 and Slc52a3 shRNAs in purely transduced MEFs, on day 0, one vial of 
passage 0 WT MEFs was thawed and seeded into a 100 mm petri dish in 15 ml of 
DMEM High glucose (Gibco) with 10% FCS (Gibco) and 1% P/S (Gibco). On day 1, 
cells were split 1:3 into 6-well plates. On day 2, cells were transduced with empty 
control, scrambled control, Slc52a2-KD (Slc52a2-1) or Slc52a3-KD (Slc52a3-1 or 
Slc52a3-2) lentivirus at a 1:100 ratio. On day 3, the virus was removed and the 
medium replaced. On day 4, puromycin was added at 4 g/ml for selection of 
transduced cells. Cells were split 1:2 on day 5 and on day 6, cells were harvested for 
RNA. Control (untransduced) wells of WT MEFs were also used to measure the 
mRNA expression levels of Slc52a2 and Slc52a3 in WT MEFs. Total RNA was 
extracted using the MiRNeasy Mini Kit (Qiagen) and the RNase-free DNase set 
(Qiagen) as described in Section 2.2.9.  
2.4.10 cDNA synthesis 
cDNA was synthesized from total RNA using the First-Strand cDNA SuperScript II 
Reverse Transcriptase kit (Life Technologies) as described in Section 2.2.10. The 
efficiency of cDNA synthesis and the possibility of DNA contamination were 
assessed as described in Section 2.2.10 (see Appendix VII Tables VII-9 and VII-10 
for DNA and cDNA primer sequences). 
2.4.11 RT-qPCR 
To assess KD efficiency of the Slc52a2 and Slc52a3 shRNAs in the MEFs, as well as 
the relative mRNA expression levels of Slc52a2 and Slc52a3 in mixed ventral horn 
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cultures and WT MEFs, RT-qPCR was performed as described in Section 2.2.11 
with minor modifications. The Taqman gene expression assay (Applied Biosystems) 
IDs were the following: Mm01205717_g1 (Slc52a2); Mm00510191 (Slc52a3); 
Mm00607939 (Actb). As the three probes were all FAM-labelled, separate reactions 
had to be prepared for each assay. Each RT-qPCR reaction contained 2 μl of 
template cDNA diluted 1:10 v/v with nuclease-free H2O, 0.5 μl 20X Taqman gene 
expression assay (Applied Biosystems), 5 μl 2X Rotor-Gene Multiplex PCR Master 
Mix (Qiagen) and 2.5 μl RNase-free H2O. The standard curve was constructed using 
a cDNA sample corresponding to the scrambled shRNA. For relative quantification, 
the scrambled shRNA was used as the calibrator. 
2.4.12 Cell harvesting for biochemical analysis 
For the MRC complex I and II activities assay, cells were seeded into 6-well plates 
as described in Section 2.4.2 and grown in 99% riboflavin-deficient, riboflavin-
supplemented modified DMEM, or regular CNB medium. After nine DIV, the 
medium was removed, and cells were washed once with 1X DPBS (Life 
Technologies) and detached with trypsin-EDTA. Cell medium was added to each 
well to quench the trypsin; for each sample, cells from three replicate wells were 
collected, combined, and centrifuged at 380 g for 5 min. The cell pellet was 
resuspended in DPBS to wash. Cells were centrifuged again at 380 g for 5 min. The 
pellet was resuspended in 160 μl DPBS in ali uots (10 μl for protein determination, 
60 μl for complex I, 60 μl for complex II, and 30 μl for CS measurements). Samples 
were stored at -80°C. 
2.4.13 Total protein determination 
The total protein content of the cell lysates was determined using the Bio-Rad DC 
protein assay (Bio-Rad Laboratories) as described in Section 2.2.7.  
2.4.14 MRC complex I assay 
The MRC complex I assay was performed as described in Section 2.2.15. 
2.4.15 MRC complex II assay 
The MRC complex II assay was performed as described in Section 2.2.16. 
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2.4.16 CS assay 
The CS assay was performed as described in Section 2.2.17. 
2.4.17 Confocal microscopy: ∆Ψm 
For live-cell confocal microscopy, mixed ventral horn cultures were seeded on 
MatTeks as described in Section 2.4.2. For studies in WT mixed ventral horn 
cultures, the day after seeding, cells were placed in riboflavin-defined medium (99% 
riboflavin-deficient, riboflavin-supplemented modified DMEM, or regular CNB 
medium) and cultured for an additional eight to nine DIV. For studies of Slc52a2 and 
Slc52a3-KD mixed ventral horn cultures, the day after seeding, cells were infected 
with empty control, scrambled control, Slc52a2-KD (Slc52a2-1) or Slc52a3-KD 
(Slc52a3-1 or Slc52a3-2) lentivirus at 1:50 ratio. The virus was removed after 24 h, 
and the medium was changed to 99% riboflavin-deficient modified DMEM to 
prevent masking a possible metabolic defect in KD cells by riboflavin 
supplementation. Cells were grown for a further eight to nine DIV. 
The cell medium was removed and cells were washed twice with warm recording 
medium (RM) at pH 7.35 (see Appendix II for recipe). Cells were incubated in 1 ml 
RM containing 20 nM TMRM for 30 min in the dark. The basal TMRM and 
response to mitochondrial toxins were measured as described in Section 2.2.18 with 
minor modifications. The final concentrations of toxins used were the following: 2 
g/ml oligomycin, 5 M rotenone, and 1 M FCCP. Motor neurones were selected 
using the following criteria: triangular appearance of the cell body, more than two 
neuritic processes (to differentiate them from interneurons), smaller size than 
fibroblasts and astroglia, and usually growing on the upper focal plane (above the 
layer of fibroblasts and astroglia) (Bilsland et al., 2008) (Figure 2-8).  
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A.  
B.  
Figure 2-8 Example of a cell representing a motor neurone (A) and a cell which is 
not a motor neurone (B) according to specific criteria (Bilsland et al., 2008). Both 
cells are of a similar size, but the motor neurone has three neuritic processes while 
cell B has only two. 
Basal ΔΨm measurements were analysed using the Zeiss Zen software (Carl Zeiss 
AG). For each z-stack, the focal plane corresponding to the highest TMRM intensity 
was selected and the mean TMRM fluorescence intensity across the pixels 
containing mitochondria was measured for each coverslip, each representing a 
minimum of three cells. In the WT mixed ventral horn cultures, for each 
experimental day all measurements were compared to the mean intensity in cells 
grown in riboflavin-supplemented modified DMEM. For studies of Slc52a2 and 
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Slc52a3-KD mixed ventral horn cultures, all measurements for each experimental 
day were compared to the mean intensity in the scrambled control. 
Time-series experiments were only performed in the study of Slc52a2 and Slc52a3-
KD mixed ventral horn cultures. Time-series data was analysed using the Zeiss Zen 
software (Carl Zeiss AG) as described in Section 2.2.18, except that only areas 
within GFP-expressing cells were selected. Due to poor transduction efficiency, only 
one GFP-positive cell was usually present within the chosen field for each coverslip 
(Figure 2-9). 
 
Figure 2-9 A GFP-positive (green) motor neurone incubated with 20 nM TMRM 
(red). 
2.5 Statistical analysis 
All statistical analyses were performed using the R software package (http://www.R-
project.org/; R Development Core Team, 2008). For comparison of means of >2 
groups, a Tukey’s two-tailed post-hoc test or Dunnett’s post-hoc test was performed 
after a one-way analysis of variance (ANOVA). For fibroblast experiments (which 
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involved more than one control), a one-way ANOVA was initially performed to 
determine if the controls were significantly different from one another. If the results 
of the ANOVA showed that the controls were not significantly different from each 
other at the p<0.05 level, the data from the three controls was pooled and considered 
as a whole. In this case, a Dunnett’s two-tailed post-hoc test was performed for 
pairwise comparison of the control group to each patient and carrier. If the ANOVA 
suggested that the controls differed significantly from each other (p<0.05), a Tukey’s 
two-tailed post-hoc test was performed for pairwise comparison between each 
control and patient/carrier individually. In this case, the highest p-value resulting 
from each of the three control-patient or control-carrier comparisons was used to 
assess significance. Additional details of statistical analysis for fibroblast 
experiments are provided in Section 7.3.16. For experiments with a single control 
sample (e.g. scrambled control shRNA) where data had to be normalised to this 
control for each experimental day, it is mathematically incorrect to test for statistical 
significance as the control sample has zero variance (control is set at 100% on all 
experimental days). 
2.6 Additional Web resources and software 
The functional impact of variants detected in the Sanger sequencing and exome 
sequencing studies was assessed using in-silico prediction programmes including 
PolyPhen-2 (http://genetics.bwh.harvard.edu pph2  ; Adzhubei et al., 2010), which 
uses sequence, structural and phylogenetic information, Sorting Intolerant From 
Tolerant (SIFT) (http://sift.jcvi.org; Ng & Henikoff, 2001) which uses sequence 
homology and biochemical properties, and Mutation Taster 
(www.mutationtaster.org ; Schwarz et al., 2010 ), which takes into account 
evolutionary, biochemical and structural features to classify variants. SpliceView, a 
splicing signal prediction programme (http://zeus2.itb.cnr.it/~webgene/ 
wwwspliceview_help.html; Rogozin & Milanesi, 1997), was used to assess the 
functional impact of splicing variants. The TMHMM Server v.2 was used for 
membrane protein topology prediction in the transmembrane riboflavin transporters 
(http://www.cbs.dtu.dk/services/TMHMM-2.0/; Krogh et al., 2001). Details of gene 
expression in various tissues were obtained from the Human Protein Atlas 
(http://www.proteinatlas.org). Location of the mutated amino acid with respect to 
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protein domains and other features was assessed using UniProtKB 
(http://www.uniprot.org). 
Conservation amongst species is powerful for assessing the pathogenicity of variants 
as purifying selection usually removes deleterious variants (Cooper & Shendure, 
2011). To assess conservation among species of the mutated amino acid residues, 
Ensembl was used to retrieve the orthologous sequences and the Clustal Omega 
software (http://www.ebi.ac.uk/Tools/msa/clustalo/; Thompson et al., 1994) was 
used for multiple sequence alignment. The genomic evolutionary rate profiling 
(GERP) score was also used to estimate the degree of se uence conservation 
(mendel.stanford.edu SidowLab downloads gerp  ; Cooper & Shendure, 2011). This 
program compares the observed rate of evolutionary change at the nucleotide level 
with that expected for a neutral position; higher scores refer to nucleotides with 
fewer substitutions, and therefore higher evolutionary constraint (Cooper & 
Shendure, 2011).  
The following websites or browsers were used to search for SNP and gene 
information: Ensembl, National Centre for Biotechnology Information (NCBI) 
(http://www.ncbi.nlm.nih.gov/gene/), and University of California Santa Cruz 
(UCSC) genome browser (http://genome.ucsc.edu). The NCBI Single Nucleotide 
Polymorphism database (dbSNP) (http://www.ncbi.nlm.nih.gov/projects/SNP/), the 
1000 Genomes Project database (http://browser.1000genomes.org/index.html; 
v.2011) the UCL HEX database of control human brain sequences 
(http://hex.ion.ucl.ac.uk), the Complete Genomics 69 database (CG69; 
http://www.completegenomics.com/public-data/), and the National Heart, Lung, and 
Blood Institute Exome Variant Server (NHLBI EVS) database 
(http://evs.gs.washington.edu/EVS/) were used to filter against polymorphisms. The 
GEM.app, provided by University of Miami’s Miller School of Medicine, was used 
during exome sequencing analysis to search for variants in the candidate genes in 
families with similar phenotypes. This tool allows for the storage, annotation and 
analysis of variants in the genome (Gonzalez et al., 2013). The Cyrillic software was 
used to draw pedigrees (www.cyrillicsoftware.com). The DOG2.0 software (Ren et 
al., 2009) was used to prepare figures of protein domain structures.  
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The R software package was used for statistical analysis and graphics using the 
ggplot2 plotting system. This software was also used to construct quantile-quantile 
(QQ) plots in the CMT1A association study (see Appendix IV for command lines), 
and to assess intra- and interfamilial variability in CMT1A, as described in Chapter 
4.  
The gPLINK software package (pngu.mgh.harvard.edu  purcell plink gplink.shtml ; 
Purcell et al., 2007) was used for Immunochip data quality control and association 
analyses in the CMT1A study. gPLINK is an open-source Java-based C/C++ tool set 
commonly used for whole-genome association analysis. It is run from the command 
line and was used for large-scale data management, summary statistics for quality 
control and basic association testing. Command lines used in gPLINK are found in 
Appendix IV.  
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Chapter 3 CMT gene screening 
3.1 Introduction 
3.1.1 Frequency of genetic subtypes 
Following the finding of the Chr17p11.2 duplication as the genetic cause of CMT1A, 
more than 60 additional genes or loci have been shown to cause CMT (Pandraud et 
al., 2012; Reilly et al., 2011; Rossor et al., 2013). Although these discoveries have 
uncovered an array of proteins involved in Schwann cell myelination and axonal 
function, the high phenotypic and genotypic heterogeneity found in CMT has made 
the diagnosis of this condition a much more complex endeavour (Patzkó & Shy, 
2011). Screening known disease-causing genes in diverse populations provides 
invaluable information for clinicians by helping them target genetic tests according 
to the frequency of genetic subtypes in a particular population. 
Although CMT is said to affect 5-40 per 100,000 people, the prevalence of CMT as a 
whole and the frequency of the genetic subtypes vary in different populations 
(Braathen et al., 2011; Foley et al., 2012; Skre, 1974). CMT is found in people of all 
ethnicities. Approximately 90% of CMT cases are inherited in an AD or X-linked 
manner in European/UK and USA populations. However, in geographical areas 
where the practice of consanguineous marriage is frequent such as the Mediterranean 
basin, 40% of CMT cases display AR inheritance (Reilly et al., 2011). 
The most common genetic subtypes of CMT overall are as follows: CMT1A (55% of 
CMT and 66.8% of CMT1); CMT1X (15.2% of CMT and 18.4% of CMT1); HNPP 
(9.1% of CMT), CMT1B (8.5% of CMT and 10.4% of CMT1); CMT2A (4% of 
CMT and 21.9% of CMT2) (Saporta et al., 2011); most other subtypes make up 
fewer than 1% of all CMT cases (Boerkoel et al., 2002; Foley et al., 2012; Nelis et 
al., 1996; Pareyson & Marchesi, 2009; Saporta et al., 2011; Shy & Patzkó, 2011). 
Importantly for genetic testing targeting strategies, 92% of the CMT patients who 
received a genetic diagnosis in the Saporta et al. (2011) study carried either the 
Chr17p11.2 duplication/deletion, MPZ, GJB1, or MFN2 mutations (Amato & Reilly, 
2011). LITAF mutations accounted for 0.6% of patients with AD CMT1 (Latour et 
al., 2006). Studies of CMT patients in other populations such as Norway and 
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Germany resulted in a similar frequency distribution of genetic subtypes, with the 
most frequent subtypes being CMT1A, and then CMT1X, CMT2A and CMT1B 
(Braathen et al., 2011; Gess et al., 2013). SH3TC2 mutations are the most common 
cause of AR cases of CMT (42.9% of CMT4) (Murphy, Laura, et al., 2012; Saporta 
et al., 2011). Some AR CMT subtypes are present at higher rates in certain 
genetically isolated populations, such as n-myc downstream regulated 1 (NDRG1), 
SH3TC2 and hexokinase 1 (HK1)-linked CMT subtypes, which are especially 
frequent in the Gypsy population (Reilly et al., 2011). 
Frequency studies of CMT subtypes in the UK, Greek and Russian populations are 
described below as these populations were studied in the context of this Chapter. In a 
recent large UK study, a genetic diagnosis was obtained in 62.6% of patients seen at 
the inherited neuropathy clinic in Queen Square, London (in 80.4% of CMT1 
patients and 25.2% of CMT2 patients); a diagnosis was made in 37.7% of CMT 
patients not attending this clinic (Murphy, Laura, et al., 2012). In agreement with 
previous studies (Foley et al., 2012; Saporta et al., 2011) the Chr17p11.2 duplication, 
GJB1, MPZ and MFN2 mutations were most common, accounting for more than 
90% of genetic diagnoses (Murphy, Laura, et al., 2012). I was involved in the 
determination of EGR2 mutation frequencies in this UK cohort, the results of which 
are presented in this Chapter.  
A study by Karadima et al. (2011) uncovered the genetic cause of disease in 30% of 
Greek CMT1 cases; 26% had the Chr17p11.2 duplication, 5% had mutations in 
GJB1 and 1% in MPZ. The frequency of CMT1A due to the Chr17p11.2 duplication 
in the Greek population is relatively low compared to most populations in Europe 
and the USA, but is similar to that found in certain populations such as Japan and 
Norway (Braathen et al., 2011; Karadima et al., 2011; Mostacciuolo et al., 2001; 
Nelis, et al., 1996; Nicolaou et al., 2010; Numakura et al., 2002; Silander et al., 
1998).  In Greece, only approximately 35% of CMT1 patients have a mutation in the 
genes associated with AD demyelinating CMT (Karadima et al., 2011). This 
frequency contrasts with the 80.4% of UK CMT1 patients attending an inherited 
neuropathy clinic who received a genetic diagnosis in the Murphy, Laura, et al. 
(2012) study. 
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In a study of 174 CMT patients of Russian origin, 53.7%, 7.4%, 4.6% and 1.9% of 
CMT1 patients had the Chr17p11.2 duplication, GJB1, MPZ, and PMP22 mutations, 
respectively. Amongst CMT2 patients, 3.1% had a GJB1 mutation. In cases with 
unspecified CMT, 2.9%, 17.6% and 2.9% had the Chr17p11.2 duplication, GJB1 and 
MPZ mutations, respectively (Mersiyanova et al., 2000).  
Taking into consideration the frequencies of CMT subtypes above, the Chr17p11.2 
duplication should be tested first in patients with demyelinating sporadic or AD 
CMT followed by GJB1 if there is no male-to-male transmission. If there is male-to-
male inheritance, screening of MPZ and PMP22 should follow, ending with the less 
common genes, EGR2, LITAF and NEFL (Pandraud et al., 2012; Pareyson & 
Marchesi, 2009; Reilly et al., 2011; Saporta et al., 2011; Siskind & Shy, 2011). 
MFN2 and GJB1 should be prioritized in AD cases of classic, axonal CMT with no 
male-to-male transmission, followed by MPZ, NEFL, AARS, GDAP1 and TRPV4. 
Testing MFN2 is generally more appropriate for severe early-onset cases, while MPZ 
is usually associated with later-onset AD axonal CMT (Pandraud et al., 2012; Reilly 
et al., 2011; Saporta et al., 2011). In certain cases, CMT, HSAN and HMN may be 
difficult to distinguish from one another. Screening of serine palmitoyltransferase, 
long chain base subunit 1 (SPTLC1) and RAB7 is warranted in patients with CMT2 
and AD inheritance with significant sensory symptoms and signs. If motor symptoms 
predominate, GARS (patients with prominent upper-limb involvement), HSPB1, 
HSPB8, BSCL2 and TRPV4 should be sequentially screened (Pandraud et al., 2012; 
Reilly et al., 2011; Shy & Patzkó, 2011). ICMT cases should be screened for GJB1, 
followed by MPZ, NEFL, DNM2 and YARS (Pareyson & Marchesi, 2009). A 
consideration for specific clinical features as well as the patient’s ethnic background 
is especially valuable for AR CMT cases (Reilly et al., 2011); GDAP1 should 
generally be tested first when the inheritance pattern is AR (Pareyson & Marchesi, 
2009). 
Diagnostic algorithms which take into account frequencies of CMT subtypes are 
particularly useful in highly genetically and phenotypically heterogeneous diseases 
such as CMT and especially for AD CMT1. Algorithms have allowed for a genetic 
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diagnosis to be obtained in 70% of CMT patients (Pareyson & Marchesi, 2009; 
Reilly et al., 2011; Saporta et al., 2011). 
Following diagnostic guidelines adapted for the patient’s ethnicity avoids the 
unwarranted and costly use of large gene panels (Amato & Reilly, 2011). However, 
as is evident from the above reports, rates of CMT subtypes have not been 
extensively studied in certain populations, and in most populations, the frequency of 
the less common CMT genes remains unknown as these genes are not available for 
routine diagnostic testing. Although no treatments are available at this time for CMT, 
receiving a genetic diagnosis is essential for patients as it allows the physician to 
provide a more accurate prognosis, to give appropriate counselling for family 
planning, and it provides the patient with the possibility of predictive, pre-natal or 
pre-implantation diagnosis (Pandraud et al., 2012; Pareyson & Marchesi, 2009; 
Reilly et al., 2011). As Amato & Reilly (2011) acknowledge, assigning a genetic 
diagnosis to a patient will admittedly not affect the way a single patient is managed 
and will not predict exactly how that patient’s condition is going to progress. 
However, a genetic diagnosis allows the physician to exclude inflammatory causes of 
neuropathy such as CIDP which may be treatable, and also helps to limit the number 
of unnecessary medical interventions and treatment trials (Amato & Reilly, 2011; 
Reilly et al., 2011). Eventually, therapies will be developed which will likely target 
specific genetic subtypes of disease, providing further incentive for finding the 
causative gene in patients (Reilly & Shy, 2009; Reilly et al., 2011).  
3.1.2 Phenotypes associated with selected CMT subtypes 
The range of phenotypes resulting from PMP22, MPZ, EGR2, NEFL, LITAF and 
GJB1 mutations are described below as these were screened in cohorts of CMT1 
patients and canines with neuropathies as part of our study. Point mutations in 
PMP22 may cause DSD, CHN or HNPP. The phenotype is usually more severe with 
earlier onset than in CMT1A, but it may also be classical CMT1A. Patients with 
MPZ mutations generally fall into two groups: the severe, early-onset demyelinating 
form or the less severe axonal form with later onset. Mutations in MPZ may 
sometimes lead to typical CMT1. The phenotype associated with LITAF mutations is 
generally similar to that seen in CMT1A. EGR2 mutations generally cause severe 
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disease with early-onset and possible cranial nerve involvement, but may also cause 
CMT1. Both AD and AR inheritance have been described for PMP22, MPZ and 
EGR2 mutations (Reilly et al., 2011; Siskind & Shy, 2011). Mutations in NEFL may 
cause either axonal or demyelinating NCVs with either a classical CMT phenotype 
or early-onset severe disease. MFN2 mutations often lead to severe disease with 
early-onset, which may involve the CNS; the phenotype may also be classical CMT. 
Finally, the X-linked form of CMT caused by mutations in GJB1 causes a severe 
phenotype with earlier onset and slower NCVs in males compared to females. 
Females are usually mildly affected although the phenotype is variable most likely 
due to X-inactivation (Murphy, Ovens, et al., 2012; Patzkó & Shy, 2011; Reilly et 
al., 2011; Siskind & Shy, 2011). 
3.1.3 Genotype-phenotype studies in CMT 
Correlating clinical manifestations with genetic mutations as is done in genotype-
phenotype studies and carrying out large natural history studies will be important for 
predicting disease progression in individual patients in the future (Amato & Reilly, 
2011). From a biological perspective, determining the mutation leading to a 
particular phenotype helps to elucidate protein function and disease mechanisms 
(Reilly & Shy, 2009; Reilly et al., 2011). However, as is apparent in Section 3.1.2, 
variable phenotypes can result from genetic defects in one particular gene, and 
sometimes from identical mutations in the same gene.  
Studies using animal models of CMT are also invaluable for assessing the effect of 
selected CMT gene mutations on protein function and phenotype. As discussed in 
Section 1.3.3, these studies have shed light on some of the possible disease 
mechanisms in certain CMT subtypes, and are a useful tool for identifying potential 
therapeutic targets (Fledrich, Stassart, et al., 2012). Interestingly, naturally occurring 
peripheral neuropathies have been reported in several species, including canines. 
Canine axonal and demyelinating peripheral neuropathies were introduced in Section 
1.3.3, and will now be discussed in detail as they are of particular interest in this 
study. 
 117 
3.1.4 CMT genes in canines with peripheral neuropathies or neuroaxonal 
dystrophy 
CMT-like neuropathies have been described in several dog breeds, which are 
reviewed in Granger (2011). Leonberger dogs with inherited CMT-like axonal 
neuropathy and vocal cord paresis have been described; these dogs had high-
steppage gait, weakness and wasting of distal limb muscles as well as decreased 
tendon reflexes. Electrophysiological studies showed changes characteristic of 
polyneuropathy with denervation, and nerve biopsies displayed loss of myelinated 
fibres (Shelton et al., 2003). A sensory ataxic neuropathy due to a mutation in the 
mitochondrial tRNA
Tyr
 gene was described in Golden Retriever dogs (Baranowska et 
al., 2009). A deletion in NDRG1, a gene mutated in human CMT, was found in a 
family of Greyhounds with predominantly axonal polyneuropathy, thus representing 
the first canine CMT model (Drögemüller et al., 2010). A missense mutation in 
NDRG1 was recently identified in Alaskan Malamute dogs with early-onset 
progressive polyneuropathy (Bruun et al., 2013).  
The first demyelinating polyneuropathy with focally folded myelin sheaths was 
recently described in a family of highly inbred Miniature Schnauzer dogs 
(Vanhaesebrouck et al., 2008). In humans, such tomaculae resulting from excessive 
myelin folding is associated with HNPP, demyelinating forms of CMT, as well as 
CIDP. Affected dogs in this family of Schnauzer dogs presented with respiratory 
dysfunction with no generalised weakness. They had decreased motor and sensory 
nerve conduction velocities and segmental demyelination. The histopathological 
changes seen in these dogs are similar to that seen in demyelinating CMT with 
tomaculae. The genes mutated in demyelinating forms of CMT in humans are 
candidate genes for the neuropathy in these Schnauzer dogs (Vanhaesebrouck et al., 
2008). These Schnauzers dogs were screened as part of our study in this Chapter. 
Investigating canines with mutations in genes known to cause CMT in humans may 
help clarify the function of the mutant protein and elucidate disease pathways in the 
human disease, even if not associated with CMT in canines. A small deletion in 
MFN2, associated with axonal CMT in humans, has recently been found in a family 
of dogs with AR foetal-onset neuroaxonal dystrophy (FNAD) mimicking the human 
phenotype (Fyfe et al., 2011). NAD is a neurodegenerative pathology in the CNS 
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and/or PNS distinguished by spheroids, or swellings, and axonal atrophy. In humans, 
AR infantile NAD has been associated with phospholipase A2, group VI (PLA2G6) 
mutations and may cause hypotonia, amyotrophy, areflexia and psychomotor 
problems, as well as a sensorimotor axonal neuropathy (Yiu & Ryan, 2012). As 
suggested in the Fyfe et al. (2011) study, MFN2 may be a candidate gene for human 
cases of FNAD. The association of known CMT genes with non-CMT diseases is 
interesting to study as it may uncover novel functions for these genes and expands 
the phenotypes associated with CMT genes (Fyfe et al., 2011). A silent 
polymorphism in MFN2 leading to a splicing defect has also been found in cattle 
with degenerative axonopathy in the CNS (Drögemüller et al., 2011). 
Canines are particularly suited for genetic studies as they benefit from close 
examination by veterinary experts and a well-characterised genome (Matiasek & 
Drögemüller, 2011). Dogs have developed in the same environment as humans and 
their genome is highly similar to ours, therefore disease pathways are likely to be 
comparable (Karlsson et al., 2007).  
3.2 Aims of this study 
CMT is a disease with particularly high phenotypic and genotypic heterogeneity. 
This study had three primary aims. The first aim was to assist clinicians in targeting 
genetic tests for patients with CMT by determining frequencies of genetic subtypes 
in different ethnicities. The second aim was to expand the phenotypes associated 
with particular CMT genetic subtypes and mutations. To fulfil these two aims, we 
screened CMT1 genes including PMP22, EGR2, LITAF, NEFL and/or GJB1 in three 
cohorts of CMT1 patients from different geographical areas, namely the UK, Greece, 
and the Yakutsk province in Russia. We were particularly interested in screening 
genes not available for routine diagnostic testing to determine their frequency. The 
third aim of this study was to screen known CMT genes, specifically PMP22 and 
MPZ in canines with peripheral neuropathy and MFN2 in a canine with neuroaxonal 
dystrophy and cerebellar abiotrophy (NAD-CA) in the hope that they may serve as 
potential animal models of human peripheral nerve disease and provide clues into 
pathogenic mechanisms of disease in peripheral neuropathies. 
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3.3 Methods 
3.3.1 CMT1 patient cohorts 
Patients from the UK, Greece, and the Yakutsk province in Russia who have 
demyelinating CMT disease according to NCS and neurological examination but 
lacked a genetic diagnosis were screened for mutations in selected CMT1-associated 
genes. Details of ethics approval and patient consent are found in Section 2.1.1. 
The UK cohort consisted of 135 CMT1 patients negative for the Chr17p11.2 
duplication/deletion with or without a family history. Patients were assessed by 
consultant neurologists Professor Mary Reilly and Dr Matilde Laurá at the inherited 
neuropathy clinic at the NHNN or by consultant neurologists in other UK CMT 
clinics. DNA was obtained from the Neurogenetics diagnostic laboratory at the 
NHNN or was sent to our centre from throughout the UK for research genetic 
testing. Patients in the UK cohort were tested for Chr17p11.2 rearrangements by 
semi-quantitative fluorescent PCR or multiplex ligation-dependent probe 
amplification (MLPA) in diagnostic laboratories, including the Neurogenetics 
diagnostic laboratory at the NHNN. The UK cohort was screened as part of a larger 
study published in Murphy, Laura, et al. (2012). DNA of UK controls was obtained 
from the 1958 British Birth Cohort of the WTCCC. 
The Greek cohort was comprised of 86 Greek CMT1 patients (64 familial, 22 
sporadic) who had previously tested negative for the Chr17p11.2 duplication/deletion 
and MPZ and GJB1 mutations, as described in Karadima et al., 2011. The 
Chr17p11.2 duplication/deletion was tested by the long PCR method. DNA of Greek 
CMT1 patients was obtained from our collaborator Dr George Koutsis at Eginitio 
Hospital, Athens, Greece. The average median NCV of the patients in this cohort 
was 23.7 m/s. DNA of Greek controls was provided by Dr George Koutsis. 
Dr Polina Innokentyevna from Yakutsk in Russia (Figure 3-1) kindly provided the 
DNA samples for the Russian CMT1 patients. The Yakutsk cohort consisted of 54 
patients who were negative for the Chr17p11.2 duplication/deletion. 
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Where available, clinical information for the CMT1 patients in whom variants were 
found is discussed in Sections 3.4.1, 3.4.2 and 3.4.3. 
 
 
Figure 3-1 Yakutsk province in Russia. Obtained from http://en.wikipedia.org/wiki/ 
Yakutsk. 
3.3.2 Cohort of canines with peripheral neuropathies or neuroaxonal 
dystrophy and cerebellar abiotrophy (NAD-CA)  
Samples were obtained from Dr Nicolas Granger at the Queen's Veterinary School 
Hospital at the University of Cambridge, UK. Our cohort was comprised of eight 
affected dogs with peripheral neuropathies. Among these were two Miniature 
Schnauzers with AR demyelinating CMT-like polyneuropathy with focally folded 
myelin sheaths resembling HNPP as well as MTMR2 and MTMR13-linked CMT 
(Vanhaesebrouck et al., 2008; Matiasek & Drögemüller, 2011); these dogs 
correspond to the two affected males in the family of dogs with multiple 
consanguineous loops described in the report by Vanhaesebrouck and colleagues 
(2008) and in the review by Granger (2011), as well as in Section 3.1.4. We also had 
samples for one Labrador Retriever with sporadic unspecified peripheral nerve 
disease, one Leonberger with unspecified familial peripheral neuropathy, and one 
Cocker Spaniel with sporadic, late-onset demyelinating neuropathy with onion bulb 
formation. Other canines in our cohort included two Black Russian Terriers with 
familial juvenile axonal neuropathy with one specific type of fibre loss. Finally, the 
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last member of our cohort was a Golden Retriever with late-onset generalised 
peripheral nerve disease; a number of large breed dogs are reportedly affected by a 
similar disease (N. Granger, personal communication). Inheritance is likely to be AR 
or X-linked in most of these canines. Samples were obtained as DNA, EDTA blood 
or snap-frozen muscle.  
DNA for the Papillon dog with NAD-CA was provided by Dr Urs Giger at the 
School of Veterinary Medicine at the University of Pennsylvania, USA. The Papillon 
dog was negative for PLA2G6 mutations. 
3.3.3 DNA extraction from canine blood and tissue 
For the cohort of canines with peripheral neuropathies, DNA was extracted from 
canine EDTA blood and snap-frozen muscle as described in Section 2.1.3. 
3.3.4 Whole-genome DNA amplification 
gDNA from the Yakutsk cohort was whole-genome amplified as described in 
Section 2.1.4 prior to Sanger sequencing, as an insufficient amount of DNA was 
available for sequencing in this cohort. 
3.3.5 Gene screening in CMT1 patient and canine cohorts 
Purity and concentration of DNA samples were assessed as described in Section 
2.1.5. PCR, agarose gel electrophoresis, purification of PCR products, Sanger 
sequencing, dye removal and sequencing analysis were performed using standard 
conditions as described in Sections 2.1.9-2.1.12. Coding exons and flanking intronic 
sequences were sequenced for human PMP22, EGR2, GJB1, LITAF and NEFL, and 
for canine PMP22, MPZ and MFN2 using species-appropriate reference sequences. 
Transcript references used for primer design, as well as sequences of gene-specific 
primers and PCR cycling conditions can be found in Appendix III Tables III-1 and 
III-2. SNP chromosomal locations are based on Genome Build 37.3. 
At the time of this study, neuropathy gene panels were not available and genetic 
testing was done on a gene-by-gene basis. In the UK cohort, EGR2 was screened in 
135 CMT1 patients as this gene is not available for routine diagnostic testing due to 
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its low frequency. Patients in the Greek CMT1 cohort (n=86) who remained without 
a genetic diagnosis after the gene screening described in Karadima et al. (2011) were 
tested for mutations in PMP22, EGR2, LITAF and NEFL. This sequencing was done 
both by Dr George Koutsis and myself. CMT1 patients in the Yakutsk cohort were 
selectively screened for mutations in PMP22, GJB1, and/or EGR2 depending on 
inheritance pattern and phenotype. PMP22 and GJB1 were screened in 10 patients 
and EGR2 in 54 patients. This sequencing was done both by Dr Polina 
Innokentyevna and myself. 
All eight canines in the peripheral neuropathy cohort were screened for mutations in 
canine PMP22 and MPZ. The affected Papillon dog with NAD-CA was screened for 
mutations in canine MFN2.  
Both canine PMP22 and human PMP22 have four coding exons and encode a 
protein 160 amino acids long. Canine MPZ and human MPZ have six coding exons 
but the canine gene is 258 amino acids long while the human gene is 10 amino acids 
shorter. Both human and canine MFN2 have 17 coding exons and are 757 amino 
acids long. Canine PMP22, MPZ and MFN2 have 93%, 92%, and 97% of the 
sequence matching with the human PMP22, MPZ and MFN2, respectively 
(corresponding values are 86%, 94% and 95% between the mouse and human 
PMP22, MPZ and MFN2, respectively). Although the percentage alignment match 
between human/canine and human/mouse CMT genes like PMP22, MPZ and MFN2 
are similar, canines represent a better model for human CMT than rodent models 
given their larger size and similar body structure to humans (Drögemüller et al., 
2010). 
In-silico analyses were performed as described in Section 2.6. Variants were 
searched in the dbSNP, 1000 Genomes and/or EVS databases. Segregation analysis 
of variants in family members was performed where DNA was obtainable. 
Potentially pathogenic variants were screened in controls of matching ethnicity 
where available.  
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3.3.6 Fragment analysis of small duplication and deletion 
Fluorescent PCR amplification and subsequent capillary electrophoresis were 
performed as described in Section 2.1.8. Primers used for fluorescent PCR 
amplification were the same as those used for PCR and Sanger sequencing of 
PMP22 exons 4 and 5, with the addition of a fluorescent tag. The fragment analysis 
as well as the transcriptional analysis described below were carried out entirely by 
Dr George Koutsis. 
3.3.7 Transcriptional analysis of small duplication and deletion 
RNA was extracted from peripheral blood and cDNA was synthesized as described 
in Section 2.1.7. Sequences of primers used to amplify the 391 bp-long cDNA region 
of interest in PMP22 for the small duplication and deletion identified in the Greek 
cohort are found in Appendix III Table III-3. cDNA was sequenced according to the 
DNA sequencing protocol as described in Section 2.1.12. 
3.4 Results 
3.4.1 UK CMT1 cohort: Early growth response 2 (EGR2) sequencing 
As mentioned previously, the screening of EGR2 in the UK CMT1 cohort was part 
of a larger study aiming to determine the frequency of genetic subtypes in CMT to 
provide a guideline for genetic testing (Murphy, Laura, et al., 2012). 
Sequencing of EGR2 in the UK cohort of 135 patients with demyelinating CMT 
revealed a total of seven unique heterozygous variants, three of which are likely to be 
pathogenic: p.Arg359Trp (c.1075C>T) in one patient (0.74%); p.Arg381Cys 
(c.1141C>T) in two patients (1.48%); p.Arg426Gln (c.1277G>A) in one patient 
(0.74%) (see Appendix III Table III-4 for complete list of mutations and 
pathogenicity predictions). The other four mutations (p.Pro209Pro (c.627A>G); 
p.Thr215Met (c.644C>T); p.Arg362Arg (c.1086A>C); p.Gly451Val (c.1352G>T)) 
are likely to be polymorphisms as they are either synonymous variants, found in our 
UK control cohort and/or were present in dbSNP, 1000 Genomes or EVS databases. 
The p.Arg362Arg variant has been reported as a polymorphism in several studies 
(Choi et al., 2004; Timmerman et al., 1999). The p.Gly451Val mutation was 
previously found in the heterozygous state in a patient with unspecified CMT 
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(Takashima et al., 2001). However, it was also present in 1/185 (0.54%) of our UK 
control cohort and therefore it is likely to be a non-pathogenic, albeit rare, variant.  
All three likely pathogenic mutations were located in exon 2 of EGR2, were found in 
the heterozygous state, were predicted damaging by Polyphen-2 and SIFT and were 
located at amino acids partially (p.Arg426Gln) or highly (p.Arg359Trp; 
p.Arg381Cys) conserved across species. p.Arg426Gln has not been previously 
described in the literature. The p.Arg381Cys and the p.Arg426Gln mutations were 
not found in 257 and 264 UK controls, respectively. p.Arg359Trp was not screened 
in controls as its pathogenicity is well established in the literature (Boerkoel et al., 
2001; Choi et al., 2004; Chung et al., 2005; Taroni et al., 1999; Timmerman et al., 
1999; Warner et al., 1999). No family members were available for segregation 
analysis for any of the variants identified in the UK cohort. 
Our patient with the p.Arg359Trp mutation had facial weakness, ophtalmoplegia, 
difficulty swallowing, kyphoscoliosis, deformity of fingers and feet, and sensory 
loss. The patient’s MNCV was 11 m/s. This mutation was discovered previously in 
patients with generally sporadic DSD and cranial nerve involvement (Boerkoel et al., 
2001; Taroni et al., 1999; Timmerman et al., 1999) although it has also been found to 
cause a classic CMT1 phenotype with severe loss of myelinated fibres and onion 
bulb formation (Choi et al., 2004; Chung et al., 2005). It is located in the alpha-helix 
domain of the first zinc-finger of EGR2 and is predicted to act in a dominant-
negative manner (Szigeti et al., 2007).  
The p.Arg381Cys mutation was found in two patients. The first patient had a two-
year history of peripheral sensory loss and weakness, as well as deafness. There was 
severe MNCV slowing on NCS. The second patient had a MNCV of 46 m/s with 
dispersion. In the literature, it is associated with late-onset, mild cases of CMT1 and 
the phenotype is less severe than that associated with the p.Arg381His mutation 
(Briani et al., 2010; Pareyson et al., 2000; Taroni et al., 1999; Vandenberghe et al., 
2002; Yoshihara et al., 2001). In one study, a patient with the p.Arg381Cys mutation 
had a mild phenotype with late-onset of disease, severe loss of myelinated fibres and 
onion bulb formation (Yoshihara et al., 2001). Another patient carrying the 
p.Arg381Cys mutation had sporadic CMT1 with MNCV of 22 m/s and CMTNS of 9 
 125 
(Briani et al., 2010). This mutation is located in the second zinc-finger domain. As 
with other EGR2 zinc-finger mutations like p.Arg359Trp, this mutation is predicted 
to act in a dominant-negative manner and interfere with DNA binding. Disease 
severity has been found to correlate with the amount of residual binding for EGR2 
zinc-finger mutations (Warner et al., 1999).  
No clinical details were available for the patient carrying the p.Arg426Gln mutation. 
Unlike most EGR2 mutations associated with CMT, this variant is not located within 
a zinc-finger domain (Szigeti et al., 2007; Warner et al., 1999). Its pathogenicity 
remains uncertain. 
The prevalence of EGR2 mutations in our selected cohort of CMT1 patients from the 
UK negative for the Chr17p11.2 duplication was 2.96% (4/135). 
3.4.2 Greek CMT1 cohort 
The mutational screening of CMT genes in Greek patients was part of a collaborative 
study and resulted in two publications (Koutsis et al., 2012; Koutsis et al., 2013). A 
complete list of mutations with pathogenicity prediction and patient phenotypes is 
available in Appendix III Table III-5. 
Three heterozygous variants were found in PMP22; all are likely to be pathogenic 
and none have been previously reported in the literature. All three variants were 
found in 1/86 patients (1.2%), were not found in 225 Greek controls and were absent 
from dbSNP, 1000 Genomes and EVS databases. As described below, one of the 
variants was in fact associated with an HNPP rather than a CMT1 phenotype due to 
misdiagnosis.  
The first mutation, p.(Gln27_Asn59 del_Glu60AsnfsX10) (c.79-2A>G), is located at 
a splice site in the 3’ region of the intronic se uence between exons 2 and 3, and is 
expected to disrupt the acceptor site by SpliceView (Figure 3-2). It is predicted to 
cause skipping of exon 3 and frameshift, leading to a premature stop codon. The 
transcript is likely to undergo nonsense-mediated decay (NMD) as the stop codon is 
predicted to occur further than 55 bp from a downstream intron/exon boundary 
(Nagy & Maquat, 1998). Unfortunately, transcriptional analysis could not be 
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performed as RNA was not available. Nonsense mutations usually cause an HNPP 
phenotype (Reilly et al., 2011). In fact, our patient (family 3) had been diagnosed as 
CMT1, but was found to have an HNPP phenotype upon further investigation 
(Koutsis et al., 2012). She was mildly affected and had an ulnar sensory neuropathy 
starting in adolescence with transient positional sensory symptoms. Her median and 
peroneal MNCVs were 45.4 m/s and 28 m/s respectively. Her right ulnar MNCV 
above the elbow was 37 m/s, and 42 m/s below the elbow. She had pes cavus and 
reduced tendon reflexes. There were no other affected family members  (Koutsis et 
al., 2012). Interestingly, frameshift mutations leading to a truncated PMP22 protein 
have been known to lead to an HNPP phenotype clinically and 
electrophysiologically, but with additional neuropathic characteristics resembling 
CMT1 such as pes cavus, areflexia, greater NCV slowing and onion bulb formation 
on nerve biopsy; it is therefore not surprising that our patient was initially 
misdiagnosed as CMT1. It has been proposed that the disease mechanism in this case 
may be haploinsufficiency coupled with additional impairment of Schwann cell 
function (Lenssen et al., 1998). 
The second mutation is an in-frame 6 bp deletion in exon 4, p.Thr99_Gly100del 
(c.296_301delCTGGAA). Upon PCR amplification, two fragments of 388 bp (size 
of WT PCR amplicon) and 382 bp (amplicon with deletion) were seen as two bands 
on agarose gel electrophoresis with hetero-duplex formation (Figure 3-2). Although 
the two fragments were not resolved well on the agarose gel, fragment analysis and 
cDNA sequencing confirmed the presence of the two fragments. The proband 
(family 2, II-6) was 22 years old and his phenotype was severe CMT1/DSD. Onset of 
disease was in infancy, when he was unsteady and fell frequently. He was never able 
to walk independently and required orthotics and bilateral support. He also had 
scoliosis, absent reflexes and weakness, atrophy and sensory signs in the upper and 
lower limbs. Nerve biopsy showed evidence of hypomyelinating neuropathy and 
MNCV was 2.3 m/s. This is likely to be a de novo mutation in the family (Koutsis et 
al., 2012).  
The third mutation is p.Val110_Ile116dup (c.328_348dup21), an in-frame 21 bp 
duplication in exon 5 of PMP22. Two fragments of 406 bp (WT amplicon) and 427 
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bp (amplicon with duplication) were distinguishable upon PCR amplification, 
although three bands were seen on agarose gel electrophoresis due to hetero-duplex 
formation (Figure 3-2). The presence of the two fragments was confirmed by 
fragment analysis. cDNA analysis and sequencing confirmed that two fragments of 
different lengths were present; formation of a hetero-duplex was once again seen on 
the agarose gel. The proband in this family (III-1 in family 1), a 14 year-old male, 
had disease onset at 18 months with frequent falls and unsteadiness of gait. He had 
difficulty walking and needed assistance for climbing stairs. Lack of reflexes, lower 
and peripheral upper limb atrophy and weakness, pes cavus, scoliosis, and upper and 
lower limb sensory signs were noted on neurological examination. His MNCV was 
severely slowed, at 14.3 m s. The proband’s mother (II-4 in family 1) was found to 
carry the same mutation upon segregation analysis. Although she had severe MNCV 
slowing (7.1 m/s), she was more mildly affected with disease onset in adolescence. 
Her gait was unstable; she had problems with fast walking and could not wear high-
heeled shoes. Neurological examination showed pes cavus, sensory signs in the 
lower limbs, absent reflexes and peripheral lower limb weakness. The unaffected 
sister of patient III-1 did not carry the mutation. Although no additional DNA 
samples were available for analysis, no other family members suffered from the 
same condition therefore the mutation likely arose de novo in the proband’s mother. 
To our knowledge, this variant is the first small duplication of a few bps in PMP22 
to be associated with CMT1 (Koutsis et al., 2012). 
As with other CMT1-associated PMP22 mutations located in the third 
transmembrane domain, it is likely that p.Thr99_Gly100del and p.Val110_Ile116dup 
act via a dominant-negative or toxic gain-of-function mechanism by causing protein 
aggregation and disturbed trafficking of mutant PMP22 to the plasma membrane 
(Koutsis et al. 2012). 
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Figure 3-2 Pedigrees, agarose gel electrophoresis and sequencing results of families 
with PMP22 micromutations. (A) Pedigree and DNA agarose gel electrophoresis of 
family 1 with the c.328_348dup21 mutation; a third band visible in affected 
members is due to hetero-duplex formation. (B) Pedigree and DNA agarose gel 
electrophoresis of family 2 with the c.296_301delCTGGAA mutation; a second band 
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visible in the proband is due to hetero-duplex formation. (C) cDNA agarose gel 
electrophoresis of probands from families 1 and 2, as well as two controls; probands 
have extra bands due to hetero-duplex formation. (D) Graphic representation of the 
c.328_348dup21 (p.Val110_Ile116dup) mutation; DNA and cDNA sequencing 
results of the proband compared with the WT sequence. (E) Graphical representation 
of the c.296_301delCTGGAA (p.Thr99_Gly100del) mutation; DNA and cDNA 
sequencing results of the proband compared with the WT sequence. (F) DNA 
sequencing results of the c.79-2A> G splice site mutation; proband compared with 
WT sequence. del=deletion; dup=duplication (reproduced from Koutsis et al., 2012). 
 
Four heterozygous variants were detected in EGR2: p.Arg362Arg (c.1086A>C), 
p.Arg381His (c.1142A>G), p.Gly451Val (c.1352G>T), p.Gly451Asp (c.1352G>A). 
Only the p.Arg381His is predicted to be pathogenic. Although the p.Gly451Val was 
not found in 225 Greek controls, it has been detected in our UK control cohort, as 
mentioned in Section 3.4.1, and was found in the unaffected mother of the proband. 
The other mutation at the same amino acid, p.Gly451Asp, was detected in 1/224 
(0.45%) Greek controls and was found in the unaffected father of the proband. 
Neither is likely to be pathogenic although it remains possible that they are rare 
variants with decreased penetrance (Koutsis et al., 2013). 
The p.Arg381His mutation was found in 1/86 (1.2%) patients. This mutation was 
previously described in a severe CMT1 patient with cranial nerve involvement 
(Pareyson et al., 2000) and a case of congenital hypomyelination (Vandenberghe et 
al., 2002). The p.Arg381His EGR2 mutation was associated with a case of early-
onset severe CMT1 in our cohort. Inheritance was likely AD but this could not be 
confirmed. At three years old, the patient had weak legs, was unsteady, and fell 
frequently. At 12 years old, she walked with assistance. She had no cranial nerve 
involvement but had atrophy, weakness and sensory signs in the lower and peripheral 
upper limbs, pes cavus, scoliosis and absent reflexes in the lower limbs. Her NCV 
was 27.5 m/s and nerve biopsy showed onion bulb formation and loss of myelinated 
fibres (Koutsis et al., 2013). This mutation is located at the same amino acid as the 
p.Arg381Cys variant identified in our UK cohort.  
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The three variants identified in LITAF (p.Thr78Thr (c.234G>A); p.Ile92Val 
(c.274A>G); p.Ala111Ala (c.333C>T)) and the three found in NEFL (p.Leu223Leu 
(c.667C>T), p.Asp468Asn (c.1402G>A), p.Glu527del (c.1579_1581 delGAG)) are 
not predicted to be pathogenic as they are either synonymous variants and/or found 
in dbSNP, 1000 Genomes or EVS databases (Koutsis et al., 2013). The p.Glu527del 
variant in NEFL had been previously labelled as pathogenic (Jordanova et al., 2003), 
but was later found in controls (Abe et al., 2009; Yamamoto et al., 2004; Yoshihara 
et al., 2002), albeit not in our Greek control cohort (Koutsis et al., 2013). 
3.4.3 CMT1 cohort from the Yakutsk province, Russia 
No variants were identified in PMP22 in the cohort of Yakutsk CMT1 patients 
(n=10). Two synonymous variants were identified in EGR2; both have been found in 
our UK cohort and are unlikely to be pathogenic: p.Pro209Pro (c.627A>G) in 2/54 
(3.7%) patients and p.Arg362Arg (c.1086A>C) in 8/54 patients (seven heterozygous 
(13%) and one homozygous (1.85%)). One hemizygous variant, p.Cys280Ser 
(c.839G>C), was identified in exon 2 of GJB1 in 1/10 patients (10%). The list of 
variants identified in the Yakutsk CMT1 patients along with pathogenicity 
predictions can be found in Appendix III Table III-6.  
The p.Cys280Ser mutation is novel and is located at an amino acid partially 
conserved across species. It is predicted benign by Polyphen-2 but damaging by 
SIFT. No Yakutsk controls were available to screen for the mutation in healthy 
individuals. Over 400 mutations have been described in GJB1 to date and only one is 
thought to be a polymorphism (Kleopa et al., 2012). The patient is male and had 
demyelinating CMT with onset at 35 years and weakness in the feet and foot 
deformities. Both parents were unaffected. No further clinical details were available. 
Another mutation, p.Cys280Gly, has been previously reported at this amino acid in a 
Hungarian family (Castro et al., 1999). The proband in this Hungarian family was a 
30-year-old male with CMT; his mother was reportedly healthy and carried the 
mutation, however she had decreased NCV. Three other unaffected family members 
did not carry the mutation and the variant was not present in 100 controls (Castro et 
al., 1999). The same group studied the effects of this mutation on the formation of 
hemichannels, which are the precursors of gap junction channels, and on the gap 
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junction channels themselves. The p.Cys280Gly mutant expressed in Xenopus 
oocytes had near normal hemijunctional conductance and voltage-gating properties 
were similar to WT hemichannels. This mutant had a negligible effect on the ability 
to form gap junction channels (Castro et al., 1999). The mutation affects an 
evolutionarily conserved prenylation motif which is usually necessary for the 
attachment of cytosolic proteins (rather than intrinsic membrane proteins like 
connexin-32) to the cell membrane. The p.Cys280Gly mutants did not display altered 
trafficking in myelinating Schwann cells and were able to rescue demyelination in 
GJB1-null mice. Although a milder phenotype might be predicted for this mutation 
and nearby mutations, it was not the case for a patient with a p.Ser281Stop mutation 
(Huang et al., 2005; Kleopa et al., 2012). The pathogenicity of the p.Cys280Gly 
mutation, as well as the variant identified in our study remains uncertain. 
3.4.4 Canines with peripheral neuropathies cohort 
No variants were identified in canine PMP22 in the cohort of dogs with peripheral 
neuropathies. Three variants were found in canine MPZ. The first variant is a 
heterozygous c.-4G>A in the 5’ untranslated region (UTR). The variant is not 
predicted to introduce a new start codon. The second variant in MPZ is a 
heterozygous synonymous mutation, p.Ser17Ser (c.51A>G); although unlikely, a 
pathogenic effect of synonymous mutations cannot be ruled out (Taioli, Cabrini, 
Cavallaro, Simonati, et al., 2011). The c.-4G>A  and p.Ser17Ser variants were found 
in the Golden Retriever with generalised peripheral nerve disease. A third variant, 
c.625-5dupC was found in the homozygous state in the Golden Retriever and in the 
heterozygous state in the Leonberger with unspecified familial peripheral 
neuropathy. None of these variants were found in dbSNP. Although this was not 
performed in this study, transcriptional analysis would be useful to rule out a 
potential effect of the c.625-5dupC variant on splicing. We did not have access to a 
large cohort of canine controls to screen for these variants in healthy dogs of the 
same breed.  
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3.4.5 Mitofusin 2 (MFN2) screen in Papillon dog with neuroaxonal dystrophy 
and cerebellar abiotrophy (NAD-CA) 
Three homozygous synonymous variants were found in MFN2 in the Papillon dog 
with NAD-CA: p.Val112Val (c.336A>G), p.Phe240Phe (c.720T>C) and 
p.Ala507Ala (c.1521G>A). Only the p.Phe240Phe was found in dbSNP (rs8738884), 
although the frequency of this variant is not available. None of these variants are 
predicted to be pathogenic as they do not lead to an amino acid change. 
3.5 Discussion  
The prevalence of EGR2 mutations in our selected cohort of CMT1 patients from the 
UK negative for the Chr17p11.2 duplication was 2.96% (4/135). Although EGR2 
mutations are a rare cause of CMT in our cohort (Murphy, Laura, et al., 2012), this 
frequency nonetheless represents a non-negligible number of CMT patients who 
have now received a genetic diagnosis. The frequency of EGR2 mutations is in 
agreement with previous studies of the European/UK and USA populations, which 
have found EGR2 mutations in 0.1-2% of CMT1 cases (Boerkoel et al., 2001; 
Mostacciuolo et al., 2001; Saporta et al., 2011; Timmerman et al., 1999; 
Vandenberghe et al., 2002). CMT1 patients with EGR2 mutations in our cohort 
generally had more severe and complex forms of CMT1, although one patient with 
the p.Arg381Cys mutation had a CMT2-like MNCV. This screening uncovered one 
novel mutation in EGR2, p.Arg426Gln. 
PMP22 and EGR2 mutations were found in 2.3% and 1.2% of our cohort of Greek 
CMT1 patients respectively, therefore mutations in these genes are likely to be a rare 
cause of disease in Greek CMT1 patients. As mentioned above, this is in accordance 
with the consensus in the literature. Small PMP22 duplications and deletions may be 
more common in the Greek population. LITAF and NEFL mutations were not found 
in our Greek cohort. These low frequencies are similar to previously published 
reports in other populations (Abe et al., 2009; Jordanova et al., 2003; Latour et al., 
2006; Murphy, Laura, et al., 2012; Pareyson & Marchesi, 2009). A genetic diagnosis 
was obtained in 3.5% of our Greek cohort previously found negative for Chr17p11.2 
duplication as well as MPZ and GJB1 mutations. One HNPP patient previously 
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misdiagnosed as CMT1 was found to carry a mutation in PMP22 (Koutsis et al., 
2012; Koutsis et al., 2013).  
In the Greek cohort, we have identified three novel micromutations in PMP22, two 
in CMT1 patients and one in an HNPP patient. In our study, as in previous reports, 
PMP22 small deletions and duplications displayed high phenotypic variability 
(Koutsis et al., 2012; Taioli, Cabrini, Cavallaro, Acler, et al., 2011). The first 
mutation, a splice site mutation before exon 3, is predicted to cause skipping of exon 
3 and frameshift leading to a premature stop codon and was associated with an 
HNPP phenotype. Although analysis at the RNA level was not possible in our 
patient, frameshift changes leading to delayed or premature stop codons in PMP22 
are usually associated with HNPP (Reilly et al., 2011; Taioli, Cabrini, Cavallaro, 
Acler, et al., 2011). An exception occurs when the premature stop codon is not 
expected to undergo NMD, which may cause CMT1 or DSD (Choi et al., 2004; 
Ionasescu, Searby, Ionasescu, Reisin, et al., 1997; Koutsis et al., 2012; Numakura et 
al., 2002), as well as HNPP (Taioli, Cabrini, Cavallaro, Acler, et al., 2011). The 
second mutation, an in-frame 6 bp deletion, caused severe CMT1/DSD. The third 
mutation is an in-frame 21 bp duplication; there was high intra-familial phenotypic 
variability associated with this mutation (Koutsis et al., 2012). In agreement with our 
study, in-frame deletions and duplications in PMP22 are generally associated with a 
CMT1 phenotype (Ekici et al., 2000; Koutsis et al., 2012; Mersiyanova et al., 2000; 
Park et al., 2006; Sambuughin et al., 2003; Taioli, Cabrini, Cavallaro, Acler, et al., 
2011). 
The EGR2 p.Arg381His mutation found in the Greek cohort is usually associated 
with variably severe CMT1 phenotypes with or without cranial involvement 
(Pareyson et al., 2000; Vandenberghe et al., 2002). Our patient had severe CMT1 but 
no cranial involvement, however cranial palsies may be seen later in the patient’s life 
as with previous cases carrying this mutation (Koutsis et al., 2013; Pareyson et al., 
2000). 
The large majority of CMT1 patients in our Greek cohort remain without a genetic 
diagnosis, indicating that many novel causative genes are yet to be uncovered in the 
Greek CMT1 population (Koutsis et al., 2013). The well-defined geographical 
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location of the Greek population may point to a higher frequency of AR causes of 
CMT disease; therefore, AR causes of CMT may be explored in cases where AD 
inheritance cannot be fully ascertained (Koutsis et al., 2013). We have also suggested 
that the low frequency of mutations in CMT1 genes in our cohort may be explained 
by the cut-off of 40 m/s used to discriminate CMT1 from CMT2 in this particular 
cohort of patients. Consequently, it is possible that some CMT2 patients were 
mistakenly included in our gene screening (Koutsis et al., 2012; Koutsis et al., 2013). 
Phenotypic variability between patients carrying the same mutation as in our Greek 
family with the in-frame 21 bp duplication in PMP22 further complicates prognosis 
and confirms that genetic modifiers are likely to play a role in disease severity in 
CMT. 
The screening of PMP22, GJB1 and EGR2 in the Yakutsk CMT1 cohort revealed 
one GJB1 variant out of the 10 patients tested for this gene. In a study of Russian 
patients, GJB1 mutations accounted for 7.4% of CMT1, 3.1% of CMT2 and 17.6% 
of unspecified CMT cases (Mersiyanova et al., 2000). Although the pathogenicity of 
this novel variant is unclear and our cohort was small, the finding of a GJB1 
mutation in our Yakutsk CMT1 patients confirms that GJB1 mutations are likely to 
be an important cause of disease in Yakutsk CMT patients and perhaps in other 
provinces of Russia. 
Some important issues previously discussed in studies of CMT and other genetic 
diseases have once again been highlighted in this study. Segregation of mutations in 
families, the use of in-silico prediction software like Polyphen-2 and SIFT, 
assessment of conservation of amino acids across species and screening of the 
variant in control groups remain insufficient to prove pathogenicity. Furthermore, 
previous publication in scientific journals does not establish pathogenicity, as some 
mutations once thought to be deleterious have now been categorized as 
polymorphisms. Although functional studies are usually thought to be the gold 
standard in assessing pathogenicity of mutations, some mutations causing 
dysfunction in vitro have been found in healthy individuals (Kochañski, 2006). 
Finally, screening the coding exons and flanking intronic sequences of genes does 
not completely rule out the possibility of that gene being involved in the disease. 
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Variants in the 5’UTR and 3’UTR regions and deep intronic or synonymous variants 
may cause disease by affecting microRNA binding, splicing, stability of mRNA or 
translational efficiency, or they may modify protein structure and activity (Parmley 
& Hurst, 2007). For example, a synonymous mutation in MPZ in a DSD patient was 
found to activate a cryptic splice site leading to an in-frame partial deletion of one 
exon (Taioli, Cabrini, Cavallaro, Simonati, et al., 2011). 
In the future, gene panels, exome sequencing and whole genome sequencing will 
become faster and more affordable, thus single gene testing as performed herein may 
become obsolete. In the meantime however, the diagnostic guidelines described in 
Section 3.1.1 should be followed to avoid inappropriate genetic tests (Amato & 
Reilly, 2011). Genotype-phenotype correlations and assessment of subtype 
frequencies in different populations such as those presented in this study should also 
guide clinicians in their task. 
Although the causative genes have not been identified in our canine peripheral 
neuropathy cases as well as in the canine with NAD-CA, our screen was only 
preliminary. Screening of other demyelinating and axonal CMT genes targeted 
according to the dog’s phenotype is warranted, including the genes associated with 
AR inheritance (Granger, 2011). Sequencing of MTMR2 and MTMR13 should be 
prioritised in future molecular studies of the Schnauzer dogs with demyelinating 
polyneuropathy and focally folded myelin sheaths (Vanhaesebrouck et al., 2008). 
Granger (2011) also highlights some differences between human CMT and CMT-
like disease in canines: there is no equivalent of the 38 m/s MNCV cut-off value to 
delineate demyelinating from axonal forms of CMT in canines; only AR cases have 
been described in canines, while AD forms are more common in humans; 
demyelinating forms of neuropathies with onion bulbs are much less frequent in 
canines than they are in humans. These differences should be kept in mind in studies 
linking canine and human CMT disease (Granger, 2011).  
The finding of new disease-associated genes would provide strong candidates for the 
human forms of the disease and would allow us to gain further insight into the 
pathogenesis of disease, especially as the collection of tissue such as nerve and 
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muscle will be easier than in humans. The causative gene in the Papillon dog may be 
a candidate gene for AR infantile NAD in humans. We have obtained DNA from 
five unrelated control Schnauzer dogs in addition to the two affected Schnauzers 
with AR demyelinating CMT-like polyneuropathy with focally folded myelin 
sheaths which were screened in this study. We also now have 5 affected, 31 
unaffected and 1 obligate carrier of the highly-inbred Papillon dogs with NAD-CA. 
Future studies will involve genotyping of these two cohorts on the Illumina HD 
Canine array (Illumina). Because both the Schnauzers and the Papillon dog are part 
of highly inbred families, we will search for mutant homozygous alleles identical by 
descent located in a large region of homozygosity shared by the affected dogs and 
not shared with unaffected dogs, as was done in the Drögemüller et al (2010) study. 
The array will also allow us to detect large duplications or deletions that may be 
disease-causing. Recent studies have shown that genes underlying Mendelian traits 
in dogs can be uncovered by genome-wide association analysis using just 10 affected 
and 10 control dogs (Karlsson et al., 2007; Matiasek & Drögemüller, 2011). 
3.6 Conclusion 
In conclusion, this study has provided additional data on the frequency of CMT 
genetic subtypes in three populations: the UK, Greece and the Yakutsk province in 
Russia. It has widened the spectrum of phenotypes associated with particular 
mutations in CMT genes, and has confirmed that in-frame deletions and duplications 
in PMP22 cause CMT1 while nonsense mutations are usually associated with HNPP. 
Such gene screening studies and phenotype-genotype descriptions are essential in 
elucidating the natural history of disease and providing accurate counselling to 
patients. We have also highlighted some issues associated with pathogenicity 
assessments of mutations; these issues apply not only to CMT but to most other 
genetic diseases as well. Solving these issues will become more important as we 
identify thousands of new variants in “next-generation sequencing” (NGS) studies. 
This study has also ruled out PMP22 and MPZ mutations in a cohort of dogs with 
peripheral neuropathy and MFN2 mutations in a dog with NAD-CA. Although the 
genetic cause of disease remains unexplained in these dogs, it has provided a 
stepping ground for further genetic research including sequencing of other CMT 
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genes and homozygosity mapping. These studies may result in a new canine model 
of CMT in the near future. 
This Chapter has highlighted the phenotypic and genotypic heterogeneity of CMT. 
The next Chapter will focus on one particular CMT subtype, CMT1A, which 
displays high variability in disease severity despite all patients carrying the 
Chr17p11.2 duplication.  
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Chapter 4 Genetics modifiers of the CMT1A phenotype 
4.1 Introduction 
4.1.1 Phenotypic variability in CMT1A 
As discussed in Section 1.4.4, most CMT1A patients carry the same sized 
Chr17p11.2 duplication, yet they exhibit a wide range of severities both within and 
between families. Age of onset, weakness and wasting, NCVs and sensory signs are 
the most variable features (Birouk et al., 1997; Garcia et al., 1995; Kaku et al., 1993; 
Thomas et al., 1997). As highlighted in Section 1.4.2, several cases of CMT1A and 
other CMT subtypes have been reported to display coexistent CIDP-like 
inflammatory features, with abrupt worsening of disease in some instances. This 
association is thought to occur more often that would be expected by chance 
(Ginsberg et al., 2004). The high intra- and interfamilial variability in disease 
severity in CMT1A and other CMT subtypes renders it difficult for clinicians to 
advise patients on disease progression and family planning. The phenotypic 
heterogeneity in CMT1A suggests that genetic factors as well as epigenetic, 
stochastic and environmental effects may influence disease severity as identical 
twins have shown disparate phenotypes (Boerkoel et al., 1999; Fraga et al., 2005; 
Garcia et al. 1995). As discussed in Section 1.4.4, comorbid conditions such as 
diabetes may worsen the CMT1A phenotype (Sheth et al., 2008), however most of 
the disease variability is likely to be due to genetic background or epigenetics as no 
environmental factor has been found to contribute significantly to disease severity 
(Pareyson & Marchesi, 2009). 
4.1.2 Genetic modifiers of disease 
Although not disease-causing on their own, common variants may act as genetic 
modifiers of a phenotype by modulating the effect of a disease-associated variant 
(Génin et al., 2008). Genetic modifiers are defined as genes that influence the 
phenotypic expression of another gene; they may be monogenic, where variation in 
one gene explains most of the variability, or multi-factorial, where several genes are 
involved in modifying a disease phenotype (Génin et al., 2008). The multi-factorial 
model is likely to be more common (Génin et al., 2008). The past few years have 
witnessed an increased interest in finding potential genetic modifiers of various 
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diseases including hereditary neuropathies. Detecting biomarkers of disease severity 
in CMT will help provide more accurate disease prognoses and further clues about 
CMT disease pathways. Modifiers may influence a patient’s response to treatment 
and may also be disease-causing in other forms of inherited neuropathy. The 
mechanism of disease modification will be a potential therapeutic target (Fledrich, 
Schlotter-Weigel, et al., 2012; Reilly et al., 2011).  
4.1.3 Genetic modifiers in CMT1A 
Genes such as PMP22 which cause disease via a gene dosage mechanism may be 
especially sensitive to the effect of genetic modifiers and the environment (Boerkoel 
et al., 1999). Genetic modifiers of CMT1A disease have not been extensively 
studied. Variants in other genes within the Chr17p11.2 duplication may modify the 
CMT1A phenotype, however given the restricted phenotype of CMT1A, these genes 
are probably not very sensitive to gene dosage, and most are only expressed in foetal 
tissues (Inoue et al., 2001; Murakami et al., 1997). A study of CMT1A rats has 
identified lipid metabolism genes such as peroxisome proliferator-activated receptor 
gamma (Pparg) that are dysregulated in sciatic nerve transcriptomes; these genes 
may be modifiers of disease progression. Skin biopsy studies of CMT1A patients 
confirmed some of the results found in the rat, and also found that the age of the 
patient, as well as the mRNA levels of glutathione S-transferase theta 2 (GSTT2) and 
cathepsin A (CTSA) together could account for 47% of the variance in the patients’ 
CMTNS (Fledrich, Schlotter-Weigel, et al., 2012).  
A concomitant mutation in another CMT gene is likely to affect the phenotype of 
CMT1A patients. Patients with compound forms of CMT carrying a Chr17p11.2 
duplication as well as a GJB1, LITAF or MPZ mutation in the compound 
heterozygous state have been described. These patients had severe phenotypes likely 
due to an additive effect of the two genetic defects (Hodapp et al., 2006; Meggouh et 
al., 2005; Young et al., 2013). A p.Ser72Leu PMP22 point mutation on the same 
chromosome as a CMT1A duplication has been found in a CMT1A family with 
unusual and mild disease (Gouvea et al., 2010). These compound forms of CMT may 
remain undetected as CMT1A patients are not usually tested for point mutations in 
PMP22 and other CMT genes. Although they are probably rare, additional mutations 
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in CMT genes may account for a minor portion of the phenotypic variability in 
CMT1A. It may be worthwhile to search for additional pathogenic variants in 
atypically severe or mild CMT cases (Hodapp et al., 2006). To illustrate, we 
collaborated on the investigation of a patient with a severe DSD phenotype and 
additional features including congenital hip dysplasia, partial craniosynostosis and 
respiratory failure. This patient was found to carry a PMP22 point mutation and a 
microdeletion on chromosome 3q23. The genes located within this deletion may be 
candidate genetic modifiers of the phenotype in other CMT patients, especially in 
severely affected patients with respiratory involvement (Voermans et al., 2012). 
4.1.4 A role for the immune system in CMT1A phenotypic heterogeneity 
As described in Section 1.4.2, various cases of superimposed inflammatory 
neuropathy have been reported in CMT1A, and immunological mechanisms may 
play a role in disease pathogenesis. The immune system in humans detects foreign 
agents to protect against disease and therefore needs to be able to differentiate “self” 
from “non-self” agents such as antigens. Its two main components are the innate 
immune response, which is non-specific but immediate, and the adaptive immune 
response, which is specific to certain pathogens and antigens and develops a memory 
to improve its response over time. Macrophages, a type of leukocyte, are an 
important part of the innate immune system; macrophages remove debris by 
phagocytosis and may also act as antigen-presenting cells to activate the adaptive 
immune system (Male et al., 2006). Lymphocytes, another type of leukocyte, are 
important cells in the adaptive immune response. B-cells and T-cells are types of 
lymphocytes; B-cells mediate humoral immunity, which involves antibody 
production in response to an antigen, while T-cells mediate cell-mediated immunity, 
which results in the activation of macrophages, the release of cytokines and the 
production of cytotoxic CD8-positive T-cells in response to an antigen. T-cells 
require antigen presentation by a major histocompatibility complex (MHC) 
molecule. The MHC is a group of cell surface molecules encoded by a large set of 
genes in humans, the most well-known of which are the nine principal human 
leukocyte antigen (HLA) genes: HLA-A, HLA-B, HLA-C, HLA-DPA, HLA-DPB, 
HLA-DQA, HLA-DQB, HLA-DRA, and HLA-DRB (Male et al., 2006). The MHC, 
composed of class I, II and III, is a 7.6 Mb region on chromosome 6p21-22 
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containing a dense cluster of 224 loci (128 of which are expressed) in high linkage 
disequilibrium (LD). Approximately half of the expressed loci in the MHC region 
play a significant role in the immune system and its associated diseases (Gough & 
Simmonds, 2007; MHC Sequencing consortium, 1999). Inflammatory and 
autoimmune diseases are disorders of the immune system. In autoimmune diseases, 
the immune response is mistargeted towards the body’s own healthy tissue, 
specifically the myelin sheath in CIDP. Although the triggering antigen remains 
unknown in CIDP, it is suggested that antigens in non-compact myelin and at the 
axolemma are attacked by the immune system (Dalakas, 2011; Pollard & Armati, 
2011).  
Several models of myelin-mutant mice have reported an involvement of the immune 
system in CMT disease pathogenesis. Heterozygous knockout MPZ mice and GJB1-
deficient mice both have a demyelinating neuropathy with presence of CD8-positive 
T-lymphocytes and activation of macrophages with myelin-macrophage interactions. 
In both cases, demyelination was less severe and macrophages were not upregulated 
when mice were crossbred with immunodeficient mice, indicating that macrophages 
and CD8-positive T-cells may play an active role in the demyelinating process in this 
animal model of neuropathy (Carenini et al., 2001; Ip et al., 2006; Mäurer et al., 
2002; Schmid et al., 2000). In PMP22 overexpressing mice, levels of macrophages 
were also increased in demyelinated nerves and macrophages were noted to 
phagocytose intact myelin; however, CD8-positive T-lymphocytes were not found to 
mediate demyelination in this mouse model of CMT1A (Kobsar et al., 2005; Kohl et 
al., 2010). It is possible that the immune system is activated in CMT1A during early 
stages of demyelination in animal models (Kobsar et al., 2005; Ip et al., 2006). Of 
course, it may be that the involvement of immune cells in peripheral nerves of 
PMP22 mutant mice is neuroprotective rather than pathogenic (Ip et al., 2006). The 
animal models mentioned here do not show a CIDP-like phenotype, do not respond 
to anti-inflammatory drugs, and unlike in CMT1 patients with CIDP-like features, T-
cells are mainly CD8-positive rather than CD4-positive (Martini & Toyka, 2004). 
Hence, it is likely that the involvement of the immune system in these CMT1 animal 
models is chronic and does not model CIDP-like disease in human CMT1. It may 
however suggest that immune-mediated components of disease could be present in 
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typical CMT1 at a subclinical level (Martini & Toyka, 2004).  
Vasculitis and infiltration of macrophages and CD4-positive T-lymphocytes close to 
myelinated axons have been reported on some nerve biopsies in CMT1A and 
unspecified AD CMT1 (Carvalho et al., 2005; Ginsberg et al., 2004; Malandrini et 
al., 1999; Martini & Toyka, 2004; Pál et al., 2009; Vital et al., 1992; Vital et al., 
2003; Williams et al., 1993). These patients typically develop CIDP-like acute or 
sub-acute worsening of symptoms and often respond well to steroids or IVIG 
treatment (Dyck et al., 1982; Malandrini et al., 1999). Another study found 
upregulation of MHC class II molecules and activation of macrophages but no 
lymphocytic infiltration in eight CMT1A patient nerve biopsies; however, it is 
unknown whether these patients had CIDP-like features clinically (Stoll et al., 1998). 
Inflammatory infiltration on nerve biopsy was not seen in a large cohort of CMT1A 
patients without CIDP-like features, therefore these findings may not be a common 
phenomenon in typical CMT1A (Gabriel et al., 2002).  
Interestingly, autoantibodies against PMP22 were present in 66% of CMT1A, 75% 
of CMT1 and 60% of CMT2 patients; however they were also present in 23% of 
controls (Ritz et al., 2000). In another study, anti-PMP22 antibodies were more 
frequent in CMT1A patients than in controls, especially in those with stepwise 
progression of disease, but not more frequent than in patients with other 
neuropathies. It is possible that anti-PMP22 antibodies are merely a response to 
nerve damage rather than a primary cause of pathology (Gabriel et al., 2002). It is 
noteworthy that the presence of anti-PMP22 antibodies and the concentration of 
cytokines in the serum did not correlate with disease severity in CMT1A (Gabriel et 
al., 2002). Exposure to PMP22 in rats was able to induce experimental autoimmune 
neuritis, an animal model of immune-mediated neuropathy (Gabriel et al., 1998). 
PMP22 autoantibodies were found in 50% of CIDP patients in the Ritz et al. (2000) 
study. One study similarly found antibodies against PMP22 in 35% of patients with 
CIDP and in none of the controls (Gabriel et al., 2000). However, myelin protein 
peptides did not elicit immune responses in CIDP patients (Sanvito et al., 2009). It is 
still uncertain whether PMP22 may play a role in the pathogenesis of inflammatory 
neuropathy (Gabriel et al., 2000). 
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Some CMT1A patients may develop a superimposed acquired inflammatory 
neuropathy because of exposure to damaged components of myelin, leading to 
increased susceptibility to autoimmune reactions against this myelin debris and 
healthy myelin (Martini & Toyka, 2004). This mechanism has been suggested to 
explain the co-existence of CIDP in other CMT subtypes, including CMT4C 
(Houlden et al., 2009), CMT1B (Donaghy et al., 2000) and CMT1X (Ginsberg et al., 
2004). A dysimmune reaction against PMP22 due to increased dosage is a possible 
explanation for the development of CIDP in CMT1A; however, as discussed above, 
PMP22 antibodies have also been found at high levels in other inherited neuropathies 
and the presence of PMP22 antibodies in CMT1A is not correlated to disease 
severity, therefore a nonspecific response to nerve damage may be a more plausible 
explanation (Gabriel et al., 2000; Vital et al., 2003). The peripheral nerve may also 
have increased susceptibility or fragility due to the hereditary neuropathy leading to 
activation of macrophages by Schwann cell-related factors, facilitating additional 
immune-mediated demyelination (Ben Youssef-Turki et al., 2011; Ginsberg et al., 
2004; Mäurer et al., 2002). Alternatively, immunogenic neuritogens may be exposed 
as a result of myelin damage (Kobsar et al., 2005; Martini & Toyka, 2004). It 
remains unclear how the activation of the immune system in CMT1A may 
sometimes lead to an additional inflammatory autoimmune disease (Kobsar et al., 
2005). 
The involvement of the immune system in the pathogenesis of inherited neuropathies 
is considered debatable. Indeed, it is still undetermined whether autoimmune 
involvement concerns most CMT1 patients at a subclinical level, or a selection of 
patients who develop a secondary acquired autoimmune-mediated neuropathy 
(Martini & Toyka, 2004). As previously mentioned, most CMT1 patients do not 
improve with immunosuppressant therapy, therefore the former is perhaps less likely 
(Ginsberg et al., 2004; Martini & Toyka, 2004). It remains possible that SNPs 
associated with autoimmune and inflammatory diseases may modulate disease 
severity in CMT1A (Ginsberg et al., 2004). Although the exact function of all the 
genes located within the CMT1A duplicated region has not been elucidated, none of 
the genes with known function are thought to be involved in the immune system. 
Therefore, an Immunochip (Illumina) array was used herein to study the association 
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of inflammatory markers with the CMT1A phenotype and determine whether certain 
SNPs are associated with severe or mild disease. This methodology employs a 
candidate gene approach to genetic modifier identification; a candidate gene 
approach involves studying genes either in the same disease pathway, or as in this 
case, genes located in another pathway which are involved in somewhat more 
indirect disease consequences (Génin et al., 2008). 
4.1.5 Description of the Immunochip 
The Immunochip is an Illumina Infinium customised genotyping chip that contains 
196,524 common and rare variants (195,806 SNPs and 718 small insertions-deletions 
(indels)). The Immunochip was designed by the WTCCC for deep replication of 
genome-wide association studies (GWAS) of autoimmune and inflammatory 
diseases, as well as fine mapping of the significant loci identified in various GWAS 
studies by leading investigators. The majority of these variants have been previously 
found to be associated with autoimmune and inflammatory diseases including 
multiple sclerosis, rheumatoid arthritis, Type 1 Diabetes, Crohn’s disease, systemic 
lupus erythematosus (SLE), ankylosing spondylitis, autoimmune thyroid disease, 
celiac disease, ulcerative colitis and psoriasis. SNPs in the HLA region are especially 
well covered on the Immunochip (Cortes & Brown, 2011). SNPs from GWAS of 
non-immunological diseases performed by the WTCCC are also included. The chip 
requires only a small amount of DNA, and is relatively inexpensive compared to 
whole-genome chip-based SNP assays (Cortes & Brown, 2011). The chip contains 
20 SNPs located within the Chr17p11.2 duplicated region, one of which is located 
within the PMP22 gene (dbSNP ID rs3785651).  
4.2 Aims of this study 
The principal aim of this study was to identify the genetic factors modifying the 
CMT1A phenotype. Specifically, this Chapter seeks to determine whether alleles 
associated with immune-related mechanisms and diseases may be responsible for 
some of the heterogeneity in CMT1A disease severity. It is hoped that this work will 
be a stepping stone in identifying novel drug targets and will help in predicting 
CMT1A disease progression during patient counselling.  
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4.3 Methods  
4.3.1 CMT1A patient cohort 
CMT1A patients were recruited and clinically evaluated by consultant neurologists 
leading CMT clinics around the world, including Professor Mary Reilly and Dr 
Matilde Laurá at the NHNN, Professor Mike Shy at the University of Iowa, USA and 
Professor Wilson Marques Jr. at the University of São Paulo, Brazil.  
CMT1A was diagnosed based on physical examination, electrophysiological tests 
and genetic tests (microsatellites and/or MLPA) performed by consultant 
neurologists and laboratories at the corresponding centres. DNA was either obtained 
from the Neurogenetics diagnostic laboratory at the NHNN or was sent to our centre 
from the participating centres mentioned above. Details of ethics approval and 
patient consent are found in Section 2.1.1. Purity and concentration of DNA samples 
were assessed using a NanoDrop as described in Section 2.1.5 
4.3.2 Patient disease severity assessment 
The CMT examination scores (CMTES) as well as the CMTNS, where possible, 
were calculated for each patient by the consultant neurologist. As discussed in 
Section 1.3.1, the CMTNS is measured on a scale of 0 to 36; patients with mild, 
intermediate and severe disability typically have a CMTNS between 1–10, 11–20 
and 21 or greater, respectively. The CMTES is a sub-score of the CMTNS and is 
calculated out of 28 points. It contains the sum of the symptoms plus the signs, but 
does not include the electrophysiological results (Murphy, Herrmann, et al., 2011). 
Either the first or second version of the CMTNS and/or CMTES was calculated for 
each patient due to variability in year and location of clinical assessment. The 
components that were found to differ the most between these two versions in the 
Murphy, Herrmann and colleagues (2011) study include sensory symptoms, motor 
symptoms in the arms, sensibility to pinprick, arm strength, and SNAPs. 
4.3.3 Confirmation of Chr17p11.2 duplication by quantitative polymerase 
chain reaction (qPCR) 
Before cases were genotyped, the Chr17p11.2 duplication was confirmed in CMT1A 
cases where a proof of genetic diagnosis could not be obtained. Dosage of PMP22 
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exon 4 was assessed by qPCR using SYBR Green chemistry (Applied Biosystems) 
and the StepOnePlus Real-Time PCR System (Applied Biosystems) as described in 
Section 2.1.6. The delta-delta Ct method (described in Section 2.1.6) was used for 
relative quantitation of PMP22 exon 4; ACTBL2 was used as the housekeeping gene. 
Primer sequences for PMP22 and ACTBL2 can be found in Appendix IV Table IV-1. 
4.3.4 Adjustment of CMT examination score (CMTES) for age at examination 
(AAE) 
A study of CMT1A patients found an increase in disease severity of 0.257 CMTNS 
points per year and a Pearson correlation coefficient of 0.4 between age at 
examination (AAE) and CMTNS (Steiner et al., 2008). Another study has found the 
age-adjusted CMTNS of CMT1A patients to increase by 0.686 points per year (Shy 
et al., 2008). To determine whether AAE should be taken into account when 
considering the CMTES in the Immunochip association study, the AAE for each 
CMT1A patient in the cohort was plotted against their CMTES. A linear regression 
was performed to confirm the pattern between the CMTES and AAE.  
As expected, the AAE had a non-negligible positive linear correlation with the 
CMTES (Figure 4-1), with an increase of 0.1557 CMTES points per year and a 
Pearson correlation coefficient of 0.29. 
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Figure 4-1 Graph of CMTES as a function of AAE in CMT1A patients. 
The graph of the residuals after regression shows that once AAE is accounted for, the 
positive linear trend disappears, confirming the effect of AAE on CMTES. The 
residual of the regression was then used as the age-corrected CMTES. Negative 
values (values falling below the regression line) and positive values (values falling 
above the regression line) represent patients with a phenotype milder and more 
severe than expected for their AAE, respectively (Figure 4-2).  
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Figure 4-2 Graph of the residuals of age-corrected CMTES as a function of AAE 
after regression in CMT1A patients. 
Although there is a minor increase in variance in age-corrected CMTES distribution 
in the older CMT1A patients, the age-corrected CMTES is mostly independent in 
value and variance from the AAE (Figure 4-3). 
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Figure 4-3 Graph of the variance of age-corrected CMTES as a function of AAE in 
CMT1A patients. 
4.3.5 Assessment of intrafamilial and interfamilial variability in CMT1A 
To characterize the extent of intrafamilial variability in our patient cohort, the age-
corrected CMTES (Section 4.3.4) of one family member was plotted against the age-
corrected CMTES of another member of that family in a total of 36 CMT1A families 
with two to nine family members each.  
To assess the extent of intra- and interfamilial variability, the difference in age-
corrected CMTES between members of the same family was compared to the 
difference in age-corrected CMTES of unrelated CMT1A patients. The difference of 
one member from the rest of the group refers to the mean of the absolute value of the 
difference between the age-corrected CMTES of that individual compared to every 
single member of that group. The average size of a CMT1A family in our study was 
2.57 members. Using the R software package, 100,000 groups of an average size of 
2.57 individuals were randomly created using 185 unrelated CMT1A patients. It was 
critical that similar-sized groups were compared for analysis of related and unrelated 
CMT1A patients. 
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4.3.6 Immunochip association study: patient cohort 
A total of 366 CMT1A patients (120 UK, 151 USA, and 95 Brazil patients), 135 
CIDP patients and 150 controls were included in the Immunochip association study 
before quality control was performed. Additional details regarding the CMT1A 
patient cohort are available in Section 4.3.1. CIDP patients were recruited and 
clinically evaluated by consultant neurologists at the NHNN and other specialist 
centres throughout the UK. CIDP cases were analysed in this study to test for shared 
immune-related disease mechanisms with CMT1A. Control Immunochip data for 
healthy individuals of Northern European ancestry were provided by the WTCCC2. 
4.3.7  Immunochip association study: patient classification and severity 
scoring 
The CMTES was available for all patients in the Immunochip cohort and was 
therefore used as a measure of disease severity. For the association study, CMT1A 
patients were classified as mild or severe. According to our categorization, mildly 
affected patients have a CMTES of 0-8, inclusive and severe patients have a CMTES 
of 11 or above. Any patient with CMTES of 9 or 10 was excluded to avoid false 
negative results and to more clearly delineate the two categories. Similarly, using the 
age-corrected CMTES, any patient with a score between -1 and 1 was excluded. 
Patients with age-corrected CMTES of -1 and below were considered mild; patients 
with age-corrected CMTES of 1 and above were considered severe. 
4.3.8 Immunochip association study: genotyping 
Genotyping of samples on the Illumina Infinium HD Human Immuno BeadChip 
(Illumina) was performed entirely by UCL Genomics according to the 
manufacturer’s protocol using 300 ng of gDNA. Further details of the genotyping 
protocol are available in Appendix II. GenomeStudio (v.2010.1, Illumina) was used 
to extract data files in the PED and MAP file formats for compatibility with the 
gPLINK software, an open-source C/C++ tool set used here for data quality control 
and association analyses. A description of gPLINK is available in Section 2.6. 
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4.3.9 Immunochip association study: data quality control 
GenomeStudio (Illumina) was used to examine the X chromosome of all samples 
(except controls for which gender was not available) and discard individuals with 
discordant sex information in the eventuality that sample processing errors had 
occurred. B allele frequencies (defined in Section 2.1.13) of the male X chromosome 
indicate widespread hemizygosity while the female X chromosome has a much 
higher rate of heterozygous SNPs (Figure 4-4). 
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Female X chromosome 
 
Figure 4-4 B allele frequencies and log R ratios of sample male and female X 
chromosomes. The B allele frequency is used to infer genotype calls as it is a 
measure of the allelic intensity ratio of two alleles. The log R ratio is the total signal 
intensity for two alleles of a SNP. X chromosomes with B allele frequencies (top 
panels) indicating male (top) and female (bottom) gender in GenomeStudio.  
Command lines used in gPLINK for quality control are found in Appendix IV. PED 
and MAP files from GenomeStudio were converted to binary PED (BED) files using 
the gPLINK software. PED files contain the sample ID, affectation status and 
genotypes while MAP files contain SNP information including the chromosome, 
marker ID, genetic distance and physical position. “Per individual” and “per SNP” 
quality control measures were performed in gPLINK to eliminate bias and errors as 
described by Anderson et al. (2010). Any CMT1A patient of non-Northern European 
 153 
origin including all patient DNA obtained from the University of São Paulo in Brazil 
were excluded to avoid population stratification or spurious associations due to 
ethnicity-based rather than disease-based differences in allele frequencies. 
Individuals with incomplete phenotypic grading, those with more than 10% missing 
genotypes and individuals with CMTES falling between the mild and severe 
categories were also removed from the analysis. One member of each family was 
randomly selected; other family members were excluded to avoid introducing bias 
and over-representing a particular genotype. Gender was ignored in all analyses as it 
was not available for the control group; gender is not believed to be linked to disease 
severity in CMT1A (Swan et al., 2007). A total of 187 CMT1A cases, 125 CIDP 
cases and 150 controls remained after the exclusion criteria were applied: 103 
individuals were of unmatched ethnicity, 12 had incomplete phenotypic grading, 67 
were excluded based on familial relationship and 4 had high rates of missing 
genotypes. 33 CMT1A patients with CMTES of 9 or 10 were excluded from the mild 
versus severe, mild versus controls and severe versus controls analyses; 40 CMT1A 
patients with unavailable AAE or an age-corrected CMTES between -1 and 1 were 
excluded from the corresponding age-corrected analyses. The gender, AAE and 
CMTES (non-age-corrected and age-corrected) of the 187 CMT1A patients who 
passed the quality control measures are found in Appendix IV Table IV-3.  
SNPs showing a significant deviation from Hardy-Weinberg equilibrium (HWE) in 
controls were discarded from further analyses as these may indicate genotype-calling 
errors or selection; the significance threshold used in this test was 0.001 (Anderson et 
al., 2010). Other “per SNP”  uality control filters used in gPLINK to reduce the 
probability of genotype-induced artefacts included exclusion of SNPs with a 
genotype rate below 90% and removal of all markers with a very low MAF 
(MAF<0.01). A total of 138,103 SNPs remained for analysis after data quality 
control: 1,588 SNPs showed deviation from HWE (in controls only), 6085 SNPs had 
a genotyping rate lower than 90% and 51,965 SNPs had a MAF less than 0.01 in the 
CMT1A/CIDP/control combined dataset. 
 
The R software package was used to construct QQ plots of p-value distributions to 
check for systematic sources of bias such as the possibility of population 
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stratification. QQ plots show the expected distribution of p-values for all SNPs tested 
on the x-axis, against the observed p-values for these SNPs on the y-axis. A 
deviation of p-values from the x=y line indicates a deviation from the null hypothesis 
of no association. A deviation in the bottom 90% of the values from the x=y line 
suggests the presence of spurious associations due to bias (persistent differences 
between cases and controls throughout the entire genome). A sharp deviation from 
the x=y line in the top right hand corner (smallest p-values) indicates a true 
association or a false positive association (Balding, 2006). Command lines used to 
construct QQ plots in the R software are found in Appendix IV. 
4.3.10 Immunochip association study: association analyses 
All association analyses were performed using specific command lines in gPLINK 
(Appendix IV). Two sets of standard case/control allelic association analyses based 
on Chi-squared (Clarke et al., 2011) were performed: one using the non-age-
corrected CMTES, and a second using the age-corrected CMTES. Age-correction of 
CMTES is described in Section 4.3.4. For the non-age-corrected set, analyses were 
performed between: CMT1A cases (n=187) and controls (n=150); mild (n=69) and 
severe (n=85) CMT1A cases; severe CMT1A cases (n=85) and controls (n=150); 
mild CMT1A cases (n=69) and controls (n=150). Allelic association tests using age-
corrected CMTES were also performed on mild (n=66) versus severe (n=81) 
CMT1A cases, severe CMT1A cases (n=81) versus controls (n=150), and mild 
CMT1A cases (n=66) versus controls (n=150). Association tests were performed 
between mild CMT1A and controls as well as between severe CMT1A and controls 
to ensure that any significant difference in allele frequency in the mild versus severe 
CMT1A analysis was not specific to that population; any variant significantly 
associated with mild or severe CMT1A cases needed to be significantly associated 
either in the mild CMT1A versus controls or severe CMT1A versus controls 
analysis. An allelic association analysis was also performed for CMT1A cases 
(n=187) versus CIDP cases (n=125), and controls (n=150) versus CIDP cases 
(n=125). For each analysis above, association was performed on the entire chip 
(138,103 SNPs), on the HLA region (7,969 SNPS), and on the HLA region after 
pruning of SNPs in LD (1,094 SNPs). SNPs in LD have alleles which are non-
randomly associated (Anderson et al., 2010). Including only tagging SNPs in the 
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HLA region and excluding ones in LD (i.e. “pruning”) is preferable for small sample 
sizes as it decreases the number of tests and therefore increases power. The NCBI 
website was used to find the chromosomal position of the HLA region in Genome 
Build 36.1.  
The pointwise and genome-wide p-values were calculated for each SNP. Pointwise 
p-values represent the probability of observing a test statistic greater than or equal to 
the observed test statistic at that particular locus under the null hypothesis (Balding, 
2006). Given the large number of SNPs tested, a correction for multiple testing was 
needed to avoid false-positive results (Génin et al., 2008). The significance 
thresholds obtained using the Bonferroni correction for multiple testing (α=0.05 n; α 
is the significance threshold and n is the number of comparisons) would be 
somewhat conservative as this correction assumes independence between tests and is 
not appropriate when LD may be present, as is the case in the HLA region. Instead, 
the genome-wide p-value was used to correct for multiple testing by performing 
100,000 random permutations of case and control labels (Balding, 2006). The 
genome-wide p-value represents the probability of observing the test statistic or 
higher at any locus across the genome by chance. The pointwise and genome-wide p-
value significance thresholds were set at α=0.05. SNPs in which the MAF is 
significantly lower in cases (or severe cases) compared to controls (or mild cases) 
indicates a protective effect of the allele; in this case, the odds ratio (OR) is lower 
than 1. The OR is a measure of the relative odds of the occurrence of an outcome of 
interest given exposure to a particular variable. SNPs in which the MAF is 
significantly higher in cases (or severe cases) compared to controls (or mild cases) 
indicates susceptibility to disease; in this case, the OR is higher than 1. A 95% 
confidence interval (CI) was used for the OR. The UCSC, dbSNP, NCBI, UniProtKB 
and Ensembl browsers were used to search for SNP and gene information.  
4.4 Results  
4.4.1 Confirmation of Chr17p11.2 duplication 
The RQ was greater than 1.3 in all tested CMT1A cases (refer to Section 2.1.6 for an 
explanation of RQ), thus confirming the presence of the Chr17p11.2 duplication in 
cases where the genetic diagnosis could not be confirmed. 
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4.4.2 Assessment of intrafamilial and interfamilial variability in CMT1A 
Determining the extent of intra- and interfamilial variability in our patient cohort 
provided an estimation of the importance of genetic factors in modulating the disease 
phenotype. If familial relationship could predict disease severity, we would expect a 
larger number of data points in the bottom left (both family members are mild) and 
top right (both family members are severe) quadrants in the graph in Figure 4-5. As 
no such pattern is seen and the Pearson correlation coefficient is 0.00059, disease 
severity of one family member cannot be predicted from that of a second family 
member. 
 
Figure 4-5 Comparison of the age-corrected CMTES between CMT1A family 
members. 
Given the low concordance between family members, trans-acting rather than cis-
acting modifying factors are probably involved in causing CMT1A phenotypic 
variability. By the same logic, genetic modifiers in CMT1A are most likely multi-
factorial rather than monogenic (Génin et al., 2008). 
Although as shown above there is high intrafamilial phenotypic variability in 
CMT1A, if genetic factors are modulating the CMT1A phenotype, variability 
 157 
between families should still be greater than variability within families (Génin et al., 
2008). The average difference in age-corrected CMTES between one individual and 
the other members of his family was 3.96 age-corrected CMTES points. In 
comparison, the corresponding value for unrelated CMT1A patients was 4.87 age-
corrected CMTES points. The density graph shown in Figure 4-6 shows the 
distribution of the difference in age-corrected CMTES for members of the same 
family and unrelated patients. Excluding one outlier, the distribution of the 
difference in CMTES within families appears to be centred closer to zero and is 
narrower than the difference in CMTES between unrelated individuals, suggesting 
that interfamilial variability is greater than intrafamilial variability in 
CMT1A.
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Figure 4-6 Density graph showing the distribution of the difference in age-corrected 
CMTES for members of the same family and unrelated patients. 
4.4.3 Immunochip association study of variants associated with autoimmune 
and inflammatory diseases in CMT1A patients 
The QQ plots generated for further quality control are represented in Appendix IV 
Figure IV-1; an example is shown below in Figure 4-7.  
 158 
 
Figure 4-7 QQ plot of the mild versus severe CMT1A allelic association analysis. 
The QQ plots showed that the CMT1A cases, CIDP cases and controls were 
generally appropriately matched. The p-values adhere relatively closely to the x=y 
line (i.e. null hypothesis) for the bottom 90% of the values for most of the analyses. 
As some data points do deviate from the x=y line in some analyses, such as the age-
corrected severe CMT1A versus controls analysis, results from these analyses should 
be interpreted with caution. Points deviating from the x=y line in the top right hand 
corner (lowest p-values), which are most evident in the QQ plot for the CIDP versus 
controls analysis, may indicate real associations or false associations due to 
genotyping errors. Therefore, SNPs reaching significance were checked individually 
for accurate calling of genotypes using the genotype cluster plots in GenomeStudio 
(Illumina) (see Appendix IV Figure IV-2 for cluster plots and call rates of all top hit 
SNPs on the Immunochip). SNPs reaching significance but which showed poor 
clustering were excluded. 
The results of the CMT1A versus controls, mild versus severe CMT1A, and CIDP 
versus controls allelic association analyses are shown in Tables 4-1 to 4-3. The 
results of the remaining allelic association analyses are located in Appendix IV Table 
IV-4 but are also described below. Chromosomal positions refer to Genome Build 
36.1. In analyses in which no SNP had both a pointwise and genome-wide p-value 
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below α=0.05, the SNPs with the two lowest genome-wide p-values are provided and 
written in italics. If the SNP was not located within a gene, the closest protein-coding 
gene(s) to the SNP is given. Where available, the MAF in the 1000 Genomes 
European population is provided for each SNP. For selected SNPs, the MAFs in 
other cohorts from our study are provided for reference. For the CIDP versus 
controls analyses, the potential effect of the allele on the disease state (i.e. causative 
or protective) is given for significantly associated SNPs; a question mark is written 
when the 1000 Genomes MAF is in conflict with the MAF found in our control 
group.  
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Table 4-1 Results of top hits in the mild versus severe CMT1A allelic association analysis on the Immunochip. 
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Table 4-2 Results of top hits in the CMT1A versus controls allelic association analysis on the Immunochip. 
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Table 4-3 Results of top hits in the CIDP versus controls allelic association analysis on the Immunochip. 
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The aims of this association study were to determine whether alleles at SNPs 
associated with inflammatory and autoimmune diseases and/or CIDP may modulate 
disease severity in CMT1A, and whether these alleles may be involved more 
generally in CMT1A pathogenesis. To confirm the first hypothesis, we would expect 
a significant association of some Immunochip SNPs with mild or severe CMT1A in 
the mild versus severe CMT1A analysis. No SNP had both pointwise and genome-
wide p-values below 0.05 in the mild versus severe CMT1A analysis (Table 4-1). 
The lowest (but non-significant) genome-wide p-value for the mild versus severe 
CMT1A analysis was found in the non-age-corrected analysis on the pruned HLA 
region (p-value=0.1678 for rs7771432 at chr6:31,388,729). It is worth noting that 
none of the top hits in the mild versus severe CMT1A analysis was common to both 
the age-corrected and non-age-corrected analyses, suggesting that age-correction of 
the CMTES modifies the mild and severe categories considerably. If an overlap of 
CIDP with CMT1A could explain some phenotypic variability, some alleles 
significantly associated with CIDP in the CIDP versus controls analysis should also 
be significantly associated with either mild or severe CMT1A. No top hit SNP was 
found in both the CIDP versus controls and the mild versus severe CMT1A analyses.  
To confirm the second hypothesis that some alleles at SNPs on the Immunochip may 
play a role in CMT1A disease, we would expect a significant association of some 
Immunochip SNPs with CMT1A in the CMT1A versus controls analysis. No SNP 
had both pointwise and genome-wide p-values below 0.05 in the CMT1A versus 
controls analysis (Table 4-2). One SNP on the pruned HLA region, rs9258740, was 
close to reaching significance; the CMT1A and controls MAF were 0.2219 and 
0.1007, respectively (genome-wide p-value=0.05104; OR=2.548; 95% CI of 
OR=1.626-3.993). This SNP is located close to HLA-G, a non-classical MHC class I 
gene. However, the MAF in the 1000 Genomes European population (0.194) was 
similar to that found in our CMT1A cohort (0.2202), therefore it is unlikely to be 
causative for CMT1A disease. 
Two SNPs were significantly associated with CIDP in the CIDP versus controls 
analysis on the entire chip, supporting the role of the immune system in the 
pathogenesis of CIDP (Table 4-3). Both SNPs also have significantly different MAF 
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in the CMT1A versus CIDP analysis, where CMT1A cases have a similar MAF to 
controls. One SNP (imm_3_58370541 at chr3:58,370,541) is predicted to be 
causative for CIDP (genome-wide p-value=0.00001; OR=4.138; 95% CI of 
OR=2.864-5.978). This SNP is located within an intron of the PX domain containing 
serine/threonine kinase (PXK) gene, which encodes a Phox PXK homology domain–
containing serine-threonine kinase; it may have a role in trafficking of the epidermal 
growth factor receptor. This PXK locus is unlikely to be a risk allele for CMT1A as 
CMT1A patients had similar MAF to controls (MAF in CMT1A=0.2204; 
controls=0.2333; CIDP=0.5574). 
In Europeans, this gene contains known susceptibility loci for systemic sclerosis 
(rs2176082 at chr3:58,306,226 (Martin et al., 2013)), rheumatoid arthritis 
(rs13315591 at chr3:58,531,881 (Stahl et al., 2010)) and SLE (rs2176082, as well as 
rs6445975 at chr3:58,345,217 (Martin et al., 2013; SLEGEN et al., 2008)). In the 
GWAS of SLE patients versus controls, association was also found with SNPs within 
the HLA region, in genes previously associated with SLE, and with several other loci 
(SLEGEN et al., 2008). In the Martin et al. (2013) study, a pan-meta-GWAS 
combining both systemic sclerosis and SLE patients, the association with the PXK 
locus was common to both groups of patients. Several novel susceptibility loci were 
also identified in this study (Martin et al., 2013). The Stahl et al. (2010) study 
identified new risk loci for rheumatoid arthritis, and confirmed associations with 
previously known rheumatoid arthritis and other autoimmune disease risk loci. In my 
study, approximately 230 SNPs located within the PXK exons, introns, upstream and 
downstream regions were included in the Immunochip association analysis 
(including rs6445975 and rs2176082); however, no other SNP in this gene or nearby 
regions besides the chr3:58,370,541 SNP was significantly associated with CIDP.  
The effect could not be predicted for the second significantly associated SNP 
(rs4841519); the MAF in the 1000 Genomes database (0.471) was closer to the MAF 
in CIDP (0.56) than to the MAF in our control group (0.2099), suggesting that this 
difference in MAF between our control group and CIDP patients may not be real. No 
SNPs reached significance on the HLA region or pruned HLA region in the CIDP 
versus controls analysis.  
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If CMT1A and CIDP shared certain risk alleles and therefore perhaps some disease 
mechanisms, some alleles significantly associated with CIDP in the CIDP versus 
controls analysis should also be associated with CMT1A in the CMT1A versus 
controls analysis. No SNP fulfilled this criterion. 
Interestingly, none of the top hit SNPs in any of the CMT1A analyses was located in 
the Chr17p11.2 duplicated region; this finding would suggest that alleles at SNPs 
located in this area of the genome on the Immunochip are unlikely to play a role in 
CMT1A pathogenesis or in modifying the CMT1A phenotype. However, this 
conclusion is premature given the small number of samples and other limitations of 
our study, which will be discussed in Section 4.5.2. 
4.5 Discussion 
4.5.1 Assessment of intrafamilial and interfamilial variability in CMT1A 
The inability to predict disease severity in one family member given the CMTES of 
another family member confirms the high intrafamilial phenotypic variability in 
CMT1A families, and supports a role of the environment and epigenetics in 
modulating the phenotype. However, as interfamilial variability was found to be 
greater than intrafamilial variability, genetic modifying factors are nonetheless likely 
to be involved to some extent in modifying the CMT1A phenotype. 
4.5.2 Association study of inflammatory and autoimmune disease-associated 
SNPs in CMT1A  
When considering both age-corrected and non-age-corrected analyses of the mild 
versus severe CMT1A groups, no Immunochip SNPs genotyped in CMT1A patients 
showed an association with disease severity after 100,000 permutations. 
Furthermore, no SNP significantly associated with CIDP (as compared to controls) 
was amongst the SNPs with the lowest genome-wide p-values in the mild versus 
severe CMT1A analysis. It seems unlikely that alleles associated with CIDP and with 
autoimmune and inflammatory diseases are modifying the CMT1A phenotype. No 
SNP reached genome-wide significance in the CMT1A versus controls analysis. No 
SNP was found to be significantly associated with both CIDP in the CIDP versus 
controls analysis and with CMT1A in the CMT1A versus controls analysis, 
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suggesting that SNPs associated with CIDP are probably not involved in CMT1A 
pathogenesis. One SNP within the PXK gene was associated with CIDP (but not with 
CMT1A); this gene also contains susceptibility loci for other autoimmune diseases. 
If the association of CIDP with the PXK locus identified in our study 
(chr3:58,370,541) can be replicated in a larger cohort, this would suggest that CIDP 
shares a susceptibility locus (and perhaps disease mechanisms) with other 
autoimmune diseases. 
These results suggest that there is no evidence for a role of the immune system in 
CMT1A or in modifying the CMT1A phenotype. However, the results of this study 
are very preliminary, and any SNP close to reaching significance in this study should 
be considered for future studies with larger cohorts of patients. The substantial 
limitations of this study are discussed below. 
One important limitation of this study is the considerable lack of power due to 
insufficient patient numbers. Association studies are usually performed on much 
larger cohorts of patients. However, obtaining both DNA and complete phenotypic 
details for unrelated CMT1A cases of matching ethnicity is not trivial. Significant 
findings from this study need to be replicated in a larger cohort of patients for 
validation.  
In one set of Immunochip analyses, the CMTES were corrected for AAE. However, 
one assumption of this model is that CMT1A progresses in a steady manner (Shy et 
al., 2008; Steiner et al., 2008), which is generally true except when there is an 
overlapping inflammatory neuropathy. There is also a suggestion of a slight increase 
in rate of disease progression with age (Shy et al., 2008) and of anticipation or 
increase in disease severity over successive generations (Steiner et al., 2008). The 
model used for age-correction in this study assumed linearity of disease progression 
and therefore may not be appropriate if disease progression is no longer linear in the 
older CMT1A population. This model also assumes that the CMTES scale is linear, 
which is not necessarily the case (Steiner et al., 2008). These assumptions are further 
drawbacks of this study.  
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The CMTES used to describe the “severe” and “mild” categories do not follow the 
traditional description of severe and mild CMT; however, because most of the 
patients in our cohort were mildly affected, and because the two categories needed to 
contain similar numbers of patients, we had to adjust what we considered mild and 
severe disease so that it would be appropriate to our cohort. It must also be kept in 
mind that the exclusion of gender in our analysis precludes us from validating any 
associations located on the X chromosome; therefore, analysis of association data 
was limited to autosomes. Finally, the association tests performed herein are 
qualitative and only consider individual alleles; further association tests could be 
performed, including a genotype association test and a quantitative trait analysis.  
Unlike a GWAS, the use of the Immunochip is focused and hypothesis-driven, and 
may suffer from bias as the markers are a selection of SNPs already found to be 
associated with autoimmune disorders. Indeed, a more appropriate method of 
identifying genetic modifiers of disease would be to perform a GWAS. This 
powerful approach makes no a priori assumptions about which genes are involved in 
producing or modifying a given phenotype. To this end, we have contributed 
CMT1A DNA samples to collaborators in the USA to perform a GWAS. Although 
GWAS studies are less biased as they involve a systematic approach, the sheer 
number of potential interactions (i.e. loci modifying the phenotype) it involves 
reduces statistical power. A more pragmatic methodology would be to predict 
genetic interactions via “network-guided modifier screening” using functional gene 
networks and to test specifically for associations of these loci with the phenotype 
(Lee et al., 2010). 
4.5.3 Supplementary study into genetic modifiers of the CMT1A phenotype 
A supplementary study was conducted in the cohort of CMT1A patients described in 
this Chapter to assess the involvement of additional genetic factors in modifying the 
CMT1A phenotype. The other potential sources of phenotypic modification in 
CMT1A studied therein include: variants in the nerve-specific PMP22 promoter and 
5’UTR region, concomitant pathogenic variants in the PMP22 coding region, the 
presence of the PMP22 p.Thr118Met variant, and the size of the Chr17p11.2 
duplication. The results of this supplementary study are: 
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 Sequencing of the nerve-specific PMP22 promoter and 5’UTR revealed very 
few rare variants. 
 No concomitant pathogenic variants were found in the PMP22 coding region. 
 The frequency of the PMP22 p.Thr118Met variant with ambiguous 
pathogenicity was comparable to that reported in control databases. 
 The small number of CMT1A patients with duplications of an atypical size 
had a classic CMT1A phenotype.  
Due to space restrictions and the significant limitations of this particular study, 
further details are available in Appendix VIII. 
4.6 Conclusion 
In conclusion, this Chapter has emphasised the phenotypic heterogeneity of CMT1A 
and has assessed the potential contribution of alleles associated with inflammatory 
and autoimmune diseases in modifying the CMT1A phenotype. The discovery of 
disease severity markers is critical for identification of drug targets as well as for 
patient counselling (Reilly et al., 2011). The next Chapter will seek to elucidate the 
genetic cause of disease in CMT patients who remain without a genetic diagnosis.  
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Chapter 5 Exome sequencing in CMT 
5.1 Introduction 
The recent shift from traditional “first-generation” Sanger se uencing and linkage 
analysis to high-throughput NGS methods such as exome sequencing and whole-
genome sequencing has revolutionised gene discovery and diagnostics for Mendelian 
and complex diseases (Choi et al., 2009; Metzker, 2010). NGS requires only 1-2 μg 
of gDNA and allows the investigation of small families and isolated individuals who 
could not have been studied using linkage or positional cloning (Singleton, 2011). 
Exome sequencing involves target enrichment and high-throughput re-sequencing of 
nearly all protein-coding regions of the genome, including exons and flanking 
intronic sequences. Protein-coding regions make up only 1% of the genome and yet 
account for the vast majority (85%) of mutations associated with Mendelian diseases 
(Choi et al., 2009; Montenegro et al., 2011). Exome sequencing is more cost-
efficient and less data-intensive than whole-genome sequencing, requiring only 5% 
of the sequencing needed for an entire human genome (Ng et al., 2010). Exome 
sequencing generally uncovers approximately 20,000 variants in a single European 
individual; on average, about 2% of these variants are novel (Bamshad et al., 2011). 
In 2009 and 2010, Choi et al. (2009) and Ng et al. (2010) demonstrated two of the 
first applications of exome sequencing and found the disease-causing gene in a small 
number of cases with rare monogenic disorders. 
CMT disease is an excellent example of a Mendelian disease which has greatly 
benefited from the advent of NGS technologies. Indeed, the number of genes to be 
associated with peripheral neuropathies has nearly doubled in the past few years 
(Rossor et al., 2013). This NGS technology is especially time and cost-effective in 
highly penetrant, phenotypically and genetically heterogeneous diseases like CMT 
(Singleton, 2011). NGS may also uncover mutations in known but rare CMT genes 
for which testing is often restricted to the research setting (Montenegro et al., 2011). 
Novel CMT-associated genes or new mutations in known CMT genes were 
successfully identified using exome sequencing and whole-genome sequencing. In 
the early years of NGS, whole-genome sequencing was used to identify a mutation in 
a known CMT gene, SH3TC2, in an AR CMT family that did not carry mutations in 
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some of the common CMT genes (Lupski et al., 2010). Exome sequencing was also 
used to perform a comprehensive diagnostic screen in an undiagnosed CMT patient; 
the patient was found to carry a mutation in GJB1, a known CMT gene (Montenegro 
et al., 2011). One early example of a novel CMT gene identified with exome 
sequencing is DYNC1H1, a cause of axonal CMT (Weedon et al., 2011). In the past 
few years, many additional studies have used NGS to identify the genetic cause of 
disease in CMT patients. A recent study has performed exome sequencing in 25 
unrelated CMT patients without the Chr17p11.2 duplication/deletion or mutations in 
major CMT genes; they focused on genes previously linked to CMT and found 
mutations in 32% of patients, thus highlighting the usefulness of exome sequencing 
in CMT (Choi et al., 2012). 
Although the advent of NGS has enabled many CMT patients to receive a genetic 
diagnosis, many cases remain genetically undiagnosed. As discussed in Chapter 3, 
the UK study by Murphy, Laura, et al. (2012) determined that 62.6% of CMT 
patients seen at the inherited neuropathy clinic in Queen Square (London) received a 
genetic diagnosis; the proportion was 80.4% and 25.2% for CMT1 and CMT2 
patients, respectively. In the Saporta et al. (2011) study, 67% of CMT patients were 
successfully assigned a genetic subtype. Therefore, many CMT genes remain to be 
unveiled, especially in CMT2. As highlighted previously, obtaining a genetic 
diagnosis is essential for patient counselling, family planning, and to exclude 
treatable acquired causes of neuropathy (Reilly et al., 2011). 
Over 60 genes or loci have been associated with CMT (Braathen et al., 2011; Reilly 
et al., 2011). As discussed in the introduction to this Thesis, proteins encoded by 
CMT genes are involved in a wide array of cellular functions, some of which include 
myelin structural components, mitochondrial fusion and fission, endocytosis, 
intracellular protein sorting and quality control, transcription factors and regulation 
of gene expression, ion channels, protein synthesis, cytoskeletal dynamics, axonal 
transport and vesicular motility (Pandraud, in press; Patzkó & Shy, 2011). 
Furthermore, the expression of many CMT genes is not restricted to neurones or 
Schwann cells, and several genes had no prior known role in Schwann cells or axons 
(Scherer & Wrabetz, 2008). Ubiquitously expressed CMT genes include FIG4, 
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DNM2, LMNA, the t-RNA synthetases, MTMR2, MTMR13, MFN2, RAB7, HSPB1, 
HSPB8 and others. The variety of protein functions and ubiquitous expression of 
many CMT genes render it difficult to identify the causative variant leading to 
peripheral nerve degeneration within the exome sequencing data. Identifying novel 
CMT genes and carrying out functional studies expands the list of pathomechanisms 
involved in CMT, allowing for a better understanding of peripheral nerve biology 
and neurodegeneration along with the discovery of potential drug targets (Azzedine 
et al., 2012). 
5.2 Aims of this study 
The first aim of this study was to identify the disease-causing gene in two CMT 
families without a genetic diagnosis; the second aim was to provide further evidence 
for the pathogenicity of a mutation in a candidate gene by screening this gene in a 
cohort of CMT patients. 
5.3 Methods: exome sequencing of CMT families 
5.3.1 CMT families for exome sequencing 
Patients in this study were recruited from the inherited neuropathy clinic at the 
NHNN. DNA extracted from peripheral blood using standard procedures was 
obtained from the NHNN Neurogenetics Unit. Details of ethics approval and patient 
consent are found in Section 2.1.1.  
Although comparatively less expensive and data-intensive than whole-genome 
sequencing, families for exome sequencing do have to be chosen strategically to 
maximise the probability of identifying the causative gene with this technology. 
Selection is often based on the number of previous genetic tests performed as well as 
availability of DNA and detailed phenotypes. Two CMT families were selected for 
exome sequencing in this study. Family IS was chosen because DNA and 
comprehensive phenotypes were available for three affected siblings; this family was 
negative for many CMT genes (detailed below). The second family, family AD, has 
dominantly inherited demyelinating CMT and most of the common genes have been 
excluded by Sanger sequencing; this family is therefore particularly interesting to 
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study as the vast majority of CMT1 patients have received a genetic diagnosis 
(Murphy, Laura, et al., 2012). 
CMT family IS is from the United Kingdom; three siblings had late-onset CMT2 
disease with intermediate NCVs. They had slowly progressive sensory symptoms in 
the lower limbs and mild walking difficulties starting in the fifth or sixth decade of 
life. One of the siblings required ankle-foot orthoses for mobility in the seventh 
decade of life; the other two siblings could walk without aid. Upon neurological 
examination of the index case (individual II-2 in Figure 5-1) at age 64, the patient 
had distal weakness, normal tone, lack of ankle jerk reflexes and reduced pinprick 
sensation in the feet. At age 53 his brother, individual II-3, had normal muscle power 
and tone in the upper and lower limbs, lack of right ankle jerk reflex, reduced 
pinprick sensation and reduced vibration sense to the knees in the lower limbs. At 
age 67 their sister, individual II-1, had bilateral foot drop, distal muscle wasting in 
the upper and lower limbs, normal ankle plantar flexion, and absent reflexes at the 
left ankle. Pinprick sensation was reduced in the hands and normal in the lower 
limbs. Vibration sense was reduced to the ankles bilaterally but normal in the upper 
limbs. All three siblings had similar neurophysiological results consistent with a 
length-dependent sensory-motor axonal neuropathy. Some of the motor NCVs were 
within the intermediate range; median NCVs were 37 m/s for individual II-2, 34 m/s 
for individual II-3 and 41 m/s for individual II-1. A fourth sibling (individual II-4) 
may be affected. According to his children’s account, the father (individual I-2) 
developed bilateral foot drop in his early sixties, and required splints at the age of 65 
years. Inheritance is presumed to be AD, however as the father was not examined in 
our clinic, AR inheritance cannot be ruled out. DNA was available on three affected 
siblings (individuals II-1, II-2 and II-3). One of the siblings was genetically tested 
and was negative for rearrangements on Chr17p11.2 and for mutations in PMP22, 
MPZ, MFN2, EGR2, GDAP1, NEFL, TRPV4, HSPB1, HSPB8 and GJB1. 
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Figure 5-1 Pedigree of CMT family IS. 
Affected members of CMT family AD, also from the United Kingdom, consisted of 
a mother (individual I-2 in Figure 5-2) and her daughter (individual II-I) who both 
had severe CMT1. The index case (individual I-2) was a 37-year old woman who 
presented with slowly progressive distal weakness and sensory loss in the upper and 
lower limbs. She walked abnormally from 13 months and was never able to run. She 
developed high arches during the first decade and had several operations to her feet. 
Her motor and sensory symptoms were slowly progressive. At 15 years old, her 
MNCV was 8.4 m/s in her right ulnar nerve. At the age of 37, she required crutches 
to walk and used a scooter for mobility outdoors. She had numbness in the lower 
limbs distally and occasional pain as well as pins and needles. On examination, she 
had distal muscle wasting in all limbs and no movement below the ankles. She had 
reduced pinprick sensation to the elbows and the top of the thighs, as well as no 
reflexes or plantar responses. She had inexcitable nerves on neurophysiology, except 
for the facial nerves for which she had reduced CMAP amplitudes and prolonged 
distal motor latencies.  
DNA was available on the affected mother (individual I-2) and her affected daughter 
(individual II-1). Inheritance is predicted to be AD or X-linked (Figure 5-2). The 
consanguinity on the mother’s side of the family is not predicted to be relevant. It 
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remains possible that inheritance is AR in this family if individual I-1 (father of II-1) 
and individual I-2 belong to an inbred population and are therefore distantly related, 
in which case individual I-1 may be a heterozygous carrier for the homozygous 
disease-causing mutation in individuals I-2 and II-1. However, this possibility is 
rather unlikely. Individual I-2 tested negative for rearrangements on Chr17p11.2 and 
for mutations in PMP22, MPZ, EGR2, LITAF, NEFL, GJB1, GDAP1, and SH3TC2.  
 
Figure 5-2 Pedigree of CMT family AD. 
Given the previous successes of exome sequencing in CMT and the exclusion of 
several common CMT genes by Sanger sequencing, this NGS technology was used 
in this study. Exome sequencing was performed on individuals II-1, II-2 and II-3 in 
CMT family IS, and individuals I-2 and II-2 in CMT family AD.  
 175 
5.3.2 Exome sequencing and variant calling 
Purity and concentration of DNA samples were assessed as described in Section 
2.1.5. gDNA (2 μg) was sent to the Wellcome Trust Sanger Institute in Hinxton, UK 
for exome sequencing. Exome sequencing was performed as part of the UK10K 
Project at the Wellcome Trust Sanger Institute. DNA was sheared to 100-400 bp 
segments using a Covaris E210 or LE220 (Covaris, USA). Sheared DNA was 
subjected to Illumina paired-end DNA library preparation and enriched for target 
sequences (Agilent Technologies, USA; Human All Exon 50 Mb - ELID 
S02972011) according to manufacturer's recommendations (Agilent Technologies; 
SureSelectXT Automated Target Enrichment for Illumina Paired-End Multiplexed 
Sequencing). Exome-enriched libraries were sequenced on the HiSeq platform as 
paired-end 75 base reads with v.3 chemistry according to the manufacturer's protocol 
(Illumina). Further details on the exome sequencing protocol are found in Section 
2.1.15. Variant calling was performed by both the Wellcome Trust Sanger Institute 
and Dr Alan Pittman at the UCL ION. 
5.3.3 Assessment of gene coverage and read depth in neuropathy genes 
As described in Section 2.1.16, gene coverage and read depths were assessed for all 
known inherited neuropathy genes using the exome sequencing BAM files and 
Golden Helix GenomeBrowse software. The coverage could not be determined for 
individual II-2 in CMT family IS and individual I-2 in CMT family AD as no BAM 
files could be obtained. 
5.3.4 Exome data filtering and variant prioritisation 
The exome variant filtering steps are described in Section 2.1.17. Variants not found 
in all affected family members (three affected siblings in CMT family IS and 
affected mother/daughter pair in CMT family AD) were filtered out. Given the 
uncertainty of the inheritance pattern in CMT family IS, both heterozygous variants 
(AD model) and homozygous/compound heterozygous variants (AR model) were 
filtered independently. In CMT family AD, only heterozygous variants were selected 
in order to fit with the presumed AD or X-linked mode of inheritance. Next, 
synonymous mutations were filtered out. For all exome datasets, all known inherited 
neuropathy genes, including genes associated with HSP, were inspected for 
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potentially pathogenic variants. For the AD model in CMT families IS and AD, a 
MAF of 0.005 was used as a cut-off point for the EVS and 1000 Genomes control 
reference databases; a MAF of 0.01 was used as a cut-off point for the CG69 
database as this database is known to contain variants at frequencies higher than that 
observed in other much larger control databases. A cut-off MAF of 0.005 is 
conservative compared to the 0.001 cut-off usually used in AD disorders (Bamshad 
et al., 2011). However, this higher cut-off was used to make certain that the 
potentially pathogenic variant would not be filtered out. In addition, the disease in 
CMT family IS was relatively mild. For the AR model in CMT family IS, a MAF 
cut-off of 0.01 was used for the EVS, 1000 Genomes and CG69 databases. A MAF 
of 0.01 still provides sufficient power in AR models (Bamshad et al., 2011). Any 
variant within a segmental duplication region with identity greater than or equal to 
96% was removed. SNP chromosomal locations are based on Genome Build 37.3. 
Candidate genes were searched in the literature for any known prior disease-
association. The GEM.app, provided by University of Miami’s Miller School of 
Medicine and described in Section 2.6, was used to search for variants in the 
candidate genes in families with similar phenotypes. Conservation between species 
of the mutated amino acid, location within the protein structure, and in-silico 
pathogenicity predictions were determined for variants of interest as described in 
Section 2.6. Gene expression data was obtained from the Human Protein Atlas as 
described in Section 2.6. 
5.4 Methods: Sanger sequencing of a candidate gene from a previous exome 
sequencing study 
A family with CMT2 (CMT family BJ) from our inherited neuropathy clinic in 
Queen Square was exome sequenced by the Department of Human Genetics and 
Hussman Institute for Human Genomics at University of Miami’s Miller School of 
Medicine as part of a collaboration. The index case (individual IV-1 in Figure 5-3) 
suffered from falls, high arches and lower limb wasting from the age of two. He had 
slowly progressive distal wasting and sensory loss in the feet. Examination showed 
an unsteady gait, lack of reflexes, sensory loss in the hands, inability to stand on 
heels or toes, and mild proximal and distal weakness in the upper and lower limbs. 
An axonal sensory-motor neuropathy in the lower limbs was evident on NCS and 
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denervation and reinnervation were seen on muscle biopsy. The index case in this 
family was negative for mutations in PMP22, MPZ, GJB1, MFN2, TRPV4, HSPB1, 
HSPB8, GDAP1, and BSCL2, and for common mutations in the polymerase (DNA 
directed), gamma (POLG) and progressive external ophthalmoplegia 1 (PEO1) 
genes. He also tested negative for common point mutations and large-scale 
rearrangements of mitochondrial DNA in the muscle. 
 
Figure 5-3 Pedigree of CMT family BJ. 
One of the candidate genes emerging from the variant filtering performed by our 
colleagues was mitochondrial fission factor (MFF), encoding a protein with a role in 
mitochondrial fission (Gandre-Babbe & van der Bliek, 2008). The variant identified 
by our collaborators was p.Arg118His in exon 5 and was not found in over 2,000 
controls. In an effort to provide additional evidence for the pathogenicity of this 
variant, I screened all coding exons and flanking intronic sequences of MFF in 48 
CMT2 cases. Exon 5 was also screened in 285 additional patients with CMT2, 
dHMN or HSP. These additional 285 patients had a complex phenotype similar to 
that seen in CMT family BJ; these patients were selected by Professors Mary Reilly 
and Henry Houlden, consultant neurologists and professors in Clinical Neurology at 
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the NHNN. DNA was available at the NHNN Neurogenetics Unit. Purity and 
concentration of DNA samples were assessed as described in Section 2.1.5. PCR, 
agarose gel electrophoresis, purification of PCR products, Sanger sequencing, dye 
removal and sequencing analysis were performed using standard conditions as 
described in Sections 2.1.9-2.1.12. Sequences of MFF primers and PCR cycling 
conditions can be found in Appendix V Table V-1.  
5.5 Results 
5.5.1 The challenges of exome variant interpretation in CMT 
In the exome data analysis of both CMT families in this study, hundreds of candidate 
genes containing variants of unknown significance still remained after the filtering 
steps described in Section 5.3.4. Predicted protein function and gene expression have 
been used in the past to select candidate genes in exome sequencing, however this is 
not always practical in diseases such as CMT. The discovery of over 60 CMT genes 
has provided a list of pathways which may be involved in disease pathogenesis. It 
remains difficult to stratify candidate genes based on the biological role of the 
protein because the defective biological process involved in a particular case of CMT 
may have never been previously described to cause inherited neuropathies (Azzedine 
et al., 2012; Bamshad et al., 2011). Of course, proteins with known roles in CMT-
related processes were prioritised. For CMT family IS with ICMT, the protein 
function would be expected to involve both Schwann cells and axons (Azzedine et 
al., 2012); for CMT family AD with AD CMT1, myelin structural components and 
transcription factors regulating myelin gene expression would be potential candidate 
genes (Scherer & Wrabetz, 2008).  
Transcriptional profiles of the PNS may provide a list of candidate genes for 
inherited peripheral neuropathies, however these lists are incomplete (De Jonge et 
al., 2003; Giambonini-Brugnoli et al., 2005). Genes therefore cannot be excluded on 
the basis that they are not found in transcriptional profiles of the PNS. In any case, it 
is difficult to exclude variants based on expression profiles as many CMT genes are 
ubiquitously expressed and not nerve-specific (Azzedine et al., 2012). Variants 
predicted to have a more severe functional impact on the protein such as stop-gain, 
stop-loss, indels, frameshift coding, and essential splice-site variants may be 
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prioritised, however there is a risk of eliminating potentially disease-causing 
missense variants. 
5.5.2 Exome sequencing in an intermediate CMT (ICMT)/CMT2 family 
The exome sequencing for individual II-1 of family IS resulted in a total of 
75,912,176 reads. The mean target coverage was 83.7X (the definition of mean target 
coverage is provided in Section 2.1.16); 91.2% of the bases had at least 2-fold 
coverage, 84.3% of bases had at least 10-fold coverage and 72.3% of the bases had at 
least 30-fold coverage. The exome sequencing in individual II-3 of family IS 
produced a total of 74,978,099 reads. The mean target coverage was 81.4X; 91% of 
the bases had at least 2-fold coverage, 83.8% of bases had at least 10-fold coverage 
and 70.8% of the bases had at least 30-fold coverage. As mentioned in Section 5.3.3, 
the coverage could not be assessed for individual II-2 as the BAM file was not 
available. 
Please see Appendix V Table V-2 for a list of poorly covered exons in inherited 
neuropathy genes in individuals II-1 and II-3 of CMT family IS. Overall, 21 
inherited neuropathy genes had at least one poorly covered exon: PMP22, MPZ, 
NEFL, NDRG1, PRX, FIG4, CTDP1, GARS, DNM2, DYNC1H1, LRSAM1, serine 
palmitoyltransferase, long chain base subunit 2 (SPTLC2), LMNA, MTMR13, 
IGHMBP2, pyruvate dehydrogenase kinase, isozyme 3 (PDK3), septin 9 (SEPT9), 
DNA (cytosine-5-)-methyltransferase 1 (DNMT1), HSPB1, kinesin family member 1A 
(KIF1A) and kinesin family member 5A (KIF5A). In total, 19,681 variants were found 
in individual II-1, 20,593 in II-2 and 19,219 in II-3. The three affected siblings in 
CMT family IS shared 8,904 variants, 4,865 and 4,039 of which were homozygous 
and heterozygous, respectively. After filtering out synonymous mutations, 4,369 
variants remained (2,394 homozygous and 1,975 heterozygous). Variants found in 
known inherited neuropathy genes among these 4,369 variants are summarized in 
Table 5-1. A total of 18 non-synonymous variants in 12 different neuropathy genes 
were found in CMT family IS, but none are likely to be the real pathogenic variant as 
the variants either had a high MAF in control databases, or the gene did not fit with 
the phenotype of the patient. Of course, it remains possible that mutations in a 
particular gene may result in a new phenotype. As mentioned in Section 5.3.4, both 
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an AD and an AR model were followed independently for variant filtering in CMT 
family IS. For the AD model, 93 heterozygous variants remained after filtering out 
variants in segmental duplications and those found in control databases using the 
frequency filters mentioned in Section 5.3.4. For the AR model, 28 compound 
heterozygous and 27 homozygous variants remained after applying these same 
filters. As mentioned in Section 5.1, choosing candidate genes based on protein 
function in CMT is potentially erroneous, as genes with a wide array of functions 
have been involved in this disease. Without exome data for additional family 
members, it is extremely difficult to narrow down the list of variants any further. 
One variant, located in the tubulin-specific chaperone cofactor E-like protein 
(TBCEL) gene was however retained for further analysis. This gene was considered a 
candidate gene because a mutation in a related but unpublished gene, tubulin, beta 8 
class VIII (TUBB8) found in a family with CMT2, was recently reported at the 5
th
 
International CMT Consortium Meeting in Antwerp, Belgium in June 2013 by a 
research group at University of Miami’s Miller School of Medicine, USA. 
All affected members of CMT family IS had a heterozygous non-synonymous 
mutation in the last coding exon of TBCEL, p.Met357Val (c.1069A>G) (Ensembl 
Transcript ID: ENST00000422003). The depth and quality of this variant were 55 
and 772 in individual II-1, 34 and 418 in individual II-2, and 81 and 1,355 in 
individual II-3, respectively. The mutation is predicted to be located in a potential 
coiled-coil region of the ubiquitin-like domain (UniProtKB ID: Q5QJ74). This 
variant was not found in dbSNP, 1000 Genomes, CG69 or EVS control databases. It 
was predicted benign by SIFT and PolyPhen-2 (score=0.009), but disease-causing by 
Mutation Taster (score=0.57, probability=0.98694). It is conserved in vertebrates but 
not in Drosophila melanogaster or Caenorhabditis elegans (GERP score=2.93). Two 
families with peripheral neuropathy were found to carry mutations in this gene in the 
GEM.app. One family with pure HSP had a p.Ile359Val (c.1075A>G) mutation and 
one family with unspecified CMT carried a p.Trp242Stop (c.725G>A) mutation. In 
both cases, inheritance was AD and mutations segregated with the phenotype. The 
MAF in the GEM.app were 0.06 and 0.03 for p.Ile359Val and p.Trp242Stop, 
respectively.    
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TBCEL, located on chromosome 11, is 424 amino acids long and has eight exons, 
seven of which are coding exons. It contains seven leucine-rich domains, one 
leucine-rich C-terminal domain and one ubiquitin-like domain. According to the 
Human Protein Atlas, TBCEL is expressed ubiquitously at low to moderate levels, 
and is most highly expressed in the male reproductive system. TBCEL is moderately 
expressed in neuronal and glial cells in the cerebral cortex and peripheral nerve. 
TBCEL is thought to play a role in spermatogenesis in animals (Nuwal et al., 2012). 
When overexpressed in-vitro, TBCEL depolymerises microtubules and targets 
tubulin to the proteasome for degradation; therefore, it is also thought to be involved 
in regulation of tubulin turnover and microtubule organisation (Bartolini et al., 
2005). A non-synonymous mutation in TBCEL may cause microtubule 
disorganisation via a gain-of-function mechanism. Microtubules form part of the 
cytoskeleton and are essential for intracellular transport, including axonal transport. 
Many CMT genes encode proteins involved in the axon cytoskeleton, in vesicle 
formation and/or in axonal transport, and several CMT mutations result in defective 
axonal transport. These include such genes as NEFL, RAB7, DNM2, DYNC1H1, 
HSPB1, heat shock 27kDa protein 3 (HSPB3), HPSB8, LMNA, KIF1B and MFN2 
(D’Ydewalle et al., 2012). 
TBCEL shows sequence homology to tubulin-specific chaperone cofactor E (TBCE). 
In the mouse, a homozygous mutation in the tubulin-specific chaperone E (Tbce) 
gene causes a progressive motor neuronopathy associated with shortened axons and 
axonal swelling due to defects in tubulin assembly (Bommel et al., 2002). In humans, 
TBCE mutations cause Sanjad–Sakati syndrome, an AR disease characterised by 
hypoparathyroidism, mental retardation and dysmorphism (Padidela et al., 2009). 
Further assessment of this candidate gene will be taken forward by another member 
of staff as this work was out of the remit of this PhD. To this end, the variant in 
TBCEL in CMT family IS has now been confirmed by Sanger sequencing to ensure 
that the mutation was not an artefact of exome sequencing. 
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5.5.3 Exome sequencing in a severe CMT1 family 
The exome sequencing in individual II-1 of CMT family AD produced a total of 
119,890,846 reads. The mean target coverage was 98X; 87.3% of the bases had at 
least 2-fold coverage, 80.7% of bases had at least 10-fold coverage and 72.5% of the 
bases had at least 30-fold coverage. As explained in Section 5.3.3, the coverage 
could not be assessed for individual I-2 as no BAM file could be obtained. 
Please see Appendix V Table V-3 for a list of poorly covered exons in inherited 
neuropathy genes in individual II-1 of family AD. Overall, 24 inherited neuropathy 
genes had at least one poorly covered exon: PMP22, NEFL, EGR2, NDRG1, PRX, 
FIG4, CTDP1, TRPV4, GARS, DNM2, DYNC1H1, LRSAM1, SPTLC1, SPTLC2, 
histidyl-tRNA synthetase (HARS), LMNA, MTMR13, IGHMBP2, PDK3, MARS, 
SEPT9, DNMT1, HSPB1 and KIF1A. In total, 19,619 variants were found in 
individual I-2 and 18,161 variants in individual II-1. These two individuals shared 
10,339 variants. After filtering for the heterozygous variants, 5,207 variants 
remained. 2,614 variants were left after filtering out synonymous mutations. Variants 
found in known inherited neuropathy genes amongst these 2,614 variants are 
summarized in Table 5-2. A total of 8 non-synonymous variants in 7 different 
neuropathy genes were found; no variant was predicted to be the disease-causing 
variant as all variants were either found at a high MAF in control databases, or the 
gene did not fit with the patient’s clinical description. A total of 181 variants 
remained after filtering out variants in areas of segmental duplication as well as 
variants found in control databases using the frequency filters mentioned in Section 
5.3.4. 
Amongst the list of remaining variants, a variant in rho guanine nucleotide exchange 
factor 11 (ARHGEF11) was retained for further analysis.  Mutations in rho guanine 
nucleotide exchange factor 10 (ARHGEF10) were reported in an ICMT family and a 
CMT2 family at the 5
th
 International CMT Consortium Meeting in Antwerp, 
Belgium in June 2013 (unpublished). A mutation in ARHGEF10 with AD inheritance 
was also associated with slowed nerve conduction and thinly myelinated axons 
(Verhoeven et al., 2003). 
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Both individuals I-2 and II-1 of CMT family AD had a heterozygous non-
synonymous mutation in ARHGEF11, p.Gly1393Arg (c.4177G>A) (Ensembl 
Transcript ID: ENST00000368194). This variant (dbSNP ID rs142548089) has a 
MAF of 0.001 in Europeans and 0.006 in individuals from Great Britain according to 
the 1000 Genomes database. Its MAF is 0.001047 in Europeans in the EVS database; 
it is not found in the CG69 database. This variant is not found in the GEM.app 
database; only common SNPs are reported for this gene in CMT patients in this 
database. SIFT, Polyphen-2 and Mutation Taster in-silico analyses predicted this 
variant to be pathogenic (Polyphen-2 score=0.995 (probably damaging); Mutation 
Taster score=3.41 with probability of 0.85118). This amino acid is highly conserved, 
with a GERP score of 4.92. According to the Human Protein Atlas, the ARHGEF11 
protein is ubiquitously expressed with moderate to high expression in neuronal and 
glial cells in the brain and moderate expression in peripheral nerve. The depth and 
quality of this variant were 41 and 293.92 in individual I-2, and 47 and 678.29 in 
individual II-1, respectively. 
ARHGEF11, located on chromosome 1, is 1,562 amino acids long and has 41 exons, 
all of which are coding exons. It acts as a guanine nucleotide exchange factor for 
RhoA GTPase. ARHGEF11 activates Rho/Rho kinase signalling and is involved in 
neurite retraction and actin cytoskeleton reorganisation (Banerjee & Wedegaertner, 
2004; Togashi et al., 2000). GTPases of the Rho subfamily play a role in myelination 
in the nervous system; furthermore, mutations in the Rho GTPase guanine nucleotide 
exchange factor Frabin/FGD4 are known to cause CMT (Stendel et al., 2007).  
Additional analysis of ARHGEF11 will be performed by another member of staff, as 
is the case for the candidate gene in CMT family IS. The ARHGEF11 mutation in 
CMT family AD needs to be confirmed by Sanger sequencing. For both CMT 
families IS and AD, segregation of the variants in the families needs to be performed. 
If the candidate variants do not segregate, additional family members for which 
DNA is available could be exome sequenced to further narrow down the list of 
remaining variants. Exome sequencing of the father (individual I-2) in family IS 
would reduce the final list of remaining variants by about 50%, and exome 
sequencing the fourth, possibly affected sibling (individual II-4) would reduce it by 
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about 25%. Performing exome sequencing on both parents of individual I-2 in family 
AD would have been ideal as parent-child trios are very informative in identifying de 
novo mutations; indeed, multiple de novo events within a single gene or pathway are 
rare (Bamshad et al., 2011). Unfortunately, DNA was not available for these 
individuals. Furthermore, TBCEL and ARHGEF11 should be screened in a large 
number of in-house CMT cases with a similar phenotype, as well as in controls of 
matching ethnicity. The exons of CMT genes poorly covered by exome sequencing 
should also be Sanger sequenced. Finally, functional studies will be necessary to 
provide further evidence of pathogenicity.  
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Table 5-1 Variants identified in known inherited neuropathy genes in CMT family IS. 
Gene Position
Reference 
allele
Observed 
allele
Amino acid 
change Type Functional change Call
1000 
Genomes 
MAF
EVS 
MAF
CG69 
MAF dbSNP ID
PRX 40900865 C T p.Gly1132Arg exonic nonsynonymous hom 0.96 0.953791 0.942 rs268674
HK1 71060610 A G p.His7Arg exonic nonsynonymous hom 0.91 0.920655 0.826 rs906220
LRSAM1 130242166 A G p.Asn318Asp exonic nonsynonymous hom 0.74 0.741809 0.703 rs1539567
ASAH1 17918934 A G p.Val262Ala exonic nonsynonymous hom 0.86 0.8666 0.833 rs10103355
GALC 88401213 T C p.Thr641Ala exonic nonsynonymous hom 0.94 0.959477 0.942 rs421262
IGHMBP2 68678962 T C p.Leu201Ser exonic nonsynonymous het 0.7 0.778565 0.775 rs560096
IGHMBP2 68705674 C A p.Thr879Lys exonic nonsynonymous het 0.23 0.210117 0.196 rs17612126
WNK1 994487 G C p.Cys1506Ser exonic nonsynonymous hom 0.99 0.986083 0.993 rs7955371
SCN9A 167099158 A G p.Trp1150Arg exonic nonsynonymous hom 0.89 0.877448 0.855 rs6746030
SETX 135203231 C T p.Gly1252Arg exonic nonsynonymous hom 0.59 0.693065 0.645 rs1183768
SETX 135202829 T C p.Ile1386Val exonic nonsynonymous hom 0.59 0.693757 0.645 rs543573
SETX 135203409 A C p.Asp1192Glu exonic nonsynonymous hom 0.66 0.792942 0.739 rs1185193
ZFYVE26 68234539 T C p.Asn1891Ser exonic nonsynonymous hom 0.92 0.941719 0.92 rs3742883
DST 56463410 T C p.Gln1308Arg exonic nonsynonymous het 0.34 0.381045 0.391 rs4712138
DST 56470551 T A p.Thr2422Ser exonic nonsynonymous het 0.27 0.307263 0.29 rs13194995
DST 56471402 G A p.Pro2464Leu exonic nonsynonymous het 0.37 0.432662 0.442 rs9382658
DST 56482801 C G p.Val2011Leu exonic nonsynonymous het 0.4 0.469245 0.449 rs6459166
ATM 108183167 A G p.Asn1983Ser exonic nonsynonymous hom 1 N/A 1 rs659243
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Table 5-2 Variants identified in known inherited neuropathy genes in CMT family AD. 
Gene Position
Reference 
allele
Observed 
allele Amino acid change Type Functional change Call
1000 
Genomes 
MAF
EVS 
MAF
CG69 
MAF dbSNP ID
KARS 75661803 G C p.Thr623Ser exonic nonsynonymous het 0.11 0.136504 0.13 rs6834
SBF2 9879838 C T p.Glu679Lys exonic nonsynonymous het 0.06 0.078522 0.065 rs7102464
GAN 81411091 C G p.Pro562Ala exonic nonsynonymous het 0.0037 0.003384 NA rs79901179
AP4B1 114438951 A G p.Leu480Ser exonic nonsynonymous het 0.35 0.437952 0.312 rs1217401
WNK1 990912 A C p.Thr1056Pro exonic nonsynonymous het 0.85 0.852606 0.826 rs956868
SPG11 44918690 C T p.Ala695Thr exonic nonsynonymous het 0.01 0.009698 N/A rs78183930
SPG11 44944037 C T p.Glu370Lys exonic nonsynonymous het 0.01 0.014624 N/A rs77697105
ZFYVE26 68249499 C T p.Cys1457Tyr exonic nonsynonymous het 0.19 0.263494 0.167 rs2235967
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5.5.4 Sanger sequencing of a candidate gene from a previous exome 
sequencing study 
The p.Arg118His variant in MFF was not detected in our cohort of 333 
CMT2/HSP/dHMN patients. All variants detected in MFF in this cohort were known 
polymorphisms and were not predicted to be pathogenic (refer to Appendix V Table 
V-4 for list of variants found in MFF). MFF was one of several candidate genes 
retained for further analysis by colleagues at University of Miami’s Miller School of 
Medicine in this CMT family. Upon additional genetic and functional studies, 
another candidate gene, trafficking protein kinesin binding 2 (TRAK2), was 
subsequently considered more likely to be the true disease-causing variant in CMT 
family BJ (unpublished). TRAK2 encodes a protein needed for mitochondrial 
transport in axons and dendrites; specifically, it connects mitochondria to motors on 
microtubules (Van Spronsen et al., 2013). However, studies in other CMT families 
performed by the University of Miami’s Miller School of Medicine now suggest that 
TRAK2 is in fact unlikely to be the causative gene. MFF, which had not been firmly 
excluded, as well as other candidate genes, are being further evaluated by our 
colleagues.  
5.6 Discussion  
This study has identified candidate disease-causing variants in two CMT families 
who have so far remained without a genetic diagnosis. These results are very 
preliminary; as mentioned previously, further assessment of pathogenicity will be 
carried out by another member of staff as this work could not be carried out within 
the timeframe of this study.  
Although exome sequencing is often considered the gold standard for identifying 
novel disease genes or assigning novel phenotypes to known disease genes, this view 
is perhaps biased as negative exome sequencing results are rarely published 
(Bamshad et al., 2011). In our experience, many families for which exome 
sequencing has been performed remain without a genetic diagnosis. In the event that 
a suitable candidate gene is selected for further study, there remains the significant 
hurdle of proving its pathogenicity. Comparative genomics are sometimes considered 
one of the most accurate measures of deleteriousness, although there are some 
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exceptions (Bamshad et al., 2011). In vitro studies may be helpful but are not 
definitive; a deleterious effect on the molecular level will not always cause a 
phenotype in an organism. Using an inappropriate cell type or outcome measure may 
also lead to false negative or false positive results (Bamshad et al., 2011). 
Furthermore, severe functional disturbances in vitro have been known to occur as a 
result of mutations found in control individuals; similarly, certain known pathogenic 
mutations have not been found to cause defects in vitro (Kochañski, 2006). 
It is possible that the mutation causing CMT in these two families was not detected. 
Exome sequencing will not reveal large indels, duplications, translocations and 
repeat sequences (Singleton, 2011). Variants outside of coding regions which may be 
disease-causing are also not detected, such as in introns, promoters, microRNAs or 
UTRs. Another limitation of exome sequencing is that coverage is not always 
sufficient or homogeneous throughout the genome; for example, the first exon in a 
gene is commonly missed (Azzedine et al., 2012; Bamshad et al., 2011; Singleton, 
2011). Synonymous mutations were excluded during filtering but the effect of these 
variants is not necessarily neutral (Parmley & Hurst, 2007). The mutation may also 
be located in a poorly covered gene or in an as-of-yet uncharacterised gene. 
Technical problems with mapping or alignment cannot be discarded as well 
(Bamshad et al., 2011). 
In addition to its role in novel-gene identification, exome sequencing allows 
simultaneous testing of all CMT genes with relatively little DNA, and in this regard 
is faster and cheaper than Sanger sequencing of individual genes (Rossor et al., 
2013). It may uncover variants in CMT genes which were previously screened but in 
which the variant was missed. Although the cost of exome sequencing, as well as the 
lack of complete gene coverage, prevent it from being used for routine testing at 
present, it is predicted that exome sequencing will become a diagnostic screening 
tool within the next few years (Azzedine et al., 2012). As discussed in Chapter 3, 
since 92% of CMT patients in the Saporta et al. (2011) study had a Chr17p11.2 
duplication/deletion or mutation in MPZ, GJB1, or MFN2, these genes should still be 
tested by Sanger sequencing first, as appropriate for each patient (Amato & Reilly, 
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2011). In addition to identifying rare variants, exome sequencing may become a 
useful tool to detect modifier genes and risk factors.  
5.7 Conclusion 
This Chapter has highlighted the difficulties of exome sequencing, particularly in 
diseases such as CMT caused by defects in a wide array of biological pathways. An 
undisputable challenge of exome sequencing is to identify the disease-causing 
variant among the large number of potentially pathogenic variants remaining after 
extensive filtering. The mutations in the candidate genes identified in this study will 
be subject to further genetic and functional analyses to support their pathogenicity. 
Despite its limitations, exome sequencing remains an effective way to identify causal 
variants in CMT patients who are negative for the common CMT genes. The 
advantages of exome sequencing include rapidity, low cost and the possibility of 
screening nearly all protein-coding regions of the genome in parallel with only 2 μg 
of DNA.  
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Chapter 6 Screening of riboflavin transporter genes and searching 
for novel genetic causes of BVVL and related neuropathies 
6.1 Introduction 
6.1.1 Riboflavin transporter mutations as a novel cause of hereditary sensory-
motor neuropathy 
Exome sequencing has been used by our group and colleagues to identify the genetic 
cause of disease in patients suffering from BVVL. As described in Section 1.6.1, 
BVVL syndrome is a childhood-onset, progressive pontobulbar palsy with sensory-
motor neuropathy, bilateral sensorineural hearing loss and respiratory insufficiency; 
it is often fatal in childhood due to respiratory failure (Brown, 1894; Van Laere, 
1966; Vialetto, 1936). The phenotype of BVVL may overlap with that of ALS and 
SMA, as discussed previously (Green et al., 2010; Horvath et al., 2012), and is also 
likely allelic with FL syndrome (Fazio, 1892; Londe, 1893; Londe, 1894). As 
detailed in Section 1.6.3, homozygous and compound heterozygous mutations in 
SLC52A2 and SLC52A3, encoding human riboflavin transporters RFVT2 and RFVT3 
respectively, have recently been found in several BVVL patients using exome and 
Sanger sequencing (Anand et al., 2012; Bandettini di Poggio et al., 2013; Bosch et al, 
2011; Ciccolella et al., 2012; Ciccolella et al. 2013; Dezfouli et al., 2012; Green et 
al., 2010; Haack et al., 2012; Johnson, Gibbs, et al., 2010; Johnson et al., 2012; Koy 
et al., 2012; Yamamoto et al., 2009; Yao et al., 2010). Haploinsufficiency in 
SLC52A1, encoding RFVT1, was associated with mild maternal riboflavin deficiency 
and a riboflavin-responsive MADD (RR-MADD)-like biochemical profile in her 
newborn infant (Chiong et al., 2007; Ho et al., 2010; Yonezawa et al., 2008). No 
treatment had previously proven successful in BVVL patients (Sathasivam, 2008); 
these genetic discoveries have uncovered high-dose riboflavin therapy as a potential 
treatment for BVVL patients with riboflavin transporter mutations, with clinical and 
biochemical improvements evident in most patients (Bosch et al., 2012). It is likely 
that many patients with mutations in these riboflavin transporters who may benefit 
from riboflavin therapy remain to be identified. 
Defective riboflavin transport as a result of mutations in the riboflavin transporters 
causes decreased intracellular levels of riboflavin and its active coenzyme forms, 
FAD and FMN (Bosch et al., 2011). FAD and FMN are components of 
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flavoenzymes and flavoproteins and are therefore needed for a wide range of cellular 
functions, including energy metabolism, glutathione recycling, oxidative protein 
folding, DNA repair, and others (Section 1.6.6) (Lienhart et al., 2013; Massey, 
2000). 
The mechanisms of riboflavin absorption, transport, metabolism and homeostasis 
will now be described; this will be followed by a description of the mutations which 
have been described to date in the riboflavin transporters. 
6.1.2 Riboflavin absorption, transport and metabolism 
As mentioned in Section 1.6.6, unlike plants and many microorganisms, humans 
cannot synthesise riboflavin and thus need to obtain it from exogenous sources in the 
diet (McCormick, 1989; Northrop-Clewes & Thurnham, 2012). The riboflavin 
synthesized by the microflora of the large intestine in humans provides only a minor 
percentage of the riboflavin needed for health (Powers, 2003). Although a small 
amount of riboflavin is actually required by the body, the symptoms associated with 
riboflavin deficiency (as delineated in Section 1.6.4) clearly demonstrate that this 
vitamin is an essential micronutrient (Northrop-Clewes & Thurnham, 2012). 
Most riboflavin in food is found in the form of FAD, and a lesser portion is found as 
FMN and free riboflavin. FAD and FMN must be released from flavoproteins by 
gastric proteases during digestion, and hydrolysed by pyrophosphatases and 
phosphatases to free riboflavin for absorption (Henriques et al., 2010; McCormick, 
1989; Powers, 2003, Said & Mohammed, 2006). Free riboflavin is then absorbed at 
the luminal surface of the epithelial cells in the proximal small intestine (Levy & 
Jusko, 1966); the riboflavin uptake process via specialised transporters will be 
described below. In the blood, the riboflavin level increases fastest in the plasma, and 
slowly equilibrates between the plasma and the blood erythrocytes (Stripp, 1965). 
Upon entering circulation, riboflavin is distributed throughout the body and into 
target tissues. In the plasma, most of the free riboflavin associates with other proteins 
such as albumin and immunoglobulins (McCormick, 1989). In humans, a very low 
amount of riboflavin is stored in the body; the highest levels of its coenzyme forms 
FMN and FAD were found in kidney and liver (Burch et al., 1956; McCormick, 
 192 
1989). It is also stored in the spleen and cardiac muscle in minute quantities (Depeint 
et al., 2006). The kidney controls riboflavin excretion as a large portion of filtered 
riboflavin is re-absorbed at the luminal surface of renal urinary ducts; when plasma 
concentrations of riboflavin are too high (above 0.5 μM), the excess is excreted in 
the urine (Kumar et al., 1998; Moriyama, 2011; Spector & Johanson, 2006). 
Therefore, the intestines and kidney are critical in maintaining riboflavin 
homeostasis in the body (Subramanian et al., 2013).  
Riboflavin is absorbed very rapidly in humans (Levy & Jusko, 1966; Zempleni et al., 
1996); given the size of this substance (molecular weight of 376.36) and its lipid-
insoluble nature, a specialised transport mechanism was suspected to be more likely 
than absorption by passive diffusion only (Levy & Jusko, 1966). The amount of 
riboflavin that would be allowed through by passive diffusion would likely not be 
sufficient to meet the cell’s re uirement (Fujimura et al., 2010). Indeed, the majority 
of in vitro studies using various human cell lines have found evidence of an energy-
dependent, largely Na
+
-independent, highly specific, and saturable carrier-mediated 
system for riboflavin uptake (Foraker et al., 2003; Huang & Swaan, 2001; Kansara et 
al., 2005; Kumar et al., 1998; Levy & Jusko, 1966; Said & Ma, 1994; Said et al., 
1998). Riboflavin synthesised by bacteria in the colon is also absorbed efficiently by 
a similar mechanism (Said & Mohammed, 2006). When given orally, absorption 
decreased with increasing dose, showing evidence of tissue saturation (Levy & 
Jusko, 1966; Zempleni et al., 1996); the excretion rate decreased exponentially with 
time and the absorption half-life was 1.1 h on average (Levy & Jusko, 1966). 
Pharmacokinetic variables for riboflavin absorption did not exhibit gender 
differences (Zempleni et al., 1996). A fraction of the administered riboflavin was 
rapidly eliminated early on, while a second fraction was excreted more slowly after 
several hours; this was not significantly dependent on dose or route of administration 
and suggests the presence of a peripheral compartment (likely uptake into cells and 
tissues) in riboflavin distribution (Levy & Jusko, 1966; Zempleni et al., 1996). 
Although a saturable carrier system predominated when intake of riboflavin was low 
or normal, at higher intakes or when plasma concentrations were higher than 12 nM, 
transport occurred principally by passive diffusion (Feder et al., 1991; Foraker et al., 
2003; McCormick, 1989). It has been suggested that the maximal absorption for 
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pharmacological doses of riboflavin administered orally is 25-27 mg per dose, and 
that unused riboflavin is excreted within 8 to 24 h following the intake (Gregersen, 
1985; Zempleni et al., 1996). However, there is enhanced absorption of higher doses 
of riboflavin when taken orally after a meal, possibly due to decreased transit in the 
intestine and therefore prolonged exposure to intestinal sites of absorption (Levy & 
Jusko, 1966). 
Once inside the cell, riboflavin kinase converts riboflavin to FMN, most of which is 
then converted to FAD by FAD synthetase in an ATP-dependent process (Henriques 
et al., 2010; McCormick, 1989). Whether the conversion of riboflavin to FMN and 
FAD occurs only in the cytosol has long been a subject of controversy; however, 
recent evidence suggests that FAD synthesis can also occur in the mitochondria and 
in the nucleus after uptake of riboflavin into these organelles via an uncharacterised 
carrier-mediated process (Barile et al., 2000; Depeint et al., 2006; Giancaspero et al., 
2013; Henriques et al., 2010; McCormick, 1989). FAD in the mitochondria can be 
incorporated into flavoproteins or reconverted to free riboflavin in the outer 
mitochondrial membrane by FAD pyrophosphatase and FMN phosphohydrolase 
(Bafunno et al., 2004; McCormick, 1989). The FLX1 gene in Saccharomyces 
cerevisiae encodes an FAD transporter protein on the mitochondrial membrane 
necessary for the balance of flavin nucleotides in yeast mitochondria (Bafunno et al., 
2004; Tzagoloff et al., 1996). The human orthologue of FLX1, the mitochondrial 
folate transporter (MFT), is a mitochondrial FAD transporter which may be involved 
in FAD export from the mitochondria (Spaan et al., 2005). Although the studies 
described above would suggest a riboflavin-FAD cycle in the cell as a recycling 
pathway (Barile et al., 2000), the exact mechanism used by the cell to maintain flavin 
homeostasis is still uncertain, and no mammalian mitochondrial or nuclear riboflavin 
transporter has been characterised to date (Giancaspero et al., 2013).  
As with many membrane-bound transporter systems, riboflavin uptake is thought to 
be regulated by signalling pathways including the protein kinase A (PKA) pathway 
and the calcium/calmodulin-mediated pathways with variations between tissues 
(Foraker et al., 2003; Kansara et al., 2005; Kumar et al., 1998; Patel et al., 2012; Said 
et al., 1994). Calmodulin inhibitors, as well as compounds such as forskolin which 
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activate the PKA pathway by increasing intracellular cyclic adenosine 
monophosphate (cAMP) levels, were found to decrease riboflavin uptake (Foraker et 
al., 2003; Kansara et al., 2005; Patel et al., 2012; Said et al., 1994). Riboflavin 
transport was also regulated by extracellular levels of riboflavin; deficiency and 
high-dose supplementation of riboflavin led to up and down-regulation of riboflavin 
uptake in the intestine, respectively (Said & Ma, 1994; Said & Mohammed, 2006).  
The minimal required daily intake of riboflavin is determined by factors including 
tissue growth/metabolic demand, respiratory infections, age, dietary intake/fasting, 
absorption and transport, FMN/FAD synthesis, and mitochondrial metabolism and 
transport (Hustad et al., 2002; Vergani et al., 1999). Growing children and pregnant 
women have a higher demand for riboflavin (Gregersen, 1985). Riboflavin was 
mobilised from tissue to blood during respiratory infections in humans and mice, and 
urinary excretion of riboflavin increased (Hustad et al., 2002; Prasad et al., 1991). 
These studies may provide an explanation for the observation that BVVL is often 
initiated or worsened by events such as viral infection and fever, as discussed in 
Section 1.6.1.   
The median baseline blood plasma concentrations of riboflavin, FMN and FAD in 
human subjects were determined to be 10.5 nM, 6.6 nM and 74 nM, respectively, 
with riboflavin displaying much greater variability (Hustad et al., 2002; Zempleni et 
al., 1996). Although riboflavin and FMN levels increased significantly upon 
riboflavin supplementation in riboflavin-deficient individuals, levels of FAD in 
plasma did not increase. FAD levels have also been found to remain relatively more 
stable compared to riboflavin levels during the development of riboflavin deficiency 
in humans and monkeys (Burch et al., 1956; Hustad et al., 2002). A homeostatic 
mechanism probably exists to regulate and maintain levels of flavin coenzymes in 
the tissues, especially that of FAD (Hustad et al., 2002). 
6.1.3 Identification and characterisation of the riboflavin transporters 
Riboflavin transporters have been identified in other species, including the RibU 
protein in Lactobacillus lactis (Burgess et al., 2006) and the Mch5p protein in 
Saccharomyces cerevisiae (Reihl & Stolz, 2005). Although a carrier-mediated 
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mechanism for transport of riboflavin and homeostasis of riboflavin levels 
throughout the body had been suspected for decades from studies of human-derived 
cell lines (Foraker et al., 2003; Huang & Swaan, 2001; Kansara et al., 2005; Kumar 
et al., 1998; Levy & Jusko, 1966; Said & Ma, 1994; Said et al., 1998), human 
riboflavin transporters (encoded by SLC52A1, SLC52A2 and SLC52A3) were only 
recently cloned from human tissues (Fujimura et al., 2010; Subramanian, 
Subramanya, et al., 2011; Yamamoto et al., 2009; Yao et al., 2010; Yonezawa et al., 
2008). These transporters showed no similarity to riboflavin transporters described in 
other species or to other SLC transporters (Foraker et al., 2003; Yonezawa et al., 
2008; Yonezawa & Inui, 2013). 
RFVT1 was the first member of this new mammalian riboflavin transporter family to 
be identified based on its similarity to the rat rRFVT1 with which it shares 87% 
similarity (Yonezawa et al., 2008). This transporter is encoded by SLC52A1, a gene 
with five exons (four coding exons) on Chr17p13.3. This gene was first known as 
GPR172B, however it is not related to G-protein coupled receptor proteins (Yao et 
al., 2010). SLC52A1 has two mRNA transcript variants (GenBank accession numbers 
NM_017986 and NM_001104577); the two transcripts differ only in the 5’UTR and 
encode the same protein of 448 amino acids (NP_001098047.1 and NP_060456.3). 
The protein is predicted to have eleven transmembrane domains (TMHMM v.2 
prediction). RFVT1 is most highly expressed in the placenta and also has high 
expression in the small intestine and in the colon. It has very low expression in the 
CNS, and overall is expressed at lower levels throughout the body than RFVT2 and 
RFVT3 (Yao et al., 2010; Yonezawa et al., 2008). Expression in the small intestine 
suggests a role of RFVT1 in riboflavin uptake from food into the blood. 
Furthermore, its expression in the colon suggests it is important for absorption of 
riboflavin synthesized by the bacterial microflora of the large intestine (Yonezawa et 
al., 2008). It is worthy of note that RFVT1 is highly expressed in the placenta, which 
may explain the phenotype seen in the infant of a riboflavin-deficient mother with 
haploinsufficiency of SLC52A1 (Chiong et al., 2007; Ho et al., 2010).   
RFVT3, encoded by SLC52A3, was the second member of the riboflavin transporter 
family to be identified based on its 83% similarity to the rat rRFVT3 (Fujimura et al., 
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2010; Yamamoto et al., 2009). The rat rRFVT3, highly expressed in the small 
intestine, was originally identified due to its similarity to a putative bacterial 
riboflavin transporter, impX (Yamamoto et al., 2009). SLC52A3 has five exons (four 
coding exons) and is located on Chr20p13 (GenBank accession number 
NM_033409). The encoded protein is 469 amino acids long (NP_212134.3) and is 
predicted to have eleven transmembrane domains (TMHMM v.2 prediction). RFVT3 
is highly conserved across species. It is most highly expressed in the testes, and is 
also highly expressed in the small intestine and prostate (Yao et al., 2010); its 
expression was also detectable in skeletal muscle, spinal cord, colon, kidney and 
stomach (Fujimura et al., 2010; Yamamoto et al., 2009). RFVT3 is moderately 
expressed in the CNS, with minimal expression in the brain (Yamamoto et al., 2009; 
Yao et al., 2010). Polymorphisms in this gene have been found to modulate 
susceptibility to oesophageal squamous cell carcinoma (Wei et al., 2013); similarly, 
decreased plasma riboflavin levels resulting from defective expression of SLC52A3 
have been associated with development of gastric carcinoma (Eli et al., 2012). Two 
orthologues of RFVT3 encoded by the riboflavin transporter genes rft-1 and rft-2 
have been recently identified in Caenorhabditis elegans, which also lack the ability 
to synthesise riboflavin. Both of these orthologues are expressed in the intestine and 
rft-1 shared transport characteristics with RFVT3. Knocking down these transporters 
resulted in a severe loss of fertility. As expected, there was a drop in rft-1 mRNA 
when worms were supplemented with riboflavin (Biswas et al., 2013). 
SLC52A2 encodes RFVT2, the third riboflavin transporter to be identified. SLC52A2, 
a gene with five exons (four coding) on Chr8q24.3, was discovered on the basis of its 
homology to SLC52A1 (Yao et al., 2010). The gene has three mRNA transcript 
variants (GenBank accession numbers NM_024531.4, NM_001253816.1 and 
NM_001253815.1); the transcripts differ only in the 5’UTR and encode the same 
protein of 445 amino acids (NP_001240745.1, NP_078807.1 and NP_001240744.1) 
with eleven predicted transmembrane domains (TMHMM v.2 prediction). Unlike 
RFVT1 and RFVT3, RFVT2 is expressed ubiquitously but is particularly highly 
expressed in the brain, foetal brain, spinal cord and salivary gland (Yao et al., 2010). 
RFVT1 and RFVT2 were initially reported to act as receptors for porcine 
endogenous retrovirus subgroup A, but their function had not been fully elucidated 
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until recently (Ericsson et al., 2003). RFVT3 shares 43% amino acid identity with 
RFVT1, while RFVT2 shares 87% and 44% amino acid identity with RFVT1 and 
RFVT3, respectively (Yamamoto et al., 2009; Yao et al., 2010).  
Initial experiments in transfected HEK293 cells confirmed localisation of all 
transporters at the cellular plasma membrane (Yao et al., 2010). The uptake of [
3
H]-
riboflavin via all three transporters increased in a time and concentration-dependent 
manner (Yao et al., 2010). In human intestinal epithelial cells in vitro, riboflavin 
uptake via RFVT3 was significantly higher than uptake via RFVT1 and RFVT2 
(Subramanian, Subramanya, et al., 2011). RFVT1 had low riboflavin transport 
activity in Caco-2 cells (Yonezawa et al., 2008). RFVT1, RFVT2 and RFVT3 had 
similar substrate specificities and uptake for all three transporters was independent of 
extracellular Na
+
 and Cl
-
 (Yao et al., 2010). Although certain previous in vitro 
studies had found riboflavin transport to be independent of extracellular Na
+
, other 
carrier-mediated mechanisms for riboflavin uptake in intestinal cells had been found 
to be Na
+
-dependent, suggesting that other transporters of riboflavin may exist 
(Foraker et al., 2003; Fujimura et al., 2010). Riboflavin transport via RFVT3 in 
HEK293 cells favoured a slightly acidic pH, while transport via RFVT1 and RFVT2 
was pH-independent (Yamamoto et al., 2009; Yao et al., 2010). Transport via all 
three transporters was strongly inhibited by riboflavin and riboflavin analogues such 
as lumiflavin, and was moderately inhibited by FMN. FAD only slightly inhibited 
uptake via the RFVT2 transporter therefore it is likely that riboflavin is principally 
carried across the plasma membrane. Transport through all transporters was not 
inhibited by D-ribose, indicating that the isoalloxazine ring of riboflavin is necessary 
for transporter recognition (Fujimura et al., 2010; Yao et al., 2010; Yonezawa & 
Inui, 2013). Therefore, both the amino acid sequence and mechanistic characteristics 
of riboflavin transport of RFVT2 are more similar to that of RFVT1 than that of 
RFVT3 (Yao et al., 2010). Overall however, additional research is needed to further 
elucidate the riboflavin transport mechanisms via the RFVTs (Moriyama, 2011). 
In the enterocyte of the intestine, riboflavin is transported first across the apical 
brush-border membrane domain, and subsequently across the basolateral membrane 
domain (Subramanian, Subramanya, et al., 2011). RFVT3 was located exclusively at 
 198 
the apical brush border membrane domain in human-derived Caco-2 cells and in the 
renal MDCK cell line, therefore RFVT3 is likely responsible for riboflavin uptake on 
the luminal surface of the small intestine (Fujimura et al., 2010; Subramanian, Rapp, 
et al., 2011; Yoshimatsu et al., 2014). In these cell lines, intracellular trafficking of 
RFVT3 involved vesicular structures and required an intact microtubule network; the 
velocity of the vesicles was temperature-dependent (Subramanian, Rapp, et al., 
2011). In Caco-2 cells and MDCK cells, RFVT1 was mainly localised at the 
basolateral membrane of polarised enterocytes, although some RFVT1 was retained 
in intracellular vesicles; RFVT2 was localised mostly in intracellular vesicles (most 
likely endosomes) but was also found at the basolateral membrane of some cells 
(Subramanian, Subramanya, et al., 2011; Yao et al., 2010). While the intracellular 
trafficking vesicles containing tagged RFVT1 and RFVT2 co-localised with 
lysosomal-associated membrane protein 1 (LAMP1), a late endosomal and lysosomal 
marker, RFVT3 did not co-localise with LAMP1 (Subramanian, Subramanya, et al., 
2011). The localisation of RFVT2 within endosomes of intestinal cells may suggest 
that its translocation to and from the basolateral membrane can be regulated 
(Subramanian, Subramanya, et al., 2011).  
Given their high expression in the small intestine, RFVT1 and RFVT3 are probably 
mainly responsible for distribution of riboflavin from the intestinal lumen (i.e. from 
food) into the blood by intestinal epithelial cells, although RFVT3 was the most 
efficient at transporting riboflavin in native human intestinal cells (Fujimura et al., 
2010; Subramanian, Subramanya, et al., 2011; Yao et al., 2010). The different 
localisation of RFVT1 and RFVT3 in polarised epithelial cells suggests that transport 
of riboflavin from the lumen to the bloodstream occurs via two transporters 
sequentially: RFVT3 followed by RFVT1. It is probable that SLC52A1 and SLC52A3 
mutations result in deficient uptake of riboflavin from food, leading to the decreased 
plasma flavin levels seen in these BVVL patients (Bennett, 2012). It may be that the 
effects of haploinsufficiency of RFVT1 can be prevented via compensation by 
RFVT3, however this remains to be investigated. RFVT2 may provide further 
opportunity for regulating riboflavin homeostasis in the intestine and is likely to be 
important for riboflavin homeostasis and energy metabolism in the brain (Fujimura 
et al., 2010; Subramanian, Subramanya, et al., 2011; Yao et al., 2010). Its lower 
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expression in the small intestine may provide a rationalisation for the normal levels 
of flavins in the plasma of most BVVL patients with SLC52A2 mutations (Bennett, 
2012). As discussed previously however, it is likely that some riboflavin uptake may 
occur via passive diffusion when riboflavin intake is high (Foraker et al., 2003). 
Transporters of nutrients possess targeting motifs and signals which are often located 
within the COOH terminus (Subramanian, Rapp, et al., 2011). Accordingly, the 
COOH-terminal sequence was shown to be necessary for cell surface expression of 
RFVT3 and riboflavin uptake via this transporter in transfected Caco-2 cells. In 
particular, mutation of the cysteine residues 463 and 467 in the COOH-terminal 
caused defective riboflavin uptake with retention of the construct in the endoplasmic 
reticulum (ER), which is the site of synthesis, folding, and assembly of 
transmembrane and secretory proteins in the cell (Sevier & Kaiser, 2008). A 
potential disulphide bridge was also predicted between the cysteine residues at amino 
acids 386 and 463. Indeed, when cysteine 386 was mutated the construct was also 
retained intracellularly, supporting the role of the disulphide bridge in membrane 
localisation and proper function of this transporter (Subramanian, Rapp, et al., 2011). 
The amino acids encompassing the COOH-terminals in human RFVT1, RFVT2 and 
RFVT3 are amino acids 430-448, 427-445 and 451-469, respectively (Subramanian, 
Rapp, et al., 2011).  
Although rodents carry the Slc52a2 and Slc52a3 genes (encoding RFVT2 and 
RFVT3, respectively), no orthologue encoding a third riboflavin transporter has been 
identified in rodents. The characteristics of riboflavin uptake via the mouse mRFVT2 
were similar to that of human RFVT2. mRFVT2 shares approximately 80% of its 
amino acids with both human RFVT1 and RFVT2 and is therefore predicted to be an 
orthologue of both these human transporters (Yao et al., 2013). Since higher animals 
such as humans, chimpanzees (Pan troglodytes) and rhesus monkeys (Macaca 
mulatta) have three riboflavin transporters, the third riboflavin transporter has likely 
evolved more recently in evolution (Yonezawa & Inui, 2013). Experiments suggest 
mRFVT3 may be important for riboflavin transport under acidic conditions (Yao et 
al., 2013). mRFVT2 is expressed at a higher level in the mouse liver than mRFVT3. 
Riboflavin deprivation in mice led to decreased intracellular concentration of 
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riboflavin in the plasma but not in the liver, concomitant with upregulation of 
Slc52a2 but not Slc52a3 mRNA expression in this organ (Yao et al., 2013). 
mRFVT2 likely plays an important role in riboflavin uptake in various tissues 
including the liver. As acyl-CoA dehydrogenase was found to be highly expressed in 
the liver, defective riboflavin transport in this tissue may explain the biochemical 
abnormalities in BVVL patients (Yao et al., 2013). 
Studies of riboflavin uptake in the rat have shown the mRNA expression of rRFVT3 
to be upregulated in the small intestine of rats fed a riboflavin-deficient diet, likely as 
an adaptive response; this response is common to several B vitamin transporters in 
the intestine (Fujimura et al., 2010). Interestingly, mRNA expression of rRFVT2 was 
not upregulated in response to riboflavin deprivation, providing evidence that its role 
in intestinal absorption in the rat is limited (Fujimura et al., 2010).  
Chronic alcohol consumption is often associated with riboflavin deficiency in 
humans. In rats, chronic alcohol intake was found to inhibit carrier-mediated 
transport of riboflavin across brush border and basolateral membranes of the 
intestine and kidney, and was associated with decreased mRNA and protein levels of 
the rat riboflavin transporters rRFVT2 and rRFVT3 in the intestine and kidney. Thus 
intestinal absorption and renal re-absorption of riboflavin is impaired by elevated 
alcohol consumption, and this mechanism involves the aforementioned riboflavin 
transporters in the rat (Subramanian et al., 2013). 
6.1.4 Riboflavin homeostasis in the brain 
In addition to the saturable absorption system in the gut, and excretion system in the 
kidney, riboflavin entry and exit is also controlled in the CNS by a saturable 
transport system. Transport mechanisms of essential nutrients into the brain have 
often developed independently from intestinal transporters used for absorption of 
nutrients from food (Yao et al., 2010). Riboflavin can cross the blood-brain barrier 
while FAD and FMN are unable to do so (Nagatsu et al., 1967). Over 85% of the 
total riboflavin (riboflavin, FAD and FMN) in rat brain as well as in rabbit brain and 
choroid plexus was present as FMN or FAD (the major flavin in the brain), therefore 
riboflavin is rapidly converted into FMN and FAD which are metabolically trapped 
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within the cell (Nagatsu et al., 1967; Spector, 1980b). The concentration of total 
riboflavin in rabbit brain was approximately fifty times higher than in rabbit plasma 
(Nagatsu et al., 1967; Spector, 1980a). Riboflavin homeostasis appears to be 
particularly tightly regulated in the brain (Spector & Johanson, 2006). Indeed, unlike 
other organs such as the liver, the levels of FMN and FAD in the brain have been 
found to stay relatively constant during severe riboflavin deficiency and after 
elevated doses of riboflavin (Burch et al., 1956; Nagatsu et al., 1967). Although 
riboflavin is quickly transported from the plasma into the brain, the stable 
intracellular levels of total riboflavin seen in the brain could possibly be explained by 
the slow turnover of total riboflavin in this organ (about 1% per hour) (Nagatsu et al., 
1967; Spector, 1980b; Spector & Johanson, 2006). 
Several mechanisms at the level of the blood-brain barrier, in the brain cells, and 
across the choroid plexus are likely to maintain riboflavin homeostasis in the brain. 
Entry via the blood-brain barrier is thought to be the predominant passageway for 
riboflavin into the CNS (Spector & Johanson 2006). In rabbit brain slices, riboflavin 
transport was saturable and riboflavin accumulation was inhibited by other flavins 
(Spector, 1980a; Spector, 1980b). The characteristics of riboflavin accumulation in 
rabbit brain slices were similar to that of human RFVT2, which is highly expressed 
in the brain (Spector, 1980a; Spector, 1980b; Yao et al., 2010). Transport was 
suspected to occur by facilitated diffusion first through the blood-brain barrier, and 
subsequently into the brain cells; both these systems prevent excessive amounts of 
riboflavin from reaching the brain (Spector & Johanson, 2006). 
A saturable, high-affinity carrier-mediated riboflavin uptake system on the luminal 
side of rat brain capillary endothelial cells was recently described. Uptake was 
temperature, energy and Na
+
-dependent but pH-independent; uptake was inhibited by 
structural analogues of riboflavin but not D-ribose and was modulated by the 
Ca
2+/
calmodulin and PKA pathways. A second transport system via the rRFVT3 was 
considered unlikely to be functional in the rat brain capillary endothelial cells (Patel 
et al., 2012). Since uptake via RFVT1, RFVT2 and RFVT3 was independent of 
extracellular Na
+
 (Yao et al., 2010), it may be that an additional as-yet-unknown 
riboflavin transporter exists in rat, and possibly human, brain capillary endothelial 
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cells. Although RFVT2 is highly expressed in the human brain and may play a role 
in riboflavin uptake into neurons and astrocytes, the transport mechanism via RFVT2 
remains uncharacterised in human brain tissue and neuronal models (Moriyama, 
2011; Yao et al., 2010). 
The choroid plexus, the region of the blood-CSF barrier, is thought to play a major 
role in transport of riboflavin between the brain and the blood through the CSF 
(Spector, 1980b; Spector, 1980c; Spector & Johanson 2006). The choroid plexus is 
critical for clearance of riboflavin from the CSF (Spector, 1980b; Spector, 1980c; 
Spector & Johanson, 2006). In rabbits, riboflavin was suspected to be transported 
from the CSF into the blood via two carrier-mediated systems in the choroid plexus: 
one located at the apical membrane (likely via the organic acid transporter 3 carrier) 
for influx into the CSF, and one at the basolateral membrane for efflux into blood via 
an unknown carrier. These riboflavin carriers were thought to have broad specificity 
and to function by facilitated diffusion (Spector, 1980b; Spector, 1980c; Spector & 
Johanson, 2006). 
When levels of riboflavin were low in rabbit plasma, for example during starvation, 
higher levels of riboflavin were transported to the choroid plexus and the brain from 
the plasma to counteract the lower riboflavin levels; in contrast, when riboflavin 
concentration was high in the plasma, the transport system was saturated and less 
riboflavin was able to enter via the blood-CSF and blood-brain barriers. This 
observation may further explain how total riboflavin levels remain stable in the brain 
(Burch et al., 1956; Spector, 1980b). Riboflavin transport in the peripheral nerve has 
not yet been extensively studied. 
6.1.5 Solute carrier family 52, riboflavin transporter member 1 (SLC52A1), 
SLC52A2 and SLC52A3 mutations in BVVL syndrome 
Thus far, non-synonymous, stop-gain, frameshift and splice site altering pathogenic 
variants have been identified in the homozygous or compound heterozygous state in 
SLC52A3; only non-synonymous mutations in the homozygous or compound 
heterozygous state have been reported in SLC52A2 up until now (Appendix VI Table 
VI-1) (Bosch et al., 2012; Spagnoli et al., 2014). Mutations in both SLC52A2 and 
SLC52A3 were spread throughout the genes and were located in transmembrane, 
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intracellular and extracellular loops (Dezfouli et al., 2012). Besides the deletion of 
two exons in SLC52A1 causing mild maternal riboflavin deficiency, no other 
pathogenic mutations associated with MADD or BVVL have been reported in this 
gene (Chiong et al., 2007; Ho et al., 2010). A table of polymorphisms located in 
SLC52A1, SLC52A2 and SLC52A3 is available in Appendix VI Table VI-2. 
As mutations in these riboflavin transporters have only recently been associated with 
BVVL, phenotype-genotype correlations are not yet possible. However, in agreement 
with the findings highlighting the importance of the RFVT3 COOH-terminal 
(Subramanian, Rapp, et al., 2011), preliminary observations indicate that mutations 
causing pre-mature truncations of SLC52A3 or non-synonymous mutations in the 
COOH-terminal of SLC52A3 may be associated with increased disease severity and 
lower levels of riboflavin in the plasma (Bosch et al., 2011; Ciccolella et al., 2012; 
Green et al., 2010; Subramanian, Rapp, et al., 2011).  
6.2 Aims of this study 
The finding by our group and colleagues of a homozygous mutation in SLC52A2 in 
two families with BVVL-like MND without mutations in SLC52A3 (Johnson et al., 
2012) has prompted us to screen this gene and the other two riboflavin transporters in 
a larger cohort of patients. Indeed, although the recent identification of mutations in 
riboflavin transporters in BVVL patients has revealed the genetic cause of disease in 
several individuals, it is likely that many patients remain to be uncovered. The first 
aim of this Chapter was to detect unrecognised cases of BVVL, thereby facilitating 
access to early treatment with high doses of riboflavin and widening the phenotype 
associated with riboflavin transporter mutations. To fulfil this aim, the three known 
riboflavin transporters were screened in a cohort of BVVL, BVVL-like and spinal 
muscular atrophy with respiratory distress (SMARD)-like patients. As will be 
discussed later on in this Chapter, results of this study were combined with findings 
from other centres and resulted in a publication (Foley et al., 2014). A second aim of 
this Chapter was to use exome sequencing to identify the genetic cause of disease in 
patients with BVVL-like phenotypes and in patients with AR polyneuropathy with a 
predominant motor component without mutations in the three genes encoding the 
riboflavin transporters. Any novel genes identified in this study may also contribute 
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to diseases such as ALS and spinal muscular atrophy/SMARD, as their phenotypes 
overlap with BVVL. 
6.3 Methods 
6.3.1 BVVL and BVVL-like patient cohort 
This study was an important collaboration of many clinicians and scientists in the 
UK and rest of the world.  
Amongst patients known to the NHNN, we selected 35 patients that had BVVL-like 
features, with two of the following four criteria: severe cranial neuropathy, sensory-
motor neuropathy, deafness, and respiratory insufficiency. A total of 35 patients were 
screened for mutations in SLC52A1, SLC52A2, and SLC52A3. The majority of 
patients in this cohort were from the UK. DNA or blood had already been or was 
subsequently sent to the NHNN Neurogenetics Unit. Patients had previously had 
diagnostic testing of genes associated with related disorders (e.g. ALS, CMT, and/or 
SMA genes, mitochondrial DNA mutations); patients had been found negative for 
mutations in these genes.  
A second cohort of patients studied herein consisted of 57 patients (including two 
pairs of siblings (55 probands)) referred specifically for research genetic testing of 
riboflavin transporters. Most of these patients were expressly referred for SLC52A2 
sequencing as their phenotype was very similar to that described in the first report of 
SLC52A2-mutated patients (Foley et al., 2014; Johnson et al., 2012). DNA for this 
second cohort was obtained from the NHNN Neurogenetics Unit or was sent to our 
centre from hospitals worldwide. Institutions which sent DNA included: the 
Dubowitz Neuromuscular Centre and MRC Centre for Neuromuscular Disorders, 
UCL ICH and GOSH in London, UK, the Evelina Children’s Hospital, King’s 
College Hospital, St George’s Hospital, Royal London Hospital, Guy’s Hospital and 
St. Thomas’ Hospital in London, UK, the Royal Manchester Children’s Hospital in 
Manchester, UK, the Royal Aberdeen Children’s Hospital in Aberdeen, UK, the 
Institute of Genetic Medicine at the University of Newcastle upon Tyne, UK, the 
Southern General Hospital and the Royal Hospital for Sick Children in Glasgow, 
Scotland, UK, the Sheffield Children’s Hospital in Sheffield, UK, the St. James's 
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University Hospital in Leeds, UK, the Children’s University Hospital and Beaumont 
Hospital in Dublin, Ireland, the Vrije Universiteit Medical Centre in Amsterdam, the 
Netherlands, the Université Saint Joseph in Beirut, Lebanon, the University of Sao 
Paulo in Ribeirão Preto, Brazil, the National University Hospital at the University of 
Iceland, Iceland, the Institut de Myologie, Groupe Hospitalier Pitié-Salpêtrière in 
Paris, France, the Gothenburg University in Sweden, the Mater Dei Hospital in 
Malta, the Sakhalin Hospital in Russia and the Children's Hospital of Pittsburgh at 
the University of Pittsburgh Medical Centre in Pittsburgh, USA.  
Sequencing results from these two patient cohorts were combined with results 
obtained by collaborators at the University of Sydney and Institute for Neuroscience 
and Muscle Research at the Children’s Hospital at Westmead, Sydney, Australia and 
at the University of Miami’s Miller School of Medicine in the USA. Where 
available, clinical information for the patients in whom variants were found is 
included in the appropriate section. 
6.3.2 Spinal muscular atrophy with respiratory distress (SMARD)-like and 
atypical diaphragmatic weakness patient cohort 
As discussed in Section 1.6.1, SMARD1 patients share some clinical features with 
BVVL patients. DNA was available for four patients with SMARD-like disease 
and/or atypical diaphragmatic weakness without mutations in the known SMARD 
genes. Patient AHH had a severe peripheral neuropathy with distal denervation and 
reinnervation. These features resembled that seen in SMARD, however disease onset 
was later than expected. This patient also had scoliosis, as well as bulbar and 
respiratory problems. Patient MM had motor and respiratory weakness, with severe 
reduction of CMAPs, severe decrease of MNCVs in the legs and preserved sensory 
responses. This patient showed evidence of denervation in the muscles of the leg, but 
also muscles involving the diaphragm and the tongue; these features are also 
suggestive of SMARD. Patient HS had cataracts, sensorineural deafness, failure to 
thrive and respiratory failure. A detailed phenotype was not available for the fourth 
patient. DNA for the four patients in this cohort was obtained from GOSH in 
London, UK. 
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6.3.3 Patients for exome sequencing 
Exome sequencing was performed for three families in this study. Individual II-10 of 
family SP and individuals III-3 and III-8 of family TB were part of the BVVL patient 
cohort (Section 6.3.1), thus mutations in the three known riboflavin transporters had 
been excluded. Sanger sequencing of the three riboflavin transporters was not 
performed in individual III-3 of family MO. DNA for family SP was obtained from 
Dr Jose Berciano at the University Hospital Marqués de Valdecilla in Santander, 
Spain. DNA for families TB and MO was obtained from the Dubowitz 
Neuromuscular Centre and MRC Centre for Neuromuscular Disorders, UCL ICH in 
London, UK. Affected members of family SP had a BVVL-like phenotype with 
pontobulbar palsy and AR inheritance. Families MO and TB had an AR 
polyneuropathy with a predominant motor component. Although the clinical picture 
is not that of classical BVVL in families MO and TB, there are some overlapping 
features. 
Family SP is of Spanish origin. Three siblings (individuals II-3, II-7 and II-10) were 
affected in this family; the parents were unaffected and there was no known 
consanguinity in the family (Figure 6-1).  
 
Figure 6-1 Pedigree of family SP. 
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The proband, individual II-3 is now in her seventies. She had progressive dysarthria, 
intermittent dysphagia, bilateral pes cavus, toe clawing and walking clumsiness since 
infancy. She had mild amyotrophy of the hand and lower leg. The patient was not 
able to walk on her heels and there was minimal spasticity while walking. She did 
not notice any deafness, however pure-tone audiometry studies showed a subclinical 
high-frequency deficit. She had tongue weakness and atrophy, as well as furrowing 
of the tongue with occasional fasciculations. Her tendon reflexes were brisk except 
for absent plantar and ankle reflexes. This patient had sensory abnormalities with 
stocking hypoesthesia. Bilateral palatal and facial paresis were seen, along with an 
absent gag reflex. Laboratory investigations including cranio-spinal MRI, 
electrocardiogram and thoracic X-rays were normal. Electrophysiological studies 
showed chronic denervation and features of an axonal sensory-motor neuropathy. 
She also displayed evidence of a central sensory axonopathy with delayed central 
motor conduction times. She had fatty atrophy of distal foot muscles on MRI. 
Mutations in X25/frataxin and SMN1 had been previously excluded. Both individuals 
II-7 and II-10 had a similar clinical picture to the proband. The working diagnosis 
was FL syndrome, although BVVL was also considered possible given the pure-tone 
audiometry findings. 
Individual III-3, the proband in family MO was the only affected member of the 
family. This patient is from the UK and was born to non-consanguineous parents; the 
pedigree is compatible with an AR mode of inheritance (Figure 6-2).  
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Figure 6-2 Pedigree of family MO. 
At three months, the proband had progressive hypotonia leading to breathing 
difficulties therefore she was put on invasive ventilator support. She had cataracts 
and renal tubulopathy at five months of age. At seven months, she had recurring 
unexplained fevers. A severe progressive sensory-motor axonal neuropathy, 
demyelination and axonal degeneration were seen on nerve biopsy; denervation was 
evident on muscle biopsy, with no sign of reinnervation. MRI brain scans, MRC 
enzyme activity and plasma amino acids were normal. Urine organic acids and 
intermittent lactic acidosis suggested a mitochondrial disorder. Maleic acid was 
present in the urine. Urine amino acids showed strong generalised aminoaciduria and 
liver ultrasonography showed hepatomegaly. At nine months of age, she remained 
ventilator-dependent and was minimally responsive. She had facial weakness and 
muscle weakness, absent deep tendon reflexes and decreased light touch sensation. 
Her acylcarnitine profile showed raised hydroxybutyrylcarnitine; fatty acid β-
oxidation studies were normal. Her electroencephalogram (EEG) had 
encephalopathic patterns. Treatment included dichloroacetate, riboflavin, ascorbic 
acid and CoQ10 since a mitochondrial disorder was suspected. Acquired 
neuromuscular causes were excluded. Mitochondrial DNA sequencing was negative 
for POLG, mpv17 mitochondrial inner membrane protein (MPV17) (exons 2-8), 
PEO1, ribonucleotide reductase M2B (RRM2B), deoxyguanosine kinase (DGUOK) 
(exons 1-7) and Twinkle (partial sequencing). Further sequencing of SMA (SMARD1, 
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SMN1), myotonic dystrophy (dystrophia myotonica 1 (DM1)), Emery-Dreifuss 
muscular dystrophy (Lamin A/C), CMT (DNM2, PMP22, MPZ, EGR2) and 
congenital central hypoventilation syndrome (paired-like homeobox 2b (PHOX2B)) 
genes was negative. Prader-Willi syndrome as well as peroxisomal and nutritional 
disorders were also ruled out. A deficiency of maleylacetoacetate isomerase (MAAI, 
also known as glutathione-5-transferase zeta-1 (GSTZ1)) was suspected given the 
presence of maleic acid in the urine and the renal tubulopathy. MAAI catalyses the 
last step in the catabolism of tyrosine to fumarate. It remained unclear whether these 
metabolic abnormalities might have occurred as a result of treatments administered 
to this patient. The motor neurone dysfunction remained the most important feature 
in the proband.  
Family TB is from the UK and Greece. The two affected individuals in family TB 
are cousins. The parents of individual III-8 are consanguineous, however there is no 
known consanguinity on individual III-3’s side of the family (Figure 6-3).  
 
 
Figure 6-3 Pedigree of family TB. 
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The proband, individual III-3, had a clinically-relapsing motor neuropathy. He asked 
to be fed frequently in infancy and showed personality changes if not fed regularly. 
At 18 months, he had episodes of vomiting and became too weak to walk; he 
subsequently made an almost complete recovery. At 2.5 years, he had an infection 
leading to leg weakness. A further infection at age three caused arm and leg 
weakness. At 4.5 years, he had a viral infection leading to paralysis, compromised 
breathing and speech loss. At 9.5 years, there was weakness of movement of palate 
and tongue as well as weakness of all limb muscles. He also had absent deep tendon 
reflexes at this stage. Electrophysiological studies showed features of an axonal 
neuropathy, including reduced CMAP amplitudes and slight reduction of median 
NCVs. Muscle biopsy showed severely atrophic fibres and denervation and 
reinnervation; the nerve biopsy was normal. He had low plasma acetylcarnitines and 
low fibroblast fatty acid β-oxidation. Activities of MRC complexes II/III and IV 
were normal. He had low plasma serine with possible evidence of increased serine 
catabolism. There was mitochondrial DNA depletion on muscle biopsy. A fatty acid 
β-oxidation defect or a carnitine acetyl transferase deficiency was suspected. The 
proband was administered carnitine and riboflavin; he showed a slow improvement. 
He was then given L-serine and displayed improvement in speech and in antigravity 
movement in all limbs.  
Individual III-8, his cousin, developed normally in her first year. At age two, she had 
an upper respiratory tract infection, leading to generalized weakness and hypotonia.  
Her ulnar and median NCVs were decreased and there was evidence of a 
demyelinating polyneuropathy. Her nerve biopsy was normal. Individual III-8 was 
initially diagnosed with CIDP, with overlapping features of CMT1. At age four, she 
had another attack of generalized weakness with involvement of respiratory muscles. 
A more severe attack at age six put the patient in intensive care. She made a partial 
recovery with IVIG and steroids. She had weakness of face, trunk, and limb muscles, 
which was more distal than proximal. She had absent reflexes and no sensory 
impairment. A year later, she showed some improvement. Further studies showed 
prominent neuropathy affecting mostly the motor fibres. There were some sensory 
changes and a severe decrease in CMAPs. She was diagnosed with “familial, 
episodic, primarily motor peripheral neuropathy” of unknown cause. Additional 
 211 
studies of urine organic acids showed increased excretion of urate. The organic acid 
results of individuals III-3 and III-8 had some similarities such as raised glycolate 
and citrate, but were not identical. Furthermore, unlike her cousin, individual III-8’s 
plasma serine levels were normal. She was left wheelchair-bound with severe 
scoliosis, reduced muscle bulk, and no antigravity movement in her arms. Her 
brother (individual III-5) had seizures from six months of age and he died at 15 
months. Her sister (individual III-6) had delayed walking. Individual III-6 became 
weak after a flu-like illness at 3.5 years of age. At seven years of age, individual III-6 
had a widespread infection, increasing weakness and a rash on her trunk and arms, 
and did not survive. It remains possible that the biochemical changes (low serine and 
acetyl carnitine) seen in individual III-3 and individual III-8 were secondary to loss 
of motor neurones.  
6.3.4 Patient consent and DNA samples 
Details of ethics approval and patient consent for all patients described in Sections 
6.3.1-6.3.3 are found in Section 2.1.1. Purity and concentration of DNA samples 
were assessed as described in Section 2.1.5.  
6.3.5 DNA extraction from human saliva 
For one BVVL sample, DNA was extracted from human saliva as described in 
Section 2.1.3. 
6.3.6 PCR and Sanger sequencing of three riboflavin transporters 
PCR, agarose gel electrophoresis, purification of PCR products, Sanger sequencing, 
dye removal and sequencing analysis were performed in all cohorts using standard 
conditions as described in Sections 2.1.9-2.1.12. Coding exons and flanking intronic 
sequences were sequenced for human SLC52A1, SLC52A2 and SLC52A3. Transcript 
references used for primer design, as well as sequences of gene-specific primers and 
PCR cycling conditions can be found in Appendix VI Table VI-3. The sequences for 
all SLC52A3 primers and some SLC52A2 primers were obtained from Johnson et al., 
2012. However, some SLC52A3 primers used by Johnson and colleagues (2012) had 
to be redesigned; the primer binding was inefficient due to a common SNP being 
present at one of the primer-binding bases, which would have caused potential 
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mutations to be missed. SNP chromosomal locations are based on Genome Build 
37.3. In-silico analyses were performed as described in Section 2.6. Variants were 
searched in the dbSNP, 1000 Genomes and/or EVS databases. To assess 
conservation among species of the mutated amino acid residues, Ensembl was used 
to retrieve the sequences and the Clustal Omega software was used for multiple 
sequence alignment. TMHMM v.2 was used to predict transmembrane domains and 
intracellular/extracellular loops. Where DNA was available, segregation analysis of 
variants in family members was performed. 
6.3.7 Sanger Sequencing and exome sequencing performed by collaborators 
Our collaborators used Sanger and exome sequencing to screen for SLC52A1, 
SLC52A2 and SLC52A3 mutations in their BVVL patients. Patients A1 and A2 were 
Sanger sequenced at the University of Sydney as described in Foley et al., 2014. 
Exome sequencing for patients A3, A4, U1 and U2 was performed by the University 
of Miami. Briefly, exome sequencing was carried out using the SureSelect Human 
All Exon 50 Mb exome capture kit (Agilent Technologies) and was sequenced on the 
Illumina HiSeq2000 (Illumina). Sequence data analysis was performed by the 
University of Miami as described in Foley et al., 2014. Patients A5-A7 were exome 
sequenced by BGI Inc (USA; http://www.genomics.cn/en/index) using the 
NimbleGen sequence capture exome array kit (44Mb) (Roche). Exome sequencing 
was carried out on the Illumina HiSeq2000 instrument (Illumina) by BGI Inc. 
Sequence data analysis was performed by the University of Sydney as described in 
Foley et al., 2014. 
6.3.8 High-dose oral riboflavin therapy 
High-dose oral riboflavin therapy was commenced in the majority of patients who 
were found to carry riboflavin transporter mutations in the combined cohort. 
Generally, patients were initially treated with 10 mg/kg/day of oral riboflavin and 
this was increased to a maximum of 50 mg/kg/day in children and 1500 mg/day in 
adults, as recommended by Dr Annet Bosch (Department of Paediatrics, University 
of Amsterdam, the Netherlands) and published online (http://www.bvvl 
international.org/B2_Therapy_Protocol.html). Clinical and biochemical 
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examinations were performed by the patients’ respective neurological care teams 
before and following the start of treatment, where possible (Foley et al., 2014). 
6.3.9 HumanCytoSNP-12 BeadChip analysis 
As will be discussed in Section 6.4.5, one patient was found to carry a homozygous 
mutation in SLC52A2, however there was no reported consanguinity in this particular 
family. Although the patient’s mother was a carrier for the mutation, paternal DNA 
was not available to confirm the father’s carrier status. A HumanCytoSNP-12 v.2.1 
BeadChip (Illumina) was therefore used to exclude a large deletion on the other 
allele and to assess the likelihood of the mutation truly being homozygous by 
evaluating the frequency of homozygous genotypes in the surrounding genomic 
region. The array data was analysed using GenomeStudio
 
(v.2010.1, Illumina). 
Further details on the HumanCytoSNP-12 v.2.1 BeadChip and the data analysis are 
available in Section 2.1.13. 
6.3.10 Haplotype analysis in Lebanese patients carrying the homozygous 
SLC52A2 p.Gly306Arg mutation 
Several BVVL cases in the combined cohort were of Lebanese origin and carried the 
SLC52A2 p.Gly306Arg mutation in the homozygous state. To assess whether this 
mutation was inherited as a shared ancestral allele, haplotype analysis was performed 
in these BVVL patients, as well as in obligate carriers (parents) and unaffected 
siblings for whom DNA was available. While our collaborators used a SNP-based 
array to establish the haplotype, I genotyped 11 SNPs upstream and downstream of 
the SLC52A2 gene using Sanger sequencing in the remaining families. Four SNPs 
were located within or downstream of F-box and leucine-rich repeat protein 6 
(FBXL6) and seven SNPs were located within or downstream of aarF domain 
containing kinase 5 (ADCK5); these genes are upstream and downstream of 
SLC52A2, respectively. PCR and sequencing were performed as described in 6.3.6. 
Sequences of primers used to determine the genotype at the 11 SNPs, as well as PCR 
cycling conditions can be found in Appendix VI Table VI-4. The carrier status of the 
p.Gly306Arg variant was also confirmed by re-sequencing of the appropriate 
SLC52A2 exon, following procedures described in Section 6.3.6. 
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6.3.11 SLC52A2 patient fibroblasts  
Patient skin biopsies were performed by the patients’ neurologists and fibroblasts 
grown from these biopsies were sent to our centre. For biopsies performed at the 
NHNN/GOSH, patient fibroblasts were grown from skin biopsies by Diana Johnson, 
as described in Section 2.2.2. Five BVVL patient fibroblast lines (patients E1-E4 and 
I1), one carrier fibroblast line (mother of patient E1) and three age-matched control 
fibroblast lines were available for transcriptional analysis of SLC52A2 mutations (see 
Section 2.2.2 for full details of control fibroblast lines). Details of consent are 
available in Section 2.2.1. 
6.3.12 Cell culture of fibroblasts 
Patient, carrier and control fibroblasts were cultured in regular DMEM as described 
in Section 2.2.3.  
6.3.13 Transcriptional analysis 
RNA was extracted from patient, carrier and control fibroblasts, and cDNA was 
synthesized as described in Sections 2.2.9-2.2.10. cDNA was sequenced according to 
the Sanger sequencing protocol as described in Section 2.1.12. Sequences of primers 
and cycling conditions used for cDNA sequencing can be found in Appendix VI 
Table VI-5. 
6.3.14 Exome sequencing 
Exome sequencing was performed on individuals II-3 and III-1 of family SP, 
individual III-3 of family MO, and individuals III-3 and III-8 of family TB. Exome 
sequencing for families SP and TB was performed by Oxford Gene Technology 
(UK). Exome sequencing for family MO was performed at the UCL ION by Dr 
Deborah Hughes and Dr Alan Pittman. In both instances, 2 μg of gDNA was 
supplied. 
The exome sequencing carried out by Oxford Gene Technology used Agilent’s 
SureSelect protocol v.1.2 (Agilent Technologies) for library preparation and 
enrichment of samples. Sequencing was performed on the Illumina HiSeq 2000 
platform using the TruSeq v.3 chemistry (Illumina). For the exome sequencing 
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performed in-house at the UCL ION, library preparation for exome sequencing was 
performed as per the TruSeq
 
(Illumina) sample-preparation protocol. DNA libraries 
were hybridized to exome-capture probes with TruSeq chemistry (Illumina). Samples 
were clustered on a cBot
 
(Illumina) and exome-enriched libraries were sequenced on 
the HiSeq 1000 (Illumina). Variant calling was performed by both Oxford Gene 
Technology and Dr Alan Pittman at the UCL ION. Further details on the exome 
sequencing protocol are found in Section 2.1.15. 
6.3.15 Assessment of gene coverage and read depth 
As described in Section 2.1.16, gene coverage and read depths were assessed for all 
three known riboflavin transporter genes using the exome sequencing BAM files and 
Golden Helix GenomeBrowse software. The coverage and read depth of the GSTZ1 
gene was also assessed for individual III-3 in family MO. 
6.3.16 Exome data filtering and variant prioritisation 
The exome variant filtering steps are described in Section 2.1.17. Briefly, 
synonymous mutations were first filtered out. Following this step, all three riboflavin 
transporter genes, as well as the GSTZ1 gene in individual III-3 of family MO, were 
inspected for potentially pathogenic variants. For all three families, the pedigrees 
were consistent with AR inheritance. In families SP and MO, the variant was 
predicted to be compound heterozygous as there was no known consanguinity in the 
family. In family TB, consanguinity was only thought to be present on individual III-
8’s side of the family. Three possibilities were considered in the exome data analysis 
for this family. The disease-causing variant could be in the homozygous state in both 
individual III-3 and III-8; alternatively, individual III-3 and III-8 may carry 
compound heterozygous mutations in the same gene. In the latter case, the two 
individuals may share one or both variants in the compound heterozygous state. In 
the third scenario, individual III-8 may be homozygous for the disease-causing 
variant, and individual III-3 may carry the same variant in the compound 
heterozygous state with another mutation in the same gene. For all families, a lower 
MAF of 0.01 was used as a cut-off point for the control reference databases (1000 
Genomes, CG69 and EVS). Any variant within a segmental duplication region with 
identity greater than or equal to 96% was removed. SNP chromosomal locations are 
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based on Genome Build 37.3. For certain variants of interest, the conservation of the 
amino acid between species, location within the protein structure, and in-silico 
pathogenicity predictions were assessed as explained in Section 2.6. Gene expression 
data was obtained from the Human Protein Atlas as described in Section 2.6. 
Candidate genes were searched in the literature for any known association to disease. 
Candidate genes for families SP, MO and TB were predicted to be highly expressed 
in the brain and spinal cord. Potential candidates included genes encoding enzymes 
involved in riboflavin, FAD and FMN synthesis and metabolism. Additionally, 
riboflavin transporters found in other species were evident candidates. For example, 
Mch5p functions as a plasma membrane riboflavin transporter in yeast 
Saccharomyces cerevisiae which operates via a facilitated diffusion mechanism 
(Reihl & Stolz, 2005); solute carrier family 16, member 12 (SLC16A12), the human 
homologue of Mch5p, is also thought to encode a monocarboxylate transporter that 
causes juvenile cataract with microcornea and renal glycosuria when mutated 
(Kloeckener-Gruissem et al., 2008). The gene encoding the human mitochondrial 
FAD transporter, MFT, was another candidate gene (Spaan et al., 2005), as well as 
genes encoding proteins responsible for FAD and FMN homeostasis in the 
mitochondria (Rhead et al., 1993). Genes encoding flavoproteins and proteins with a 
role in FAD or FMN-dependent pathways, in mitochondrial fatty acid β-oxidation, or 
more generally in cell energy metabolism were also possible candidates. Given the 
phenotypic overlap, juvenile ALS genes and SMA genes were also considered in the 
exome analysis. Other candidate genes for family TB included serine transporters or 
enzymes involved in serine metabolism or synthesis. Additional candidate genes 
specifically for individual III-3 of family MO included the GSTZ1 gene, as discussed 
above, as well as the three known riboflavin transporters as these genes were not 
sequenced in this patient.  
6.4 Results 
6.4.1 Results of Sanger sequencing of SLC52A1, SLC52A2 and SLC52A3 in the 
BVVL, BVVL-like and SMARD-like cohorts 
The screening of the three riboflavin transporters in BVVL and BVVL-like patients 
has resulted in a publication in collaboration with colleagues in Australia (Sydney 
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Children’s Hospitals Network) and the USA (University of Miami’s Miller School of 
Medicine) (see Foley et al., 2014). For simplicity, IDs used herein for patients with 
SLC52A2 mutations refer to those used in our recent publication (Foley et al., 2014). 
Since this publication, two additional patients carrying mutations in SLC52A2 have 
been identified as part of this thesis (E8 and B1), and several patients with 
heterozygous SLC52A3 mutations have been found, as will be discussed below. In 
the combined cohort, a total of 19 patients were found to carry compound 
heterozygous or homozygous mutations in SLC52A2, ten of which were sequenced at 
our centre for this PhD thesis work. All ten patients in our cohort were unrelated. 
Nine of the ten patients (patients E2-E6, E8, L1, I1 and B1) were part of the cohort 
of patients specifically referred for research testing of SLC52A1, SLC52A2 and 
SLC52A3 (9/55 probands or 16.4%); one patient (patient E7) was part of the cohort 
of patients with BVVL-like features as determined by a database search (1/35 
probands or 2.9%). The nine additional patients identified by our collaborators to 
carry SLC52A2 mutations were spread across four families; two patients (one 
proband) were identified by Sanger sequencing (A1 and A2) and seven were found 
using exome sequencing (A3-A7 and U1-U2, three of which are probands; A5 and 
A6 are identical twins). Therefore, the 19 patients found to carry SLC52A2 mutations 
in this study were from 14 different families (Foley et al., 2014). We will also 
discuss herein a patient (patient E1) who has been previously described and found to 
carry a homozygous SLC52A2 mutation using Sanger sequencing (Johnson et al., 
2012). Patients E1-E8 are from the UK, patients A1-A7 are from Australia, patients 
U1 and U2 are from the USA, I1 is from Ireland, L1 is from Lebanon and B1 is from 
Brazil. The female to male ratio was 13:7, which is lower than the reported 3:1 
female to male ratio in BVVL (Foley et al., 2014; Sathasivam, 2008).  
In total, nine non-synonymous mutations and one premature stop were identified in 
SLC52A2 in our combined cohort; details of the SLC52A2 mutations are listed in 
Table 6-1. The p.Gly306Arg and p.Leu339Pro mutations have been previously 
reported (Haack et al., 2012; Johnson et al., 2012); all other mutations are novel. The 
most frequent mutation was p.Gly306Arg, which was found both in the homozygous 
and compound heterozygous states. All mutations were predicted not tolerated by 
SIFT; all variants were predicted probably damaging by Polyphen-2, except the 
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p.Ser128Leu and p.Ala284Asp which were predicted possibly damaging. Six of the 
mutations were located within predicted transmembrane domains. Three of the 
mutations were found in the EVS and dbSNP databases (p.Ser128Leu; p.Leu339Pro; 
p.Ala420Thr), but at a very low frequency (MAF≤0.0002). All mutations were 
located at amino acids highly conserved between species and in human RFVT1 and 
RFVT3, except for the p.Gln234Stop and p.Ala284Asp mutations. The nonsense 
mutation was only conserved in the Gorilla gorilla and in RFVT1; the p.Ala284Asp 
mutation was not conserved in Danio rerio (Foley et al., 2014). None of the 
SLC52A2 mutations were localised in the COOH terminal domain. The predicted 
transmembrane domains and intracellular/extracellular loops of RFVT2, as well as 
the SLC52A2 gene structure and location of mutations identified in the combined 
cohort are displayed in Figure 6-4. The conservation of affected amino acid residues 
in RFVT2 across species and in human RFVT1 and RFVT3 is illustrated in Figure 6-
5.   
Figure 6-4 Location of SLC52A2 mutations identified in this study with respect to 
gene structure and predicted transmembrane domains, intracellular and extracellular 
loops in RFVT2 (as predicted by TMHMM v.2; produced using the DOG2.0 
software (Ren et al., 2009)). Reference sequence NM_024531.4 (adapted from Foley 
et al., 2014). 
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Figure 6-5 Structural conservation of relevant amino acid residues in RFVT2 
(ENSP00000333638) across species and in RFVT1 (ENSP00000254853) and 
RFVT3 (ENSP00000217254). The Ensembl protein IDs for the RFVT2 orthologous 
sequences reported are: ENSGGOP00000028056, ENSSSCP00000028741, 
ENSMUSP00000023220 and ENSDARP00000045674. An * (asterisk) indicates 
positions which have a single, fully conserved residue. A : (colon) indicates 
conservation between groups of strongly similar properties. A . (period) indicates 
conservation between groups of weakly similar properties (Adapted from Foley et 
al., 2014). 
Segregation analysis was performed for the families of patients E2-E6, L1, I1, E1, 
E7 (only maternal DNA tested in family of E1 and E7) and B1 (only paternal DNA 
tested in family of B1). Where DNA was available, all mutations segregated within 
the families with all parents tested found to be heterozygous carriers. Pedigrees, 
along with sequencing chromatograms of affected and unaffected family members 
are available in Appendix VI Figure VI-1 (Foley et al., 2014). Phenotypic details of 
the patients with SLC52A2 mutations will be discussed in Section 6.4.2. Results of 
functional evaluations of some of the SLC52A2 mutations found in this study will be 
presented in Chapter 7. 
Seven patients (RDB, NDB, JG, HM, LF, KG, and LS; RDB and NDB are siblings 
(6 probands)) were found to carry heterozygous non-synonymous mutations in 
SLC52A3, representing six different mutations in total. No other mutation was 
detected in SLC52A3 or the other riboflavin transporters in these patients. All 
patients with SLC52A3 mutations belonged to the cohort of patients referred for 
BVVL research testing. Therefore, the frequencies of mutations in SLC52A3 in the 
cohort of patients with BVVL-like features as determined by a database search and 
in patients specifically referred for BVVL testing were 0% (0/35 probands) and 
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10.9% (6/55 probands), respectively. Details of these mutations are listed in Table 6-
1. The pathogenicity of these mutations is unclear, as BVVL patients usually carry 
riboflavin transporter mutations on both alleles. Four of the mutations (p.Gly13Arg, 
p.Glu36Lys, p.Thr125Asn, and p.Phe457Leu) were predicted damaging by both the 
SIFT and Polyphen-2 in-silico analyses. The p.Ile20Leu variant was predicted 
tolerated by SIFT but probably damaging by Polyphen-2. The p.Thr135Ala mutation 
was predicted benign by both prediction programmes. The p.Gly13Arg, p.Ile20Leu 
and p.Phe457Leu mutations were found at very low MAF in the EVS database (MAF 
of 0.0001, 0.0001 and 0.0007, respectively); the other mutations were not found in 
the EVS database. All mutations except the p.Thr125Asn and p.Thr135Ala mutations 
were found in dbSNP, however in all cases, no MAF was provided. The p.Gly13Arg, 
p.Glu36Lys, p.Thr125Asn, and p.Phe457Leu mutations alter amino acids 
evolutionarily conserved from humans to Danio rerio and also conserved in the other 
two human riboflavin transporters. The p.Ile20Leu variant alters an amino acid 
conserved from humans to Danio rerio but not conserved in the human RFVT1 and 
RFVT2. The p.Thr135Ala mutation affects an amino acid conserved from humans to 
Mus musculus but not conserved in Danio rerio, human RFVT1 and RFVT2 (Figure 
6-6). The p.Gly13Arg, p.Ile20Leu, p.Thr125Asn, and p.Thr135Ala variants are 
located within transmembrane domains of RFVT3; the p.Glu36Lys is located in an 
extracellular loop. The p.Phe457Leu mutation is located in the COOH terminal 
domain in the extracellular tail. As mentioned in Section 6.1.3, the COOH-terminal 
sequence was determined to be essential for cell surface expression of RFVT3 and 
therefore for riboflavin uptake via this transporter in human intestinal epithelial cells 
(Subramanian, Rapp, et al., 2011). The amino acid residue 457 is one of the four 
residues within the COOH-terminal sequence to be entirely conserved in rat and 
mouse and in the other two riboflavin transporters (Subramanian, Rapp, et al., 2011). 
The p.Gly13Arg, p.Ile20Leu, and p.Thr135Ala variants are novel, although 
mutations have been described at nearby amino acids (p.Trp17Arg (Bosch et al., 
2011); p.Asn21Ser (Dezfouli et al., 2012); p.Arg132Trp (Green et al., 2010)). The 
p.Thr125Asn variant has been previously found by a London-based diagnostic 
laboratory; the mutation was in the compound heterozygous state with a 
heterozygous pathogenic mutation in SLC52A3 (C. Ridout, personal 
communication). The p.Glu36Lys and p.Phe457Leu variants have been previously 
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found in BVVL patients (Green et al., 2010; Johnson et al., 2012), as will be 
described in Section 6.4.3.  
Figure 6-6 Structural conservation of relevant amino acid residues in RFVT3 across 
species and in RFVT1 and RFVT2. The Ensembl protein IDs for the RFVT3 
orthologous sequences reported are: ENSGGOP00000004951, ENSSSCP-
00000007667, ENSMUSP00000072961 and ENSDARP00000062715. An * 
(asterisk) indicates positions which have a single, fully conserved residue. A : 
(colon) indicates conservation between groups of strongly similar properties. A . 
(period) indicates conservation between groups of weakly similar properties. 
DNA was available for both unaffected parents of patient HM. While the father was 
a carrier of the heterozygous p.Glu36Lys variant, no mutation was found in 
SLC52A3 in the mother of patient HM. DNA was available for the unaffected father 
of patient LF, who was found to be a carrier of the heterozygous p.Thr125Asn 
mutation. DNA for the mother of patient LF was not available. Segregation analysis 
could not be performed for the other five patients with heterozygous SLC52A3 
mutations. Sequencing chromatograms from individuals carrying heterozygous 
SLC52A3 mutations are available in Appendix VI Figure VI-2. Phenotypic details of 
patients with SLC52A3 mutations will be discussed in Section 6.4.3. 
All mutations identified in SLC52A1 in both cohorts of patients were common 
polymorphisms. None of the SMARD and SMARD-like patients described in 
Section 6.3.2 had pathogenic mutations in any of the three riboflavin transporters; all 
identified variants were commonly found in control populations.  
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Table 6-1 Summary of mutations identified in SLC52A2 and SLC52A3 in our cohort and by our collaborators. 
MUTATION SUMMARY 
Gene Mutation Type SIFT prediction Polyphen-2 Prediction
Region 
(TMHMM 
prediction)
EVS MAF in 
Europeans
1000 Genomes/dbSNP
SLC52A2 c.92G>C; p.Trp31Ser Non-synonymous Not tolerated Probably damaging Transmembrane N/A N/A
SLC52A2 c.383C>T; p.Ser128Leu Non-synonymous Not tolerated Possibly damaging Transmembrane 0.0002 rs374071862 (no MAF)
SLC52A2 c.700C>T; p.Gln234Stop Stop-gained Not tolerated Probably damaging Intracellular loop N/A N/A
SLC52A2 c.851C>A; p.Ala284Asp Non-synonymous Not tolerated Possibly damaging Transmembrane N/A N/A
SLC52A2 c.914A>G; p.Tyr305Cys Non-synonymous Not tolerated Probably damaging Extracellular loop N/A N/A
SLC52A2 c.916G>A; p.Gly306Arg Non-synonymous Not tolerated Probably damaging Extracellular loop N/A N/A
SLC52A2 c.935T>C; p.Leu312Pro Non-synonymous Not tolerated Probably damaging Transmembrane N/A N/A
SLC52A2 c.1016T>C; p.Leu339Pro Non-synonymous Not tolerated Probably damaging Transmembrane 0.0002 rs148234606 (no MAF)
SLC52A2 c.1088C>T; p.Pro363Leu Non-synonymous Not tolerated Probably damaging Extracellular loop N/A N/A
SLC52A2 c.1258G>A; p.Ala420Thr Non-synonymous Not tolerated Probably damaging Transmembrane 0.0001 rs368924997 (no MAF)
SLC52A3 c.37G>A; p.Gly13Arg Non-synonymous Not tolerated Probably damaging Transmembrane 0.0001 rs146302587 (G>C change, no MAF)
SLC52A3 c.58A>C; p.Ile20Leu Non-synonymous Tolerated Probably damaging Transmembrane 0.0001  rs148387972 (no MAF)     
SLC52A3 c.106G>A; p.Glu36Lys Non-synonymous Not tolerated Probably damaging Extracellular loop N/A  rs267606686 (no MAF)
SLC52A3 c.374C>A; p.Thr125Asn Non-synonymous Not tolerated Probably damaging Transmembrane N/A N/A
SLC52A3 c.403A>G; p.Thr135Ala Non-synonymous Tolerated Benign Transmembrane N/A N/A
SLC52A3 c.1371C>G; p.Phe457Leu Non-synonymous Not tolerated Probably damaging Extracellular tail 0.0007 rs145431028 (no MAF)  
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6.4.2 Phenotypes of patients with SLC52A2 mutations 
The phenotype descriptions below refer to all patients with SLC52A2 mutations in 
our study, with the exception of patient B1, for whom an extensive phenotype could 
not be obtained. Patient B1 had a persistent lactic acidemia, respiratory insufficiency, 
as well as moderate to severe deafness requiring hearing aids.  
Phenotypes of patients with SLC52A2 mutations are provided in Table 6-2. The 
phenotype of patient L1, as well as that of his affected sister is also extensively 
described in the recent clinical report by Urtizberea et al. (2013). Nearly half of the 
patients presented with a sensory ataxic gait (9/19 or 47%) associated with a 
progressive sensory neuropathy. The earliest symptom reported occurred at seven 
months (nystagmus), while the latest age of onset was eight years of age and an 
ataxic gait was the presenting symptom. Bilateral sensorineural hearing loss was 
evident in 18/19 (95%) patients; patient E8 died at two years of age, therefore any 
impairment might not have developed by this time. Optic atrophy was seen in 15/16 
(93.8%) patients for whom ophthalmologic studies had been performed. Tongue 
fasciculations were noted in 11 of 19 patients. Almost all patients had severe, rapidly 
progressive weakness of axial and upper limb muscles with no antigravity 
movement. Neck and distal upper limb muscles were affected before the proximal 
upper limbs (Figure 6-7). However, patients generally had mild lower limb weakness 
with preserved ability to walk with head and trunk support. Deep tendon reflexes 
were usually absent, and a flexor plantar response was present in the majority of 
cases. Fourteen patients had respiratory insufficiency; ventilator support did not 
suffice to prevent respiratory failure and death in patients A3 and E8. None of the 
patients suffered from cognitive dysfunction (Foley et al., 2014).  
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Figure 6-7 Clinical features of BVVL patients with SLC52A2 mutations. A) Patient 
I1 at 1.8 years old displaying severe weakness of neck extension and upper limbs, 
with relative preservation of lower limb strength. B) Patient E4 at 5.8 years old. C) 
Patient E1 at 8.6 years old. D) and E) Patient E1’s left and right hands at 10.5 years 
old showing symmetric atrophy of intrinsic hand muscles (reproduced from Foley et 
al., 2014). 
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Table 6-2 Clinical and genetic features of patients with mutations in SLC52A2 at the time of diagnosis (prior to riboflavin therapy) (from Foley 
et al., 2014).  
Patient E1 E2 E3 E4 E5 E6
SLC52A2 mutations
homozygous: 
c.[916G>A]; 
p.[(Gly306Arg)]
compound 
heterozygous: 
c.[92G>C]; [935T>C] 
p.[(Trp31Ser)]; 
[(Leu312Pro)]
compound 
heterozygous: 
c.[700C>T]; 
[1258G>A] 
p.[(Gln234Stop)]; 
[(Ala420Thr)] 
compound   
heterozygous: 
c.[916G>A]; 
[1016T>C] 
p.[(Gly306Arg)]; 
[(Leu339Pro)]
compound 
heterozygous:        
c.[916 G>A]; 
[1016T>C]  
p.[(Gly306Arg)]; 
[(Leu339Pro)]
compound     
heterozygous: 
c.[935T>C]; 
[1016T>C] 
p.[(Leu312Pro]; 
[(Leu339Pro)]
Sex female female female female female female
Ethnicity Scottish English and Icelandic English English and Scottish Scottish English
Consanguinity not reported no no no no no
First symptom ataxic gait ataxic gait ataxic gait right-sided ptosis upper limb weakness nystagmus
Age at first symptom 1.5 years 1 year 3.5 years 1.5 years 3 years 0.6 years
Optic atrophy yes yes yes yes not done yes
Sensorineural hearing loss yes yes yes yes yes yes
Sensorimotor neuropathy 
(based on NCS)
yes yes yes yes yes yes
Distribution of weakness
upper 
limbs>lower 
limbs; neck 
extension
upper limbs>lower 
limbs; neck extension
upper limbs>lower 
limbs; neck extension
upper limbs>lower 
limbs; neck extension
upper limbs>lower 
limbs; neck extension
upper limbs>lower 
limbs; neck 
extension
Overall maximal motor 
function 
independent 
ambulation
independent 
ambulation
independent 
ambulation
independent 
ambulation
independent 
ambulation
independent 
ambulation
Maximal motor function at 
the time of diagnosis                           
(prior to riboflavin therapy)
taking a few 
steps with head 
and trunk 
supported
unable to sit
walking if trunk 
supported
walking if trunk 
supported
taking a few steps with 
head and trunk 
supported
taking a few steps 
with head and trunk 
supported
Respiratory function
nocturnal non-
invasive 
ventilation
ventilator dependent ventilator dependent
nocturnal non-invasive 
ventilation
nocturnal non-invasive 
ventilation
nocturnal non-
invasive ventilation
Feeding by mouth by gastrostomy only
by mouth and 
gastrostomy
by mouth by gastrostomy only
by mouth and 
gastrostomy
Age at genetic diagnosis 10 years 6 years 5 years 5 years 12 years 17.5 years
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Patient E7 E8 B1 I1 L1 A1 A2
SLC52A2 mutations
compound    
heterozygous: 
c.[916 G>A]; 
[1258G>A] 
p.[(Gly306Arg)]; 
[(Ala420Thr)] 
homozygous:  
c.[935T>C] 
p.[(Leu312Pro]
compound 
heterozygous: 
c.[383C>T]; 
[1088C>T] 
p.[(Ser128Leu)]; 
[(Pro363Leu)]
compound 
heterozygous: 
c.[914A>G]; 
[916G>A] 
p.[(Tyr305Cys)]; 
[(Gly306Arg)]
homozygous: 
c.[916G>A]; 
p.[(Gly306Arg)]
homozygous: 
c.[916G>A]; 
p.[(Gly306Arg)]
homozygous: 
c.[916G>A]; 
p.[(Gly306Arg)]
Sex male female female male male female female
Ethnicity English English Brazilian Irish Lebanese Lebanese Lebanese
Consanguinity no no unknown no yes yes yes
First symptom hearing loss
horizontal nystagmus 
and motor-
developmental arrest
unknown nystagmus hearing loss ataxic gait ataxic gait
Age at first symptom 2 years 7 months unknown 1.3 years 3 years 8 years 3 years
Optic atrophy yes yes unknown yes not done no yes
Sensorineural hearing loss yes no yes yes yes yes yes
Sensorimotor neuropathy 
(based on NCS)
yes yes unknown yes yes sensory only yes
Distribution of weakness
upper 
limbs>lower 
limbs
upper limbs>lower 
limbs
unknown
upper limbs>lower 
limbs; neck extension
upper limbs>lower 
limbs; neck extension
none detected upper limbs
Overall maximal motor 
function 
independent 
ambulation
crawling, pulling to 
stand, could hold 
objects with pincer 
grip
unknown
independent 
ambulation 
independent 
ambulation
independent 
ambulation
independent 
ambulation
Maximal motor function at 
the time of diagnosis                           
(prior to riboflavin therapy)
taking a few 
steps with head 
and trunk 
supported
hypotonic, 
deteriorated arm 
function
unknown sitting
independent 
ambulation
independent 
ambulation
independent 
ambulation
Respiratory function
nocturnal non-
invasive 
ventilation
ventilator dependent 
respiratory 
insufficiency
ventilator dependent normal normal normal
Feeding
by mouth and 
gastrostomy
by gastrostomy only unknown
by nasogastric tube 
only 
by mouth by mouth by mouth
Age at genetic diagnosis 21.5 years deceased (2.1 years) 24 years 1.9 years 6 years 10 years 9 years
Family 1
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Patient A3 A4 A5 A6 A7 U1 U2
SLC52A2 mutations
compound 
heterozygous: c.[916 
G>A]; [1016T>C]  
p.[(Gly306Arg)]; 
[(Leu339Pro)]
compound 
heterozygous: c.[916 
G>A]; [1016T>C]  
p.[(Gly306Arg)]; 
[(Leu339Pro)]
homozygous: 
c.[916G>A]; 
p.[(Gly306Arg)]
homozygous: 
c.[916G>A]; 
p.[(Gly306Arg)]
homozygous: 
c.[916G>A]; 
p.[(Gly306Arg)]
compound 
heterozygous: 
c.[851C>A]; [916G>A] 
p.[(Ala284Asp)]; 
[(Gly306Arg)]
compound 
heterozygous: 
c.[851C>A]; [916G>A] 
p.[(Ala284Asp)]; 
[(Gly306Arg)]
Sex female female male male male female male
Ethnicity English and Scottish English and Scottish Lebanese Lebanese Lebanese
Native American, 
Scottish, Irish, English 
and German
Native American, 
Scottish, Irish, English 
and German
Consanguinity no no yes yes yes no no
First symptom
ataxic gait and upper 
limb weakness
hearing loss
ataxic gait and 
hearing loss
ataxic gait and 
hearing loss
ataxic gait respiratory failure vision loss
Age at first symptom 2 years 5 years 3 years 3 years 5 years 2 years 4 years
Optic atrophy not done yes yes yes yes yes yes
Sensorineural hearing loss not done yes yes yes yes yes yes
Sensorimotor neuropathy 
(based on NCS)
yes yes yes yes yes yes yes
Distribution of weakness upper limbs
upper limbs; neck 
extension
upper limbs; neck 
extension
upper limbs; neck 
extension
upper limbs
upper limbs>lower 
limbs
upper limbs>lower 
limbs
Overall maximal motor 
function 
independent 
ambulation
independent 
ambulation
independent 
ambulation
independent 
ambulation
independent 
ambulation
independent ambulation independent ambulation
Maximal motor function at 
the time of diagnosis                           
(prior to riboflavin 
therapy)
taking a few steps 
with head and trunk 
supported
independent 
ambulation
taking a few steps 
with head and trunk 
supported
taking a few steps 
with head and 
trunk supported
independent 
ambulation
independent ambulation walking with a cane
Respiratory function
decreased; on 
ventilator at the time 
of death
decreased; nocturnal 
non-invasive 
ventilation 
recommended
ventilator 
dependent
nocturnal non-
invasive 
ventilation
normal
nocturnal non-invasive 
ventilation
normal
Feeding by mouth by mouth
by gastrostomy 
only
by gastrostomy 
only
by mouth by mouth by mouth
Age at genetic diagnosis deceased (3.5 years) 15 years 16 years 16 years 21 years 52 years 44 years
Family 2 Family 3 Family 4
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Plasma acylcarnitine profiles were abnormal prior to riboflavin therapy in 10 out of 
17 patients tested (59%). Acylcarnitine profiles and plasma concentrations of 
riboflavin, FAD and FMN prior to riboflavin therapy are available for patients E1-
E7, A1-A7, U1-U2 and I1 (Appendix VI Table VI-7). Activity of MRC complexes in 
muscle was determined in seven patients (E1, E2, E5, E6, E8, I1 and A6). Three 
patients had complex activities falling outside the normal range: E2 had decreased 
complex IV activity (0.012 (reference range: 0.014-0.034)), E6 had decreased 
complex I activity (0.089 (reference range: 0.104-0.268)) and I1 had decreased 
complex II/III activity (0.026 (reference range: 0.040-0.204)). Electrophysiological 
studies revealed an axonal sensory-motor neuropathy for all 19 patients. In all cases, 
the motor neuropathy was more severe in the upper limbs than the lower limbs. The 
sensory neuropathy appeared earlier than the motor neuropathy in patients for whom 
multiple tests were performed. Neurophysiological findings for patients E1-E7, A1-
A7, U1-U2, L1 and I1 are detailed in Appendix VI Table VI-8. Sural nerve biopsies 
were available for patients E2, E3, E5, A3, A6 and I1; findings revealed a chronic 
axonal neuropathy with fibrosis and continuous degeneration with no regeneration. 
The absence of regeneration may be more suggestive of a neuronopathy. Preferential 
involvement of large myelinated fibres may explain the sensory ataxia and areflexia. 
No signs of inflammation, hypomyelination or demyelination were seen on the 
biopsies. The remaining axons were mostly normal or atrophic in a few cases 
(Appendix VI Table VI-9) (Foley et al., 2014). 
Brain MRI was normal in the 15 patients in whom it was performed. Brain MRI is 
usually normal in BVVL although several reports have noted structural and signal 
abnormalities, as described in Section 1.6.1 (Ciccolella et al., 2012; Dakhil et al., 
2010; Foley et al., 2014; Francis et al., 1993; Koul et al., 2006; Koy et al., 2012; 
Malheiros et al., 2007; Sathasivam, 2008).  
6.4.3 Phenotypes of patients with SLC52A3 mutations 
Limited phenotypes could be obtained for the patients with heterozygous SLC52A3 
mutations. The siblings RDB and NDB carried the heterozygous p.Gly13Arg 
SLC52A3 mutation. These siblings are the product of a consanguineous marriage; 
 229 
both patients have a typical BVVL phenotype with sensorineural hearing loss and 
LMN disease with bulbar signs. 
Patient JG carried the heterozygous p.Ile20Leu mutation in SLC52A3; there is 
consanguinity in this patient’s family and inheritance is likely AR. The two most 
likely diagnoses were considered to be AR spastic ataxia of Charlevoix-Saguenay 
and X-linked bulbospinal muscular atrophy. Patient JG had optic nerve pressure from 
two years of age; his gait was abnormal from the age of five. He had multiple system 
involvement suggesting a mitochondrial abnormality including peripheral 
neuropathy, some myopathy with neck flexion and extension weakness, ptosis, 
cerebellar signs with some bulbar involvement (speech), mild dysdiadochokinesis, 
spasticity, gaze-evoked nystagmus, tonic pupils and raised pressure in the eye. This 
patient also had some oral facial myokymia, diplopia, oxycephaly, possible mild 
hearing loss, slurred speech, and difficulty chewing and swallowing. At age 25, 
walking was increasingly difficult with unsteadiness, fatigue and falls. He also had 
distal upper limb weakness, proximal and distal lower limb weakness, distal muscle 
atrophy as well as bilateral facial weakness. Pinprick sensation was reduced in the 
extremities, and temperature sensation was reduced in the forearm and lower leg. 
Reflexes were absent at the ankles. 
Patient HM, who carried the heterozygous p.Glu36Lys mutation in SLC52A3 had a 
very mild phenotype with bilateral optic and auditory neuropathies; sequencing of 
the full mitochondrial DNA and optic atrophy 1 (OPA1) were negative. No further 
clinical details were available. The same mutation has been found in the cis 
configuration with a heterozygous p.Val413Ala mutation in SLC52A3. The patient 
presented in his twenties with peripheral neuropathy and could walk a short distance 
with a stick in his fifties. He had muscle wasting, truncal ataxia, sensorineural 
deafness but no respiratory compromise. As the p.Val413Ala mutation was tolerated 
by SIFT, it was suggested to be a possible polymorphism, which would fit with the 
milder phenotype of the patient in that study (Green et al., 2010) and in our study. 
Patient LF carried the heterozygous p.Thr125Asn mutation in SLC52A3. This patient 
is currently 12 years of age; the principal phenotypic features include poor hearing, 
neuropathy, ataxia, weight loss, and breathing problems. Patient KG carried the 
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heterozygous p.Thr135Ala variant. This patient is a 15 year-old girl who presented 
with a partial right third nerve palsy and hemi-atrophy of the right side of her tongue. 
An MRI scan was normal. There was no history of deafness. Over 6-8 weeks, she 
developed progressive weakness starting in the face, progressing to the shoulders and 
eventually the lower limbs. She also developed significant neuromuscular scoliosis 
requiring spinal surgery. The patient required a wheelchair and a nasogastric tube for 
feeding. NCS was suggestive of an axonal neuropathy. The patient was treated with 
IVIG with no significant improvement, but she showed dramatic improvement in her 
strength when treated with steroids. After the first course (four months) of steroids, 
this patient’s condition returned to the baseline level of functioning. Investigations 
for CMT1, HNPP, and Friedreich’s Ataxia were all negative. Riboflavin was recently 
trialled with no dramatic improvement, but treatment with steroids has been 
successfully weaned down.  
Patient LS carried the heterozygous p.Phe457Leu mutation. No detailed phenotype is 
available but the patient was described as having a typical BVVL phenotype with 
stabilisation on high-dose riboflavin therapy. As mentioned in 6.1.5, mutations 
located in the COOH terminal such as this one are usually associated with severe 
phenotypes (Bosch et al., 2011; Ciccolella et al., 2012; Green et al., 2010; 
Subramanian, Rapp, et al., 2011). The p.Phe457Leu mutation has been previously 
found in the homozygous state in two patients (Green et al., 2010; Johnson et al., 
2012). In the Green et al. (2010) study, the patient presented at three months and had 
breathing difficulties, deafness, respiratory compromise and generalised weakness, 
leading to death at 11 months (Green et al., 2010). No phenotype was provided in the 
Johnson et al. (2012) study.  
It is possible that another mutation in the compound heterozygous state in SLC52A3 
was missed. However, single heterozygous mutations in SLC52A3 causing BVVL 
disease have been described in several studies (Ciccolella et al., 2012; Dezfouli et al., 
2012). In the Dezfouli et al. (2012) study, the two heterozygous SLC52A3 mutations 
each found in one patient were located at highly conserved amino acids. The two 
patients had later disease onset; however, inheritance was unlikely to be AD as the 
parents were unaffected (Dezfouli et al., 2012; Houlden, 2012). AD inheritance has 
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only rarely been described in BVVL (De Grandis et al., 2005; Hawkins et al., 1990). 
Incomplete penetrance has been considered in some BVVL families where affected 
siblings of BVVL patients showed a very mild phenotype (Dezfouli et al., 2012; 
Hawkins et al., 1990). In the Ciccolella et al. (2012) study, a BVVL patient carried a 
heterozygous SLC52A3 p.Cys432Stop mutation and no other mutation in the coding 
region and UTRs; the authors suggested that the protein may be partially functional. 
As suggested by these authors, BVVL patients with heterozygous SLC52A3 
mutations may have a heterozygous copy number variant on the other allele or a 
pathogenic mutation in a non-coding region of SLC52A3 such as a deep intronic or 
promoter variant (Ciccolella et al., 2012; Dezfouli et al., 2012). Although this could 
not be carried out during this study, the DNA of these patients will be run on a 
custom array to determine whether copy number defects are present in SLC52A3. 
Analysing the cDNA and performing family segregation studies would also help 
assess the pathogenicity of the SLC52A3 mutations identified in this study. 
Where this information was available, a brief clinical description of patients who 
tested negative for all three riboflavin transporters in both cohorts screened at our 
centre is available in Appendix VI Tables VI-12 and VI-13. The phenotypes of 
individual II-10 of family SP and individuals III-3 and III-8 of family TB who were 
part of the patient cohort specifically referred to us for BVVL testing are available in 
Section 6.3.3. 
6.4.4 Response of BVVL patients to high-dose oral riboflavin treatment 
High-dose oral riboflavin therapy was commenced in 16 patients with SLC52A2 
mutations, with treatment durations lasting from one month to 20 months. There 
were no reported adverse events or toxicity. One patient did not agree to 
administration of the therapy and two died (patients A3 and E8) prior to the genetic 
diagnosis. Stable function or significant, sustained improvement clinically and 
biochemically was reported in 15 of the 16 patients in whom high-dose oral 
riboflavin was administered; one patient could not be followed-up. The therapy was 
effective after just four weeks of treatment in patient I1 and proved to be life-saving; 
this is likely due to the fact that the therapy was initiated near to symptom-onset in 
this patient. For all nine patients with abnormal plasma acylcarnitine profiles in 
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whom repeat tests were performed, the acylcarnitine profile normalised upon 
treatment with riboflavin (within two weeks after the first riboflavin dose in patient 
I1). The levels of riboflavin, FAD and FMN (or FAD only, when measured on its 
own) increased in 9/10 patients with tests performed before and after the start of 
treatment. Partial acylcarnitine profiles and plasma concentrations of riboflavin, 
FAD and FMN following riboflavin therapy are available for patients E1, E3, E4, 
E7, A1-A2, A4, A5-A7, U1-U2 and I1 (Appendix VI Table VI-10). Observed 
responses to riboflavin therapy including treatment dose and duration for patients 
E1-E4, E6, E7, A1-A2, A4-A7, U1-U2, I1 and L1 are summarised in Appendix VI 
Table VI-11. Detailed clinical responses to therapy were available for patients E1 
and I1 and are described below (Foley et al., 2014). 
Patient E1 was first described in the report by Johnson et al. (2012). This patient 
initially presented at 18 months of age with a sensory ataxia; at age six, there was 
progressive weakness in the upper limbs, vision and hearing loss, and respiratory 
insufficiency. The homozygous SLC52A2 p.Gly306Arg mutation was detected at age 
10; following this finding, treatment with 10 mg/kg/day of riboflavin was 
commenced. Over a period of 12 weeks, the dose was steadily increased up to 50 
mg/kg/day. Patient E1 showed improvement in biochemical and clinical tests 
performed three months after initiation of treatment, including normalization of the 
acylcarnitine profile, improved visual evoked potentials, audiometry testing and 
pulmonary function (Table 6-3). These last three tests had previously shown steady 
deterioration prior to treatment. Although patient E1’s hair, shoe size, weight and 
height had stayed stable between the ages of six and ten, these measures have also 
shown an improvement with riboflavin therapy. She remains stable after 20 months 
of therapy and has shown particularly significant improvement in motor function; 
she can now sit and stand on her own, something she had not been able to do for 
three years (Foley et al., 2014). 
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Table 6-3 Response to high-dose riboflavin therapy in patient E1 (reproduced from 
Foley et al., 2014). 
 
A thorough report on response to high-dose riboflavin treatment was also available 
for patient I1. At 22 months of age, this patient presented with a six-month history of 
nystagmus, four-month history of ataxic gait and rapidly progressive weakness of 
hand and bulbar muscles over the preceding three weeks. Upon first evaluation, 
patient I1 could not walk or hold a bottle. Respiratory failure and severe swallowing 
difficulties quickly followed. Further examinations revealed bilateral optic atrophy, 
vision loss and bilateral sensorineural hearing loss. The C6, C8, C10 and C14:1 
carnitine species were raised in plasma (Appendix VI Table VI-7). Riboflavin 
treatment with a dose of 10 mg/kg/day was initiated only eight days after first 
presentation; dosage was increased to 50 mg/kg/day over a four-week period. 
Respiratory support was no longer necessary only ten days after the start of 
treatment, and the patient has remained stable since this time. After four weeks of 
treatment, he could hold his head upright, grab objects, feed by mouth and walk with 
trunk support (Foley et al., 2014). 
6.4.5 Array analysis of SLC52A2 and surrounding region in patient E1 
As described in Section 6.3.9, the HumanCytoSNP-12 v.2.1 BeadChip was used to 
provide further evidence that the SLC52A2 p.Gly306Arg variant was indeed 
homozygous in patient E1 despite there being no known consanguinity in the family. 
Although the BeadChip array did not contain SNPs within the SLC52A2 gene, the 
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SLC52A2 gene was located within a large 2 Mb region of homozygosity in this 
patient. It is worth noting that Sanger sequencing in this patient did not reveal any 
heterozygous bases in SLC52A2 exons or flanking intronic sequences. The log R 
ratio did not support the possibility of a large deletion encompassing the SLC52A2 
gene or exons. It is likely that the p.Gly306Arg mutation was indeed homozygous in 
this patient. Due to time constraints, such an assessment could not be carried out in 
patient E8 with the homozygous SLC52A2 p.Leu312Pro mutation who also had no 
reported consanguinity in her family. 
6.4.6 Haplotype analysis of patients of Lebanese origin carrying the 
homozygous SLC52A2 p.Gly306Arg mutation 
The haplotype was established around the SLC52A2 p.Gly306Arg mutation in the 
families of Lebanese origin including A1-A2, A5-A7, L1 (proband L1, his 
unaffected parents and affected sister) and in the family described in Mégarbané et al 
(2000) (proband, two unaffected siblings, unaffected father and affected cousin). In 
all these families, the heterozygous and homozygous state of the mutation was 
confirmed in all unaffected parents and affected individuals, respectively. The 
haplotype analysis showed all affected patients to be homozygous at all 11 
genotyped SNPs (Appendix VI Table VI-6). The Australian families of Lebanese 
origin A1-A2 and A5-A7 had a different genotype at one SNP located close to the 
end of the analysed segment (dbSNP ID: rs4993862). If the mutation is a founder 
mutation and has its origins on a common haplotype in the Lebanese population, it 
would imply that there must have been a recent recombination event between the two 
variants, or that the variant located at rs4993862 has arisen after the p.Gly306Arg 
mutation (Foley et al., 2014). The haplotype around the homozygous p.Gly306Arg 
mutation in patient E1, who is of non-Lebanese origin, has previously been 
established to be different from the haplotype in the family described by Mégarbané 
et al. (2000) (Johnson et al., 2012). 
6.4.7 Transcriptional analysis of mutations in BVVL patients 
In all patients for whom fibroblasts were available (patients E1-E4 and I1) and in the 
carrier fibroblast line (mother of E1), the cDNA analysis did not show aberrant 
transcripts. With the exception of the stop mutation in patient E3 discussed below, 
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the cDNA sequencing confirmed all mutations found at the genomic level. In patient 
E3, the p.Ala420Thr mutation was confirmed by cDNA analysis; however, only the 
WT allele was present on analysis of the cDNA for the p.Gln234Stop mutation, 
suggesting that this mutation results in NMD (Figure 6-8).  
Figure 6-8 DNA and cDNA sequencing of SLC52A2 exon 3 in patient E3 showing 
NMD at the cDNA level. 
6.4.8 Exome sequencing 
The reader is referred to Appendix VI Table VI-14 for a list of poorly covered exons 
in the three known riboflavin transporter genes for families SP, MO and TB. The 
only poorly covered exons in these three genes were exons 4 in SLC52A2 and 
SLC52A3 in individual III-3 of family MO. The GSTZ1 gene, a candidate gene in 
individual III-3 of family MO, was well covered in this individual. 
The exome sequencing for individual II-3 of family SP resulted in a total of 
47,212,177 reads. The mean target coverage was 58.9X; 95.7% of the bases had at 
least 2-fold coverage, 89.9% of bases had at least 10-fold coverage and 68.6% of the 
bases had at least 30-fold coverage. There were a total of 49,049,895 reads in the 
exome sequencing of individual III-1 in family SP. The mean target coverage was 
63X; 95.8% of the bases had at least 2-fold coverage, 90.5% of bases had at least 10-
fold coverage and 70.9% of the bases had at least 30-fold coverage. A total of 22,925 
variants were found in individual II-3. After filtering out synonymous variants, 
11,589 variants remained. In agreement with the Sanger sequencing results, no 
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variant amongst these was located in SLC52A2 or SLC52A3; two non-synonymous 
variants were found in SLC52A1, however both variants are common polymorphisms 
(Appendix VI Table VI-15). After filtering out homozygous variants, 6,974 variants 
remained. 505 variants remained after removing variants in segmental duplications 
and those found in control databases using the frequency filters mentioned in Section 
6.3.16. By selecting only variants in the compound heterozygous state with at least 
one other variant in the same gene, 60 variants in 28 different genes remained. The 
unaffected son of individual II-3, individual III-1 should only carry one of the two 
variants found in the compound heterozygous state in his mother. Individual III-1 
carried the same two common non-synonymous variants in SLC52A1 as those found 
in his mother. For 14 out of the 28 genes remaining, the son did not carry any of the 
same variants as his mother; for six of these genes, the son carried all the same 
variants in a particular gene as his mother. Therefore, eight genes remained in which 
individual II-3 had at least two variants, and individual III-1 did not carry at least one 
of the variants found in his mother. The genes remaining included titin (TTN), 
transmembrane protein 184A (TMEM184A), mucin 6 (MUC6), olfactory receptor, 
family 4, subfamily C, member 45 (OR4C45), achalasia, adrenocortical 
insufficiency, alacrima syndrome (AAAS), phosphatidylinositol glycan anchor 
biosynthesis, class Q (PIGQ), tektin 5 (TEKT5) and dynein, axonemal, heavy chain 
17 (DNAH17). Based on protein function, the most likely candidate gene amongst 
these was AAAS; the protein encoded by this gene, ALADIN, is a nucleoporin of the 
nuclear pore complex and is a member of the WD-repeat family of regulatory 
proteins. It is thought to be involved in the development of the CNS and PNS 
(Handschug et al., 2001; Koehler et al., 2013; Tullio-Pelet et al., 2000). Homozygous 
and compound heterozygous mutations in this gene cause Achalasia-Addisonianism-
Alacrima Syndrome (AAAS), also known as Triple-A syndrome or Allgrove 
syndrome (Handschug et al., 2001; Tullio-Pelet et al., 2000). 
Individual II-3 carried two heterozygous non-synonymous mutations in the first exon 
of AAAS, p.Gln15Lys (c.43G>T) and p.Tyr19Cys (c.56T>C) (Ensembl Transcript 
ID: ENST00000209873). The proband’s son, individual III-1, only carried the 
p.Gln15Lys (c.43G>T) variant in the heterozygous state in this gene, along with a 
synonymous mutation. The depth and quality of the p.Gln15Lys variant were 69 and 
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194 respectively in individual II-3; corresponding values for the p.Tyr19Cys variant 
were 68 and 201. Neither of the two variants is located within a WD-repeat region 
(UniProtKB ID: Q9NRG9). The p.Gln15Lys variant may be in a region needed for 
AAAS protein β-strand stability (Sandrini et al., 2001). The p.Gln15Lys variant was 
found in dbSNP (ID: rs121918549), however it was classified as pathogenic and no 
frequency data was available. Its MAF in the EVS database was 0.000186; it was 
not found in the CG69 or 1000 Genomes databases. The p.Tyr19Cys was not found 
in the dbSNP, 1000 Genomes, CG69 or EVS control databases. The p.Gln15Lys 
variant was predicted benign by SIFT, possibly damaging by PolyPhen-2 
(score=0.779), and disease-causing by Mutation Taster (score=1.45, 
probability=0.977). The p.Tyr19Cys variant was predicted benign by SIFT and 
PolyPhen-2 (score=0), but disease-causing by Mutation Taster (score=5.29, 
probability=0.995). However, SIFT had low confidence in its prediction ability at 
these amino acids. Furthermore, the specificity of the Polyphen-2 prediction for 
p.Tyr19Cys was zero, therefore the prediction cannot be trusted in this case. Both 
amino acids altered in AAAS in individual II-3 are conserved in Pan troglodytes, 
Macaca mulatta, Mus musculus, Felis catus and Xenopus tropicalis; there is no 
homologue or alignment for Drosophila melanogaster and Caenorhabditis elegans. 
The GERP scores were 3.33 and 4 for p.Gln15Lys and p.Tyr19Cys, respectively, 
confirming that the two amino acids are under evolutionary constraint.  
Triple-A syndrome is a rare, AR multi-system disease. The main features include 
alacrima, achalasia and adrenal failure (Allgrove et al., 1978). However, neurologic 
features involving the CNS, PNS and autonomic nervous system have been reported. 
These features include wasting and weakness of distal limb muscles, brisk tendon 
reflexes with absent ankle jerks, inability to walk on toes, pes cavus, dysarthria, 
autonomic abnormalities, hyperreflexia, amyotrophy, ataxia, gait disturbance, optic 
atrophy, cognitive deficits and sensory impairment (Dixit et al., 2011; Houlden et al., 
2002; Sandrini et al., 2001; Tullio-Pelet et al., 2000; Vallet et al., 2012). These 
reports have also highlighted the phenotypic heterogeneity and the variable disease 
severity which may be seen in Triple-A syndrome; indeed, patients may only have a 
subset of the typical clinical problems usually associated with the disease (Houlden 
et al., 2002). Both sensory-motor axonal and demyelinating neuropathies have been 
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reported (Dixit et al., 2011; Dumić et al., 2011). Neurological symptoms are 
especially predominant in late-onset cases; endocrine and gastrointestinal issues may 
be minor in these cases (Vallet et al., 2012). Alacrima, adrenal abnormalities and 
autonomic involvement were not reported in individual II-3 in family SP; however, 
the patient did have prominent neurological involvement with several of the features 
noted above including: dysarthria, pes cavus, gait disturbance, amyotrophy, brisk 
tendon reflexes with absent ankle jerks, sensory deficits and an axonal sensory-motor 
neuropathy. Individual II-3 also had dysphagia, one of the features of achalasia. 
Palatal paresis, atrophic furrowed tongue with fasciculations and prolonged central 
motor conduction times as seen in individual II-3 have also been previously 
described in the literature in Triple-A syndrome (Houlden et al., 2002).  
The p.Gln15Lys variant in AAAS has been previously reported in the homozygous 
and compound heterozygous state in cases of Triple-A syndrome (Handschug et al., 
2001; Houlden et al., 2002; Sandrini et al., 2001; Vallet et al., 2012). When found in 
the homozygous state, this mutation led to a milder phenotype and was associated 
with alacrima, achalasia, learning disabilities, neurologic deficiencies and 
glucocorticoid deficiency (Sandrini et al., 2001). The other mutation p.Tyr19Cys is 
novel. Most mutations in this gene lead to a truncated protein and are therefore 
predicted to act via a loss of function mechanism (Handschug et al., 2001). 
Frameshift and nonsense mutations are generally associated with a more severe 
phenotype (Houlden et al., 2002), which may explain the milder phenotype seen in 
our patient. 
AAAS, located on chromosome 12, is 546 amino acids long and has 16 coding exons. 
It contains four WD-repeat regions. It is ubiquitously expressed although it is most 
highly expressed in a subset of cells in the CNS, as well as in gastrointestinal 
structures, in the blood and immune system, heart muscle, kidney, endocrine glands 
and the male reproductive system (Handschug et al., 2001; 
http://www.proteinatlas.org). It is weakly expressed in peripheral nerve 
(http://www.proteinatlas.org). Nucleoporins such as ALADIN are responsible for 
transport of macromolecules between the cell nucleus and cytoplasm. ALADIN is 
needed for the import of several factors into the cell nucleus, including aprataxin, 
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DNA ligase I, and ferritin heavy chain, and is important for preventing DNA damage 
and associated oxidative stress (Koehler et al., 2013). In fibroblasts of Triple-A 
syndrome patients, several genes associated with antioxidant defence and oxidative 
stress were differentially regulated; it was postulated that Triple-A syndrome patients 
have a defective response to oxidative stress (Koehler et al., 2013). We believe that 
Triple-A syndrome due to mutations in the AAAS gene is likely to be the cause of the 
neuropathy in family SP. 
The exome sequencing for individual III-3 of family MO resulted in a total of 
64,488,853 reads. The mean coverage was 47.7X; 93% of the bases had at least 2-
fold coverage, 87.1% of bases had at least 10-fold coverage and 67.1% of the bases 
had at least 30-fold coverage. Individual III-3 of family MO had severe progressive 
sensory-motor axonal neuropathy, tubulopathy and cataracts. In total, 21,468 variants 
were found in this proband. After filtering out synonymous variants, 10,901 variants 
remained. Amongst these variants, no variants were found in SLC52A2. Two non-
synonymous variants were found in SLC52A1 and GSTZ1, and three non-
synonymous variants were detected in SLC52A3; however, all of these variants were 
common polymorphisms (Appendix VI Table VI-16). 6,671 variants remained after 
filtering out homozygous variants. 418 variants remained after filtering out variants 
in segmental duplications and those found in control databases using the frequency 
filters mentioned in Section 6.3.16. After selecting only variants in the compound 
heterozygous state with at least one other variant in the same gene, 47 variants in 21 
different genes remained. 
The most probable candidate gene amongst these 21 genes based only on protein 
function was neurofilament heavy polypeptide (NEFH). NEFH, located on 
chromosome 22, has four exons and encodes a protein of 1,020 amino acids. 
According to the Human Protein Atlas, NEFH is highly expressed in neuronal cells 
of the CNS and in the salivary gland, and is moderately expressed in the peripheral 
nerve, pancreas and liver. Neurofilaments, the intermediate filaments of neurons, are 
structural proteins involved in stability of the cytoskeleton and in determination of 
the axon diameter (Lariviere & Julien, 2004; Lees et al., 1988). 
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Individual III-3 of family MO carried a heterozygous non-frameshift insertion 
p.Lys651_Ala652insProLysSerProGluLys (c.1953_1954insCCCAAGTCCCCTGA-
GAAG) and a heterozygous non-frameshift substitution p.Glu658delinsProSer-
ProHisArgArg (c.1972_1973insCCAAGTCCCCATAGA-AGG), both located in the 
fourth exon of NEFH (Ensembl Transcript ID: ENST00000310624). The depth and 
quality of both variants were 217 and 113, respectively. The variants identified in our 
study are located within a repeat region of the Lys-Ser-Pro sequence motif in the 
heavily phosphorylated tail domain of the NEFH protein (UniProtKB ID: Q9NRG9). 
A common polymorphism results in either 43 or 44 of these repeats. Neither of the 
two variants was found in the dbSNP, 1000 Genomes, CG69 or EVS control 
databases. Although similar in-frame insertions and deletions are reported in these 
databases between amino acids 525 and 832, most have no frequency data. 
The tail domain is involved in forming cross-links between filaments (Figlewicz et 
al., 1994). Phosphorylation of this domain has been involved in determining the 
density of the neurofilament and the axonal calibre (Lariviere & Julien, 2004; Lees et 
al., 1988). The variants identified herein could disrupt the phosphorylation pattern, 
thus dysregulating the filament crosslinking and the assembly of the neurofilaments, 
potentially leading to abnormal protein accumulation within neurons (Figlewicz et 
al., 1994; Tomkins et al., 1998). Mice overexpressing the human NEFH gene 
develop a progressive neuronopathy with impairment of neurofilament transport 
causing axonopathy and muscle atrophy, suggesting that regulation of this gene is 
crucial for neuronal health (Côté et al., 1993). Although the common 43/44 repeat 
polymorphism mentioned above is neutral, other deletions and insertions in the 
repeat domain were found in sporadic ALS patients and were not found in controls in 
several studies (Lariviere & Julien, 2004; Tomkins et al., 1998). Mutations in the 
neurofilament light polypeptide (NEFL) gene causing defects in neurofilament 
assembly are associated with CMT2E (Rossor et al., 2013). Additional studies are 
required before it can be concluded that NEFH mutations are the cause of the 
neuropathy in individual III-3 of family MO. 
There were a total of 45,866,011 reads in the exome sequencing of individual III-3 in 
family TB. The mean target coverage was 57.6X; 95.6% of the bases had at least 2-
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fold coverage, 89.6% of bases had at least 10-fold coverage and 67.9% of the bases 
had at least 30-fold coverage. The exome sequencing for individual III-8 of family 
TB resulted in a total of 49,890,292 reads. The mean coverage was 62.5X; 95.7% of 
the bases had at least 2-fold coverage, 90.2% of bases had at least 10-fold coverage 
and 70.6% of the bases had at least 30-fold coverage. Individuals III-3 and III-8 in 
family TB had an AR, predominantly motor polyneuropathy. A total of 22,950 
variants were found in individual III-8. After filtering out synonymous variants, 
11,767 variants remained. As expected, no variant amongst these was found in 
SLC52A2 or SLC52A3; two common non-synonymous variants were found in 
SLC52A1, neither of which is likely to be pathogenic (Appendix VI Table VI-17). 
770 variants remained after removing variants in segmental duplications and those 
found in control databases using the frequency filters mentioned in Section 6.3.16. A 
total of 22,767 variants were found in individual III-3 of family TB. After filtering 
out synonymous variants, 11571 variants remained. Again, no variant amongst these 
was found in SLC52A2 or SLC52A3; the same two common SLC52A1 variants as in 
individual III-8 were detected. 596 variants remained in individual III-3 after 
removing variants in segmental duplications and those found in control databases 
using the frequency filters mentioned in Section 6.3.16.  
Three models were then followed. In the eventuality that both cousins carried the 
same mutation in the homozygous state, all heterozygous variants were filtered out in 
individuals III-3 and III-8: 89 variants and 86 variants remained for individuals III-3 
and III-8, respectively. 39 homozygous variants in 38 different genes were common 
to both individuals. The number of homozygous variants in common between the 
two individuals could not be further reduced; no variant was considered especially 
likely to be disease-causing based on protein function. For the second model, 
homozygous variants were filtered out from the list of 596 variants remaining for 
individual III-3; 507 heterozygous variants remained. Twenty genes had at least two 
variants in the compound heterozygous state. Upon searching for variants in the 
compound heterozygous state in individual III-3 for which one of the two variants 
was also found in the homozygous state in individual III-8, no variants remained. For 
the third model, homozygous variants were filtered out from the list of 770 variants 
remaining in individual III-8, and only compound heterozygous variants were 
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selected out of the list of 684 remaining heterozygous variants. Amongst these, a 
total of 33 genes had at least two heterozygous variants in individual III-8. Three 
genes were common to both lists of compound heterozygous variants in individuals 
III-3 and III-8 (MUC6, OR4C45 and dentin sialophosphoprotein (DSPP)); however, 
none of the variants in DSPP were found in both individuals, and OR4C45 and 
MUC6 are unlikely to be the cause of disease based on their predicted protein 
function in UniProtKB.  
6.5 Discussion 
SLC52A2 mutations were more frequent than mutations in SLC52A3 and SLC52A1 in 
both cohorts of patients screened for BVVL genes in our study. Amongst patients 
screened at our centre as part of this Thesis, SLC52A2 mutations were found in 
16.4% of the cohort of patients specifically referred for BVVL testing and 2.9% of 
the cohort designed by a database-search of patients with BVVL-like features; 
corresponding values for SLC52A3 mutations were 10.9% and 0%, although the 
pathogenicity of the heterozygous SLC52A3 mutations remains uncertain. Therefore, 
frequencies of mutations in SLC52A2 and SLC52A3 were higher in the referred 
patient series compared to the series of patients selected from the NHNN database. 
SLC52A2 mutations have only very recently been associated with BVVL, yet from 
our gene screening and that of our collaborators, it now appears that they may be a 
common cause of BVVL. Given the high proportion of patients in both cohorts who 
were found to be negative for mutations in the three known riboflavin transporters, it 
is likely that novel genetic causes of this disease remain to be uncovered, especially 
as some negative patients had phenotypes typical for BVVL. Admittedly, copy 
number changes and mutations in introns, UTRs and promoter regions cannot be 
ruled out in patients found to be negative for mutations in all three riboflavin 
transporters.  
This study also confirms previous findings that SLC52A1 mutations are rare in 
BVVL patients (Johnson et al., 2012). This study has identified the first stop 
mutation in SLC52A2, which was found to cause NMD at the mRNA level. In 
agreement with previous studies, mutations in SLC52A2 and SLC52A3 were spread 
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throughout the genes and were found in intracellular and extracellular loops as well 
as in transmembrane domains (Dezfouli et al., 2012).  
All patients with SLC52A2 mutations in our cohort had rapidly progressive axonal 
sensory-motor neuropathy causing sensory ataxia, upper limb and trunk weakness, 
and respiratory insufficiency. There was also involvement of the cranial nerves, as 
evidenced by optic atrophy (cranial nerve II), hearing loss (cranial nerve VIII) and 
tongue fasciculations with or without weakness and atrophy (cranial nerve XII). 
Patients had severe weakness in the upper limb and axial muscles, with preservation 
of lower limb strength. Although the upper limb predominance contrasts with length-
dependent inherited sensory-motor polyneuropathies, some inherited neuropathies do 
have predominant upper extremity weakness such as those associated with BSCL2 
mutations (Rossor et al., 2013). Of course, SLC52A2-mutated patients differ from 
those with BSCL2 mutations with regards to the mode of inheritance and associated 
features specific to BVVL such as hearing loss, sensory neuropathy, optic atrophy 
and respiratory insufficiency. In contrast to genetically uncharacterized BVVL cases 
and patients with SLC52A3 mutations who usually have a more generalised disease 
onset (Green et al., 2010; Bosch et al., 2011), our patients with SLC52A2 mutations 
had early-onset weakness of the neck and upper limbs. SLC52A2 patients were also 
unique in that they did not exhibit UMN signs in the lower limbs, which are 
commonly reported in BVVL and SLC52A3 patients (De Grandis et al., 2005; Dipti 
et al., 2005; Francis et al., 1993; Gallai et al., 1981; Green et al., 2010; Hawkins et 
al., 1990; Koul et al., 2006; Voudris et al., 2002). Although most reports have cited 
bilateral hearing loss as the presenting symptom in BVVL (Gallai et al., 1981; 
Sathasivam, 2008), ataxic gait and nystagmus were the two most frequent presenting 
symptoms in our cohort of SLC52A2-mutated patients. Some patients with 
pathogenic mutations in SLC52A2 in our study had normal acylcarnitine profiles; this 
finding has been previously noted in patients with SLC52A2 and SLC52A3 mutations 
(Bosch et al., 2012; Ciccolella et al., 2012; Ciccolella et al., 2013; Koy et al., 2012). 
Interestingly, although NCS do not always show abnormalities in BVVL patients 
(Dipti et al., 2005; Koul et al., 2006; Voudris et al., 2002), an axonal sensory-motor 
neuropathy was seen in our patients with SLC52A2 mutations. However, it remains 
unclear whether the axonal damage in the SLC52A2 patients is due to a neuronopathy 
 244 
of the dorsal root ganglia and anterior horn neurons, or to a primary axonopathy 
causing hearing loss, optic atrophy and a sensory-motor neuropathy (Foley et al., 
2014). Plasma FAD levels were normal in all patients with SLC52A2 mutations in 
whom testing was performed. This finding is in agreement with the role of RFVT2 in 
uptake of riboflavin from the blood into target cells (Ciccolella et al., 2012; Haack et 
al., 2012).  
Only limited clinical information was available for the patients with heterozygous 
SLC52A3 mutations. The phenotype was typical of BVVL in siblings RDB and NDB 
and in patient LS. Patient LF also had a typical BVVL phenotype including hearing 
loss, neuropathy, ataxia and impaired breathing. Although patient HM had mild 
disease with bilateral optic and auditory neuropathies, both of which may be seen in 
BVVL, the phenotypic details available for this patient were limited. Patient KG had 
some features of BVVL including tongue atrophy, axonal neuropathy and facial 
weakness progressing distally to the limbs, although no hearing loss was present. 
This patient also had a third cranial nerve palsy; palsies of the oculomotor nerve have 
been reported in BVVL, although these remain relatively rare (Sathasivam et al., 
2000; Sathasivam, 2008; Vialetto, 1936). In the recent review by Bosch and 
colleagues, palsies of the III, IV or VI cranial nerves combined were seen in 32% of 
BVVL patients (Bosch et al., 2012). Patient JG had a complex phenotype with 
several features of BVVL including AR inheritance, gait abnormalities, peripheral 
neuropathy, bilateral facial weakness, weakness of the neck muscles, distal limb 
weakness, ptosis, cerebellar signs with bulbar involvement, reduced reflexes, sensory 
abnormalities, nystagmus, mild hearing loss, speech abnormalities and difficulty 
swallowing. Plasma flavin levels could not be obtained for the patients with 
SLC52A3 mutations in our cohort. Some studies have reported normal plasma flavin 
levels in SLC52A3 mutated patients; in this case, the effect of the SLC52A3 
mutations on localisation or expression of RFVT3 was suggested to be restricted to 
the CNS via an unknown mechanism (Ciccolella et al., 2012). Further studies are 
needed to determine whether the heterozygous SLC52A3 mutations are the cause of 
BVVL disease in the patients identified herein. 
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Given the distinct phenotypes associated with defects in the three riboflavin 
transporters, Bosch and colleagues had suggested to rename these subtypes of BVVL 
as riboflavin transporter deficiency, type 1 (SLC52A1-encoded RFVT1, previously 
hRFT1), type 2 (SLC52A3-encoded RFVT3, previously hRFT2) and type 3 
(SLC52A2-encoded RFVT2, previously hRFT3) to better delineate them clinically 
(Bosch et al., 2012). However, given the new protein nomenclature, we have 
suggested that type 2 should refer to SLC52A2-associated forms of BVVL and type 3 
to SLC52A3-associated BVVL (Foley et al., 2014). 
In agreement with the majority of previous findings in patients with mutations in 
SLC52A2 (Haack et al., 2012) and SLC52A3 (Anand et al., 2012; Bosch et al., 2011; 
Bosch et al., 2012; Ciccolella et al., 2012) (Section 1.6.5), our study has shown that 
BVVL associated with SLC52A2 mutations is potentially treatable with high-dose 
oral riboflavin (Foley et al., 2014). While the literature suggests that high-dose 
riboflavin supplementation can apparently benefit both SLC52A2 and SLC52A3-
mutated patients if administered early on, treatment should be trialled in a greater 
number of patients to assess whether BVVL cases associated with each of these 
genetic subtypes respond differently to therapy.  
In accordance with previous observations, in our study the therapy was effective 
even in patients with normal plasma flavin levels (Bosch et al., 2011; Bosch et al., 
2012). No adverse events associated with the therapy were seen in our cohort. 
Siblings of affected patients should be screened soon after the genetic finding to 
allow for pre-symptomatic initiation of therapy, if necessary (Foley et al., 2014). As 
discussed in Section 1.6.5, high-dose oral riboflavin therapy should be initiated as 
soon as BVVL is suspected and before results of genetic studies are obtained to 
prevent irreparable damage (Bosch et al., 2011; Spagnoli & De Sousa, 2011), 
especially as riboflavin is not known to be toxic at high doses (Alhadeff et al., 1984; 
Foley et al., 2014; McCormick, 1989). The effectiveness of the therapy in older 
patients with a long disease duration is unknown. Patients in our cohort who showed 
stable functioning as opposed to improvement with high-dose riboflavin therapy 
were largely the patients who were older at the time of treatment initiation. It is 
likely that the extent of neurological damage was too advanced in these patients for 
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riboflavin therapy to be effective (Bosch et al., 2012; Foley et al., 2014; Spagnoli & 
De Sousa, 2011). Finally, the trial period of treatment should be continued even if no 
improvement is seen initially as severely affected patients usually show more gradual 
improvement (Bosch et al., 2012). 
The lack of toxicity may be due to the fact that riboflavin is rapidly excreted in the 
urine when present at very high concentrations in the blood (Gregersen, 1985; Haack 
et al., 2012). Although patients in our study were treated with 10-50 mg/kg/day of 
oral riboflavin or 1,500 mg/day in adults, as discussed in Section 6.1.2 the maximal 
absorption for pharmacological doses of riboflavin administered orally is 25-27 mg 
per dose (Gregersen, 1985: Zempleni et al., 1996). Due to the potentially saturable 
nature of the transporters, further studies are needed to determine how to best 
optimise the uptake of riboflavin via diffusion or via the other two functional 
riboflavin transporters, RFVT1 and RFVT3 (Bosch et al., 2012; Foley et al., 2014). 
Furthermore, the optimal dose, frequency and length of treatment, as well as the best 
method of administration of riboflavin treatment remains to be elucidated (Bosch et 
al., 2012; Foley et al., 2014). 
While none of the SMARD-like patients carried mutations in the three riboflavin 
transporters, further studies are warranted to fully exclude riboflavin transporter 
mutations in other SMARD patients given the positive response to riboflavin 
treatment reported in this and other studies. Mutations in these genes could also be 
linked to other overlapping syndromes including ALS (especially infantile or early-
onset familial ALS), Nathalie syndrome, Boltshauser syndrome and Madras MND; 
screening of the BVVL-associated genes in these patients is also justified (Green et 
al., 2010). The riboflavin transporters should also be screened in children with optic 
atrophy and/or sensory ataxia as well as in children with some BVVL-like features, 
even if the phenotype is not typical of BVVL (Houlden, 2012). 
Although the exome sequencing results in family SP are still very preliminary, our 
study would confirm previous findings that AAAS mutations should be considered in 
patients with complex axonal neuropathy (Dixit et al., 2011; Houlden et al., 2002). 
For both families SP and MO, additional assessments of pathogenicity of the 
candidate genes could not be performed within the timeframe of this Thesis. The 
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variants detected in the AAAS and NEFH genes should be confirmed by Sanger 
sequencing and screened in a large cohort of controls. Segregation studies should be 
carried out in additional family members. The poorly covered exons in SLC52A2 and 
SLC52A3 in individual III-3 of family MO should be Sanger sequenced. The 
pathogenic nature of the mutations found in AAAS and NEFH needs to be confirmed 
in vitro. We also highlight again the difficulties associated with exome sequencing 
data analysis. As discussed in Chapter 5, the causative variant in these three families 
may have been missed by the exome sequencing; reasons may include poor 
coverage, if the variant was a large deletion, insertion, duplication, translocation or 
repeat sequence, or if it was located in a non-coding region. The pathogenic variant 
in families SP and MO may have been in the homozygous state, although this is 
unlikely given the absence of reported consanguinity in these families. Finally, it is 
possible that individuals III-3 and III-8 of family TB were suffering from diseases 
with different aetiologies.  
6.6 Conclusion 
In conclusion, this study has highlighted the relatively high frequency of SLC52A2 
mutations in BVVL patients and has expanded the range of clinical phenotypes 
associated with riboflavin transporter mutations. Importantly, patients in our cohort 
found to carry mutations in SLC52A2 were immediately initiated on high-dose 
riboflavin therapy following the genetic finding. Riboflavin may also be an effective 
treatment in other MNDs with overlapping phenotypes, such as those described in 
Section 1.6.1.  
Defects of riboflavin transporters represent a new genetic cause of neuropathy 
associated with a previously largely unknown disease pathway. However, the 
question remains as to how mutations in these proteins may cause a complex 
syndrome involving a sensory-motor neuropathy. The next Chapter will seek to 
elucidate the pathomechanisms leading to BVVL disease in patients with SLC52A2 
mutations and to understand how this disease pathway may differ from that 
associated with nutritional riboflavin deficiency. 
Finally, although further proof of pathogenicity is required, exome sequencing was 
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used in this study to ascribe mutations in a known gene, AAAS, to a relatively 
atypical phenotype. It is unlikely that this gene would have been deliberately 
screened in this family. 
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Chapter 7 BVVL: A functional investigation of a treatable 
neuropathy 
7.1 Introduction 
7.1.1 Riboflavin transporter mutations in BVVL, a novel neuropathy-
associated disease pathway 
The genetic screening of SLC52A1, SLC52A2, and SLC52A3 mutations in a cohort of 
BVVL patients (Chapter 6) has unveiled SLC52A2 mutations as a significant cause 
of this disease. The requirement for three genes encoding riboflavin transporters 
suggests that this pathway is indispensable. In contrast to the phenotype associated 
with nutritional riboflavin deficiency, which either remains subclinical or is 
primarily dermatological in nature (Foraker et al., 2003), BVVL patients present with 
a severe and complex phenotype characterised by early-onset progressive 
pontobulbar palsy with bilateral sensorineural hearing loss, sensory-motor 
neuropathy and respiratory insufficiency (Brown, 1894; Van Laere, 1966; Vialetto, 
1936). The patients with SLC52A2 mutations in our cohort shared a phenotype of 
rapidly progressive axonal sensory-motor neuropathy leading to sensory ataxia, 
upper limb and trunk weakness, and respiratory insufficiency, with involvement of 
selected cranial nerves. It remains unknown how the pathomechanisms leading to 
BVVL may differ from that of riboflavin deficiency associated with low intakes of 
riboflavin in the diet. 
A selection of the cellular pathways in which riboflavin and its cofactor forms FMN 
and FAD are involved will now be described in detail. Studies of riboflavin 
supplementation in riboflavin-responsive metabolic and mitochondrial diseases will 
also be discussed, to be followed by a summary of the effects of riboflavin 
deprivation in various human cell lines and animal models. Finally, results of the 
limited previous studies into the functional effect of riboflavin transporter mutations 
will be presented. 
7.1.2 Cellular energy metabolism 
FAD and FMN serve as cofactors in a variety of cellular energy metabolism 
processes and play crucial roles in aerobic respiration (McCormick, 1989). Aerobic 
respiration is the process by which eukaryotes use O2 to release the energy stored in 
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food in the form of substrates like glucose, fatty acids, and amino acids to generate 
ATP. During glycolysis, glucose is converted to pyruvate in the cytosol. In the 
mitochondria, there are two main enzyme systems for cellular metabolism and 
energy generation: the Krebs cycle and the MRC. Prior to entering the Krebs cycle, 
the pyruvate from glycolysis is converted to acetyl-CoA by the pyruvate 
dehydrogenase complex, a flavoprotein which uses FAD as an electron carrier 
(Duchen, 2004). Acyl-CoA fatty acids are metabolised in the mitochondrial matrix to 
acetyl-CoA via fatty acid β-oxidation. In the first instance, the fatty acid moiety is 
oxidised by acyl-CoA dehydrogenase, a flavoprotein with a bound FAD molecule, 
forming a fatty acyl-CoA molecule two carbons shorter. Electrons are transferred 
first to the FAD in ETF in the matrix and then to the FAD in ETF:QO in the inner 
mitochondrial membrane (Henriques et al., 2010). During the Krebs cycle, acetyl-
CoA produced by the breakdown of pyruvate, fatty acids and amino acids is 
catabolised, resulting in the production of CO2, NADH and reduced flavin adenine 
dinucleotide (FADH2). A small amount of ATP is produced by glycolysis and the 
Krebs cycle by substrate-level phosphorylation (Duchen, 2004). 
Mitochondria are the power plants of the cell, as they provide the cell with most of 
its energy in the form of ATP via the MRC and subsequent oxidative 
phosphorylation (Cozzolino & Carrì, 2012). The MRC is composed of four 
membrane-bound electron-transporting multimeric protein complexes, complexes I-
IV. The complex II enzyme is the only complex which is also part of the Krebs 
cycle, where succinate dehydrogenase (SDH) catalyses the oxidation of succinate to 
fumarate and reduces FAD to FADH2 in the process. The NADH and FADH2 
generated during glycolysis, pyruvate processing, fatty acid β-oxidation and the 
Krebs cycle serve as reducing equivalents for the MRC. Complexes I and II are both 
flavin-dependent complexes of the MRC. Complex I (NADH: ubiquinone 
oxidoreductase), the largest MRC complex with 45 subunits, is a major point of entry 
into the MRC and is considered to be the rate-limiting complex. Its FMN moiety, 
located within the soluble fraction of the complex along with the iron protein 
subunit, accepts electrons from NADH; these electrons then travel through a series of 
iron-sulphur centres. Complex II (succinate: ubiquinone oxidoreductase)/SDH is the 
simplest complex and is the sole complex to be only encoded by nuclear DNA. It is 
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made up of four subunits, SDHA, SDHB, SDHC, and SDHD; the SDHA subunit 
contains a succinate binding site, as well as the covalently attached FAD, which 
serves as the initial electron acceptor (Cecchini, 2003). Formation of the covalent 
linkage of FAD to SDH occurs in a complex process (Baker & Tarnopolsky, 2003; 
Cecchini, 2003; Distelmaier et al., 2009; Duchen, 2004).  
NADH and FADH2 are therefore oxidised to NAD
+
 and FAD in complexes I and II, 
respectively. High-energy electrons from these molecules are transferred from iron-
sulphur centres in complexes I and II to ubiquinone (CoQ), which is reduced to 
ubiquinol. CoQ, a mobile electron carrier, is a lipid-soluble molecule located in the 
inner mitochondrial membrane. Electrons in FADH2 are also donated into the MRC 
by ETF:QO of fatty acid β-oxidation to CoQ, thus providing a link between fatty 
acid metabolism and the MRC. Ubiquinol is oxidised by complex III (ubiquinone-
cytochrome c oxidoreductase), which contains cytochromes b and c. Electrons are 
carried by cytochrome c to complex IV (cytochrome c oxidase), the terminal 
cytochrome oxidase, before being donated to O2, the terminal electron acceptor, 
which is reduced to H2O. In the process, protons are pumped out of the matrix into 
the intermembrane space at complexes I, III and IV against their concentration 
gradient, generating an electrochemical gradient across the mitochondrial inner 
membrane known as the ΔΨm (Section 2.2.18). Complex II and ETF:QO are 
mechanistically unable to pump protons across the inner membrane. Complex V, 
also known as ATP-synthase or F1F0-ATPase, uses this gradient to phosphorylate 
adenosine diphosphate (ADP) and produce ATP by allowing protons to translocate 
back into the matrix (Duchen, 2004). 
Monovalent cationic fluorescent dyes such as TMRM can be used to monitor the 
ΔΨm in vitro, as described in Section 2.2.18. A common techni ue to specifically 
assess the implication of complex I in maintaining the ΔΨm in live cells is to 
monitor the TMRM intensity after the addition of rotenone, a toxin which blocks the 
transfer of electrons from the iron-sulphur cluster in complex I to ubiquinone by 
binding to the CoQ binding site (Murphy, 2009). 
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Inhibition of respiration, impaired respiratory complex activity, reduced substrate 
supply and mitochondrial uncoupling are some of the mechanisms which may affect 
the ΔΨm by decreasing or dysregulating proton pumping (Duchen, 2004). A loss of 
ΔΨm leads to reduced cellular ATP levels and mitochondrial dysfunction, which can 
result in cellular dysfunction or cell death (Distelmaier et al., 2009; Duchen, 2004; 
Grad & Lemire, 2006; Mancuso et al., 2010). Mitochondrial depolarisation can lead 
to swelling of the mitochondria and release of cytochrome c and apoptosis (Duchen, 
2004).  
When the ΔΨm dissipates as a result of damage or inhibition of respiration (e.g. due 
to a decrease in MRC complex activities), in certain conditions ATP synthase may 
act in reverse mode to preserve the ΔΨm. In this case, it can function as an ATPase 
by hydrolysing glycolytic ATP to pump protons out across the inner membrane 
against the gradient (Nicholls, 2002). Determining whether ATP synthase is 
operating in reverse is a common way of assessing mitochondrial function in 
neurodegenerative diseases (Abramov et al., 2010; Gandhi et al., 2009).  This is 
usually achieved by monitoring the ΔΨm using the TMRM dye, and observing the 
response to the mitochondrial toxin oligomycin, an inhibitor of the ATP synthase 
(Abramov et al., 2010). In healthy cells, oligomycin causes a slight transient 
hyperpolarisation (due to build-up of the proton gradient) or no response, suggesting 
that the ΔΨm is maintained by the MRC. If oligomycin results in depolarisation, the 
ΔΨm is being maintained by the hydrolysis of ATP due to reversal of ATP synthase 
(Abramov et al., 2010). Because this reversal process is harmful to cells as it uses 
ATP stores, binding of the initiation factor 1 (IF1) protein to this enzyme can serve 
as a defence mechanism to prevent the ATPase from operating in reverse mode, at 
the expense of the ΔΨm (Cecchini, 2003; Duchen, 2004).  
Inhibition of the MRC due to a genetic defect or other source of damage may cause 
the respiration rate to decrease, NADH to accumulate, and the NADH: NAD
+
 ratio to 
increase. Calculating the NADH: NAD
+
 ratio is another common way of assessing 
mitochondrial function (Bartolome et al., 2013). As discussed in Section 2.2.19, the 
NADH: NAD
+ 
ratio is measured in vitro by monitoring NADH fluorescence after the 
addition of the uncoupler drug FCCP, which reversibly depolarises the mitochondria, 
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maximises respiration and minimises NADH levels, followed by addition of NaCN, 
which completely inhibits respiration and maximises NADH levels (Bartolome et al., 
2013; Duchen, 2004). 
If aerobic respiration is defective, the cell may use anaerobic respiration to 
compensate and meet its energy requirements. However, anaerobic respiration causes 
pyruvate, the end product of glycolysis, to accumulate, and eventually to be reduced 
to lactate by NADH instead of being oxidised to acetyl-CoA and entering the Krebs 
cycle. Pyruvate can also accumulate if the activity of the pyruvate dehydrogenase 
complex is low (Bernsen et al., 1993; Grad & Lemire, 2006; Mackay & Robinson, 
2007). The lactate/pyruvate ratio measured in blood, CSF or cells such as fibroblasts 
is often used to detect MRC dysfunction. An increased lactate/pyruvate ratio is a 
typical finding in mitochondrial disorders (Bernsen et al., 1993; Mackay & 
Robinson, 2007). In order to compensate for a defect in mitochondrial respiration, 
cells may also upregulate glycolysis to maintain ATP levels, more or less effectively 
depending on the cell type. The relative expression of the β subunit of the F1-ATPase 
compared to that of GAPDH, a glycolytic enzyme, has been previously used as a 
marker of change in bioenergetics to determine whether cells predominantly obtain 
ATP from glycolysis or oxidative phosphorylation (Yao et al., 2011).  
A defect in mitochondrial function can cause a large range of phenotypes, but often 
results in muscular and neurological problems as muscle, brain nerve cells and 
peripheral nerves contain a large number of mitochondria to support their high 
energy demands (Federico et al., 2012; McInnes, 2013). The long axons of neurones, 
and especially of motor neurones, imply that molecules have to be transported over 
great distances efficiently. Furthermore, low levels of glycolysis in neurones make 
them especially reliant on oxidative phosphorylation; glycolysis alone would not 
provide sufficient ATP in these cells (Burchell et al., 2010; Davey, 1998). When 
neurones do not produce sufficient energy, calcium signalling, synaptic transmission, 
neurotransmitter release and therefore overall nervous system function is affected, 
eventually leading to apoptosis or necrosis (Burchell et al., 2010).  
The specific effect of defective oxidative phosphorylation and energy metabolism in 
the brain remains unclear. A study of synaptic mitochondria in the brain has 
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determined that the activities of complexes I, III and IV could be decreased by 25%, 
80%, and 70%, respectively, before oxygen consumption and synthesis of ATP were 
significantly compromised. Complex I was found to have the greatest control on 
oxidative phosphorylation compared to other complexes in synaptic mitochondria, 
however this is known to vary between tissues (Davey, 1998; Pathak & Davey, 
2008). In non-synaptic mitochondria of neuronal and astrocytic cells, the equivalent 
thresholds for complexes I, III and IV were 72%, 70% and 60%, which may explain 
why degeneration may preferentially take place at synapses (Pathak & Davey, 2008). 
It should be noted that these results were obtained from isolated mitochondria, and it 
is not known whether similar thresholds would be observed in vivo.  
7.1.3 Reactive oxygen species (ROS) and oxidative stress in the mitochondria 
Besides energy metabolism, mitochondria are also involved in other cellular 
processes, which are closely linked and are significantly dependent on one another 
(Burchell et al., 2010). Therefore, proper function of these complex structures is 
critical for overall cell health. Some of these functions include intracellular 
signalling, calcium homeostasis and activation of apoptosis (Cozzolino & Carrì, 
2012; McInnes, 2013). Furthermore, mitochondria are an important source of 
antioxidants; however, in many cell types, mitochondria are also a source of ROS 
production. Decreased ATP generation and increased ROS production are two of the 
central mechanisms leading to neurodegeneration. These free radicals are produced 
by the reaction of unpaired electrons generated during oxidative phosphorylation 
with O2, leading to superoxide ions which are highly reactive (Duchen, 2004; 
Nicholls, 2002). ROS are normally produced in small quantities in the cells and 
increasingly as we age; however, when antioxidant defences are unable to keep the 
ROS levels down low enough, oxidative stress ensues which further damages the 
MRC. ROS are damaging to lipids, nucleic acids and proteins, and impair the 
mitochondria’s ability to produce ATP (Murphy, 2009). ROS are especially hurtful 
to neurones due to their post-mitotic nature and high rate of oxygen consumption 
(Burchell et al., 2010; Mancuso et al., 2010). When the MRC is impaired, electrons 
which become blocked early on in the transport chain (especially in complex I) 
accumulate and are more likely to form ROS (Duchen, 2004; Mancuso et al., 2010; 
Murphy, 2009). Substrate accumulation in complex I as evidenced by a high NADH: 
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NAD
+
 ratio in the mitochondrial matrix is often associated with significant ROS 
production (Abramov et al., 2010; Murphy, 2009). This phenomenon has been 
reported in patient fibroblasts with isolated complex I deficiency (Distelmaier et al., 
2009; Duchen, 2004). Therefore, oxidative stress and energy metabolism dysfunction 
are closely linked (Baker & Tarnopolsky, 2003).  
The cell is dependent on efficient antioxidants to protect it against ROS (Abramov et 
al., 2010). In addition to its role in the MRC, CoQ10, the predominant form of CoQ, 
is also an antioxidant and free radical scavenger in its reduced form ubiquinol, and 
thereby protects against oxidative damage (Mancuso et al., 2010). CoQ10 was able to 
maintain the ΔΨm in neuronal cells undergoing oxidative stress (Mancuso et al., 
2010). Interestingly, a monooxygenase involved in the biosynthesis of CoQ10 is 
FAD-dependent (Baker & Tarnopolsky, 2003; Lienhart et al., 2013). Furthermore, 
GSH is another important antioxidant in the CNS. Glutathione reductase, the enzyme 
responsible for regenerating GSH from the oxidised form GSSG, is a flavoprotein 
with a bound FAD molecule therefore riboflavin acts indirectly as an antioxidant 
(Depeint et al., 2006; Henriques et al., 2010). High ROS production often leads to 
glutathione depletion, which in turn makes the cells more vulnerable to oxidative 
stress (Abramov et al., 2010). Therefore, as is seen in many neurodegenerative 
diseases, disturbed glutathione homeostasis may be a consequence or a cause of 
oxidative stress. Indeed, various studies have provided evidence that a decrease in 
glutathione levels in neuronal cells increases ROS production, causes defects in the 
ΔΨm, loss of mitochondrial function, and may cause cell death (Schulz et al., 2000). 
Interestingly, in neuronal, non-synaptic mitochondria, depletion of GSH in vitro 
abolished the complex I threshold mentioned in Section 7.1.2, and oxygen 
consumption started to be impaired at much lower levels of complex I inhibition, 
suggesting that maintenance of antioxidant status may be necessary for the 
preservation of energy thresholds in the mitochondria (Davey, 1998). 
7.1.4 Riboflavin and CoQ10 therapy in metabolic and mitochondrial disorders 
Riboflavin therapy has been shown to improve to variable extents the symptoms of a 
subgroup of MADD patients (RR-MADD). Deficiencies of aerobic metabolism in 
these patients were restored to normal with riboflavin supplementation; riboflavin 
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was suggested to activate the aerobic pathway (Gianazza et al., 2006; Henriques et 
al., 2010; Olsen et al., 2007; Peluchetti et al., 1991; Vergani et al., 1999). In contrast 
to non-riboflavin responsive forms of MADD, fibroblasts of patients with RR-
MADD were found to have milder folding defects, normal or supranormal fatty acid 
β-oxidation, and normal oxidation of flavoprotein-dependent substrates when 
cultured in riboflavin-supplemented medium (1010 nM or 5310 nM) (Cornelius et 
al., 2012; S. Olpin, personal communication; Olsen et al., 2007; Rhead et al. 1993). 
In parallel to these findings, vitamin B6 in the cell medium has been found to obscure 
the interpretation of in-vitro assays in fibroblasts of patients with vitamin B6-
responsive homocystinuria (Lipson et al., 1980).  
Riboflavin has also been used with some success clinically and biochemically in a 
subgroup of patients with defects of complex I and/or complex II (Baker & 
Tarnopolsky, 2003; Bernsen et al., 1993; Bugiani et al., 2006; Gerards et al., 2011; 
Gianazza et al., 2006; Jain-Ghai et al., 2013; Marriage et al., 2003; Ogle et al., 1997; 
Olsen et al., 2007; Peluchetti et al., 1991; Scholte et al., 1995; Vergani et al., 1999). 
Riboflavin therapy has also proven beneficial in some patients with mutations in 
acyl-CoA dehydrogenase family, member 9 (ACAD9), which encodes an FAD-
dependent acyl-CoA dehydrogenase in fatty acid β-oxidation with a potential role in 
complex I assembly. In these patients, supplementation of the cell medium for three 
days with 5300 nM riboflavin led to a two-fold increase in complex I activity in 
patient fibroblasts, but not in control fibroblasts (Gerards et al., 2011; Haack et al., 
2010; Horvath, 2012; Scholte et al., 1995). 
Some explanations which have been proposed for riboflavin responsiveness and 
improved mitochondrial respiration in complex I and/or II deficiency include the 
stimulation of an alternative pathway via complex I, II or ETF:QO by providing 
these enzymes with FAD molecules, and increasing electron transfer to CoQ. 
Another rationale involves reduced degradation of complex I followed by increased 
enzymatic activity of the complex (Ogle et al., 1997; Vergani et al., 1999). 
Riboflavin was also suggested to have a general stabilising effect on complex 
assembly (Bar-Meir et al., 2001). 
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Riboflavin has often been used in conjunction with CoQ10 in mitochondrial and 
metabolic disorders. CoQ10 deficiencies may either be primary, such as those due to 
mutations in CoQ10 biosynthesis genes or secondary, due to mutations in genes not 
involved in CoQ10 biosynthesis such as aprataxin (APTX) or ETFDH (Quinzii et al., 
2008). Four main phenotypes are associated with CoQ10 deficiencies; these include 
encephalomyopathy with defects of the MRC, the cerebellar type with ataxia and 
atrophy (with or without neuropathy), the multisystemic infantile type, and the pure 
myopathy with lipid storage myopathy (Quinzii et al., 2008). In fibroblasts of 
patients with CoQ10 deficiency, there was reduced activity of complexes I-IV, 
decreased ΔΨm and increased ROS production; these defects were nearly normalised 
upon CoQ10 supplementation (Quinzii et al., 2008; Spindler et al., 2009).  
Secondary CoQ10 deficiency in muscle has been reported in some RR-MADD 
patients with a myopathic phenotype due to ETFDH mutations. These patients also 
had decreased activities of complexes I, II-III and IV, as well as increased lactate 
levels, all of which improved with riboflavin and CoQ10 combination therapy 
(Gempel et al., 2007). In MADD patients, the dehydrogenation of acyl-CoA 
molecules is impaired due to defects in the transport of electrons from acyl-CoA to 
CoQ in the MRC (Horvarth, 2012). It has been proposed that the CoQ10 deficiency in 
these patients may be due to feedback inhibition and a downregulation of CoQ10 
synthesis as a result of a loss of ETF:QO activity; alternatively, a defect in ETF:QO 
may impair binding to CoQ10 and cause increased degradation of CoQ10 (Cornelius et 
al., 2013; Gempel et al., 2007; Gregersen et al., 2008; I. Hargreaves, personal 
communication).  
7.1.5 In vitro and in vivo effects of riboflavin deprivation 
Several lines of evidence from in vitro and in vivo models suggest that nutritional 
riboflavin deficiency leads to defects of cellular energy metabolism, with variable 
involvement between tissues. Moderately and severely riboflavin-deficient rats have 
abnormal amino acid metabolism and decreased fatty acid β-oxidation mainly due to 
impaired activity of acyl-CoA dehydrogenase activity (Brady & Hoppel, 1985; 
Goodman, 1981; Olpin & Bates, 1982; Sakurai et al., 1982).  
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Rats subjected to acute, severe riboflavin deficiency ceased to grow early on in the 
deficiency period. The activity of SDH decreased early on in the deficiency state in 
the brain, liver, and intestine, although this was found to be due to starvation and not 
specific to riboflavin deficiency in the latter two tissues. The magnitude of decrease 
of SDH activity was smaller in brain and skin compared to other tissues. There was 
no decline in the activity of NADH dehydrogenase in brain and skin. In the kidney 
and heart, neither SDH nor NADH dehydrogenase activities decreased. Levels of 
flavins decreased significantly in the liver in the first two weeks of riboflavin 
deficiency. Although FAD levels were more conserved than FMN levels due to 
increased activity of FAD synthetase in the liver, the FAD levels were not 
maintained to the same extent as in other tissues. The activity of flavokinase was 
decreased early on in the liver, which led to a greater concentration of riboflavin than 
FMN in this tissue. In the kidney, the decline in flavin levels was less steep, and 
FAD levels were also preferentially maintained (Prentice & Bates, 1981a).  
In man, nutritional riboflavin deficiency is most often chronic in nature and 
associated with suboptimal levels of riboflavin intake. Therefore, in a subsequent 
study of marginal chronic deficiency in rats, hepatic and renal flavin levels were 
proportional to dietary intake of riboflavin. FAD levels were again more conserved 
than FMN levels. SDH activity decreased with decreasing riboflavin intake in the 
liver, but this decrease was smaller or less specific in the brain, skin and intestine. 
The activity of NADH dehydrogenase declined in liver and intestine, but not in skin 
and brain. Despite large variability between tissues, marginal chronic riboflavin 
deficiency in the rat primarily affected the growth, food intake, tissue flavin levels 
and the glutathione reductase status. The second most affected parameter was SDH 
activity in the liver. Finally, the least sensitive variable was activity of NADH 
dehydrogenase in the liver. Overall, the kidney and brain were the least sensitive 
tissues amongst those assayed in the study (Powers, 2003; Prentice & Bates, 1981b). 
Another study showed that FAD levels fell to 25% of controls and FMN to less than 
5% of controls in riboflavin-deficient rats. In liver mitochondria, activity of NADH 
dehydrogenase was 35-50% of normal and that of SDH was 25% of normal. Oxygen 
consumption decreased by 34-48%, further suggesting that the MRC is impaired in 
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riboflavin-deficient liver (Burch et al., 1960). Riboflavin-deficient rats supplemented 
with riboflavin had improved mitochondrial respiration (Depeint et al., 2006). 
In a subsequent study, in addition to a reduction of 50% in the activity of liver SDH 
in riboflavin-deficient rats, the rates of mitochondrial oxidation via the FAD-
dependent dehydrogenases of succinate, beta-hydroxybutyrate, alpha-ketoglutarate, 
glutamate, and the complex I-linked substrates pyruvate and malate were also 
decreased by 50%. Although the MRC was impaired, the efficiency of oxidative 
phosphorylation was unaffected (Zaman & Verwilghen, 1975). A study by Hoppel et 
al. (1979) provided somewhat similar results. In accordance with other studies 
(Brady & Hoppel, 1985; Nagao & Tanakas, 1992), the most dramatic mitochondrial 
effect of moderate riboflavin deficiency in rat liver was on fatty acid β-oxidation 
(Hoppel et al., 1979). In comparison, the oxidation of non-fatty acid substrates such 
as succinate was affected only three weeks after the initiation of riboflavin 
deprivation. In contrast to previous studies, the oxidations of glutamate, pyruvate, 
and alpha-ketoglutarate were not affected (Hoppel et al., 1979). Overall, while fatty 
acid oxidation is clearly severely impaired in riboflavin deficiency in rats, oxidative 
phosphorylation is preserved; findings regarding the Krebs cycle are contradictory. 
The preservation of FAD levels in most tissues except liver is in agreement with 
previous findings in humans and monkeys of stable FAD levels after riboflavin 
deprivation and supplementation (Burch et al., 1956; Hustad et al., 2002). As 
mentioned in Section 6.1.4, levels of FAD and FMN had been determined to remain 
particularly stable in the brain during severe deficiency; this was associated with 
increased riboflavin transport into the brain to compensate for the decrease in brain 
flavin levels (Burch et al., 1956; Spector, 1980b; Spector & Johanson, 2006). These 
observations are consistent with the relative preservation of SDH and NADH 
dehydrogenase activities described herein in riboflavin-deficient rat brain. Although 
ATP production was preserved in brain during riboflavin deficiency, other less 
essential FAD and FMN-dependent pathways such as iron metabolism and the first 
step of fatty acid β-oxidation were affected (Depeint et al., 2006; Ross & Hansen, 
1992).  
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As expected given the role of FAD in recycling of the antioxidant glutathione and in 
protein folding, riboflavin deficiency was found to cause cell stress in vitro (Werner 
et al., 2005). Interestingly, glutathione reductase was determined to lose FAD faster 
than other enzymes involved in energy metabolism during riboflavin deprivation 
(Hustad et al., 2002; Ross & Hansen, 1992), therefore oxidative stress may occur 
early on in nutritional riboflavin deficiency. Within four days of growth in 
moderately riboflavin-deficient medium (3.1 nM), the activity of glutathione 
reductase decreased by 98% in HepG2 liver cells compared to those grown in 
riboflavin-replete medium (532 nM) (Werner et al., 2005). The resulting decrease in 
cellular levels of GSH was associated with increased DNA strand breaks and 
oxidative damage (Camporeale & Zempleni, 2003; Manthey et al., 2005). In an 
intestinal cell model of riboflavin depletion, defects in energy generation with 
inhibition of cell growth and reduced ATP levels were followed by an increase in 
ROS production (Lee et al., 2013). Not surprisingly, riboflavin was determined to be 
necessary for development of the gastrointestinal tract, and in adults with low 
riboflavin intake, there was impaired proliferation of crypt cells in the colon (Nakano 
et al., 2011).  
That nutritional riboflavin deficiency in humans is associated with relatively mild 
symptoms would suggest that the levels of riboflavin in the body are indeed tightly 
regulated (Foraker et al., 2003). Evidence from animal and cell models of riboflavin 
deficiency suggests that certain cells may adapt their rate of riboflavin uptake via the 
transporters according to the extracellular levels of riboflavin. In lymphoid cells, 
HepG2 liver cells, renal epithelial cells and Caco-2 intestinal epithelial cells, 
transport rates of riboflavin were elevated in moderately and severely riboflavin-
deficient medium compared to cells grown in medium with physiological and 
pharmacological levels of riboflavin (Camporeale & Zempleni, 2003; Kumar et al., 
1998; Said & Ma, 1994; Werner et al., 2005). As mentioned in Section 6.1.3, the 
mRNA expression of rRFVT3 was upregulated in the intestine of riboflavin-deficient 
rats (Fujimura et al., 2010). 
As most of the aforementioned studies were carried out in animal models or in cell 
lines, it is unclear whether these findings reflect the pathology of nutritional 
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riboflavin deficiency in humans (Olpin & Bates, 1982). In addition, the 
aforementioned in vitro and in vivo effects of nutritional riboflavin deficiency likely 
represent only a fraction of the consequences of nutritional riboflavin deficiency. As 
has been highlighted previously, FAD and FMN are components of a wide range of 
flavoproteins, which are involved in a large array of biochemical processes and are 
located in various cellular compartments including in the cytosol, peroxisome, 
lysosomes and mitochondria. The activity of any or all flavoproteins could 
theoretically be affected by reduced intracellular levels of riboflavin and its 
cofactors, as seen in nutritional riboflavin deficiency and BVVL (Henriques et al., 
2010; Lienhart et al., 2013; Massey, 2000; Powers, 2003). Since nutritional 
riboflavin deficiency usually occurs in conjunction with a deficiency of other 
vitamins rather than in isolation, the effect of additional deficiencies may influence 
the phenotype of nutritional riboflavin deficiency. In fact, it has been suggested that 
some of the features of nutritional riboflavin deficiency such as dermatitis may result 
from concomitant deficiencies of vitamins such as B6 and niacin (McCormick, 1989; 
National Research Council, 1998). 
In vitro studies have highlighted the variability in the riboflavin levels required by 
different cell types and tissues. While HepG2 liver cells and murine macrophage 
cells were found to be especially sensitive to deficiency with cell cycle arrest and 
apoptosis within four days of growth in 3.1 nM riboflavin medium (Manthey et al., 
2005; Mazur-Bialy et al., 2013), lymphoid cells were comparatively more resistant 
(Werner et al., 2005). The sensitivity of different tissues to deficiency may be 
different in humans. Indeed, it remains unknown whether ATP-generating pathways 
are also selectively preserved in the brain of riboflavin-deficient humans. 
7.1.6 Previous in vitro functional studies of mutations in SLC52A2 and 
SLC52A3 
As the discovery of the riboflavin transporter mutations in BVVL patients is 
relatively recent, very little work has been undertaken to elucidate the 
pathomechanisms of disease in BVVL. Indeed, little is known about the function of 
these proteins in the nervous system and how mutations in these genes affect the 
function of the transporter and lead to the BVVL phenotype.  
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In accordance with in vitro findings in fibroblasts of RR-MADD patients described 
in Section 7.1.4, Bosch et al. (2011) reported normal fatty acid oxidation results in 
fibroblasts of patients with SLC52A3 mutations when these cells were grown in 
medium with high concentrations of riboflavin; the authors had postulated that 
riboflavin in the cell medium may have corrected the defect. 
One study has examined the effects of clinically-relevant SLC52A3 mutations, 
including the p.Glu36Lys mutation identified in our cohort in Chapter 6, in human-
derived intestinal epithelial Caco-2 cells. They found a significant decrease in 
riboflavin uptake, which was apparently not due to a reduction in transcription and/or 
translation of SLC52A3 since mRNA and protein levels were similar in intestinal 
epithelial cells expressing the mutant and WT SLC52A3. Some of the mutant 
proteins (including p.Glu36Lys) were retained in the ER and not targeted to the 
plasma membrane (Nabokina et al., 2012). As previously mentioned in Section 6.1.3, 
certain mutations such as those located in the COOH terminal domain of RFVT3 
may affect its cell surface expression (Subramanian, Rapp, et al., 2011).  
Haack et al. (2012) found reduced riboflavin uptake when the SLC52A2 p.Leu123Pro 
and p.Leu339Pro mutations were expressed in HEK293 cells. In the Ciccolella et al. 
(2013) study, there was also reduced riboflavin uptake in fibroblasts of a patient with 
the p.[Gly419Ser];[Ser52Phe] mutations in SLC52A2, with residual activity at 29% 
of controls when cells were grown in low riboflavin medium (0.4 nM). In this 
patient, there was a significant reduction (45%) in the SLC52A2 mRNA expression, 
while the mRNA expression of SLC52A1 was unaffected; however, the protein levels 
of both RFVT1 and RFVT2 were undetectable. In vitro studies of the parents’ 
fibroblasts suggested that the p.Ser52Phe mutation may impair the SLC52A2 mRNA 
stability, while the p.Gly419Ser mutation may affect the protein function. The 
authors suggested that the reduction in protein expression of both the RFVT1 and 
RFVT2 transporters might suggest a potential cooperation between these two 
transporters. The two mutations identified in this patient are localised at a polar-xx-
polar motif, where the polar amino acids are serine residues, and a GxxxG motif; 
these were found in transmembrane helices 2 and 10 of the RFVT2 protein, 
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respectively. The authors proposed that these motifs might be needed for the 
formation of heterodimers with the RFVT1 protein (Ciccolella et al., 2013). 
Where this assay was performed, activities of MRC enzyme complexes in muscle 
were normal in patients with SLC52A2 and SLC52A3 mutations (Haack et al., 2012; 
Koy et al, 2012; Mégarbané et al., 2000). However, in some patients presenting with 
FL syndrome with no genetic diagnosis, muscle biopsies revealed a deficiency of 
MRC complexes I and III and decreased ATP production, however these results were 
not seen in patient fibroblasts. These patients also had elevated plasma lactate 
(Roeleveld-Versteegh et al., 2004). Elevations in lactate levels have been reported in 
some cases (Bosch et al., 2011; Dipti et al., 2005). Furthermore, the infant born to an 
SLC52A1-haploinsufficient mother was found to have lactic acidosis (Chiong et al., 
2007). Overall however, lactate levels in the blood and/or CSF have generally been 
reported to be normal in patients with SLC52A2 and SLC52A3 mutations, and in 
patients without a genetic diagnosis (Ciccolella et al., 2012; Koy et al., 2012; 
Mégarbané et al., 2000; Sathasivam et al., 2000; Voudris et al., 2002). Finally, 
although FAD is a cofactor for glutathione reductase as discussed in Section 7.1.3, 
one study found no difference in the blood levels of GSH and GSSG between 
SLC52A3 patients and controls (Ciccolella et al., 2012). 
Our collaborators, Dr Yonezawa and colleagues at the Kyoto University Hospital in 
Japan, have carried out a preliminary functional evaluation of some of the SLC52A2 
mutations identified in our BVVL genetic study. These results were included in our 
publication (Foley et al., 2014). Dr Yonezawa and colleagues determined the 3H-
riboflavin transport activities and protein expression in HEK293 cells transiently 
expressing the following SLC52A2 mutations: p.Trp31Ser, p.Gln234Stop, 
p.Ala284Asp, p.Tyr305Cys, p.Gly306Arg, p.Leu312Pro, and p.Leu339Pro. The WT 
and mutants had similar transfection efficiencies, as determined by RT-PCR. Cells 
expressing the p.Trp31Ser, p.Gln234Stop, p.Ala284Asp, p.Tyr305Cys, and 
p.Leu339Pro mutations displayed the greatest reduction in riboflavin uptake 
compared to WT cells. The p.Gly306Arg and p.Leu312Pro mutations showed a 
moderate but significant decrease in riboflavin transport compared with WT. 
Western blot on the crude membrane of the transiently expressing HEK293 cells 
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revealed that the expression levels of all SLC52A2 mutants were reduced compared 
to WT, except the p.Trp31Ser mutant which remained expressed near WT levels in 
the plasma membrane; the protein expression levels in the plasma membrane were 
well correlated with the riboflavin uptake data (Foley et al, 2014; Figure 7-1). 
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Figure 7-1 Functional studies of SLC52A2 mutations carried out by Dr Yonezawa 
and colleagues. (A) Uptake of 3H-riboflavin by HEK293 cells transfected with empty 
vector (Vector), WT SLC52A2 (WT), SLC52A2 (92G>C; W31S), SLC52A2 
(700C>T; Q234X), SLC52A2 (851C>A; A284D), SLC52A2 (914A>G; Y305C), 
SLC52A2 (916G>A; G306R), SLC52A2 (935T>C; L312P) and SLC52A2 (1016T>C; 
L339P). The cells were incubated with 5 nM 3H-riboflavin (pH 7.4) for 1 min at 
37°C. Each bar represents the mean ± standard error of the mean (SEM), n=3. Data 
were analysed by Dunnett’s two-tailed test after one-way ANOVA. *p < 0.05, ***p 
< 0.001 means significantly different from vector-transfected cells. #p < 0.05, ###p < 
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0.001 means significantly different from SLC52A2 (WT)-transfected cells. (B) 
Western blot analysis was performed using the crude membrane of HEK293 cells 
expressing empty vector, SLC52A2 (WT) and SLC52A2 variants. The crude 
membrane fractions were subjected to Western blotting using antibodies against 
FLAG and Na+/K+-ATPase. Na+/K+-ATPase was used as an IS. (C) RNA expression 
of SLC52A2 in HEK293 cells transfected with empty vector, SLC52A2 (WT) and 
SLC52A2 variants. RT-PCR analysis was carried out using specific primer sets 
(reproduced from Foley et al., 2014). 
7.2 Aims of this study 
Following our genetic investigation in a cohort of BVVL patients, the aim of this 
study was to understand how mutations in the SLC52A2-encoded riboflavin 
transporter RFVT2 lead to neurodegeneration, and specifically a sensory-motor 
neuropathy. Given that nutritional riboflavin deficiency has a very different clinical 
phenotype from that of BVVL, it was initially thought that the function of the 
riboflavin transporters was unlikely to be related to the disease mechanism (Green et 
al., 2010). That riboflavin supplementation improves the symptoms of BVVL 
patients supports the hypothesis that the disease is at least in part due to decreased 
availability of riboflavin and subsequently FMN and FAD, and that the role of the 
proteins as riboflavin transporters is likely to be important in disease pathogenesis 
(Bosch et al., 2011). In keeping with the role of FMN and FAD in cellular energy 
metabolism, mitochondrial dysfunction was primarily investigated as a potential 
pathway leading to neuronal damage in BVVL.  
Fibroblasts of selected patients from our cohort of BVVL patients with SLC52A2 
mutations were used in this study. Preliminary investigations in SLC52A2-KD SH-
SY5Y cells and in Slc52a2 and Slc52a3-KD primary mixed ventral horn cultures 
were also carried out. Investigating the disease pathomechanisms in BVVL may 
provide clues into novel BVVL-associated genes, and may help identify new 
therapeutic targets for this fatal infantile MND. Finally, elucidating the disease 
pathways in BVVL could help understand related MNDs such as ALS as well as the 
function of the mutated proteins. 
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7.3 Methods: SLC52A2 patient fibroblasts 
7.3.1 SLC52A2 patient, carrier and control fibroblasts 
Details regarding the source of the skin biopsies and establishment of patient, carrier 
and control fibroblast cultures are described in Sections 2.2.2 and 6.3.11. Five BVVL 
patient fibroblast lines (patients E1-E4 and I1), one p.Gly306Arg carrier fibroblast 
line (mother of patient E1) and three age-matched control fibroblast lines were 
available for study (see Section 2.2.2 for full details of control fibroblast lines). As 
determined in Chapter 6, patients carried the following mutations: E1: 
p.[Gly306Arg];[Gly306Arg]; E2: p.[Trp31Ser];[Leu312Pro]; E3: p.[Gln234Stop]; 
[Ala420Thr]; E4: p.[Gly306Arg];[Leu339Pro]; I1: p.[Tyr305Cys]; [Gly306Arg]. The 
mother of patient E1 carried the p.Gly306Arg mutation in the heterozygous state. 
Details of consent are available in Section 2.2.1. 
7.3.2 Cell culture of fibroblasts 
Fibroblast cells from control, p.Gly306Arg carrier, and patient fibroblasts were 
cultured as described in Section 2.2.3. 
7.3.3 Assessment of SLC52A2 messenger ribonucleic acid (mRNA) expression 
levels in fibroblasts  
Although gene expression studies carried out by Dr Mina Ryten at the ION had 
indicated that SLC52A2 is expressed in human fibroblasts (M. Ryten, personal 
communication), the RT-qPCR experiment carried out in this study also served to 
confirm that SLC52A2 is indeed expressed in human fibroblasts, and that, in this 
respect, this cell type is suitable to use for the experiments that follow. To assess 
whether the stability of the SLC52A2 mRNA was affected by the SLC52A2 variants, 
RNA was extracted from patient, p.Gly306Arg carrier, and control fibroblasts grown 
in regular DMEM, and cDNA was synthesized as described in Sections 2.2.9 and 
2.2.10. RT-qPCR of SLC52A2 was performed as detailed in Section 2.2.11. Details 
of the Taqman probes used for RT-qPCR of SLC52A2 and the housekeeping gene 
ACTB can be found in Section 2.2.11.  
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7.3.4 Optimisation of riboflavin concentration in fibroblast culture medium 
Based on studies of riboflavin-responsive diseases discussed in Section 7.1.4, which 
demonstrated that supraphysiological concentrations of riboflavin in the cell medium 
could correct the enzymatic defects in vitro, and given the improvement seen in 
BVVL patients upon administration of high-dose riboflavin, it was likely that any 
metabolic abnormalities would not be detectable in our patient fibroblasts if grown in 
regular cell medium which has a high riboflavin concentration (concentration in 
DMEM=1.06 M). However, as discussed in Section 7.1.5, if the medium is severely 
riboflavin-depleted, it will not be able to support normal fatty acid oxidation and 
other cellular functions for which riboflavin is required, both in healthy control cells 
as well as in patient cells. Therefore, it was necessary to establish the threshold of 
riboflavin concentration in the fibroblast culture medium which would uncover any 
potential defect in patient cells but which would not negatively affect control cells.  
For medium optimisation, MRC complex I and II activities were used as a measure 
of cell health in control fibroblasts grown in varying concentrations of riboflavin. 
Therefore, the activities of complexes I and II of the MRC as well as CS were 
assayed in control fibroblasts as described in Sections 2.2.15-2.2.17. Medium 
optimisation is detailed in Section 2.2.8. Unless otherwise specified, all fibroblast 
lines were grown for four days in modified DMEM containing physiological 
concentrations (12.6 nM) of riboflavin, followed by four days in modified DMEM 
which was either riboflavin-supplemented (300.6 nM) or low riboflavin medium (3.1 
nM). For assessment of ATP5β and GAPDH expression levels by Western blot, cells 
were grown for four days in physiological concentrations (12.6 nM) of riboflavin, 
followed by four days in low riboflavin medium (3.1 nM) only. 
7.3.5 Total protein determination 
The protein content of the cell lysates obtained from patient, p.Gly306Arg carrier, 
and control fibroblasts required for some of the experiments below was determined 
by the Bradford method as described in Section 2.2.7. 
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7.3.6 Assessment of human riboflavin transporter 2 (RFVT2) protein levels in 
fibroblasts 
To establish whether the SLC52A2 mutations affect the RFVT2 protein expression, 
the expression levels of endogenous RFVT2 protein were measured by Western blot 
in patient, p.Gly306Arg carrier, and control fibroblasts grown in regular DMEM as 
described in Section 2.2.22. 
7.3.7 Subcellular localisation of RFVT2 in fibroblasts 
To determine whether the SLC52A2 mutations cause mislocalisation of the plasma 
membrane RFVT2 protein, the subcellular localization of endogenous RFVT2 was 
assessed by immunocytochemistry in patient, p.Gly306Arg carrier, and control 
fibroblasts grown in regular DMEM, as detailed in Section 2.2.13. 
7.3.8 Uptake assay of [3H]-riboflavin in fibroblasts 
The effect of the SLC52A2 mutations on uptake of [
3
H]-riboflavin was assessed 
using scintillation counting in patient, p.Gly306Arg carrier, and control fibroblasts 
grown in modified DMEM with variable riboflavin concentrations, as described in 
Section 2.2.12.  
7.3.9 Assessment of intracellular FMN and FAD levels in fibroblasts 
To establish whether patient fibroblasts had reduced intracellular levels of FMN and 
FAD, FMN and FAD levels were measured by HPLC in patient, p.Gly306Arg 
carrier, and control fibroblasts, as described in Section 2.2.14. Peak integration and 
data analysis on the HPLC were performed with the help of Marcus Oppenheim. 
7.3.10 MRC complex I and II activities in fibroblasts 
To test for impaired activity of flavin-dependent complexes in SLC52A2 mutant 
fibroblasts, the activities of complexes I and II of the MRC as well as CS were 
assayed in patient, p.Gly306Arg carrier, and control fibroblasts, as described in 
Sections 2.2.15-2.2.17. 
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7.3.11 Basal ΔΨm measurement and response to inhibitors in fibroblasts 
TMRM was used to determine the Δψm, an indicator of mitochondrial state, by live 
cell imaging in patient, p.Gly306Arg carrier and control fibroblasts with and without 
inhibition of glycolysis, as explained in Section 2.2.18. The mechanism maintaining 
the Δψm was investigated by studying the sensitivity of the Δψm to selected 
mitochondrial inhibitors, including oligomycin, rotenone, and FCCP, as described in 
Section 2.2.18. 
7.3.12 Measurement of NADH redox index in fibroblasts 
To further study the functional effect of SLC52A2 mutations on the activity of the 
MRC as well as the rate of substrate supply, the resting levels of NADH 
autofluorescence were measured using an epifluorescence inverted microscope in 
patient, p.Gly306Arg carrier and control fibroblasts, as described in Section 2.2.19. 
The NADH redox index was calculated by calibration of the NADH fluorescence 
signal with the mitochondrial inhibitors NaCN and FCCP, as described in Section 
2.2.19. 
7.3.13 Assessment of ATP-synthase β (ATP5β) and glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) levels in fibroblasts 
To determine whether SLC52A2 patient fibroblasts increase their rate of glycolysis to 
compensate for a potential impairment in energy production, the expression levels of 
ATP5β, a subunit of the mitochondrial ATP-synthase/complex V, and GAPDH, a 
glycolytic enzyme, were assessed by Western blot in patient, p.Gly306Arg carrier 
and control fibroblasts grown in low riboflavin medium, as described in Section 
2.2.22. 
7.3.14 Quantification of CoQ10 levels in fibroblasts 
To investigate a potential effect of SLC52A2 mutations upon CoQ10 status, CoQ10 
content was determined in patient, p.Gly306Arg carrier and control fibroblasts using 
reversed-phase HPLC with UV detection or tandem mass spectrometry as described 
in Section 2.2.21. The majority of this work was performed by Dr Kate Duberley. 
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7.3.15 Assessment of lactate/pyruvate ratio in fibroblasts 
To further establish whether aerobic respiration is defective in SLC52A2 patient 
fibroblasts, the lactate/pyruvate ratio was measured in cell medium aliquots obtained 
from patient, p.Gly306Arg carrier and control fibroblasts, as described in Section 
2.2.20. This assay was performed by the Neurometabolic Unit at the NHNN. 
7.3.16 Statistical analysis 
For the experiments in fibroblasts, all statistical analyses were performed separately 
for the riboflavin-supplemented and low riboflavin conditions. For the statistical 
analysis of most experiments, the data had to be normalized to the average of the 
controls in order to eliminate variability between experiments (riboflavin-
supplemented and low riboflavin considered independently). However, wherever 
possible and for graphical purposes only, the data were normalized to the average of 
the controls in both riboflavin-supplemented and low riboflavin conditions combined 
in order to visualize the impact of the addition of riboflavin on the dependent 
variable. All results are expressed as mean ± SEM. Further details regarding the 
statistical analysis are provided in Section 2.5. 
7.4 Methods: SLC52A2-shRNA KD SH-SY5Y cells 
7.4.1 Cell culture of SH-SY5Y cells 
Human neuroblastoma SH-SY5Y cells were cultured as described in Section 2.3.2. 
7.4.2 Generation and transfection of SLC52A2-shRNA KD constructs 
After confirming by RT-PCR that SLC52A2 is expressed in SH-SY5Y cells (Section 
2.3.9), plasmid DNA for human pGIPZ lentiviral shRNAmir clones with empty 
control, scrambled control, and SLC52A2-targeting (SLC52A2-shRNA1 and 
SLC52A2-shRNA2) hairpin sequences was prepared as described in Sections 2.3.4-
2.3.6. Quality control was performed as described in Section 2.3.6. Empty control, 
scrambled control, and SLC52A2-shRNA KD cells were generated by stable 
transfection with subsequent puromycin selection, as described in Section 2.3.7. The 
two SLC52A2-KD shRNAs were either pooled or transfected as individual shRNAs. 
Sequences of shRNA clones are available in Appendix VII Table VII-3. 
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7.4.3 Assessment of KD in SLC52A2-KD SH-SY5Y cells 
To assess the level of SLC52A2-KD achieved, RNA was extracted from empty 
control, scrambled control, and SLC52A2-KD shRNA SH-SY5Y cells grown in 
regular DMEM, and cDNA was synthesized as described in Sections 2.3.8-2.3.9. 
RT-qPCR of SLC52A2 was performed as detailed in Section 2.3.10. Details of the 
Taqman probes used for RT-qPCR of SLC52A2 and the housekeeping gene ACTB 
can be found in Section 2.2.11.  
7.4.4 Total protein determination 
The protein content of cell lysates obtained from empty control, scrambled control, 
and SLC52A2-KD shRNA SH-SY5Y cells was determined by the Bradford method 
as described in Section 2.2.7. 
7.4.5 Optimisation of riboflavin concentration in SH-SY5Y culture medium 
Given the previously published findings showing correction of the metabolic defect 
upon riboflavin supplementation in fibroblasts of riboflavin-responsive patients 
(Section 7.1.4), an effect of riboflavin in the SH-SY5Y culture medium on our 
parameters of interest could not be excluded. It was again necessary to establish the 
threshold of riboflavin concentration in the SH-SY5Y culture medium which would 
uncover any potential defect in SLC52A2-KD shRNA cells, but which would not 
negatively affect empty and scrambled control shRNA cells. For medium 
optimisation, MRC complex I and II activities were used as a measure of cell health 
in empty control, scrambled control, and SLC52A2-KD shRNA (clones 1, 2 and 1+2 
combined) SH-SY5Y cells grown in varying concentrations of riboflavin. Therefore, 
the activities of complexes I and II of the MRC as well as CS were assayed in empty 
control, scrambled control shRNA and SLC52A2-shRNA KD clones in SH-SY5Y 
cells, as described in Section 2.3.14-2.3.16. Medium optimisation for SH-SY5Y cells 
is further detailed in Section 2.3.11.  
7.5 Methods: SLC52A2-mutant SH-SY5Y cells 
7.5.1 Cell culture of SH-SY5Y cells 
Human neuroblastoma SH-SY5Y cells were cultured as described in Section 2.3.2. 
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7.5.2 Generation and transfection of myc-DDK-tagged SLC52A2-mutant 
constructs 
To determine the pathogenic effect of the SLC52A2 mutations in SH-SY5Y cells, the 
open-reading frame of human SLC52A2 containing a C-terminal myc-DDK tag in a 
pCMV6 expression vector was purchased from Origene (USA). The following 
mutations were introduced by site-directed mutagenesis: c.92G>C (p.Trp31Ser), 
c.700C>T (p.Gln234Stop), c.916G>A (p.Gly306Arg), c.935T>C (p.Leu312Pro), 
c.1016T>C (p.Leu339Pro), and c.1258G>A (p.Ala420Thr). Primer sets used for the 
mutagenesis are available in Appendix VII Table VII-7. SH-SY5Y cells were 
transfected with an empty vector and vectors containing SLC52A2
WT
, SLC52A2
92G>C
, 
SLC52A2
700C>T
, SLC52A2
916G>A
, SLC52A2
935T>C
, SLC52A2
1016T>C
, and 
SLC52A2
1258G>A
 with subsequent stable selection with G-418 antibiotic. Detailed 
methods are available in Appendix II. 
Studies using the myc-DDK-tagged SLC52A2 mutant constructs in SH-SY5Y cells 
were not pursued further; instead, to maximise the impact of this PhD work, studies 
in primary mixed ventral horn cultures were prioritised as primary neuronal cells are 
a more appropriate model for in vitro studies of neurodegeneration. 
7.6 Methods: studies in wild-type (WT) primary mixed ventral horn cultures 
and WT mouse embryonic fibroblasts (MEFs) 
7.6.1 The riboflavin transporters in the mouse  
As mentioned in Section 6.1.3, the mouse has two riboflavin transporters, Slc52a2 
and Slc52a3, encoding mRFVT2 and mRFVT3, respectively. No orthologue 
encoding a third riboflavin transporter has been recognised in the mouse, therefore 
the third riboflavin transporter present in higher animals must have evolved more 
recently in evolution (Yao et al., 2013; Yonezawa & Inui, 2013). The protein 
mRFVT3 shares 41% identity with mRFVT2. The mouse mRFVT3 (NCBI 
Reference Sequence NP_081448.2) is the orthologue for the human RFVT3, with 
which it shares 75% identity. The mouse mRFVT2 (NCBI Reference Sequence 
NP_083919, ambiguously also called Gpr172b) is the orthologue for both the human 
RFVT1 and RFVT2, with which it shares approximately 80% of its amino acids 
(Yao et al., 2013; Yonezawa et al., 2008; Yonezawa & Inui, 2013). Characteristics of 
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riboflavin transport via the mRFVT2 and mRFVT3 have been previously described 
in Section 6.1.3. 
7.6.2 Culture of WT primary mixed ventral horn cultures 
Mixed ventral horn cultures from spinal cords of WT embryonic mice were obtained 
and cultured as described in Section 2.4.2. This work was performed with the help of 
Dr Bernadett Kalmar. 
7.6.3 Assessment of Slc52a2 and Slc52a3 mRNA expression levels in WT 
primary mixed ventral horn cultures and MEFs 
To establish the relative mRNA expression levels of Slc52a2 and Slc52a3 in WT 
primary mixed ventral horn cultures and WT MEFs, RNA was extracted from WT 
primary mixed ventral horn cultures and WT MEFs, and cDNA was synthesized as 
described in Sections 2.4.9-2.4.10. RT-qPCR of Slc52a2 and Slc52a3 was performed 
as detailed in Section 2.4.11. Details of the Taqman probes used for RT-qPCR of 
Slc52a2 and Slc52a3 as well as the housekeeping gene Actb can be found in Section 
2.4.11. 
7.6.4 Total protein determination 
The protein content of the lysates obtained from primary mixed ventral horn cultures 
was determined by the Bradford method as described in Section 2.4.13. 
7.6.5 Determining the effect of riboflavin deprivation on MRC complex I and 
II activities in WT primary mixed ventral horn cultures 
The WT primary mixed ventral horn cultures were grown for nine DIV in modified 
DMEM containing variable concentrations of riboflavin, as detailed in Section 2.4.2. 
Cells were also grown in regular CNB medium for comparison, as explained in 
Section 2.4.2. The activities of complexes I and II of the MRC as well as CS were 
assayed on cell lysates as described in Sections 2.4.14-2.4.16. 
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7.6.6 Determining the effect of riboflavin deprivation on basal ΔΨm in WT 
primary motor neurones 
TMRM was used to determine the Δψm by live cell imaging in WT primary motor 
neurones grown either in regular CNB medium, in riboflavin-supplemented or 99% 
riboflavin-deficient modified DMEM for nine DIV as described in Section 2.4.17. 
7.7 Methods: Slc52a2 and Slc52a3-KD in primary mixed ventral horn 
cultures 
7.7.1 Culture of primary mixed ventral horn cultures 
Mixed ventral horn cultures from spinal cords of WT embryonic mice were obtained 
and cultured as described in Section 2.4.2. This work was performed with the help of 
Dr Bernadett Kalmar. 
7.7.2 Generation of lentiviruses and viral transduction of shRNA constructs 
Plasmid DNA for empty control, scrambled control, Slc52a2-targeting (Slc52a2-1) 
and Slc52a3-targeting (Slc52a3-1 and Slc52a3-2) hairpin sequences were prepared as 
described in Section 2.4.4-2.4.6. Lentiviral particles for empty control, scrambled 
control, Slc52a2-targeting (Slc52a2-1) and Slc52a3-targeting (Slc52a3-1 and 
Slc52a3-2) hairpin sequences were generated by packaging in HEK293T cells, as 
described in Section 2.4.7. Empty control, scrambled control, Slc52a2-shRNA and 
Slc52a3-shRNA KD cells were generated by transduction of primary mixed ventral 
horn cultures, MEFs, or HEK293T cells, as described in Section 2.4.7. The viral titre 
was determined in HEK293T cells as well as in primary motor neurones as described 
in Section 2.4.8. 
7.7.3 Assessment of Slc52a2 and Slc52a3-KD in MEFs 
To assess the level of Slc52a2 and Slc52a3-KD achieved, RNA was extracted from 
MEFs transduced with either empty control, scrambled control, Slc52a2-KD 
(Slc52a2-1) or one of two Slc52a3-KD (Slc52a3-1 and Slc52a3-2) shRNA lentiviral 
vectors, and grown in regular CNB medium with subsequent puromycin selection, as 
described in Section 2.4.9. cDNA was synthesized and RT-qPCR of Slc52a2 and 
Slc52a3 was performed as detailed in Sections 2.4.10-2.4.11. Details of the Taqman 
 276 
probes used for RT-qPCR of Slc52a2 and Slc52a3 as well as the housekeeping gene 
Actb can be found in Section 2.4.11.  
7.7.4 Basal measurement and response to inhibitors in Slc52a2 and Slc52a3-
KD primary motor neurones 
TMRM was used to determine the Δψm by live cell imaging in primary motor 
neurones transduced with empty control, scrambled control, Slc52a2-KD (Slc52a2-1) 
or one of two Slc52a3-KD (Slc52a3-1 and Slc52a3-2) shRNA lentiviral vectors, and 
grown in 99% riboflavin-deficient modified DMEM for seven DIV as described in 
Section 2.4.17. The mechanism maintaining the Δψm was investigated by studying 
the sensitivity of Δψm to selected mitochondrial inhibitors, as described in Section 
2.4.17. 
7.7.5 Statistical analysis 
Statistical analysis was performed as described in Section 2.5. 
7.8 Results: SLC52A2 patient fibroblasts 
7.8.1 SLC52A2 mRNA expression levels in fibroblasts 
Patient E3 had significantly reduced SLC52A2 mRNA expression levels compared to 
controls (51.2 ± 4.8% of controls; p-value=0.00754). This finding is consistent with 
the fact that this patient carries a premature stop mutation (p.Gln234Stop) in the 
compound heterozygous state, which leads to NMD as described in Chapter 6. 
Although the SLC52A2 mRNA expression levels were also lower than controls in all 
other patients and in the p.Gly306Arg carrier, the reduction did not reach statistical 
significance in these individuals (patient E1: 89.2 ± 12.4% of controls; patient E2: 
78.9 ± 9.2% of controls; patient E4: 73 ± 8.5% of controls; patient I1: 81.4 ± 12.9% 
of controls; p.Gly306Arg carrier: 93.3 ± 16.3% of controls) (Figure 7-2). 
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Figure 7-2 SLC52A2 mRNA expression levels in patient, p.Gly306Arg carrier, and 
control fibroblasts. Results are expressed as mean ± SEM; data were normalised to 
control fibroblasts. Statistical analysis was carried out using one-way ANOVA with 
Dunnett’s post-hoc test; level of significance compared to control cells: **: p<0.01. 
Data are the mean of three separate PCR determinations performed on at least three 
different occasions. 
7.8.2 Intracellular FMN and FAD levels in fibroblasts 
All patients had reduced levels of FMN compared to controls when grown in low 
riboflavin medium. This reduction reached significance at the p<0.1 level for patient 
E3 (64.1 ± 7.6% of controls in low riboflavin medium; p=0.0736), at the p<0.05 
level for patient E4 (58.8 ± 1.6% of controls in low riboflavin medium; p=0.0308), 
and at the p<0.001 level for patient E2 and I1 (19 ± 3.6% and 36 ± 6.7% of controls 
in low riboflavin medium, respectively). The reduction was not significant in patient 
E1 (75.4 ± 19.4% of controls in low riboflavin medium). The p.Gly306Arg carrier 
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also did not have significantly reduced FMN levels in this condition (95.4 ± 13.9% 
of controls in low riboflavin medium).  
When cells were grown in riboflavin-supplemented medium, FMN levels were not 
significantly different from controls for patients E1, E3, E4 and I1 (patient E1: 115.5 
± 11.3%, patient E3: 128.9 ± 16.6%, patient E4: 70.7 ± 6.1%, and patient I1: 90.7 ± 
15.1% of controls in riboflavin-supplemented medium), as well as for the 
p.Gly306Arg carrier (134.9 ± 25.6% of controls in riboflavin-supplemented 
medium). FMN levels remained significantly lower than controls for patient E2 in 
the supplemented medium (58 ± 14.1% of controls in riboflavin-supplemented 
medium; p=0.0265). For all fibroblast lines including controls, the FMN levels were 
higher in the riboflavin-supplemented condition compared to the low riboflavin 
condition (Figure 7-3). 
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Figure 7-3 Intracellular FMN levels in patient, p.Gly306Arg carrier, and control 
fibroblasts. Results are expressed as mean ± SEM; for graphical purposes only, data 
were normalised to control fibroblasts in both media conditions combined. Statistical 
analysis was carried out using one-way ANOVA with Dunnett’s post-hoc test for 
each medium condition independently; levels of significance compared to control 
cells: “.”: p<0.1, *: p<0.05, ***: p<0.001. Data were generated from a minimum of 
three independent experiments. 
All patients had reduced levels of FAD compared to controls when grown in low 
riboflavin medium, although to varying extents. This reduction reached significance 
for patients E2 and I1 (28.7 ± 6.1% and 39.1 ± 7.1% of controls in low riboflavin 
medium, respectively; p<0.0001). The reduction was not significant in all other 
patients (patient E1: 79.6 ± 4.5%, patient E3: 79.1 ± 2.4%, patient E4: 75.8 ± 12.1% 
of controls in low riboflavin medium). The p.Gly306Arg carrier had mildly reduced 
FAD levels (90.7 ± 5.3% of controls in low riboflavin medium); this was not 
statistically significant. When cells were grown in riboflavin-supplemented medium, 
FAD levels remained significantly lower than controls for patient E2 (63.9 ± 16.5% 
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of controls in riboflavin-supplemented medium; p=0.0731). FAD levels were not (or 
no longer) significantly lower than controls for all other patients as well as the 
p.Gly306Arg carrier (patient E1: 100.6 ± 11.9%, patient E3: 115.1 ± 11.8%, patient 
E4: 90.8 ± 4.7%, patient I1: 92.9 ± 16.3%, p.Gly306Arg carrier: 114.6 ± 15.1% of 
controls in riboflavin-supplemented medium). For all fibroblast lines including 
controls, the FAD levels were higher in the riboflavin-supplemented condition 
compared to the low riboflavin condition (Figure 7-4). 
 
Figure 7-4 Intracellular FAD levels in patient, p.Gly306Arg carrier, and control 
fibroblasts. Results are expressed as mean ± SEM; for graphical purposes only, data 
were normalised to control fibroblasts in both media conditions combined. Statistical 
analysis was carried out using one-way ANOVA with Dunnett’s post-hoc test for 
each medium condition independently; levels of significance compared to control 
cells: “.”: p<0.1, ***: p<0.001. Data were generated from a minimum of three 
independent experiments. 
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7.8.3 MRC complex I and II activities in fibroblasts 
All MRC complex activities are expressed as a ratio to CS activity, a mitochondrial 
marker enzyme, to normalise for mitochondrial enrichment (Hargreaves et al., 1999). 
All patients had reduced activities of MRC complex I compared to controls when 
grown in low riboflavin medium. This reduction reached significance at the p<0.1 
level for patient E1 (47.3 ± 8.8% of controls in low riboflavin medium; p=0.0639) 
and at the p<0.05 level for patients E3 (24 ± 11.6% of controls in low riboflavin 
medium; p=0.0101), E4 (29.8 ± 10.6% of controls in low riboflavin medium; 
p=0.0195) and I1 (27.1 ± 8.9% of controls in low riboflavin medium; p=0.0144). The 
reduction was not significant in patient E2 (57.5 ± 20.1% of controls in low 
riboflavin medium). The complex I activity of the p.Gly306Arg carrier was not 
significantly different from controls in the low riboflavin medium (87.2 ± 50.1% of 
controls in low riboflavin medium). When cells were grown in riboflavin-
supplemented medium, MRC complex I activities were restored at least to control 
levels for all patients (patient E1: 151.3 ± 20.8% SEM, patient E2: 141.6 ± 20.1%, 
patient E3: 113.5 ± 29.4%, patient E4: 107.3 ± 35.5%, patient I1: 124.6 ± 27.4% of 
controls in riboflavin-supplemented medium). In the supplemented medium, 
complex I activity was also not significantly different from controls for the 
p.Gly306Arg carrier (142.2 ± 24.2% of controls in supplemented medium). For all 
fibroblast lines, the MRC complex I activity was consistently higher in the 
riboflavin-supplemented condition compared to the low riboflavin condition (Figure 
7-5). 
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Figure 7-5 MRC complex I activity in patient, p.Gly306Arg carrier, and control 
fibroblasts. All MRC complex activities are expressed as a ratio to CS activity to 
normalise for mitochondrial enrichment (Hargreaves et al., 1999). Results are 
expressed as mean ± SEM; for graphical purposes only, data were normalised to 
control fibroblasts in both media conditions combined. Statistical analysis was 
carried out using one-way ANOVA with Dunnett’s post-hoc test for each medium 
condition independently; levels of significance compared to control cells: “.”: p<0.1, 
*: p<0.05. Data were generated from a minimum of three independent experiments. 
All patients as well as the p.Gly306Arg carrier had reduced activities of MRC 
complex II compared to controls when grown in low riboflavin medium. This 
reduction reached significance at the p<0.05 level for patients E1 (53.8 ± 17.7% of 
controls in low riboflavin medium; p=0.0135), E3 (48.6 ± 2% of controls in low 
riboflavin medium; p=0.0155) and E4 (56.3 ± 15.2% of controls in low riboflavin 
medium; p=0.0495), at the p<0.01 level for patient I1 (42.5 ± 1.2% of controls in low 
riboflavin medium; p=0.0059), and at the p<0.001 level for patient E2 (33.5 ± 22.1% 
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of controls in low riboflavin medium; p=0.0003). The reduction was not significant 
in the p.Gly306Arg carrier (62.8 ± 11.9% of controls in low riboflavin medium).  
When cells were grown in riboflavin-supplemented medium, MRC complex II 
activities were no longer significantly different from controls for all patients (patient 
E1: 105 ± 4.5%, patient E2: 112.7 ± 22.3%, patient E3: 78.2 ± 14.1%, patient E4: 
88.4 ± 19.9%, patient I1: 89.3 ± 6.8% of controls in riboflavin-supplemented 
medium). In this condition, complex II activity was also not significantly different 
from controls for the p.Gly306Arg carrier (82.5 ± 32.1% of controls in supplemented 
medium). Again, for all fibroblast lines, the MRC complex II activity was 
consistently higher in the riboflavin-supplemented condition compared to the low 
riboflavin condition (Figure 7-6).  
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Figure 7-6 MRC complex II activity in patient, p.Gly306Arg carrier, and control 
fibroblasts. All MRC complex activities are expressed as a ratio to CS activity to 
normalise for mitochondrial enrichment (Hargreaves et al., 1999). Results are 
expressed as mean ± SEM; for graphical purposes only, data were normalised to 
control fibroblasts in both media conditions combined. Statistical analysis was 
carried out using one-way ANOVA with Dunnett’s post-hoc test for each medium 
condition independently; levels of significance compared to control cells: *: p<0.05, 
**: p<0.01, ***: p<0.001. Data were generated from a minimum of three 
independent experiments. 
7.8.4 Basal ΔΨm measurement and response to inhibitors in fibroblasts 
The Δψm serves as an indicator of mitochondrial health and function. Accumulation 
of TMRM within the inner membrane of healthy mitochondria is driven by the ΔΨm; 
it leads to increased TMRM-associated red fluorescence. Therefore, intensity 
measurements indicate how well mitochondria are able to maintain the potential 
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across their membrane, and therefore serve to assess MRC function (Bartolome et 
al., 2013; Duchen, 2004). When cells were grown in low riboflavin medium, the 
TMRM fluorescence signal measured in the presence of glucose (normal conditions) 
was only significantly decreased compared to controls in patient I1 (85.1 ± 5.9% of 
controls in low riboflavin medium; p=0.0985), suggesting that basal Δψm was 
decreased in this patient. The TMRM fluorescence signal measured in the presence 
of glucose was not significantly different from controls in patients E1, E2, E3 and E4 
and in the p.Gly306Arg carrier in the low riboflavin medium (patient E1: 107.1 ± 
6.3%, patient E2: 102.3 ± 6.6%, patient E3: 106.1 ± 3.6%, patient E4: 110.9 ± 7.2%, 
p.Gly306Arg carrier: 100.7 ± 4.5% of controls in low riboflavin medium).  
When cells were grown in riboflavin-supplemented medium, the TMRM 
fluorescence signal was restored to control levels for patient I1 (109.5 ± 2.6% of 
controls in low riboflavin medium) and remained not significantly different from 
controls for patients E1, E3 and E4 as well as the p.Gly306Arg carrier (patient E1: 
100.7 ± 4.1%, patient E3: 104.2 ± 8.3%, patient E4: 110.8 ± 8.6%, p.Gly306Arg 
carrier: 105 ± 4% of controls in riboflavin-supplemented medium). Patient E2 had 
significantly higher TMRM fluorescence signal compared to controls in this medium 
(118.9 ± 5.9% of controls in riboflavin-supplemented medium; p=0.0132) (Figure 7-
7).  
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Figure 7-7 Basal ΔΨm in patient, p.Gly306Arg carrier, and control fibroblasts in the 
presence of glucose using TMRM in the redistribution mode. Results are expressed 
as mean ± SEM; data were normalised to control fibroblasts in each medium 
condition independently. Statistical analysis was carried out using one-way ANOVA 
with Dunnett’s post-hoc test for each medium condition independently; levels of 
significance compared to control cells: “.”: p<0.1, *: p<0.05. Data were generated 
from a minimum of 20 cells on a single coverslip in each of three independent 
experiments.  
To investigate the mechanism of maintenance of the ΔΨm in the patient fibroblasts, 
the sensitivity of the Δψm was assessed following the addition of selected 
mitochondrial inhibitors, including oligomycin (ATP-synthase inhibitor), rotenone 
(MRC complex I inhibitor), and FCCP (uncoupler of oxidative phosphorylation to 
obtain complete depolarisation). This experiment was carried out in the presence of 
glucose in the fibroblasts grown in the low riboflavin and riboflavin-supplemented 
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media. Results are expressed as the change in TMRM intensity after addition of each 
toxin as a percentage of basal intensity (basal=baseline Δψm – Δψm after FCCP). 
For the fibroblasts grown in the low riboflavin medium, patient E2 showed a 
significantly greater reduction in TMRM fluorescence intensity following addition of 
oligomycin compared to controls, although this was not consistent across 
experiments (13.6 ± 9.8% reduction in TMRM intensity, p=0.0791). Following 
addition of rotenone, patient E1 showed a significantly smaller reduction in TMRM 
fluorescence intensity compared to controls (48.9 ± 13.3% reduction in TMRM 
intensity, p=0.0646). Responses to FCCP for patient fibroblasts grown in low 
riboflavin conditions did not differ significantly from controls; although patient E1 
did had a comparatively stronger depolarisation in response to FCCP in this medium 
(45.2 ± 14.9% reduction in TMRM intensity), this did not reach statistical 
significance (Figure 7-8). 
For the fibroblasts grown in the riboflavin-supplemented medium, responses to 
oligomycin for patient fibroblasts did not differ significantly from controls. 
Similarly, responses to rotenone for patient fibroblasts did not differ significantly 
from controls; patient E1 had a comparatively smaller depolarisation in response to 
rotenone in this medium (39.2 ± 2.8% reduction in TMRM intensity), however this 
was not statistically significant. Patient E1 showed a significantly greater reduction 
in TMRM fluorescence intensity following addition of FCCP compared to controls 
(62.9 ± 5% reduction in TMRM intensity, p=0.0783) (Figure 7-8). Representative 
TMRM traces from patient E2 and control-1 in low riboflavin medium and in the 
presence of glucose are shown in Figure 7-9. 
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C. 
 
D. 
Fibroblast line Low riboflavin
Riboflavin-
supplemented Low riboflavin
Riboflavin-
supplemented
Low 
riboflavin
Riboflavin-
supplemented
C1 1.4 ± 2.4 % 3.1 ± 3.9 % 70 ± 9.2 % 72.7 ± 9.5 % 28.6 ± 7.1 % 24.1 ± 5.7 % 
C2 3.7 ± 2.3 % 4.9 ± 2.5 % 77.2 ± 11 % 62.6 ± 1.9 % 19 ± 8.8 % 32.5 ± 4.3 % 
C3 -2.3 ± 2 % -2.2 ± 1.3 % 90.1 ± 8.1 % 77.8 ± 11.4 % 12.2 ± 6.2 % 24.5 ± 10 % 
p.G306R carrier 5.5 ± 4 % 3.2 ± 6.1 % 63.2 ± 5.2 % 80.4 ± 12 % 24.5 ± 10.1 % 31.3 ± 1.4 % 
E1 p.[G306R];[G306R] 5.9 ± 2.1 % -2.1 ± 2.6 % 48.9 ± 13.3 % (.) 39.2 ± 2.8 % 45.2 ± 14.9 % 62.9 ± 5 % (.)
E4 p.[G306R];[L339P] 8.4 ± 3.6 % 0.7 ± 4.2 % 77.4 ± 7.4 % 57 ± 21.5 % 14.1 ± 5 % 42.3 ± 24 % 
E3 p.[Q234X];[A420T] 0.5 ± 2.5 % 6.3 ± 5.4 % 80 ± 5.4 % 73 ± 2.9 % 19.5 ± 7.4 % 20.7 ± 3 % 
E2 p.[W31S];[L312P] 13.6 ± 9.8 % (.) -0.5 ± 3.2 % 60 ± 10.3 % 85.3 ± 1 % 26.4 ± 9.8 % 15.1 ± 4.1 % 
I1 p.[Y305C];[G306R] 3.3 ± 3.2 % 0.8 ± 0.8 % 64.5 ± 11.7 % 69.5 ± 23 % 32.1 ± 10.9 % 29.7 ± 22.2 % 
Oligomycin Rotenone FCCP
 
Figure 7-8 Percentage decrease in TMRM intensity after addition of oligomycin (2 
g/ml; A), rotenone (10 M; B) and FCCP (1 M; C) in patient, p.Gly306Arg 
carrier, and control fibroblasts using TMRM in the redistribution mode and in the 
presence of glucose. Negative values indicate hyperpolarisation. Results are 
expressed as mean ± SEM. Data were generated from 10-15 cells on a single 
coverslip in each of three independent experiments. Statistical analysis was carried 
out using one-way ANOVA with Dunnett’s post-hoc test for each medium condition 
independently. Values of percentage decrease in TMRM intensity are shown in the 
table (D). Values in bold represent statistically significant results compared to 
controls; level of significance compared to control cells: “.”: p<0.1.  
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A. 
 
B. 
 
Figure 7-9 Representative TMRM traces (in the presence of glucose) from patient 
E2 (A) and control-1 (B) grown in low riboflavin medium showing responses to 
oligomycin (2 g/ml), rotenone (10 M) and FCCP (1 M). Data represent results 
from 10-15 cells on a single coverslip. Error bars represent the SEM. 
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In a follow-up experiment, glycolysis was inhibited by using glucose-free incubation 
medium supplemented with 2-deoxy-D-glucose for the duration of the TMRM 
experiment. Glycolysis was blocked to enhance the cells’ reliance on mitochondrial 
respiration via oxidative phosphorylation for ATP production, in the hope that any 
deficiency in respiration may become more evident. Fibroblasts have a high 
glycolytic capacity, thus a compensatory mechanism for defective respiration would 
be very efficient in these cells (Yao et al., 2011). The TMRM fluorescence signal 
measured in the absence of glucose was significantly decreased compared to controls 
in patients E1 (90.6 ± 2.9% of controls in low riboflavin medium; p=0.0077) and E2 
(92.9 ± 1% of controls in low riboflavin medium; p=0.0528) when cells were 
cultured in low riboflavin medium. Although not significant in the other patients, 
there was a general trend for decreased Δψm in patients and in the p.Gly306Arg 
carrier compared to controls in these conditions (patient E3: 94.9 ± 1%, patient E4: 
93.4 ± 4.3%, patient I1: 96.5 ± 2.6%, p.Gly306Arg carrier: 95.3 ± 4.6% of controls 
in low riboflavin medium).  
When cells were grown in riboflavin-supplemented medium, the TMRM 
fluorescence signal measured in glucose-free conditions was restored to control 
levels for all patients (patient E1: 98.6 ± 2.2%, patient E2: 105.5 ± 2.9%, patient E3: 
102.1 ± 4.4%, patient E4: 102.6 ± 3.3%, patient I1: 109.5 ± 3.7%, p.Gly306Arg 
carrier: 104.6 ± 4.6% of controls in riboflavin-supplemented medium); none of the 
patient fibroblast lines were significantly different from controls in this condition 
(Figure 7-10).  
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Figure 7-10 Basal ΔΨm in patient, p.Gly306Arg carrier, and control fibroblasts 
using TMRM in the redistribution mode and with inhibition of glycolysis.  Results 
are expressed as mean ± SEM; data were normalised to control fibroblasts in each 
medium condition independently. Statistical analysis was carried out using one-way 
ANOVA with Dunnett’s post-hoc test for each medium condition independently; 
levels of significance compared to control cells: “.”: p<0.1, **: p<0.01. Data were 
generated from a minimum of 20 cells on a single coverslip in each of three 
independent experiments. 
As before, the sensitivity of the Δψm was assessed in glucose-free conditions 
following the addition of selected mitochondrial inhibitors, including oligomycin, 
rotenone, and FCCP; this experiment was carried out only in fibroblasts grown in 
low riboflavin medium. Results are expressed as the change in TMRM intensity after 
addition of each toxin as a percentage of basal intensity. Patient E1 showed a 
significantly greater reduction in TMRM intensity following addition of oligomycin 
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compared to controls, although there was variability between experiments (17.6 ± 
14.7% reduction in TMRM intensity, p=0.0093). Upon subsequent addition of both 
rotenone and FCCP, responses for patient fibroblasts did not significantly differ from 
controls (Figure 7-11). Representative TMRM traces from patient E1 and control-3 
in low riboflavin medium and with inhibition of glycolysis are shown in Figure 7-12. 
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A. 
 
B. 
Oligomycin Rotenone FCCP
Fibroblast line Low riboflavin
Low 
riboflavin
Low 
riboflavin
C1 -5.3 ± 3.18 % 66.3 ± 11 % 39 ± 11.9 % 
C2 -3.3 ± 1.8 % 41.7 ± 5.2 % 61.7 ± 7 % 
C3 -1.4 ± 2 % 68.1 ± 5.9 % 33.3 ± 7.7 % 
p.G306R carrier -6.5 ± 1.7 % 63.8 ± 14.8 % 42.8 ± 16.5 % 
E1 p.[G306R];[G306R] 17.6 ± 14.7 % (**) 56.2 ± 7 % 26.2 ± 11 % 
E4 p.[G306R];[L339P] -5.9 ± 2.3 % 49.3 ± 5.9 % 56.7 ± 7.9 % 
E3 p.[Q234X];[A420T] -10.1 ± 0.73 % 60.1 ± 6.2 % 50 ± 5.7 % 
E2 p.[W31S];[L312P] -3.2 ± 1.9 % 53.4 ± 6.2 % 49.8 ± 7.2 % 
I1 p.[Y305C];[G306R] -1.8 ± 1 % 39.6 ± 3.7 % 62.1 ± 4.4 %  
Figure 7-11 Percentage decrease in TMRM intensity after addition of oligomycin (2 
g/ml), rotenone (10 M) and FCCP (1 M) in patient, p.Gly306Arg carrier, and 
control fibroblasts using TMRM in the redistribution mode and with inhibition of 
glycolysis (A). Negative values indicate hyperpolarisation. Results are expressed as 
mean ± SEM. Data were generated from 10-15 cells on a single coverslip in each of 
three independent experiments. Statistical analysis was carried out using one-way 
ANOVA with Dunnett’s post-hoc test. Values of percentage decrease in TMRM 
intensity are shown in the table (B). Values in bold represent statistically significant 
results compared to controls; level of significance compared to control cells: **: 
p<0.01.  
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A. 
 
B. 
 
Figure 7-12 Representative TMRM traces (with inhibition of glycolysis) from 
patient E1 (A) and control-3 (B) grown in low riboflavin medium showing responses 
to oligomycin (2 g/ml), rotenone (10 M) and FCCP (1 M). Data represent results 
from 10-15 cells on a single coverslip. Error bars represent the SEM. 
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7.8.5 NADH redox index and NADH pool in fibroblasts 
The redox state of NADH reflects the rate of substrate supply as well as the activity 
of the MRC (Bartolome et al., 2013; Duchen, 2004). As discussed in Section 7.1.2, 
complex I deficiency may lead to decreased electron transfer, reduced NADH 
oxidation, and accumulation of NADH (Duchen, 2004). To assess the redox state of 
NADH in the SLC52A2 patient fibroblasts, the NADH autofluorescence was 
monitored in all fibroblast lines and the NADH redox index was calculated as 
described in Section 2.2.19. Unfortunately, the FAD
2+
 redox state could not be 
assessed in the fibroblasts as these cells inherently have very low levels of FAD
2+ 
autofluorescence (Bartolome et al., 2013). 
When cells were grown in low riboflavin medium, the NADH redox index was 
significantly increased compared to controls in patient E2 only (172.7 ± 18.1% of 
controls in low riboflavin medium; p<0.0001). The NADH redox index was 
marginally increased compared to controls in patient E3 in this medium type (125.1 
± 8.5% of controls in low riboflavin medium), however this elevation did not reach 
statistical significance. The NADH redox index was as follows in the remaining 
patients and the carrier: patient E1: 94.9 ± 9.5%, patient E4: 117.2 ± 14.2%, patient 
I1: 113.6 ± 8.4%, p.Gly306Arg carrier: 108.2 ± 13.1% of controls in low riboflavin 
medium.  
When cells were grown in riboflavin-supplemented medium, the NADH redox index 
decreased to below control levels for patient E2 (73.8 ± 8.6% of controls in the 
supplemented medium). In this medium type, the NADH redox index was also not 
significantly different from controls for all other patients as well as the p.Gly306Arg 
carrier (patient E1: 105.3 ± 32.5%, patient E3: 94.5 ± 13.6%, patient E4: 84 ± 20.7%, 
patient I1: 71.6 ± 12.8%, p.Gly306Arg carrier: 107 ± 8.5% of controls in riboflavin-
supplemented medium) (Figure 7-13). 
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Figure 7-13 NADH redox index in patient, p.Gly306Arg carrier, and control 
fibroblasts. Results are expressed as mean ± SEM; for graphical purposes only, data 
were normalised to control fibroblasts in both media conditions combined. Statistical 
analysis was carried out using one-way ANOVA with Dunnett’s post-hoc test for 
each medium condition independently; level of significance compared to control 
cells: ***: p<0.001. Data were generated from a minimum of 20 cells on a single 
coverslip in at least three independent experiments. 
Representative traces of average NADH autofluorescence from patient E2 and 
control-1 grown in low riboflavin medium are illustrated in Figure 7-14. The trace 
for patient E2 displays an increased NADH redox index compared to control-1 under 
basal conditions. 
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A. 
 
B. 
Figure 7-14 Representative traces of average NADH autofluorescence from a 
minimum of 20 cells on a single coverslip in patient E2 (A) and control-1 (B) after 
addition of FCCP (2 μM) and NaCN (2 mM). The NADH redox index (the initial 
NADH autofluorescence expressed as a percentage of the range) is illustrated 
graphically. Both traces were obtained from cells grown in low riboflavin medium. 
Error bars represent the SEM. 
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The NADH pool indicates how effective the Krebs cycle is in making NADH in the 
mitochondria. The NADH pool was not statistically different between 
patients/p.Gly306Arg carrier and controls for cells grown in the low riboflavin 
medium (patient E1: 113.5 ± 9.9%; patient E2: 100.1 ± 15.6%; patient E3: 108.8 ± 
12.1%; patient E4: 95.1 ± 12%; patient I1: 123.1 ± 17.2%; p.Gly306Arg carrier: 98.9 
± 6.1% of controls in low riboflavin medium), as well as in the riboflavin-
supplemented medium (patient E1: 105.3 ± 10.4%; patient E2: 96 ± 9.9%; patient 
E3: 102.9 ± 10.8%; patient E4: 98.1 ± 10.8%; patient I1: 86.6 ± 7.9%; p.Gly306Arg 
carrier: 107.1 ± 13% of controls in riboflavin-supplemented medium) (Figure 7-15).  
 
Figure 7-15 NADH pool in patient, p.Gly306Arg carrier, and control fibroblasts. 
Results are expressed as mean ± SEM; data were normalised to control fibroblasts in 
each medium condition independently. Statistical analysis was carried out using one-
way ANOVA with Dunnett’s post-hoc test for each medium condition 
independently. Data were generated from a minimum of 20 cells on a single 
coverslip in each of three independent experiments. 
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7.8.6 ATP5β and GAPDH levels in fibroblasts 
The protein levels of ATP5β and GAPDH were qualitatively assessed by Western 
blot to establish whether SLC52A2 fibroblasts increase their rate of glycolysis 
relative to their rate of oxidative phosphorylation to maintain ATP levels (Yao et al., 
2011). Although this data was generated from only two independent experiments and 
was not quantified, the protein levels of GAPDH did not increase in patient and 
p.Gly306Arg carrier fibroblasts compared to controls when grown in low-riboflavin 
medium. The protein levels of ATP5β did not decrease in most patient fibroblasts 
compared to controls when grown in low-riboflavin medium, although patient E2 
and I1 had mildly reduced ATP5β levels compared to controls. Within each 
individual, the protein levels of ATP5β and GAPDH were comparable; only patient 
I1 displayed a possible, very mild increase of GAPDH expression relative to ATP5β. 
A representative Western blot is shown in Figure 7-16, with β-actin as a loading 
control.  
 
Figure 7-16 A representative Western blot of ATP5β and GAPDH expression in 
control, p.Gly306Arg carrier and patient fibroblasts grown in low riboflavin medium. 
The housekeeping protein β-actin was used as a loading control. Data were generated 
from two independent experiments. 
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7.8.7 CoQ10 levels in fibroblasts 
CoQ10 is an antioxidant and a mobile electron carrier which accepts electrons from 
MRC complexes I and II and from fatty acid β-oxidation, and transfers them to 
complex III. As discussed in Section 7.1.4, some MADD patients carrying ETFDH 
mutations have defective fatty acid β-oxidation and reduced activity of complexes I, 
II-III and IV, along with secondary CoQ10 deficiency; the explanation for this 
secondary CoQ10 deficiency remains unknown, although a negative feedback 
mechanism is one possibility amongst others which have been proposed, as discussed 
earlier in this Chapter (Gempel et al., 2007). With the decrease in FAD availability 
observed in patients with SLC52A2 mutations, the ETF:QO activity in the ETC 
would be expected to decrease along with the defect in fatty acid β-oxidation, which 
in turn may lead to a secondary CoQ10 deficiency in these patients (I. Hargreaves, 
personal communication). 
For the riboflavin-supplemented condition in this experiment, the CoQ10 levels of the 
controls differed significantly from each other (p<0.01) as determined by an 
ANOVA, therefore a Tukey’s two-tailed post-hoc test was performed for pairwise 
comparison between each control and patient/carrier individually. The highest p-
value resulting from each of the three control-patient and control-carrier comparisons 
was used to assess significance.  
The CoQ10 levels in controls grown in low riboflavin medium were 99.2 ± 11.3 
pmol/mg in control-1, 84 ± 4.4 pmol/mg in control-2, and 79.4 ± 1.9 pmol/mg in 
control-3. When grown in this medium, patient E1, E3, E4 and the p.Gly306Arg 
carrier had CoQ10 levels which were not significantly different from controls (patient 
E1: 93.5 ± 6 pmol/mg; patient E3: 113.9 ± 10.7 pmol/mg; patient E4: 84.7 ± 4 
pmol/mg; p.Gly306Arg carrier: 92.7 ± 10.4 pmol/mg); patient E2 had significantly 
reduced CoQ10 levels compared to controls in the low riboflavin medium (43 ± 15.8 
pmol/mg; 51.8% reduction; p=0.0029).  
When the cells were grown in riboflavin-supplemented medium, the CoQ10 levels in 
controls were 96.8 ± 19.2 pmol/mg in control-1, 94.6 ± 9.7 pmol/mg in control-2, 
and 69.3 ± 2.1 pmol/mg in control-3. In this medium type, CoQ10 levels were not 
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significantly different from controls for patient E1, E3, E4 and the p.Gly306Arg 
carrier (patient E1: 82.4 ± 21.6 pmol/mg, patient E3: 120 ± 18 pmol/mg, patient E4: 
79.3 ± 6.8 pmol/mg, p.Gly306Arg carrier: 89.3 ± 33.8 pmol/mg). CoQ10 levels were 
restored to control levels for patient E2 (94.3 ± 17.2 pmol/mg) (Figure 7-17). A 
reference range for CoQ10 levels in fibroblasts was established by Dr Kate Duberley 
using the tandem mass spectrometry method (57-121.6 pmol/mg; n=50) (Duberley et 
al., 2013). In agreement with our findings above, only the CoQ10 levels in patient E2 
fell below this reference range in the low riboflavin medium; after addition of 
riboflavin to the medium, the CoQ10 levels of this patient were within the reference 
range. 
 
Figure 7-17 CoQ10 levels in patient, p.Gly306Arg carrier, and control fibroblasts. 
Results are expressed as mean ± SEM; statistical analysis was carried out using one-
way ANOVA with Dunnett’s (low riboflavin) or Tukey’s (riboflavin-supplemented) 
post-hoc tests for each medium condition independently; level of significance 
compared to control cells: **: p<0.01. Data were generated from a minimum of three 
independent experiments. 
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In this study, all fibroblast lines except patient I1 were assessed using the tandem 
mass spectrometry method described in Section 2.2.21. Levels of CoQ10 in patient I1 
had to be assessed by the reversed-phase HPLC with UV detection method due to 
equipment unavailability. A study has compared the HPLC-UV and mass 
spectrometry methods; both methods were found to give similar results for CoQ10 
levels in muscle, indicating that these analytical methods may be comparable for 
CoQ10 measurements in this tissue. Although this has not been confirmed in 
fibroblasts, we tentatively had to use the reference range for fibroblasts established 
using the mass spectrometry method for patient I1. The CoQ10 level in patient I1 was 
180.7 ± 24.5 pmol/mg in low riboflavin medium and 189.7 ± 11 pmol/mg in 
riboflavin-supplemented medium. These values are above the upper limit of the 
reference range in fibroblasts determined by the mass spectrometry method; the 
higher CoQ10 levels observed for patient I1 are likely due to the different 
methodology used. However, it can reasonably be established that patient I1 does not 
have decreased CoQ10 in either medium condition. 
7.8.8 Lactate/pyruvate ratio in fibroblasts 
As discussed in Section 7.1.2, the cell may switch to anaerobic respiration when 
aerobic respiration is inefficient. In the process, pyruvate accumulates and is 
converted to lactate, leading to an increase in the lactate/pyruvate ratio (Bernsen et 
al., 1993; Grad & Lemire, 2006; Mackay & Robinson, 2007). In this experiment, for 
both the low riboflavin and riboflavin-supplemented conditions, an ANOVA 
suggested that the lactate/pyruvate ratio of the controls differed significantly from 
each other (p<0.01), therefore a Tukey’s two-tailed post-hoc test was performed for 
pairwise comparison between each control and patient/carrier individually. The 
highest p-value resulting from each of the three control-patient and control-carrier 
comparisons was used to assess significance.  
When fibroblasts were grown in low riboflavin medium, the lactate/pyruvate ratio 
was significantly increased compared to control-2 only in patient E2 (320 ± 80.8% of 
controls in low riboflavin medium; p=0.0188). The lactate/pyruvate ratio was 
increased compared to controls in patient E3 (210.2 ± 16.9% of controls in low 
riboflavin medium), although this increase did not reach significance with respect to 
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control-2. The lactate/pyruvate ratio was not significantly different from controls in 
the other patients and the carrier when grown in low riboflavin medium: patient E1: 
146.2 ± 10.4%, patient E4: 100.4 ± 11.9%, patient I1: 97 ± 35.7%, p.Gly306Arg 
carrier: 151.1 ± 13.5% of controls in low riboflavin medium. 
When cells were grown in riboflavin-supplemented medium, the lactate/pyruvate 
ratio was restored to below control levels for patient E2 (87.2 ± 14.1% of controls in 
riboflavin-supplemented medium). The lactate/pyruvate ratio was as follows in the 
other patients and the carrier grown in riboflavin-supplemented medium: patient E1: 
120.4 ± 10.6%, patient E3: 147.8 ± 20.5%, patient E4: 87.4 ± 12.5%, patient I1: 82.5 
± 28.2%, p.Gly306Arg carrier: 139.7 ± 22.3% of controls in riboflavin-supplemented 
medium. For all patients, the addition of riboflavin to the medium tended to decrease 
the lactate/pyruvate ratio (Figure 7-18). 
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Figure 7-18 Lactate/pyruvate ratio in patient, p.Gly306Arg carrier, and control 
fibroblasts. Results are expressed as mean ± SEM; for graphical purposes only, data 
were normalised to control fibroblasts in both media conditions combined. Statistical 
analysis was carried out using one-way ANOVA with Tukey’s post-hoc test for each 
medium condition independently; level of significance compared to control-2: *: 
p<0.05. Data were generated from a minimum of three independent experiments. 
7.9 Results: SLC52A2-KD SH-SY5Y cells 
Given the findings discussed in Section 7.1.6 of reduced riboflavin uptake in 
fibroblasts of BVVL patients and in cells transfected with clinically relevant 
riboflavin transporter mutations, we had hypothesised that the riboflavin transporter 
mutations may cause BVVL via a loss of function mechanism. Therefore, in an effort 
to model the potential disease mechanism in vitro, the SLC52A2 gene was transiently 
silenced in SH-SY5Y cells. The mRNA expression levels of SLC52A2 in SH-SY5Y 
cells transfected with SLC52A2-shRNA1 or SLC52A2-shRNA2 were 42.5 ± 3% and 
77.6 ± 8.2% of scrambled control, respectively. Therefore, the SLC52A2-shRNA2 
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was less efficient at knocking down SLC52A2 than SLC52A2-shRNA1. When the 
SH-SY5Y cells were transfected with both SLC52A2-shRNA 1 and 2 combined, the 
mRNA expression level of SLC52A2 was 41.2 ± 9.1% of scrambled control; 
therefore, pooling the two shRNAs only mildly improved the level of SLC52A2-KD 
in comparison to exclusively using the SLC52A2-shRNA1. The empty clone had 
similar SLC52A2 mRNA expression levels to the scrambled control clone (97.4 ± 6% 
of scrambled control) (Figure 7-19). It would be mathematically incorrect to test for 
statistical significance in this experiment as there is only a single control sample 
(scrambled control shRNA) which has zero variance (control is set at 100% on all 
experimental days). 
 
Figure 7-19 SLC52A2 mRNA expression levels in shRNA-transfected SH-SY5Y 
cells. Results are expressed as mean ± SEM. Data were normalised to the scrambled 
control shRNA. Data are the mean of three separate PCR determinations performed 
on at least three different occasions. 
To establish the riboflavin concentration in the medium that would unmask any 
defect in SLC52A2-KD shRNA cells without affecting the empty control and 
scrambled control shRNA cells, activities of complexes I and II of the MRC were 
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measured and used as a measure of cell health in empty control, scrambled control 
shRNA and SLC52A2-shRNA KD clones in SH-SY5Y cells. Five independent 
optimisation trials were carried out, as described in Section 2.3.11 and Appendix VII 
Table VII-5. In none of the experimental conditions did any of the SLC52A2-KD 
shRNA clones show a reproducible reduction in complex I and/or II activities. In all 
of the cell lines (empty control, scrambled control, and SLC52A2-KD shRNA (clones 
1, 2 and 1+2 combined) SH-SY5Y cells), there was a mild trend for reduced 
complex I and/or complex II activities in the low riboflavin concentration medium 
compared to the medium containing a higher riboflavin concentration, however this 
was not consistently the case. This latter finding is unexpected, and may suggest that 
SH-SY5Y cells are relatively resistant to riboflavin deprivation; this would be in line 
with previous studies in brain tissue which suggested that ATP production is 
relatively preserved in this tissue during riboflavin deficiency (Depeint et al., 2006; 
Ross & Hansen, 1992). 
Overall, the riboflavin concentration in the SH-SY5Y cell medium could not be 
successfully optimised. There are several possible explanations for these results, 
some of which may include: 1) insufficient KD, as haploinsufficiency (equivalent to 
50% KD) does not cause overt disease in humans, 2) KD was not efficient at the 
protein level; this could not be assessed due to poor antibody specificity, 3) in 
contrast to fibroblasts, SLC52A2 KD may not inherently lead to a decrease in 
complex I and/or II activities in SH-SY5Y cells, and 4) the optimisation protocol did 
not test the appropriate combination of extent and length of riboflavin deprivation. 
Studies in the SLC52A2-KD SH-SY5Y cells were not pursued further following 
these observations. 
7.10 Results: studies in WT primary mixed ventral horn cultures and WT 
MEFs 
7.10.1 Slc52a2 and Slc52a3 mRNA expression levels in WT primary mixed 
ventral horn cultures and WT MEFs 
As the relative mRNA expression levels of Slc52a2 and Slc52a3 in mouse tissues are 
relatively unknown, the mRNA expression levels of both mouse riboflavin 
transporters were measured in WT primary mixed ventral horn cultures and WT 
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MEFs. Results from two independent experiments show that the mRNA expression 
level of Slc52a3 was 94.8% of the mRNA expression level of Slc52a2 in WT MEFs. 
In WT primary mixed ventral horn cultures, the mRNA expression level of Slc52a3 
was 30.9% of the mRNA expression level of Slc52a2. Therefore, although both 
riboflavin transporters are expressed at very similar levels in WT MEFs, Slc52a2 is 
much more highly expressed than Slc52a3 in primary mixed ventral horn cultures. 
Examining the data further, it can be determined that the mRNA expression of 
Slc52a2 in WT primary mixed ventral horn cultures is 170.4% of that in WT MEFs; 
the mRNA expression of Slc52a3 in WT primary mixed ventral horn cultures is 
55.6% of that in WT MEFs. In other words, Slc52a2 is expressed at higher levels in 
WT primary mixed ventral horn cultures than in WT MEFs, and Slc52a3 is 
expressed at higher levels in WT MEFs than in WT primary mixed ventral horn 
cultures (Figure 7-20). 
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Figure 7-20 Slc52a2 and Slc52a3 mRNA expression levels as determined by RT-
qPCR in WT MEFs and primary mixed ventral horn cultures. Data were generated 
from two independent experiments. Units are arbitrary; data were normalised to 
100%.  
7.10.2 Effect of riboflavin deprivation on MRC complex I and II activities in 
WT primary mixed ventral horn cultures 
As a preliminary assessment of the sensitivity of WT primary mixed ventral horn 
cultures to riboflavin deprivation, cultures were grown in modified DMEM 
containing 1,005 nM riboflavin (=100% or no deprivation) and 502.5 nM riboflavin 
(50% deprivation). As in previous bioenergetics experiments, all MRC complex 
activities are expressed as a ratio to CS activity to normalise for mitochondrial 
enrichment (Hargreaves et al., 1999). When the WT primary mixed ventral horn 
cultures were grown for nine DIV in modified DMEM with 50% deprivation of 
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riboflavin, there was no decrease in MRC complex I and II activities compared to 
mixed ventral horn cultures grown in the riboflavin-supplemented medium (n=1) 
(Table 7-1).  
Table 7-1 MRC Complex I and II activities in WT primary mixed ventral horn 
cultures grown in riboflavin-supplemented and 50% riboflavin-deficient medium. 
Data were generated from a single experiment. 
Medium Type 
MRC Complex I 
activity 
MRC Complex II 
activity 
Riboflavin-
supplemented WT 
mixed ventral horn 
cultures 
0.061259606 0.052108236 
50% riboflavin-
deficient WT mixed 
ventral horn cultures 
0.065121624 0.052887169 
 
To further test the susceptibility of the mixed ventral horn cultures to riboflavin 
deficiency, the WT primary mixed ventral horn cultures were grown for nine DIV in 
modified DMEM with 99% deprivation (0.98 nM) of riboflavin; this caused a 
reduction in MRC complex I and II activities in deprived mixed ventral horn cultures 
(0.98 nM) compared to the riboflavin-supplemented mixed ventral horn cultures 
(1,005 nM). Residual activities of complexes I and II in riboflavin-deprived cells 
were 65.7 ± 6.2% and 84.1 ± 4.8% of cells grown in riboflavin-supplemented 
medium, respectively. It is mathematically incorrect to assess statistical significance 
in this case as the experiment has a single control sample (riboflavin-supplemented 
medium) which has no variance (control is set to 100% on all experimental days). 
Of note, simply changing the medium from regular CNB medium to riboflavin-
supplemented modified DMEM (both 1,005 nM riboflavin) caused a decrease in 
MRC complex I and II activities, although both media contained the same 
concentration of riboflavin (complex I and II activities of WT primary mixed ventral 
horn cultures in regular CNB medium: 195.8 ± 8% and 119.4 ± 13.2% of cells grown 
in riboflavin-supplemented medium) (Figures 7-21 and 7-22). Therefore, nutrients 
found in CNB medium and not in riboflavin-supplemented modified DMEM are 
essential for cellular energy metabolism.  
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Figure 7-21 MRC complex I activity in WT primary mixed ventral horn cultures 
grown in regular CNB medium, in riboflavin-supplemented modified DMEM (both 
1,005 nM), or in 99% riboflavin-deficient modified DMEM (0.98 nM). All MRC 
complex activities are expressed as a ratio to CS activity to normalise for 
mitochondrial enrichment (Hargreaves et al., 1999). Results are expressed as mean ± 
SEM; data were normalised to WT primary mixed ventral horn cultures grown in 
riboflavin-supplemented modified DMEM. Data were generated from a minimum of 
three independent experiments. 
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Figure 7-22 MRC complex II activity in WT primary mixed ventral horn cultures 
grown in regular CNB medium, in riboflavin-supplemented modified DMEM (both 
1,005 nM), or in 99% riboflavin-deficient modified DMEM (0.98 nM). All MRC 
complex activities are expressed as a ratio to CS activity to normalise for 
mitochondrial enrichment (Hargreaves et al., 1999). Results are expressed as mean ± 
SEM; data were normalised to WT primary mixed ventral horn cultures grown in 
riboflavin-supplemented modified DMEM. Data were generated from a minimum of 
three independent experiments. 
7.10.3 Effect of riboflavin deprivation on basal ΔΨm in WT primary motor 
neurones 
To determine whether the reduction in MRC complex I and II activities observed 
with 99% riboflavin deprivation causes an impairment in the maintenance of the 
Δψm in WT primary motor neurones, basal TMRM fluorescence was assessed in 
WT primary motor neurones grown in riboflavin-supplemented modified DMEM 
(1,005 nM), 99% riboflavin-deficient modified DMEM (0.98 nM), and regular CNB 
medium (1,005 nM). The TMRM fluorescence signal in WT primary motor neurones 
grown in 99% riboflavin-deficient medium was 96.9 ± 7.5% of the TMRM 
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fluorescence signal observed in those grown in riboflavin-supplemented medium. 
The TMRM fluorescence signal in WT primary motor neurones grown in regular 
CNB medium was 100.1 ± 5.5% of the TMRM fluorescence signal observed in those 
grown in riboflavin-supplemented medium (Figure 7-23). Again, it is mathematically 
incorrect to assess statistical significance in this case as the experiment has a single 
control sample (riboflavin-supplemented medium) with zero variance (control is set 
to 100% on all experimental days). However, these data strongly suggest that the 
basal Δψm is not affected by riboflavin deprivation in WT motor neurones. 
Figure 7-23 Basal ΔΨm in WT primary motor neurones grown in regular CNB 
medium, in riboflavin-supplemented modified DMEM (both 1,005 nM), or in 99% 
riboflavin-deficient modified DMEM (0.98 nM), using TMRM in the redistribution 
mode. Results are expressed as mean ± SEM; data were normalised to WT primary 
motor neurones grown in riboflavin-supplemented modified DMEM. Data were 
generated from a minimum of 5-10 motor neurones on 1-2 coverslips in each of a 
minimum of three independent experiments. 
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7.11 Results: Slc52a2 and Slc52a3-KD in primary mixed ventral horn cultures 
7.11.1 Viral titre in HEK293T cells and primary motor neurones 
The viral titres for the empty control, scrambled control, Slc52a2-KD (Slc52a2-1) 
and Slc52a3-KD (Slc52a3-1 and Slc52a3-2) shRNAs transduced into HEK293T cells 
were: 1.27 x 10
5
 TU/ml (empty control clone); 2.65 x 10
5
 TU/ml (scrambled control 
clone); 1.35 x 10
5
 TU/ml (clone Slc52a2-1); 2.58 x 10
5
 TU/ml (clone Slc52a3-1); 
1.15 x 10
5
 TU/ml (clone Slc52a3-2). Although the viral titre is officially the titre as 
determined in HEK293T cells, the titre in primary motor neurones was also 
determined as this cell type is more relevant to this study. The viral titres for the 
clones transduced into primary motor neurones were: 1.57 x 10
5
 TU/ml (empty 
control clone); 0.70 x 10
5
 TU/ml (scrambled control clone); 0.48 x 10
5
 TU/ml (clone 
Slc52a2-1); 2.06 x 10
5
 TU/ml (clone Slc52a3-1); 2.81 x 10
5
 TU/ml (clone Slc52a3-
2). Due to the poor transduction efficiency observed with all clones in the primary 
motor neurones, experiments were limited to single-cell measurements (single-cell 
TMRM); the activity of the MRC complexes could not be determined in the shRNA-
transduced mixed ventral horn cultures for this reason. 
7.11.2 KD efficiency in Slc52a2 and Slc52a3-KD MEFs  
With the aim of modelling SLC52A2 and SLC52A3-associated BVVL disease in 
primary neuronal cells, the mouse Slc52a2 and Slc52a3 riboflavin transporters were 
independently silenced in WT primary mixed ventral horn cultures. MEFs grown in 
regular CNB medium were used to assess KD efficiency, as this cell type is less 
susceptible than motor neurones to selection of transduced cells with puromycin 
antibiotic. The mRNA expression levels of Slc52a2 and Slc52a3 in Slc52a2-1 
shRNA MEFs were 64.7 ± 8.7% and 70.8 ± 8.5% of scrambled control, respectively; 
although this shRNA is intended to target Slc52a2, the mRNA expression of both 
mouse riboflavin transporters was affected to similar extents. The mRNA expression 
levels of Slc52a2 and Slc52a3 in Slc52a3-1 shRNA MEFs were 96.6 ± 32.6% and 
33.6 ± 6.4% of scrambled control, respectively, therefore this shRNA appropriately 
targeted Slc52a3 without affecting the mRNA levels of Slc52a2. Finally, the mRNA 
expression levels of Slc52a2 and Slc52a3 in Slc52a3-2 shRNA MEFs were 80.3 ± 
7.7% and 50.4 ± 5.3% of scrambled control, respectively. This shRNA targeted 
Slc52a3 and decreased its mRNA expression levels; however, the mRNA levels of 
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Slc52a2 were also marginally decreased with this shRNA. The empty control clone 
had similar Slc52a2 and Slc52a3 mRNA expression levels to the scrambled control 
clone (88.6 ± 5.9% and 94.5 ± 9% of scrambled control, respectively) (Figures 7-24 
and 7-25). The statistical significance cannot be assessed as the experiment has a 
single control sample (scrambled control shRNA) with zero variance (control is set 
to 100% on all experimental days).  
Figure 7-24 Slc52a2 mRNA expression levels in shRNA-transduced WT MEFs. 
Results are expressed as mean ± SEM. Data were normalised to the scrambled 
control shRNA. Data were generated from three independent experiments. 
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Figure 7-25 Slc52a3 mRNA expression levels in shRNA-transduced WT MEFs. 
Results are expressed as mean ± SEM. Data were normalised to the scrambled 
control shRNA. Data were generated from three independent experiments. 
7.11.3 Basal ΔΨm measurement and response to inhibitors in Slc52a2 and 
Slc52a3-KD primary motor neurones 
The Δψm was estimated in empty control, scrambled control, Slc52a2-KD and 
Slc52a3-KD primary motor neurones grown in 99% riboflavin-deficient modified 
DMEM (0.98 nM). Cultures were grown in this medium to avoid the risk of masking 
any defects with supplementation of riboflavin; furthermore, 99% riboflavin 
deprivation was not found to affect the Δψm in WT primary motor neurones (Section 
7.10.3). The TMRM fluorescence signal was 106.5 ± 15.9% of scrambled control for 
the Slc52a2-1 shRNA motor neurones, 97.1 ± 16.2% of scrambled control for the 
Slc52a3-1 shRNA motor neurones, and 100.6 ± 3.5% of scrambled control for the 
Slc52a3-2 shRNA motor neurones (Figure 7-26). The statistical significance cannot 
be assessed as the experiment has a single control sample (scrambled control 
shRNA) with zero variance (control is set to 100% on all experimental days).  
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Figure 7-26 Basal ΔΨm in Slc52a2 and Slc52a3-KD primary motor neurones grown 
in 99% riboflavin-deficient modified DMEM (0.98 nM), using TMRM in the 
redistribution mode. Results are expressed as mean ± SEM; data were normalised to 
scrambled control shRNA. Data were generated from a minimum of 3-8 transduced 
motor neurones on a single coverslip in each of four independent experiments. 
The sensitivity of the Δψm was assessed following the addition of oligomycin, 
rotenone, and FCCP in the empty control, scrambled control, Slc52a2-KD and 
Slc52a3-KD primary motor neurones grown in the 99% riboflavin-deficient modified 
DMEM. Results are expressed as the change in TMRM intensity after addition of 
each toxin as a percentage of basal (basal=baseline Δψm – Δψm after FCCP). None 
of the responses to oligomycin, rotenone, and FCCP in the Slc52a2-KD and Slc52a3-
KD mouse motor neurones were significantly different from scrambled control 
shRNA. Although the primary motor neurones transduced with shRNAs Slc52a3-1 
and Slc52a3-2 showed strong depolarisation after oligomycin compared to the 
scrambled control, this finding was not observed consistently across experiments and 
is therefore not statistically significant (Figure 7-27). 
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Furthermore, due to the very low transduction efficiency, these data represent only a 
total of three transduced motor neurones (single motor neurone in each of three 
independent experiments), and results are therefore extremely preliminary. In 
addition, the depolarisation observed after oligomycin, which is especially strong in 
cells transduced with shRNAs Slc52a3-1 and Slc52a3-2, is likely due to leakage of 
dye from the mitochondria as TMRM intensity was seen to decrease from the 
beginning of the experiment. Representative TMRM traces from scrambled shRNA 
and Slc52a3-2 shRNA are displayed in Figure 7-28. In conclusion, further 
experiments are required to be able to confidently draw conclusions regarding the 
potential reversal of ATP synthase in Slc52a2 and Slc52a3-KD motor neurones. 
 319 
A.
 
B. 
Oligomycin Rotenone FCCP
Clone
99% 
riboflavin 
deficient
99% 
riboflavin 
deficient
99% 
riboflavin 
deficient
Scrambled 6.5 ± 5.2 % 69.7 ± 15.6 % 23.9 ± 14.8 % 
Empty 8.2 ± 3.1 % 72.4 ± 8.3 % 19.4 ± 6.3 % 
shRNA Slc52a2-1 9.9 ± 2 % 79.3 ± 6.3 % 10.8 ± 4.8 % 
shRNA Slc52a3-1 20.1 ± 12.6 % 63.2 ± 13.7 % 16.7 ± 7.6 % 
shRNA Slc52a3-2 39.6 ± 21.4 % 44.8 ± 13.2 % 15.6 ± 8.2 % 
 
Figure 7-27 Percentage decrease in TMRM intensity after addition of oligomycin (2 
g/ml), rotenone (5 M) and FCCP (1 M) in empty control, scrambled control, 
Slc52a2-KD and Slc52a3-KD primary motor neurones grown in the 99% riboflavin-
deficient modified DMEM using TMRM in the redistribution mode. Results are 
expressed as mean ± SEM. Data were generated from a single motor neurone in each 
of three independent experiments (A). Statistical analysis was carried out using one-
way ANOVA with Dunnett’s post-hoc test. Values of percentage decrease in TMRM 
intensity are shown in the table (B). 
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A.
B. 
 
Figure 7-28 Representative TMRM traces from Slc52a3-KD (A) and scrambled 
control (B) primary motor neurones grown in the 99% riboflavin-deficient modified 
DMEM showing responses to oligomycin (2 g/ml), rotenone (5 M) and FCCP (1 
M). Data represent results from a single cell on one coverslip.  
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7.12 Discussion 
In this study, I primarily investigated the in vitro effects of SLC52A2 mutations on 
cellular energy metabolism and mitochondrial function using several approaches in 
fibroblasts of patients with SLC52A2 mutations. Furthermore, after determining the 
relative distribution of the two mouse riboflavin transporters in MEFs and primary 
mixed ventral horn cultures, I have performed preliminary studies to explore the 
effects on mitochondrial function of riboflavin deprivation in primary mixed ventral 
horn cultures. Finally, as a stepping ground for future studies, I have silenced the 
mouse riboflavin transporters Slc52a2 and Slc52a3 in mixed ventral horn cultures 
and have started assessing the impact on basal ΔΨm in these cells. 
7.12.1 Studies in SLC52A2 patient fibroblasts 
I have shown that patient E3 has significantly reduced levels of the SLC52A2 
transcript compared to controls. This patient carries the p.Gln234Stop mutation in 
the compound heterozygous state, which leads to a premature truncation codon and 
likely destabilizes the mRNA transcript via NMD (as found in Chapter 6), thus 
leading to decreased abundance of this transcript. All other patients had mildly 
reduced levels of the SLC52A2 transcript, especially patients E2, E4 and I1, 
suggesting that the stability of the SLC52A2 mRNA transcript may be reduced in 
some of these patients. 
In low riboflavin conditions, FMN levels were most strongly reduced in patients E2 
and I1, and moderately reduced in patients E3 and E4. The mild reduction in FMN 
levels in patient E1 did not reach significance. FAD levels were strongly reduced in 
patients E2 and I1, and mildly (not significantly) reduced in all other patients. The 
addition of riboflavin to the cell medium normalised the FMN and FAD levels in all 
patients, except for patient E2 in whom both FMN and FAD remained lower than 
controls. It should be noted that FMN and FAD were measured in whole cell lysates 
rather than isolated mitochondria, and therefore represent the cellular FMN and FAD 
content rather than the co-enzymes levels found in the mitochondria exclusively. 
MRC complex I activity in low riboflavin medium was strongly reduced in all 
patients except patient E2. However, patient E2 had the most prominent reduction in 
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MRC complex II activity, followed by patient I1. All other patients had moderately 
but significantly reduced complex II activities. Riboflavin supplementation caused 
MRC complex I and II activities to increase to control levels. 
Notably, patients E2 and I1 who had the most significant decreases in complex II 
activities in low riboflavin medium also had the two lowest FAD (as well as FMN) 
levels in this medium, which is in line with the role of FAD as an electron acceptor 
in complex II. Although complex I activity was not significantly decreased in patient 
E2, patient I1 had one of the lowest complex I activities compared to controls. 
Interestingly, although the riboflavin co-enzyme levels were not restored in patient 
E2 by addition of riboflavin to the medium, the complex I and II activities were 
successfully normalised to the control level in this patient. Patient E1 was the only 
patient for whom both FMN and FAD levels were not significantly decreased; this 
patient also showed some of the smallest decreases in complex I and II activities, 
suggesting that the p.Gly306Arg mutation may have a milder phenotype in vitro. 
Finally, as expected from previous studies discussed in Sections 7.1.4-7.1.5, the 
intracellular FMN and FAD levels as well as the MRC complex I and II activities 
were affected by riboflavin deprivation in the control fibroblasts as well, although to 
a lesser extent than in patient fibroblasts.  
As described in Chapter 6, the MRC complex activities (complexes I, II/III and IV) 
of patients E1, E2 and I1 (as well as patients E5, E6, E8 and A6) had been 
determined in muscle as part of our genetic investigation. E2 had mildly decreased 
complex IV activity (not measured in fibroblasts in this study), E6 had moderately 
decreased complex I activity, and I1 had moderately decreased complex II/III 
activity (see Chapter 6 for values). MRC complex activities were normal for patients 
E1, E5, E8 and A6. The reason for the discrepancy between findings in muscle and 
fibroblasts remains unclear. 
These biochemical deficiencies may provide a rationale for FL patients being 
previously diagnosed with mitochondrial cytopathy due to MRC defects in 
complexes I and II, and other FL patients showing ragged red fibres on muscle 
biopsy (Roeleveld-Versteegh et al., 2004; Spagnoli & De Sousa, 2011). 
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When TMRM was measured in the presence of glucose, the Δψm was significantly 
decreased only in patient I1 in the low riboflavin medium. Despite the difference in 
TMRM intensity being relatively small, a small decrease in the Δψm may still 
appreciably influence the function of the mitochondria and ATP production 
(Nicholls, 2002). It is worthy of note that this patient was also on the severe end of 
the spectrum with regards to FMN and FAD levels, as well as complex I and II 
activities. 
In these conditions, with the exception of patient I1, the decrease in activity of 
respiratory complexes I and II in patient fibroblasts was not sufficiently severe to 
cause a decrease in basal Δψm in patients when glucose was present. However, the 
Δψm in patient E2 was significantly decreased upon addition of oligomycin, 
suggesting that the Δψm may be maintained by ATP hydrolysis by the F1F0-ATPase, 
and that oxidative phosphorylation is impaired when this patient’s fibroblasts are 
grown in low riboflavin conditions. This patient had the most marked decrease in 
FMN and FAD levels, as well as complex II activities. The fact that a muscle sample 
from this patient showed reduced activity of the non-flavin dependent complex IV is 
quite notable; indeed, in Caenorhabditis elegans complex I deficiency due to 
complex I mutations was found to destabilise complex IV via an unknown 
mechanism, but possibly as a consequence of the effect of complex I deficiency on 
the Δψm and subse uent damaging effect on complex IV assembly (Grad & Lemire, 
2006). Impairment of complex IV has also been noted in RR-MADD patients. Since 
heme deficiency has been found to affect complex IV assembly and activity, in these 
patients it was suggested that impaired function of the FAD-dependent 
protoporphyrinogen oxidase, an enzyme of the heme biosynthetic pathway, may be 
responsible for the complex IV deficiency (Olsen et al., 2007).  
When the fibroblasts of patient E1 when grown in low riboflavin medium and 
TMRM was performed in the presence of glucose, there is a suggestion that this 
patient’s fibroblasts activated the complex II pathway, and switched from complex I 
to complex II. Indeed, the response to rotenone, a complex I inhibitor, was 
significantly smaller than in controls, and the response to FCCP (which represents 
the remaining contribution to the Δψm by complex II) was larger than in controls, 
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although the latter was not significant. In line with these findings, patient E1’s 
fibroblasts had a relatively mild decrease in complex II activity compared to controls 
and other patients.  
Upon supplementation of the medium with riboflavin, there was a trend for increased 
Δψm compared to controls, with normalisation of the Δψm in patient I1, and 
significantly increased Δψm in patient E2 compared to controls. The fibroblasts of 
patient E2 no longer operated in reverse mode, as blocking the proton channel of 
ATP synthase with oligomycin did not result in depolarisation in this case. With 
supplementation of riboflavin, compensation by complex II was once again apparent 
in patient E1. 
Interestingly, when cells were grown in low riboflavin medium, inhibiting glycolysis 
revealed a deficiency in maintaining the Δψm in patient E1 and E2, which was not 
evident when this experiment was carried out in the presence of glucose. Oligomycin 
caused a significant depolarisation in patient E1’s fibroblasts compared to controls; 
this would suggest that, instead of activating complex II as was seen in the presence 
of glucose, ATP synthase operates in reverse mode to try to maintain the Δψm in 
patient E1 when glucose is not available for efficient glycolysis. Patient E2’s 
fibroblasts no longer operated in reverse mode when glucose was absent. Growing 
these cells in riboflavin-supplemented medium corrected the Δψm in both patients 
E1 and E2 when measuring the Δψm with inhibition of glycolysis.  
The Δψm in the other patient fibroblast lines was not significantly different from 
controls when grown in low riboflavin medium and with inhibition of glycolysis, 
possibly due to endogenous glucose remaining. There is nonetheless a clear trend for 
reduced Δψm in all patient cell lines. It is possible that, when the cells are grown in 
low riboflavin conditions, glycolysis may help to compensate for a deficiency in 
MRC activity in most of the patient fibroblast lines. However, except for patient I1, 
Western blot analysis of ATP5β and GAPDH does not support the hypothesis that 
SLC52A2 patient fibroblasts increase their rate of glycolysis to compensate for a 
potential energy deficit when grown in low riboflavin medium. Although no fatty 
acids were present in the cell medium for the TMRM experiment, in vivo, increased 
fatty acid metabolism may also serve as a compensatory mechanism. 
 325 
It should be noted that, in all conditions, inhibition of complex I by rotenone caused 
an immediate partial depolarisation in all fibroblast lines including controls, 
suggesting that complex II was at least still partly functional. The mitochondrial 
uncoupler FCCP caused complete depolarisation in patient, p.Gly306Arg carrier and 
control fibroblasts, as expected. 
In the fibroblasts of patients E3, E4 and I1, the finding of a normal basal Δψm and 
lack of a response or slight hyperpolarisation to oligomycin in all experimental 
conditions suggest that ATP was not hydrolysed by the F1F0-ATPase and the Δψm 
was still maintained by the activity of the MRC with contribution from both 
complexes I and II in these cells (Abramov et al., 2010). As discussed in Section 
7.1.2, if the damage in the mitochondria is less severe, it is possible that the reverse 
mode was prevented from operating by overexpression of the IF1 protein in these 
cells (Cecchini, 2003; Duchen, 2004). Furthermore, whether the defect in MRC 
activities is severe enough to affect oxidative phosphorylation is thought to be 
dependent on the type of mitochondria affected (Pathak & Davey, 2008); it is 
possible that fibroblasts are relatively resistant to MRC damage. 
We observed a significant increase in NADH redox index compared to control cells 
in patient E2, and a very mild elevation in the NADH redox index in patient E3. The 
increase in basal levels of NADH in low riboflavin conditions may be due to 
increased substrate delivery and faster respiration, or to decreased NADH 
consumption due to slower respiration (Distelmaier et al., 2009; Gandhi et al., 2009). 
The latter would imply functional inhibition of complex I, which may be secondary 
to reduced substrate supply or to defective MRC complexes. Given the reduction in 
intracellular FMN and FAD levels and decreased MRC complex I and II activities, 
the latter explanation is more likely to account for the increase in NADH redox index 
in these two patients. In patient E2, this is consistent with the mild decrease in 
ATP5β protein expression witnessed by Western blot. In both patients E2 and E3, 
there was no activation of glycolysis relative to oxidative phosphorylation in low 
riboflavin medium on the Western blot, providing further evidence that increased 
substrate delivery is unlikely to account for the elevation in the NADH redox index 
in these cells. Finally, as there was no difference in the NADH pool between patients 
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and controls in either medium condition, this suggests that there is no deficit in the 
Krebs cycle in patient fibroblasts compared to controls, and reduced NADH supply 
is therefore improbable in patients E2 and E3. Therefore, respiration is probably 
inhibited in the fibroblasts of patients E2 and E3 in low riboflavin conditions.  
Riboflavin addition greatly lowered the NADH redox index in patient E2, potentially 
by activating respiration or by increasing the rate of glycolysis. Given that there is no 
significant difference in the NADH pool between patient E2 and control fibroblasts 
in the riboflavin-supplemented condition, substrate supply does not appear to be 
increased therefore it is perhaps more likely that riboflavin is able to normalise the 
NADH redox index by increasing the rate of respiration in this case. Inhibition of 
respiration as seen in fibroblasts of patients E2 and E3 under low riboflavin 
conditions is consistent with the increased lactate/pyruvate ratio observed in both of 
these patient cell lines in this medium and suggests that there is severe damage to the 
MRC in these patients, which is responsive to riboflavin supplementation. Although 
patient E2 did appear to operate in reverse mode to maintain the ΔΨm in low 
riboflavin conditions, it is surprising that the ΔΨm was maintained normally in 
patient E3 in these circumstances. 
CoQ10 levels were decreased only in patient E2 in low riboflavin medium; this defect 
was riboflavin-responsive as well. CoQ10 deficiency associated with low complex IV 
activity as seen in patient E2 has been previously observed in some patient biopsies; 
the reason for this association remains unclear (I. Hargreaves, personal 
communication). Secondary CoQ10 deficiency associated with decreased MRC 
complex activities and increased lactate levels, all of which were responsive to 
riboflavin, has been described in some RR-MADD patients with mutations in 
ETFDH. As previously discussed, CoQ10 deficiency in these patients has been 
suggested to result either from feedback inhibition, downregulation of CoQ10 
synthesis, or increased degradation of CoQ10. In patient E2, a loss of activity in 
ETFDH-encoded ETF:QO resulting from decreased intracellular FAD levels may 
also cause CoQ10 deficiency via one of the above mechanisms; alternatively, 
oxidative stress due to complex I and II inhibition may affect the CoQ10 levels 
(Cornelius et al., 2013; Gempel et al., 2007; Gregersen et al., 2008; I. Hargreaves, 
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personal communication). Indeed, as previously mentioned, high basal levels of 
NADH due to substrate accumulation in complex I are often associated with 
oxidative stress  (Abramov et al., 2010; Murphy, 2009). Finally, CoQ10 deficiency 
may be caused by a defect in the function of the FAD-dependent monooxygenase, 
which is needed for CoQ10 biosynthesis (Baker & Tarnopolsky, 2003; Lienhart et al., 
2013). 
Oxidative stress may also be a consequence rather than a cause of CoQ10 deficiency. 
CoQ10 deficiency in cells of patients with genetic defects of CoQ10 biosynthesis has 
been found to cause increased ROS production and cell death and/or defects of ATP 
synthesis depending on the magnitude of CoQ10 decrease (Quinzii et al., 2010). A 
decrease in CoQ10 may therefore cause oxidative stress in patient E2, further 
contributing to pathophysiology in this patient, however this remains to be 
investigated. 
It is worth mentioning that, although this was not statistically significant, CoQ10 
levels were increased in patient E3 compared to controls in the low riboflavin 
medium. This patient also displayed the greatest decrease in complex I activity. It 
may be that levels of CoQ10, an antioxidant, are increased in this patient to 
compensate for ROS production due to complex I inhibition. Again, levels of ROS 
would need to be assessed to confirm this hypothesis. 
In this study, patient fibroblasts carried the following mutations: patient E1- 
p.[Gly306Arg];[Gly306Arg]; patient E2- p.[Trp31Ser];[Leu312Pro]; patient E3-
p.[Gln234Stop]; [Ala420Thr]; patient E4- p.[Gly306Arg]; [Leu339Pro]; patient I1-
p.[Tyr305Cys];[Gly306Arg]. As described in Chapter 6, all of the mutations carried 
by the SLC52A2 patient fibroblasts studied here-in had been predicted not tolerated 
by SIFT and probably damaging by Polyphen-2, and all except p.Gln234Stop were 
located at amino acids highly conserved between species and in the other two 
riboflavin transporters. The p.Trp31Ser, p.Leu312Pro, p.Leu339Pro, and 
p.Ala420Thr mutations are located in transmembrane domains, the p.Gln234Stop 
variant is localised within an intracellular loop, and the p.Tyr305Cys and 
p.Gly306Arg are located in an extracellular loop (Section 6.4.1). 
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As discussed in Section 7.1.6, in vitro work by Dr Yonezawa and colleagues 
performed as part of our publication in Brain had found that HEK293 cells 
transiently transfected with the p.Trp31Ser, p.Gln234Stop, p.Tyr305Cys, and 
p.Leu339Pro mutations showed the strongest decrease in riboflavin uptake compared 
to WT, while the p.Gly306Arg and p.Leu312Pro mutations showed a moderate but 
significant decrease (p.Ala420Thr was not assessed). Protein expression of all 
mutants except p.Trp31Ser was decreased in the crude membrane fraction compared 
to WT, and was most reduced for the p.Gln234Stop and p.Leu339Pro mutants (Foley 
et al., 2014). In light of these findings, it is plausible that for most mutants besides 
p.Trp31Ser, the genetic defect causes impaired delivery of RFVT2 to the plasma 
membrane.  
Due to the poor quality and specificity of the commercial RFVT2 endogenous 
antibodies used for Western blot and immunocytochemistry, whether the SLC52A2 
mutations affected the protein expression and subcellular localisation of the RFVT2 
protein could not be assessed in the fibroblasts. Additional details regarding 
troubleshooting of these experiments are provided in Sections 2.2.13 and 2.2.22. 
Similarly, despite numerous trials, the uptake assay of [
3
H]-riboflavin using 
scintillation counting could not be successfully optimised; details are available in 
Section 2.2.12. 
It remains unknown whether the defects identified in this study in these patients 
extend to other tissues and whether they parallel the situation in vivo. In addition, as 
most patients in this study carried compound heterozygous mutations, it is difficult to 
dissect the effect of individual SLC52A2 mutations. However, such patient cell lines 
remain of substantial value because the mutations are in the context of a particular 
genetic background, which is unique to each patient (Distelmaier et al., 2009). 
Although fibroblasts are not neuronal cells and are not a particularly vulnerable 
tissue, metabolic and mitochondrial abnormalities are commonly studied in patient 
fibroblasts (Distelmaier et al., 2009; Olsen et al., 2007; Rhead et al., 1993). 
Given the relatively mild phenotype of the p.Leu312Pro mutation in HEK293 cells, it 
is somewhat surprising to note that this patient’s fibroblasts showed the most 
impressive defects. Clinically, patient E2 was also particularly severely affected; she 
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had her first symptom (ataxic gait) at one year of age, and prior to riboflavin therapy, 
was unable to sit, was ventilator-dependent, and could only be fed by gastrostomy. 
These observations would suggest that the p.Trp31Ser causes severe dysfunction 
despite still being expressed in the plasma membrane (Foley et al., 2014). The 
p.Trp31Ser mutation may cause an impairment in the regulation of riboflavin uptake 
or may directly inhibit RFVT2 function via an unknown mechanism (Chiong et al., 
2007). 
 
The milder phenotype of the p.Gly306Arg mutation in HEK293 cells is consistent 
with findings in the fibroblasts of patient E1 who carried this mutation in the 
homozygous state. This patient had the mildest reductions in riboflavin cofactor 
levels and in MRC complex activities. As evidenced by the TMRM results in the 
presence of glucose, patient E1’s fibroblasts may be able to activate the complex II 
pathway to maintain MRC function due to its relatively preserved levels of FAD, 
with this no longer being the case when glycolysis is inhibited. The fact that the 
p.Gly306Arg mutation causes only partial impairment of RFVT2 function and is 
found in most patients either in the homozygous or compound heterozygous state 
may suggest that partial RFVT2 function is necessary for survival. With these 
considerations in mind, as the fibroblasts of patient E3 had a mild phenotype in vitro, 
it is probable that the p.Ala420Thr retains at least partial function since the other 
SLC52A2 mutation carried by this patient (p.Gln234Stop) causes NMD associated 
with a severe reduction in riboflavin uptake in HEK293 cells (Foley et al., 2014). 
In vivo, in addition to differences arising from the nature of the mutations 
themselves, phenotypic differences between patients may also arise from variability 
in intracellular riboflavin homeostasis; indeed, differences in rates of tissue growth, 
metabolic demand, episodes of fasting, FMN and FAD synthesis, rate of catabolism 
of FAD and FMN, or differences in metabolism of FMN and FAD in the 
mitochondria and transport of these coenzymes into the mitochondria could all 
account for some of the inter-patient heterogeneity (Ross & Hansen, 1992; Vergani 
et al., 1999).  
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It is worth remembering that different tissues and cell types may respond differently 
to MRC defects, and it is usually very difficult to correlate patient phenotypes to 
results obtained in a cell culture system (Distelmaier et al., 2009). For example, two 
patients with isolated complex I deficiency and a similar disease course displayed 
substantially different physiological findings in fibroblasts; however, the authors 
noted that some exceptions can occur when a patient is very severely affected 
(Distelmaier et al., 2009), as seen for patient E2 in our study. It could also be argued 
that the fibroblast studies in this Chapter are not replicating the situation in vivo, as 
the cells need to be placed in what is considered to be riboflavin-deficient medium to 
show abnormalities, while patients develop a phenotype with normal dietary intakes 
of riboflavin.  
In addition, growing the fibroblasts in low riboflavin medium and with dialysed FBS 
(which lacks many other nutrients besides riboflavin) may cause a multitude of other 
effects not directly related to the riboflavin transporter defect (Lee et al., 2013). As 
riboflavin uptake is known to be modulated by extracellular levels of riboflavin 
available (Camporeale & Zempleni, 2003; Fujimura et al., 2010; Said & Ma, 1994; 
Said & Mohammed, 2006), it is also unclear whether patient and control fibroblasts 
would initiate similar up and downregulation of riboflavin uptake in low riboflavin 
and riboflavin-supplemented media, respectively. To circumvent these issues, 
lumiflavin, a structural analogue of riboflavin which competitively inhibits riboflavin 
transport but is not expected to affect riboflavin transporter mRNA expression, could 
have been added to the medium, as has been recently suggested (Lee et al., 2013). 
It should also be borne in mind that experiments in which cells derived from 
different sources (patient-derived and control fibroblasts) are being directly 
compared are subject to error, as variables unrelated to the disease state may 
influence the cells’ behaviour. In order to control for any such confounding variable, 
rescue experiments in which the patient fibroblasts are transfected with the WT 
SLC52A2 gene should allow us to determine whether the phenotype observed in the 
patient fibroblasts is actually due to loss of function of the mutated gene-encoded 
protein. Another possible source of error concerns the quantification of fluorescence 
by microscopy, specifically the large variability in the raw data values in different 
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cells and between experiments, reflected by the need to transform the data to 
percentages. Such data analysis renders it difficult to assess the significance of any 
observed decrease or increase in fluorescence. An internal control for the 
fluorescence within each well assessing potential confounds such as mitochondrial 
mass and mitochondrial localisation (for instance using the Mitotracker dye) would 
provide reassurance that the wells to be measured are comparable. Finally, as has 
been discussed previously, obtaining a commercial antibody to probe the function of 
the endogenous transporters is of utmost importance. The suitability of the available 
commercial antibody for RFVT2 could have been verified by transiently expressing 
epitope-tagged proteins in tissue cell lines. As mentioned in Section 7.5, myc-DDK-
tagged SLC52A2 mutant constructs were prepared during this PhD with the aim of 
transfecting the constructs in SH-SY5Y cells. Although this work was not carried out 
to prioritise studies in the mouse motor neurones, assessing the intracellular 
localisation of the RFVT2 riboflavin transporter in cells transfected with the WT and 
mutant epitope-tagged constructs would have certainly complemented the data on 
mitochondrial dysfunction in the fibroblasts. 
7.12.2 Studies in WT, Slc52a2 and Slc52a3-KD primary mixed ventral horn 
cultures 
Studies in WT, Slc52a2-KD and Slc52a3-KD mixed ventral horn cultures presented 
herein aimed only to provide a foundation for forthcoming studies in primary motor 
neurones. The relative mRNA expression levels of Slc52a2 and Slc52a3, encoding 
the two mouse riboflavin transporters mRFVT2 and mRFVT3 (orthologues of the 
human RFVT2/RFVT1 and RFVT3, respectively), were investigated in WT MEFs 
and WT primary mixed ventral horn cultures. It is interesting to note that both 
transporters were expressed at similar levels in the MEFs, while SLC52A3 is not 
expressed in fibroblasts in humans (Ciccolella et al., 2012). The mouse Slc52a2 was 
more highly expressed in WT mixed ventral horn cultures than in WT MEFs, and 
was expressed at higher levels than Slc52a3 in the mixed ventral horn cultures, 
which perhaps parallels the high expression of the human RFVT2 in the brain and 
spinal cord (Yao et al., 2010). 
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The susceptibility of WT primary mixed ventral horn cultures to riboflavin 
deprivation in the medium was then assessed. Although mixed ventral horn cultures 
were not affected by a decrease from 1,005 nM to 502.5 nM riboflavin (50% 
deprivation) after nine DIV, activities of complexes I and II for mixed ventral horn 
cultures grown in 0.98 nM riboflavin (99% deprivation) were approximately 66% 
and 84% of those grown in 1,005 nM riboflavin for nine DIV. In comparison, results 
of the medium optimisation in control human fibroblasts had shown that the 
threshold for maintaining the metabolism in control human fibroblasts lies between 
0.85 nM and 3.1 nM riboflavin in the medium (Section 2.2.8). 
Given the high energy demands, low levels of glycolysis, and reliance on oxidative 
phosphorylation in neurones (Burchell et al., 2010; Davey, 1998; Federico et al., 
2012; McInnes, 2013), one would expect motor neurones to be relatively sensitive to 
nutritional riboflavin deficiency. However it would seem that motor neurones are 
relatively resistant to riboflavin deprivation in the medium compared to fibroblasts, 
although a titration of riboflavin concentration should be performed in these cells to 
assess the exact threshold at which the MRC is impaired. Furthermore, after nine 
DIV motor neurones only represent approximately 40% of the mixed ventral horn 
culture, therefore it may be that other cells present in the lysate (interneurons, 
astrocytes, fibroblasts, etc.) may be more resistant to deficiency and mask a more 
substantial defect in the motor neurones. Alternatively, the reduction in complex 
activities may not be specific to motor neurones in this experiment. Finally, as 
complex activities were strongly affected by the switch from CNB to modified 
DMEM medium (both 1,005 nM riboflavin), it is possible that the lack of certain 
nutrients damaged the MRC to such an extent that the effect of riboflavin deficiency 
was rendered negligible and was underestimated.  
The decrease in complex I and II activities observed in mixed ventral horn cultures 
grown in 99% riboflavin-deficient medium as well as those grown in riboflavin-
replete modified DMEM did not translate to a reduction in basal Δψm compared to 
motor neurones grown in the CNB medium. As the TMRM experiments were 
performed by exclusively imaging motor neurones, other cells within the culture 
could not have masked a defect in maintaining the Δψm in motor neurones. Hence it 
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could be that the motor neurones are indeed resistant to riboflavin deficiency and that 
the decrease in complex activities was in fact not specific to motor neurones. 
Although an issue with the experimental procedure itself cannot be ruled out, another 
possibility is that complex I and II activities were actually affected by riboflavin 
deficiency, but that inhibition of complex activity was not sufficient to cause an 
impairment of Δψm and respiration; such thresholds have been previously described 
in brain mitochondria (Davey, 1998; Pathak & Davey, 2008) (Section 7.1.2). 
Similarly, Slc52a2-KD and Slc52a3-KD in primary motor neurones did not cause a 
reduction in the Δψm compared to scrambled control when cells were grown in 99% 
riboflavin-deficient medium, and the ATP synthase was not found to operate in 
reverse mode in these cells. However, this study was performed on very few motor 
neurones due to the poor transduction efficiency, therefore these results should be 
interpreted with caution. As the Δψm was not affected in WT motor neurones grown 
in 99% riboflavin-deficient medium, it is unlikely that the Δψm was already too 
greatly reduced by the nutritional riboflavin deficiency in scrambled control to 
uncover a difference with the Slc52a2-KD and Slc52a3-KD motor neurones. Some 
more likely explanations include that KD of the riboflavin transporters was not 
efficient in motor neurones since KD efficiency was only assayed in MEFs, that KD 
was insufficient to cause damage, or that it was not efficient at protein level. Another 
possibility is that the findings observed in fibroblasts do not recapitulate what is 
happening in motor neurones with deficiencies of riboflavin transport. 
7.12.3 Mitochondrial dysfunction in other neurodegenerative diseases 
Although defects in mitochondria were once thought to occur secondary to the 
primary disease mechanism, it is now thought that mitochondrial dysfunction may 
perhaps play a role in disease onset and evolution in certain neurodegenerative 
diseases (McInnes, 2013). Decreased activity of one or more MRC complexes and 
oxidative stress have been reported in tissues, cell models and/or animals models of 
Alzheimer’s disease, Parkinson’s disease and Huntington’s disease patients (Burchell 
et al., 2010; McInnes, 2013). Overall, it is still unclear whether mitochondrial 
dysfunction is a cause or consequence of the neurodegenerative process in these 
diseases (Federico et al., 2012). 
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Due to their high metabolic rate and role in neuromuscular activity, motor neurones 
are particularly susceptible to impaired energy metabolism (Cozzolino & Carrì, 
2012; Martin, 2011; Shaw, 2005). Deficiencies of cellular energy metabolism are 
thought to underlay neuronal damage in several MNDs such as SMA and ALS 
(Acsadi et al., 2009; Ciccolella et al., 2013; Martin, 2011). In a cell culture model of 
SMA, there was evidence of decreased ATP production and increased generation of 
ROS (Acsadi et al., 2009). Along with other mechanisms including impaired axonal 
transport and protein aggregation (Shaw, 2005), mitochondrial dysfunction with 
alteration of the MRC and increased oxidative stress are known to be involved in the 
pathomechanism of neurodegeneration in ALS patients (Cozzolino & Carrì, 2012; 
Federico et al., 2012; Martin, 2011). In the spinal cord of superoxide dismutase 1 
(SOD1) mutant mouse, before disease onset and during disease progression, there 
was evidence of decreased MRC complex activities, particularly in complex I in the 
ventral horn (Jung et al., 2002). Electron microscopy studies have revealed structural 
abnormalities in mitochondria in several tissues of ALS patients including spinal 
motor neurones (Martin, 2011). The findings that mutations in cytochrome c oxidase 
subunit 1 and in a mitochondrial tRNA gene were associated with an MND 
phenotype provide further evidence for the involvement of defective oxidative 
metabolism in ALS (Martin, 2011). Recently, mutations in valosin-containing 
protein (VCP), which plays a role in the ubiquitin-proteasome system and may be 
important for regulating cellular ATP levels, were found to cause AD ALS (Johnson, 
Mandrioli, et al., 2010). In vitro studies revealed that VCP deficiency causes 
mitochondrial depolarisation, mitochondrial uncoupling, decreased ATP production 
and increased mitochondrial respiration as evidenced by decreased basal levels of 
NADH (Bartolome et al., 2013).  
Interestingly, RT-qPCR in blood samples of ALS patients revealed decreased mRNA 
levels of FAD synthetase and other electron transport proteins including riboflavin 
kinase, cytochrome C1 (a subunit of complex III) and the complex II subunit SDHB. 
Of course, it remains possible that these changes occurred as a result of inactivity 
and downregulation of energy metabolism (Lin et al., 2009). On the basis that 
riboflavin is thought to improve energy efficiency in mitochondria and to bear 
antioxidant properties, SOD1 mutant ALS mice were treated with riboflavin; 
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riboflavin supplementation was not found to alter disease onset and progression in 
this study (Moges et al., 2009).  
As discussed in Section 1.6.1, the phenotypes of SMA and ALS may overlap with 
the BVVL phenotype (Horvath, 2012; Sathasivam, 2008). Furthermore, although 
motor neurones are affected the earliest and the most severely in ALS, ALS 
pathology is not exclusive to the motor system and may involve the sensory and 
spinocerebellar tracts as well (Shaw, 2005). It may be that there is an overlap in the 
pathways leading to neuronal vulnerability in BVVL and other MNDs and 
neuropathies. 
7.12.4 Disease mechanisms in BVVL versus nutritional riboflavin deficiency 
In vitro studies of riboflavin deprivation discussed in Section 7.1.5 as well as results 
from this study confirm that sufficient uptake of riboflavin is crucial for cellular 
energy metabolism in most cell types, and that fibroblasts of patients with SLC52A2 
mutations are even more susceptible than control fibroblasts to such a deficiency. A 
crucial question that has arisen from the discovery of riboflavin transporter mutations 
in BVVL patients is to explain why nutritional riboflavin deficiency and BVVL 
cause such disparate phenotypes despite both being associated with reduced levels of 
riboflavin in the body and deficient energy metabolism in vitro.  
As discussed in Section 1.6.4, nutritional riboflavin deficiency is usually only 
observed at the biochemical level. When the deficiency does manifest clinically, 
symptoms are usually mainly dermatological, although neuropathy has been 
observed in some cases (Depeint et al., 2006; Foraker et al., 2003; Powers, 2003; 
Spagnoli & De Sousa, 2011). It must be that unique disease pathways are likely to be 
operating in BVVL and nutritional riboflavin deficiency. Due to the involvement of 
the riboflavin cofactors in a wide array of biochemical reactions (detailed in Section 
1.6.6), it is probable that cellular systems and pathways are selectively or 
differentially affected by nutritional riboflavin deficiency or by a problem with 
transport of riboflavin (Henriques et al., 2010; Lienhart et al., 2013). An 
understanding of how the mechanism of disease in BVVL may differ from that of 
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nutritional riboflavin deficiency is crucial in providing additional therapy options for 
BVVL patients. 
Why is it, then, that BVVL patients present with a severe and complex phenotype of 
progressive pontobulbar palsy with bilateral sensorineural hearing loss, sensory-
motor neuropathy and respiratory insufficiency (Brown, 1894; Van Laere, 1966; 
Vialetto, 1936)? Since carrier fibroblasts in vitro as well as humans who are 
heterozygous carriers of an SLC52A2 mutation do not develop a phenotype, it must 
be that a certain bottom threshold of riboflavin uptake must be attained to cause 
disease. It is possible that RFVT2 has an additional, as-yet-unknown function in the 
nervous system which may account for the discrepancy with the phenotype of 
nutritional riboflavin deficiency. As described in Section 7.1.6, levels of FMN and 
FAD are selectively preserved in rat brain during severe riboflavin deficiency due to 
a compensatory increase in riboflavin uptake. Although upregulation of riboflavin 
transport following riboflavin deficiency has been observed in several cell types in 
vitro, preservation of the levels of riboflavin and its cofactors was the most striking 
in the brain (Burch et al., 1956; Camporeale & Zempleni, 2003; Fujimura et al., 
2010; Said & Ma, 1994; Said & Mohammed, 2006; Spector, 1980b; Spector & 
Johanson, 2006). As SLC52A2 is highly expressed in the brain, mutations in this 
transporter may compromise this compensatory mechanism in the brain of SLC52A2-
mutated BVVL patients. However, the extent to which SLC52A3 mutations could 
also affect regulation of riboflavin levels in the brain is unknown, as this transporter 
is only moderately expressed in the CNS (Yamamoto et al., 2009; Yao et al., 2010). 
In contrast, the FMN and FAD levels in the brains of patients with low dietary 
intakes of riboflavin might remain stable, thereby protecting the brain from 
nutritional riboflavin deficiency. Although depriving WT primary mixed ventral horn 
cultures of riboflavin led to a decrease in complex I and II activities, it was not 
associated with defects of Δψm maintenance in primary motor neurones. One of the 
key questions to answer is whether the MRC is damaged in neurones in vivo during 
nutritional riboflavin deficiency states. Although in vitro studies of riboflavin 
deprivation in animals had shown that the MRC was impaired (albeit this varied 
between tissues), the most dramatic effects were seen at the level of the less critical 
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FAD and FMN-dependent pathways, such as iron metabolism and fatty acid β-
oxidation (Depeint et al., 2006; Hoppel et al., 1979; Ross & Hansen, 1992). 
As previously mentioned, the highest levels of riboflavin cofactors are found in the 
kidney and liver (Burch et al., 1956; McCormick, 1989). SLC52A2 as well as 
SLC52A3 are not particularly highly expressed in these tissues (Yao et al., 2010). It 
is possible that kidney and liver are preferentially affected in nutritional riboflavin 
deficiency. Indeed, fatty degeneration of the kidney and liver has been observed in 
riboflavin deficiency states in animals (Foraker et al., 2003). Riboflavin deficiency in 
weanling rats caused increased gastrointestinal iron loss and altered gastrointestinal 
development; the latter was also seen in riboflavin-deficient humans and may in turn 
affect the absorption of a variety of other nutrients besides riboflavin (Nakano et al., 
2011; Powers, 2003). Deficiencies of iron handling are known be involved in the 
development of anaemia in riboflavin-deficient individuals, a symptom which is not 
seen in BVVL. As the levels of riboflavin in the intestinal lumen of BVVL patients 
are not expected to be altered with normal dietary intakes of riboflavin, this may 
explain why BVVL patients do not display symptoms of iron deficiency (Powers, 
2003). 
7.12.5 Riboflavin supplementation in vitro and in BVVL patients, and other 
potential therapies for BVVL 
How might riboflavin supplementation ameliorate the phenotype in SLC52A2-mutant 
fibroblasts and in BVVL patients despite the defect in riboflavin transport via 
RFVT2? Over-supplementation with riboflavin is thought to be associated with a 
downregulation of riboflavin transporters. This may explain why previous studies 
had noted that at higher intakes of riboflavin or when plasma concentrations were 
high (above 12 nM), transport mainly occurred by a passive diffusion mechanism 
(Feder et al., 1991; Foraker et al., 2003; McCormick, 1989). It is possible that in 
BVVL patients and in BVVL fibroblasts supplemented with high doses of the 
vitamin, riboflavin is transported across the cell membrane primarily via passive 
diffusion, thus circumventing the riboflavin transporter defect. However, several 
systems in the brain are thought to prevent excessive amounts of riboflavin from 
reaching the brain (Spector & Johanson, 2006); therefore, if riboflavin treatment 
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does manage to reach the brain in BVVL patients, this mechanism must somehow be 
bypassed if the therapy is to be effective. 
Another question which remains to be answered is whether or not expression of the 
other two riboflavin transporters is upregulated in patients with BVVL, and if so, 
why this does not compensate for defective riboflavin uptake via RFVT2. As 
discussed in Section 7.1.6, Ciccolella and colleagues (2013) had found that the 
SLC52A1-encoded RFVT1 transporter expression was decreased in the fibroblasts of 
a patient with SLC52A2 mutations, therefore in this case RFVT1 could perhaps not 
have compensated for deficient riboflavin uptake. However, other studies have not 
yet confirmed that RFVT1 and/or RFVT3 expression is decreased in patients with 
SLC52A2 mutations; this would warrant further investigation. It may be that RFVT1 
and RFVT3 expression is normal but that the uptake via these transporters is simply 
not optimised prior to riboflavin therapy in SLC52A2-mutated patients; this may be 
due to the relatively low expression of both these transporters in the CNS (Yao et al., 
2010). 
As discussed in Section 7.1.4, riboflavin therapy is effective in a wide range of 
metabolic and mitochondrial disorders. The mechanisms underlying this beneficial 
effect of riboflavin remain unknown, although various hypotheses have been put 
forward, as highlighted previously. Riboflavin supplementation may feed FMN and 
FAD molecules to complex I, complex II and/or to ETF:QO in the MRC, thus 
improving energy metabolism by providing electrons to CoQ. In addition to 
activating the MRC enzymes, riboflavin may also promote the synthesis or prevent 
the breakdown of the complexes (Bernsen et al., 1993). 
Although high-dose riboflavin therapy has only been trialled for extended periods 
and/or was started soon following symptom-onset in a relatively small number of 
BVVL patients (Anand et al., 2012; Bosch et al., 2011; Bosch et al., 2012; Ciccolella 
et al., 2012; Foley et al., 2014; Haack et al., 2012), it is unlikely that this therapy will 
be able to reverse damage which has already occurred and restore normal function in 
patients following motor neurone degeneration. Therefore, high-dose riboflavin 
should be administered as soon as possible following, or ideally prior to disease-
onset, to prevent further axonal damage (Foley et al., 2014). 
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Therapies that have been trialled in patients with mitochondrial disorders could 
possibly benefit BVVL patients. Indeed, due to the mitochondrial abnormalities 
observed in BVVL patient fibroblasts, CoQ10 or idebenone, an analogue of CoQ10 
(Kerr, 2013), could be trialled in BVVL. This therapy would be especially relevant in 
patient E2 who has decreased levels of CoQ10. CoQ10 treatment may increase the 
level of antioxidants and/or may foster the transfer of electrons from complexes I and 
II to complex III and thereby potentially bypass deficiencies in complex I and/or II 
(Baker & Tarnopolsky, 2003; Burchell et al., 2010; Mancuso et al., 2010; Spindler et 
al., 2009). In addition to those described in Section 7.1.4, CoQ10 deficiency has been 
reported in many neuromuscular and neurodegenerative disorders such as ALS, 
Alzheimer’s disease, Parkinson’s disease and Huntington’s disease, in which 
mitochondrial dysfunction and oxidative stress are thought to be involved. In patient 
fibroblasts, in in vitro models of oxidative stress, as well as in animal models of 
neurodegenerative diseases, there is limited evidence for neuroprotective effects of 
CoQ10. Small patient clinical trials have shown variable efficacy (Burchell et al., 
2010; Mancuso et al., 2010; Spindler et al., 2009).  
Additional potential therapies for BVVL may include other antioxidants besides 
CoQ10 such as vitamin C and E to target potential oxidative stress (Burchell et al., 
2010). In addition to administering antioxidants, oxidative stress could also be 
mediated by increasing the expression of endogenous antioxidants. Upregulation of 
nuclear respiratory factor 2 (Nrf2), which is part of the antioxidant response element 
/Nrf2/kelch-like ECH-associated protein 1 signalling pathway involved in regulation 
of expression of antioxidant enzymes, has been suggested as a potential treatment for 
Parkinson’s disease and other neurodegenerative diseases (Burchell et al., 2010). 
Finally, therapies for BVVL could also be directed at the bioenergetics dysfunction. 
One such example is dichloroacetate, a structural analogue of pyruvate which 
activates the pyruvate dehydrogenase complex and decreases lactate production 
arising from defective oxidative phosphorylation. Dichloroacetate was somewhat 
beneficial to some patients with congenital lactic acidosis in several clinical trials, 
although side effects were not negligible (Kerr, 2013). This therapy may be 
especially applicable to BVVL patients displaying an elevated lactate/pyruvate ratio 
as seen in this Thesis. Administration of creatine, which promotes ATP production 
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and may help compensate for energy deficiency, has shown some evidence of 
neuroprotection in studies of Parkinson’s disease and Huntington’s disease (Burchell 
et al., 2010).  
7.12.6 Future studies 
The work presented in this Chapter merely provides a basis for future studies that 
could be performed in vitro, some of which have already been mentioned. It would 
be interesting to determine whether the expression of the other riboflavin transporters 
is upregulated in BVVL patient fibroblasts. As mentioned previously, oxidative 
stress which may result from MRC complex inhibition, decreased CoQ10 levels, 
and/or decreased levels of the antioxidant glutathione (the recycling of which is 
FAD-dependent) should also be investigated in SLC52A2 patient fibroblasts by 
measuring ROS production both in the cytosol and mitochondrial matrix (Gandhi et 
al., 2009). Perhaps the most important studies to be performed next would involve 
measuring oxygen consumption and ATP levels to determine whether the MRC 
dysfunction is impairing oxidative phosphorylation. Examining the morphology of 
the mitochondria in vitro would also provide valuable information regarding the 
health of the mitochondria. It would also be valuable to determine whether 
concomitant addition of riboflavin with CoQ10 or other agents mentioned in Section 
7.12.5 to the fibroblast cell medium further improves the phenotype in vitro. Again, 
much work remains to be done in the primary mixed ventral horn cultures, and 
perhaps in dorsal root ganglion cultures given the sensory component of BVVL. 
High-dose riboflavin treatment in BVVL is still in its early days, and very little is 
known about the mechanism of riboflavin transport via RFVT2 in the brain 
(Moriyama, 2011; Yao et al., 2010). It is clear that the uptake mechanism in the 
CNS, the optimal riboflavin dose to be administered, and potential uptake enhancers 
should be investigated in models such as in primary motor neurones and in riboflavin 
transporter-knockout animal models. Uptake enhancers may include H-89, an 
inhibitor of the PKA pathway which was found to potentiate riboflavin uptake in a 
human-derived retinoblastoma cell line (Kansara et al., 2005). Studies should also be 
carried out to determine how to best optimise riboflavin uptake via the other two 
transporters and via passive diffusion (Foley et al., 2014). 
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7.13 Conclusion 
The recent identification of riboflavin transporter mutations has provided clues for a 
novel mechanism leading to neurodegeneration. The principal aim of this study was 
to begin to investigate the disease pathway in BVVL patients with SLC52A2 
mutations, with a particular focus on the effect of riboflavin transporter mutations on 
mitochondrial function. Compared to age-matched control fibroblasts, patient 
fibroblasts had decreased MRC complexes I and II activities as a possible 
consequence of a deficit in FMN and FAD status. One patient was found to have 
decreased CoQ10 along with an increased lactate/pyruvate ratio compared to controls. 
The Δψm was decreased in some patient fibroblasts, and was maintained by ATP 
hydrolysis by the F1F0-ATPase in certain cases. Inhibition of complex I as evidenced 
by an increased NADH redox index was most obvious in one patient. These deficits 
were rescued to varying extents upon treatment of the cells with riboflavin.  
Given the role of riboflavin, FMN, and FAD in maintenance of energy metabolism 
and antioxidant status, it is possible that this relatively novel genetic defect may have 
overlapping disease mechanisms with other MNDs with known involvement of 
mitochondrial dysfunction and oxidative stress. A more profound understanding of 
BVVL pathogenesis may also shed light on disease pathways in other 
neurodegenerative diseases and especially in MNDs, in which riboflavin therapy 
could potentially provide some benefit. 
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Chapter 8 General conclusions 
This Thesis has utilised a variety of genetics and molecular biology-based techniques 
to investigate two inherited peripheral neuropathies, CMT and BVVL.  
CMT is characterised by high phenotypic and genotypic heterogeneity; with the 
advent of novel sequencing technologies, the number of genes and loci associated 
with CMT has increased significantly in the past decade, thus complicating genetic 
diagnosis (Pandraud et al., 2012; Patzkó & Shy, 2011; Reilly et al., 2011; Rossor et 
al., 2013). Targeting genetic tests according to inheritance pattern, neurophysiology, 
outstanding phenotypic features, as well as frequency of CMT subtypes in particular 
ethnic backgrounds is therefore essential. Following diagnostic algorithms prevents 
the use of costly and unneeded genetic tests; these algorithms have proven extremely 
useful, whereby 70% of CMT patients have received a genetic diagnosis (Pareyson 
& Marchesi, 2009; Reilly et al., 2011; Rossor et al., 2013; Saporta et al., 2011). 
Nevertheless, the frequency of CMT subtypes has not been well established in many 
populations, especially that of the rare genes which are not routinely tested.  
To provide additional frequency data and expand phenotype-genotype correlations in 
CMT1, in Chapter 3, I have screened known CMT1-associated genes in CMT1 
patients from three populations: the UK, Greece, and the Yakutsk province in Russia. 
Mutation frequencies in the studied genes were generally in agreement with those 
previously reported in the literature. The genetic cause of disease remained unknown 
in many Greek CMT1 patients. Performing exome sequencing in these patients 
should uncover novel CMT-associated genes (Koutsis et al., 2013), though it remains 
possible that variants in non-coding regions of the genes or synonymous variants 
may have been disease-causing in these patients (Parmley & Hurst, 2007; Taioli, 
Cabrini, Cavallaro, Simonati, et al., 2011). Although future studies of this nature 
would likely benefit from using NGS instead of Sanger sequencing of single genes to 
enable more patients to be diagnosed, the cost of these technologies remains too 
prohibitive to use in large cohorts of patients at this time. Nonetheless, this study has 
widened the phenotypes associated with particular CMT genes/mutations, thus 
contributing to our understanding of the disease. This study also provided further 
evidence that, while in-frame deletions and duplications in PMP22 lead to CMT1, 
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nonsense mutations are generally associated with HNPP. In addition, although this 
study generated frequency data for only a few selected populations and CMT genes, 
it has enabled an important number of patients to receive a genetic diagnosis, and 
represents one of the few (Greek cohort) or only (Yakutsk cohort) studies on CMT 
subtype frequencies in these populations. Finally, this Chapter has gathered 
important natural history data for CMT. While identifying the genetic cause of 
disease is important for patient counselling and family planning, diagnosis will 
become imperative following the development of treatments specific to particular 
CMT subtypes and/or to shared mechanisms of peripheral nerve degeneration 
(Amato & Reilly, 2011; Bouhy & Timmerman, 2013; Pandraud et al., 2012; Reilly et 
al., 2011; Reilly & Shy, 2009). 
Another aim of Chapter 3 was to screen selected CMT genes in canines with 
naturally occurring peripheral neuropathy or NAD-CA. CMT-like neuropathies have 
been reported in many dog breeds (Granger, 2011). Canines with mutations in CMT 
genes would provide an animal model of peripheral neuropathy which may more 
closely parallel the human disease than models in other, more distant species 
(Karlsson et al., 2007). While no mutations were found, this study has provided a 
basis for future investigations, specifically in the Schnauzer and Papillon dogs for 
which a reasonable number of DNA samples are available for homozygosity 
mapping and/or whole genome sequencing. Recently, whole genome sequencing was 
used to identify the disease-causing gene in a single affected dog with AR 
spinocerebellar ataxia and unaffected controls (Gilliam et al., 2013). In the future, a 
similar study in our cohort of canines with peripheral neuropathies may give clues 
for novel human CMT genes.  
Chapter 4 focused on the most common subtype of CMT, CMT1A. While most 
CMT1A patients carry Chr17p11.2 duplications of the same size, it remains 
unknown why patients exhibit such marked intra- and interfamilial heterogeneity in 
disease severity, thus making patient counselling challenging in these families. 
Interfamilial variability was determined to be greater than intrafamilial variability in 
my CMT1A cohort, providing further evidence that genetic factors may be involved 
in modifying disease severity. In addition to providing more accurate counselling, 
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genetic modifying factors of the CMT1A phenotype could serve as drug targets 
(Reilly et al., 2011). 
Given the coexistent CIDP-like inflammatory features reported in several CMT1A 
cases, as well as evidence for the involvement of the immune system in several 
animal models of CMT, in this Chapter I performed an association study using an 
Immunochip to determine whether SNPs associated with immune-related 
mechanisms and diseases could influence disease severity in CMT1A. Overall, 
results of this study suggest that alleles associated with CIDP and with autoimmune 
and inflammatory diseases are unlikely to modify the CMT1A phenotype or to be 
involved more generally in CMT1A pathogenesis. Given these preliminary results 
and the fact that most CMT1A patients do not respond to immunosuppressant 
therapy (Ginsberg et al., 2004; Martini & Toyka, 2004), it seems unlikely that 
autoimmune involvement is common to most CMT1A patients. However, it remains 
possible that a superimposed inflammatory neuropathy may worsen the phenotype in 
a small subset of CMT1A patients. The association study did reveal a potential 
susceptibility locus for CIDP, located within an intron of the PXK gene, a gene 
containing known susceptibility loci for other autoimmune diseases including 
systemic sclerosis, rheumatoid arthritis, and SLE. This finding may suggest that 
CIDP shares some pathomechanisms with these diseases. The SNP within the PXK 
gene was found at a similar frequency in CMT1A and control cases, therefore it is 
unlikely to be associated with CMT1A. This study suffers from several limitations 
(discussed in Section 4.5.2), including a significant lack of power; top hits from all 
analyses should be replicated in a much larger study. However, although DNA for 
over 1,000 CMT1A patients may be readily available, it is difficult to acquire 
detailed phenotypes obtained in a consistent manner for all patients. Studies of 
CMT1A genetic modifiers performed by collaborators on our cases and others are 
now focusing on whole genome sequencing of CMT1A cases with phenotypes on 
either end of the severity spectrum. 
In Chapter 5, exome sequencing was used to search for the causative gene in two 
CMT families without a known genetic cause of disease. The shift from “first 
generation” Sanger se uencing to high-throughput NGS methods, including exome 
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and whole-genome sequencing (Choi et al., 2009; Metzker, 2010), has dramatically 
increased the number of CMT-associated genes and has expanded the CMT 
phenotype (Rossor et al., 2013). Despite these advances, a proportion of CMT 
patients still remain without a known genetic cause, especially in CMT2 (Rossor et 
al., 2013). In this study, two candidate genes, TBCEL and ARHGEF11, were retained 
for further genetic and functional studies to be performed by another member of staff 
as these findings are very preliminary. 
Perhaps equally important, the exome sequencing study in CMT has highlighted the 
benefits and disadvantages of this NGS technology which should be borne in mind 
prior to undertaking this type of study. It is important to remember that exome 
sequencing may miss variants due to insufficient coverage or to the nature or 
location of the mutation (Bamshad et al., 2011; Singleton, 2011). Furthermore, 
although novel gene finding by exome sequencing can be performed in single 
individuals or in only two family members (Singleton, 2011), these studies often 
result in long lists of variants of unknown pathogenicity despite extensive filtering. 
From our experience, unless linkage analysis was performed in parallel, our research 
group has usually had little success with exome sequencing in singletons and very 
small families. This problem is especially pertinent to CMT, for which causative 
genes may be ubiquitously expressed and are involved in a broad range of cellular 
functions (Patzkó & Shy, 2011; Scherer & Wrabetz, 2008). In addition, as is the case 
for variants identified via Sanger sequencing of single genes, it remains extremely 
difficult to prove pathogenicity of candidate genes identified via exome sequencing 
(Bamshad et al., 2011; Kochañski, 2006). To illustrate, in this Chapter I also 
attempted to provide additional evidence for the pathogenicity of a mutation in a 
previously identified candidate gene, MFF, by screening this gene in a cohort of 
CMT patients. Genetic and functional studies of this gene and another candidate 
gene TRAK2 have thus far been inconclusive and their pathogenicity is still 
uncertain. 
Although novel gene finding using exome sequencing does present some challenges, 
its advantages, including time and cost-efficiency, as well as the small amount of 
DNA required, are evident. This technology is particularly useful in diseases such as 
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CMT which are phenotypically and genetically heterogeneous with a large number 
of rare genes which could not reasonably be tested individually (Singleton, 2011). 
Following further reduction in cost and an improvement in the depth and coverage 
achieved, NGS technologies will surely be used in the diagnostic setting (Azzedine 
et al., 2012; Rossor et al., 2013). Finally, identifying novel CMT genes via NGS 
increases our understanding of the disease and provides clues for novel drug targets 
(Azzedine et al., 2012). 
Identifying novel genes via exome sequencing may be considered more 
straightforward for diseases with a clearer pathological process. For example, the 
finding of decreased plasma levels of riboflavin, FAD and FMN in BVVL patients, 
which was not attributable to a nutritional riboflavin deficiency (Bosch et al., 2011), 
suggested that riboflavin transporters may be involved in the pathological process of 
this severe infantile neuropathy. This theory was confirmed by our group and 
colleagues through the discovery of mutations in genes encoding riboflavin 
transporters using exome sequencing. These findings in turn led to the 
recommendation that high-dose riboflavin therapy should be trialled in BVVL 
patients, for whom no treatment had been available to date (Sathasivam, 2008). 
Shortly thereafter, I undertook a study (Chapter 6) to identify unrecognised BVVL 
cases by screening the three riboflavin transporters, thereby prompting the initiation 
of riboflavin therapy in patients found to carry mutations. Mutations in SLC52A2 
were more frequent than SLC52A1 and SLC52A3 mutations in patients with BVVL 
and BVVL-like disease. As all SLC52A3 mutations identified were in the 
heterozygous state, further studies are required to assess their pathogenicity. A 
significant proportion of the BVVL cohort did not carry mutations in any of the three 
genes, thus the next step would be to perform exome sequencing in these patients 
and their family members to search for novel genes. 
Patients with SLC52A2 mutations generally had a complex and severe phenotype 
including axonal sensory-motor neuropathy, respiratory insufficiency, optic atrophy, 
and bilateral sensorineural hearing loss with upper limb and trunk weakness but 
preservation of lower limb strength; most of these patients initially presented with 
ataxic gait or nystagmus. Importantly, all patients found to carry SLC52A2 mutations 
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were immediately treated with high-dose riboflavin therapy. Clinical and 
biochemical improvements were seen in most patients, however the earlier this 
therapy was initiated, the more likely it was to be effective. Therefore, early genetic 
screening of suspected BVVL patients is essential. This treatment could also be 
useful in diseases with overlapping phenotypes, including ALS and SMA (Green et 
al., 2010; Horvath et al., 2011). Future studies should focus on optimising the 
riboflavin dose, the method of administration, and the length of treatment. Given the 
availability of this potentially life-saving treatment, additional patients with a 
broader range of BVVL-like phenotypes should be screened. 
Exome sequencing was also used in this Chapter to search for novel genes in patients 
who had a BVVL-like phenotype or an AR polyneuropathy with prevalent motor 
involvement, and whom were negative for mutations in the riboflavin transporters. 
The challenges of data analysis in exome sequencing were also noted in this study. 
However, mutations in a promising candidate gene, AAAS, were found in one out of 
the three families studied with complex axonal neuropathy. These results are 
preliminary and additional genetic and functional assessments of pathogenicity are 
required. Nonetheless, this finding provides an example of the benefits of exome 
sequencing, whereby a previously unsuspected gene which would not otherwise have 
been screened, was found to be associated with a similar but somewhat atypical 
phenotype.  
The discovery of riboflavin transporter mutations in BVVL patients has uncovered a 
novel pathway leading to neuropathy. In Chapter 7, I primarily used fibroblasts from 
patients with SLC52A2 mutations as well as primary mixed ventral horn cultures 
from embryonic mice to begin to elucidate how deficiencies in riboflavin transport 
may lead to neurodegeneration. The scarce in vitro studies available to date had 
determined that riboflavin uptake was reduced for most SLC52A2 and SLC52A3 
mutants, and some of the mutant proteins were retained in the ER and not targeted to 
the plasma membrane (Ciccolella et al., 2013; Haack et al., 2012; Nabokina et al., 
2012). In this Chapter, I have shown that fibroblasts of BVVL patients with 
SLC52A2 mutations had reduced MRC complex I and II activities, likely as a result 
of the observed reduction in intracellular FMN and FAD levels. Unfortunately, the 
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riboflavin uptake could not be measured in the fibroblasts due to technical 
difficulties; however, reduced uptake was subsequently confirmed by our 
collaborators, Dr Yonezawa and colleagues, in HEK293 cells expressing most of the 
SLC52A2 mutations identified in Chapter 6 (Foley et al., 2014). Some patient 
fibroblast lines had reduced Δψm with reversal of the ATP synthase, suggesting a 
deficiency in the MRC and cellular energy metabolism. CoQ10 levels were decreased, 
and the lactate/pyruvate ratio as well as NADH redox index were increased most 
evidently in the fibroblasts of one patient with a particularly severe phenotype. 
Notably, all defects described above were at least partially, if not completely, 
rescued in vitro by addition of high doses of riboflavin to the cell medium; 
admittedly, the mechanism by which riboflavin supplementation corrects these 
defects in the patient fibroblasts is not certain.  
Data from these in vitro studies support the role of riboflavin in maintaining cellular 
energy metabolism, and have provided additional suggestions for prospective 
therapies in BVVL, as described in Section 7.12.5. A significant limitation of these 
studies is that patient fibroblasts had to be deprived of riboflavin in order to uncover 
the metabolic defects, thus perhaps mimicking an additional nutritional riboflavin 
deficiency. However, it may be that fibroblasts have relatively low requirements for 
riboflavin, and that the concentration of riboflavin in the low riboflavin medium is in 
fact sufficient for normal cellular energy metabolism in these cells. Data from this 
study may or may not be applicable to other cell types and to the disease pathway in 
vivo.  
Although mitochondrial dysfunction was the focus of my investigations given the 
role of riboflavin and its metabolites in the MRC, these flavoproteins are involved in 
a wide range of cellular functions (Henriques et al., 2010; Lienhart et al., 2013; 
Massey, 2000; Powers, 2003). The experiments performed in this study were 
restricted in scope, thus it would be worthwhile to explore other biochemical 
processes which may be affected in BVVL. For example, ER stress could be 
investigated as a potential pathomechanism in BVVL; ER stress occurs when the 
function of the ER is disrupted, its folding capacity is exceeded, and unfolded or 
misfolded proteins accumulate and aggregate in this cellular compartment (Kanekura 
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et al., 2009). Disulphide bond formation is critical for protein biogenesis and proper 
secretion of proteins in the cell. In mammals, ER oxidoreductin 1 (Ero1), which is 
localized in the ER and has a role in oxidative protein folding and disulphide bond 
formation, uses FAD as an electron acceptor (Camporeale & Zempleni, 2003; 
Manthey et al., 2005; Papp et al., 2005; Varsányi et al., 2004; Werner et al., 2005). In 
yeast, FAD also promotes disulphide bridge formation by Ero1p (Tu & Weissman, 
2002), and depletion of riboflavin causes an impairment of oxidative folding (Tu et 
al., 2000; Tu & Weissman, 2002). Furthermore, FAD binding was determined to be 
necessary for the assembly and folding of some flavoproteins, including acyl-CoA 
dehydrogenases (Nagao & Tanakas, 1992; Saijo & Tanaka, 1995). Accordingly, it 
was suggested that flavin deficiency might cause accumulation of unfolded proteins 
and ER stress (Camporeale & Zempleni, 2003; Tu et al., 2000). 
Other cellular models besides patient fibroblasts were trialled as part of this Thesis. 
The in vitro work involving SLC52A2-KD SH-SY5Y cells was not pursued 
following difficulties with optimising the riboflavin concentration in the cell 
medium. Mutant SLC52A2 SH-SY5Y cells were also prepared as part of this Thesis; 
however, upon further consideration it was deemed more appropriate to use primary 
mixed ventral horn cultures from embryonic mice for subsequent in vitro studies. 
The ideal cell model to use would have been to grow induced pluripotent stem (IPS) 
cells from the BVVL patient fibroblasts and differentiate them into neurones. 
However, developing the model itself takes nearly a year, thus given the time 
constraints, this model could not be utilised here. IPS cells grown from patient 
fibroblasts as well as riboflavin transporter-knockout animal models should be 
prioritised for future studies into the pathomechanism of BVVL. 
Mitochondrial function was briefly assessed in the WT mixed ventral horn cultures 
deprived of riboflavin as a preliminary investigation of the resistance of these cells to 
riboflavin withdrawal. Although complex I and II activities were affected by 
riboflavin deficiency in the mixed culture, these observations did not translate to a 
defect of Δψm maintenance in individual motor neurones. Future studies may wish 
to purify the cultures for enrichment of motor neurones as the presence of other cell 
types within the mixed ventral horn culture may have been a confounding variable. 
 350 
Other possible explanations for this discrepancy are discussed in Section 7.12.2. The 
mouse riboflavin transporters Slc52a2 and Slc52a3 were also independently silenced 
in this cell model; results from measurements of basal Δψm and response to 
mitochondrial toxins were inconclusive due to the small number of cells assessed as 
a result of poor transduction efficiency.  
At this time, how mutations in riboflavin transporters can lead to a phenotype which 
so markedly differs from that of nutritional riboflavin deficiency is still unresolved. 
Possible additional functions of the riboflavin transporters should be investigated. 
Although it has been proposed that the brain is specifically protected against low 
intakes of riboflavin in the diet, mutations in riboflavin transporters may disrupt the 
ordinarily tightly regulated pathway (Foraker et al., 2003) and prevent the 
compensatory increase in riboflavin transport observed during nutritional riboflavin 
deficiency (Burch et al., 1956; Camporeale & Zempleni, 2003; Fujimura et al., 2010; 
Said & Ma, 1994; Said & Mohammed, 2006; Spector, 1980b; Spector & Johanson, 
2006). Evidently, more studies are needed to characterise the riboflavin transporters 
and their uptake mechanisms both in vitro and in vivo. 
Additional suggestions for future in vitro and in vivo studies of BVVL are detailed in 
Section 7.12.6. As previously mentioned, elucidating the BVVL pathway could 
putatively help to understand other MNDs and may generate more ideas for 
therapies. Similarly, it is likely that BVVL and other neurodegenerative diseases 
share some pathomechanisms, as the riboflavin metabolites play a role in several 
pathways already known to be involved in ALS, Parkinson’s disease, and 
Alzheimer’s disease, such as oxidative stress, ER stress and mitochondrial 
dysfunction. 
With respect to the initial aims of the Thesis, the above experiments have: 
 Chapter 3: 1) Established mutation frequencies for selected CMT1 genes in 
cohorts from the UK, Greece, and Russia, 2) expanded the phenotypes 
associated with defects in these genes, 3) enabled the genetic diagnosis of a 
group of CMT1 patients, and 4) ruled out several CMT genes as a cause of 
canine peripheral neuropathy and NAD-CA. 
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 Chapter 4: 1) Determined that alleles associated with CIDP and other 
autoimmune diseases are unlikely to modulate disease severity in CMT1A or 
to play a role in CMT1A in general, therefore a superimposed inflammatory 
neuropathy is probably not a common modifier of the phenotype in CMT1A, 
and 2) discovered a potential susceptibility locus in the PXK gene in CIDP 
patients. 
 Chapter 5: Uncovered two possible candidate genes in two undiagnosed 
CMT families using exome sequencing. 
 Chapter 6: 1) Detected riboflavin transporter mutations in unrecognised 
cases of BVVL, thus facilitating access to early treatment with high-dose 
riboflavin therapy, 2) extended the phenotype previously associated with 
BVVL, and 3) identified a strong candidate gene by exome sequencing in a 
previously undiagnosed family with complex axonal neuropathy. 
 Chapter 7: 1) Established that SLC52A2 patient fibroblasts show evidence of 
mitochondrial dysfunction, which could be rescued in vitro by 
supplementation with riboflavin, and 2) suggested additional therapies for 
BVVL based on results obtained in vitro. 
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APPENDIX I
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Table I-1: Classification of CMT, dHMN and HSAN (Adapted from Pandraud et al., 2012 and Rossor et al., 2013). 
CMT1 
Subtype Gene/Locus Phenotype
ADCMT1
CMT1A
PMP22 (Duplication 
17p11.2)
classic CMT1
PMP22 (Point mutation) CMT1/DSD/CHN (rarely recessive)
CMT1B MPZ CMT1/CMT2/DSD/CHN (rarely recessive)
CMT1C LITAF (SIMPLE) classic CMT1
CMT1D EGR2 CMT1/DSD/CHN
CMT1F NEFL CMT2, motor NCV can be in CMT1 range (rarely recessive)
Other SOX10 CMT1/CHN/Waardenburg-Hirschsprung disease
FBLN5 age-related macular degeneration/hyperextensible skin/HMN
GJB3 (Cx31) bilateral high-frequency hearing loss/sensory polyneuropathy/variable penetrance
ARCMT1 (CMT4)
CMT4A GDAP1 severe CMT1/CMT2/DSD/possible vocal cord and diaphragm paralysis/rare AD families
CMT4B1 MTMR2 severe CMT1/facial weakness/bulbar palsy/focally-folded myelin
CMT4B2 MTMR13 (SBF2) severe CMT1/glaucoma/focally-folded myelin
CMT4B3 MTMR5 (SBF1) CMT1/pain/scoliosis/focally-folded myelin
CMT4C SH3TC2 severe CMT1/scoliosis
CMT4D/HMSN-Lom NDRG1 severe CMT1/gypsy/deafness/tongue atrophy
CMT4E EGR2 CMT1/DSD/CHN
CMT4F PRX CMT1 with more sensory involvement/rare AD families/focally-folded myelin
CMT4G/HMSN Russe HK1 severe CMT1/early-onset/possible proximal weakness/gypsy
CMT4H FGD4 (Frabin) classic CMT1
CMT4J FIG4 CMT1/progressive/mainly motor
CCFDN CTDP1 CMT1/gypsy/cataracts/dysmorphic features
Other SURF1 allelic with encephalopathy/CNS involvement (nystagmus, ataxia, hearing loss)/scoliosis
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X-linked CMT
Subtype Gene/Locus Phenotype
CMTX1 GJB1 (Cx32) CMT1/CMT2/I-CMT, male motor NCVs < female motor NCVs
CMTX4/Cowchock syndrome AIFM1 CMT2/infantile-onset/deafness/learning disability/developmental delay
CMTX5 PRPS1 severe CMT2/deafness/optic atrophy
CMTX6 PDK3 CMT2/hand tremor/mild or asymptomatic females
Subtype Gene/Locus Phenotype
DI-CMTA 10q24.1-25.1 CMT2
DI-CMTB DNM2 ICMT/CMT2/cataracts/ophtalmoplegia/ptosis
DI-CMTC YARS ICMT
DI-CMTD MPZ ICMT
DI-CMTE INF2 ICMT/glomerulopathy/end-stage renal failure
DI-CMTF GNB4 ICMT/more severe motor NCV changes in males
Other ARHGEF10 hypomyelination/most patients asymptomatic
Subtype Gene/Locus Phenotype
RI-CMTA GDAP1 ICMT
RI-CMTB KARS
ICMT/dysmorphic features/developmental delay/vestibular 
schwannoma
RI-CMTC PLEKHG5 ICMT/allelic with distal SMA 4
Subtype Gene/Locus Phenotype
Hereditary neuralgic 
amyotrophy (HNA)
SEPT9 recurrent neuralgic amyotrophy
HNPP
Deletion 17p11.2/some 
PMP22 point mutations
typical hereditary neuropathy with liability to pressure palsies
Recessive intermediate CMT (RI-CMT)
Dominant intermediate CMT (DI-CMT)
Others
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HSAN
Subtype Inheritance Gene/Locus Phenotype
HSAN1A AD SPTLC1 HSN/variable distal motor involvement/acromutilation/adolescent-onset
HSAN1C AD SPTLC2 HSN//variable distal motor involvement/acromutilation/adult-onset 
CMT2B AD RAB7 sensory-motor with sensory complications/loss of nociception
HSN1D/SPG3A AD ATL1 HSN/trophic skin and nail changes/acromutilation/spasticity/adult-onset
HSN1E AD DNMT1 HSN/acromutilations/sensorineuronal hearing loss/dementia/adult-onset
HSAN2A AR WNK1
HSN/mutilations in hands and feet/acropathy/congenital or early childhood 
onset/severe
HSAN2B/HSAN1B AR FAM134B
HSN/impaired nociception/progressive mutilating ulceration of hands and 
feet/osteomyelitis/childhood onset
HSN2C/SPG30 AR KIF1A
HSN/impaired position and vibration sense/acromutilations/minor distal 
weakness/childhood to adolescent-onset
HSAN3/Riley-Day AR IKBKAP
HSN/prominent autonomic involvement with vasomotor instability and 
hyperhidrosis/absent fungiform papillae/congenital/Ashkenazi Jewish 
Channelopathy-
associated 
insensitivity to 
pain/small-fibre 
neuropathy
AR and AD SCN9A
congenital insensitivity to pain(recessive)/erythromelalgia, small-fibre 
neuropathy/paroxysmal extreme pain disorder (dominant)
CIPA/HSAN4 AR NTRK1
congenital insensitivity to pain with anhydrosis/episodic fever/ skin and corneal 
lesions/joint deformities/mental retardation/unmyelinated fibres mainly affected
HSAN5 AR NGF-B
insensitivity to pain/severe loss of deep pain perception/minimal autonomic/painless 
fractures, joint deformities/no mental retardation/mainly unmyelinated fibres affected
HSAN and dementia AD PRNP autonomic dysfunction/dementia/sensory loss
Hereditary sensory 
neuropathy with 
spastic paraplegia
AR CCT5 HSN/acromutilation/spastic paraplegia
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dHMN
Subtype Inheritance Gene Phenotype
HMN2A AD HSPB8/HSP22 classical HMN
HMN2B AD HSPB1/HSP27 classical HMN
HMN2C AD HSPB3 classical HMN
HMN with pyramidal 
features/ALS4
AD SETX HMN/pyramidal signs/early-onset
DSMA5 AR DNAJB2 (HSJ1) classical HMN
HMN5A/SPG17 AD BSCL2 hand wasting/silver syndrome/sensory involvement as in CMT2D
HMN5A AD GARS hand wasting/slowly progressive
HMN5B/SPG31 AD REEP1 hand wasting/pyramidal signs
HMN6/SMARD1 AR IGHMBP2 infantile-onset/respiratory distress
HMN7A AD SLC5A7 classical HMN/vocal cord palsy
HMN7B AD DCTN1 HMN/adult-onset/bulbar and facial weakness
SMAX3 X-linked ATP7A classical HMN
SMALED AD BICD2 contractures/congenital/pyramidal signs/lower-limb predominance
SMALED AD DYNC1H1
contractures/congenital/pyramidal signs/lower-limb predominance/learning 
difficulties/cortical migration defects
PNMHH AD MYH14 typical HMN/hoarseness/distal myopathy/hearing loss
SPSMA AD TRPV4 HMN/adult-onset/vocal cord palsy/scapular winging
HMN AD AARS typical HMN  
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Table I-2: CMT genes and associated predicted protein functions (Adapted from Azzedine et al., 2012; Pandraud, in press; Rossor et al., 2013; 
Tazir et al., 2013). 
Gene Predicted Protein Function
PMP22 Myelin structural component, myelin formation, Schwann cell differentiation
MPZ Myelin structural component, adhesion, compaction and maintenance of myelin 
LITAF (SIMPLE) Protein sorting at the early endosome 
EGR2 Transcription factor, regulation of myelination program
NEFL Organization and assembling of neurofilaments, mitochondrial dynamics
MFN2 GTPase, mitochondrial fusion and transport 
PRX Myelin structural component, membrane-protein interactions, extracellular matrix signaling during myelination
SOX10 Transcription factor, regulation of myelination program
FBLN5 Elastic fiber assembly
GJB3 (Cx31) Gap junction membrane protein
GDAP1 Glutathione metabolism, mitochondrial fission 
MTMR2 Lipid phosphatase, membrane trafficking, endocytosis  and control of myelination 
MTMR13 (SBF2) Pseudophosphatase, membrane trafficking
MTMR5 (SBF1) Probably pseudophosphatase
SH3TC2 Rab11 effector, endocytic recycling
NDRG1 Signalling and membrane trafficking
HK1 Regulation of energy metabolism and cell survival, glucose metabolism 
FGD4 Guanine nucleotide exchange factor, cytoskeletal remodelling
FIG4 Lipid phosphatase, membrane trafficking
CTDP1/FCP1 Phosphatase/RNA metabolism
SURF1 Mitochondrial, biogenesis of cytochrome C oxidase complex
KIF1B Motor protein, vesicle trafficking
RAB7 GTPase, vesicle trafficking between late endosomes and lysosomes 
TRPV4 Cation channel, transduction of sensory inputs
GARS T-RNA synthetase, protein synthesis  
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(continued)
HSP27 (HSPB1) Chaperone, protein folding/quality control, neurofilament network organization
HSP22 (HSPB8) Chaperone, protein folding, stress response, and regulation of apoptosis
DNM2 GTPase, cellular fusion and fission, vesicle trafficking, endocytosis
AARS T-RNA synthetase, protein synthesis
DYNC1H1 Motor protein, retrograde axonal transport
LRSAM1 E3 ubiquitin ligase, receptor endocytosis
DHTKD1 Part of the 2-oxoglutarate dehydrogenase complex
TFG Located at endoplasmic reticulum exit sites, possibly involved in vesicle trafficking
MARS T-RNA synthetase, protein synthesis
HARS T-RNA synthetase, protein synthesis
KIF5A Anterograde axonal transport of organelles
MT-ATP6 ATP synthase subunit 6 in the mitochondrial membrane 
IFRD1 Transcriptional co-activator/repressor 
LMNA Nuclear envelope structure, genomic stability, axonal survival and development
MED25 Transcriptional co-activator 
HINT1 Purine phosphoramidase; binds to lysyl-tRNA synthetase 
TRIM2 E3 ubiquitin ligase, ubiquitinates NEFL
GJB1 (Cx32)
Myelin structural component, cell membrane channel, formation of intracellular gap junctions between the 
folds of the Schwann cell cytoplasm
AIFM1 Oxidoreductase, role in apoptosis
PRPS1 Metabolic enzyme, nucleotide biosynthesis and purine metabolism
PDK3 Mitochondrial, regulates pyruvate dehydrogenase complex, bioenergetic pathway 
YARS T-RNA synthetase, protein synthesis
INF2 Cytoskeleton remodelling, regulator of actin polymerisation
GNB4 Guanine nucleotide-binding protein, cell signalling
ARHGEF10 Guanine nucleotide exchange factor, cytoskeletal remodelling
KARS T-RNA synthetase, protein synthesis
PLEKHG5 Nuclear factor κB–activator  
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APPENDIX II  
DNA extraction from human saliva using Oragene kit (OraSure technologies) 
Briefly, 500 μl of the mixed Oragene saliva sample was added to an Eppendorf tube. 
The tube was incubated at 50°C and spun briefly. 20 μl of Oragene Purifier was 
added to the tube and contents were vortexed. The tube was incubated on ice for 10 
min and centrifuged at room temperature for 5 min at 13,000 rpm. The clear 
supernatant was transferred to a fresh tube. 500 μl of 95-100% ethanol was added to 
500 μl of supernatant, and the contents were mixed gently by inverting 10 times. The 
tube was allowed to sit at room temperature for 10 min. The tube was centrifuged at 
room temperature for 2 min at 13,000 rpm. The supernatant was discarded, and 50 μl 
of Tris-EDTA buffer was added to the pellet. The tube was vortexed for 5 s and 
incubated at 50°C for 1 hr. 
Quantitative polymerase chain reaction for confirmation of the Chr17p11.2 
duplication  
PMP22 primer concentrations were optimised (900 nM final concentration for both 
forward and reverse primers); optimal final primer concentrations for ACTBL2 had 
been previously determined to be 500 nM for both forward and reverse primers. 
Similar amplification efficiency of reference (ACTBL2) and target (PMP22) genes 
was confirmed. All samples were run in triplicates. Each qPCR reaction for PMP22 
amplification contained 10 μl Power SYBR Green PCR master mix (Applied 
Biosystems), 3.6 μl of both forward and reverse primers at 5 μM, 0.8 μl autoclaved 
dH2O and 2 μl DNA at 10 ng/μl. qPCR reactions for ACTBL2 amplification 
contained 10 μl Power SYBR Green PCR master mix (Applied Biosystems), 1 μl of 
both forward and reverse primers at 10 μM, 6 μl autoclaved dH2O and 2 μl DNA at 
10 ng/μl. MicroAmp Fast Optical 96-well reaction plates were sealed with 
MicroAmp
 
Optical Adhesive Film (Applied Biosystems). Samples were run along 
with a no template control and two control samples (negative for the Chr17p11.2 
duplication) on the StepOnePlus Real-Time PCR System (Applied Biosystems). 
Thermalcycling conditions were as follows: 10 min at 95°C, followed by 40 cycles 
of 15 s at 95°C and 60 s at 60°C, and a final dissociation step. Cycles 28-30 were 
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excluded from the analysis as amplification was no longer linear at these cycles. 
Analysis of the dissociation curve eliminated the possibility of contamination and 
non-specific PCR products.  
Illumina Infinium HD Human Immuno BeadChip Genotyping 
Following an initial quality check, 300 ng of DNA sample was whole-genome 
amplified and incubated overnight at 37°C. The following day, the amplified DNA 
was fragmented at 37°C for 1 h and 15 min. Following alcohol precipitation and 
resuspension of DNA in hybridisation buffer, the samples were denatured. Samples 
were hybridised to the BeadChip and the DNA annealed to locus-specific 50-mers 
linked to one of more than 300,000 beadtypes, followed by overnight incubation at 
48°C. One beadtype represents one allele per SNP locus. The next day, the probes on 
the chip were extended by a single hapten-labelled ddNTP base complementary to 
the hybridised DNA. 2',3'-dideoxyadenosine-5'-triphosphate (ddATP) and 
2',3'dideoxythymidine-5'-triphosphate (ddTTP) bases were labelled with 2,4-
dinitrophenol (DNP); 2',3'-dideoxycytidine-5'-triphosphate (ddCTP) and 2',3'-
dideoxyguanosine-5'-triphosphate (ddGTP) were labelled with biotin. Formamide 
was then used to strip the DNA sample off the chip. For the staining procedure, the 
signal was amplified by multi-layer immunohistochemical staining. Streptavidin and 
an anti-DNP primary antibody conjugated to green and red fluorophores respectively 
(STM reagent, Illumina) were used to detect the haptens. To amplify the fluorescent 
signal, these were then counterstained with biotinylated anti-steptavidin and a DNP-
labelled secondary antibody to the anti-DNP primary antibody (ATM reagent, 
Illumina). The STM reagent, containing the fluorophores to allow signal detection, 
was the last layer of the stain. The stained chips were covered in a glue-like 
substance to protect the dyes. A Freedom EVO liquid handling robot (Tecan Ltd, 
Switzerland) was used for hybridisation and staining procedures by an automated 
protocol; all processing prior to hybridization was carried out manually. The 
intensity of the fluorescence from the beads was detected by an iScan scanner system 
with autoloader (Illumina).  
Data was initially analysed using the Illumina GenomeStudio software (cnvPartition 
v3.1.6, Illumina). For quality control, samples were assessed for their call rate which 
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should be >98%, and >99% average across the batch. Every array contained both 
sample-dependent and sample-independent control probes. Sample-independent 
probes tested the quality of the processing while sample-dependent probes assessed 
the DNA quality. The B-allele frequency plots and copy number analysis results 
were checked to identify potentially contaminated samples. This work was 
performed entirely by Kerra Pearce. 
Exome sequencing protocol and data processing 
For the exome sequencing performed at the UCL ION by Dr Deborah Hughes and Dr 
Alan Pittman, the sequencing data was mapped to the human reference genome build 
UCSC hg19 by Novoalign Software (Novocraft, Malaysia). After removal of PCR 
duplicates using Picard (http://picard.sourceforge.net) as well as reads without a 
unique mapping location, variants were extracted using the Maq model in SAMtools 
and filtered by the following criteria: consensus quality >30, SNP quality >30 and 
root mean square mapping quality >30. These variants were further filtered against 
the dbSNP 135 and 1000 Genomes databases by use of Annovar 
(http://www.openbioinformatics.org /annovar/). 
The data processing for the exome sequencing performed by the Wellcome Trust 
Sanger Institute in Hinxton, UK was carried out as described in Cirak et al., 2013. 
Briefly, sequencing reads that failed quality control were eliminated using the 
Illumina Genome Analyser Pipeline (Illumina). The Burrows-Wheeler Aligner was 
used for alignment to the human reference genome build UCSC hg19; PCR 
duplicates were removed using Picard. Calling of variants was performed in target 
regions plus or minus a 100 bp window using both SAMtools (v.0.1.17) and Genome 
Analysis Tool Kit (GATK) Unified Genotyper (v.1.1-5). Base quality recalibration 
and indel realignment was done with GATK. SNPs and indels were called using the 
GATK Unified Genotyper, and labelled with dbSNP132 ID numbers. GATK Variant 
Filtration was applied and variants were assigned to quality tranches by GATK. Vcf-
filter was used to filter the variants called by each method separately and the 
resulting files were merged. Variant calls were annotated using the earliest version of 
dbSNP containing this call, dbSNP132 ID numbers, and allele frequencies in the 
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1000 Genomes population (June 2011 release). Several functional scores were 
annotated to help in the filtering of variants.  
The data processing for the exome sequencing performed by Oxford Gene 
Technology was carried out as follows. Read files were generated from the 
sequencing platform via the manufacturer's proprietary software. Reads were 
mapped to the human reference genome build UCSC hg19 using the Burrows-
Wheeler Aligner package v.0.6.1. Local realignment of the mapped reads around 
potential indel sites was carried out with GATK v.1.6. Picard v.1.62 was used to 
mark duplicate reads. Additional BAM file manipulations were performed with 
SAMtools v.0.1.18. Base quality scores were recalibrated using GATK's covariance 
recalibration. The GATK Unified Genotyper was used to call SNP and indel variants, 
and variants were compared against dbSNP135. Ensembl was used to annotate genes 
and gene function for all variants.  
cDNA synthesis 
Briefly, the following was added to each well of a nuclease-free plate: 1 μl of 150 
ng μl random primers, 1 μl dNTP mix (each at 10 mM), 500 ng RNA, and 
autoclaved dH2O to a total volume of 12 μl. The plate was heated to 65°C for 5 min 
and chilled on ice. 4 μl of 5X First-Strand buffer and 2 μl of 0.1 M DTT were added 
to each well. Contents were mixed and the plate was incubated at 25°C for 2 min. 1 
μl (200 units) of SuperScript II Reverse transcriptase (200 U μl; Life Technologies) 
was added to all wells except the “no RT” control. Contents were mixed and the 
plate was incubated at 25°C for 10 min, 42°C for 50 min, and 70°C for 15 min. 
Optimisation of [
3
H]-Riboflavin uptake assay in fibroblasts 
Precautions required for working with radioactive material were followed throughout 
the procedure. Cells and incubation buffer were pre-warmed to 37°C. Uptake of 
[
3
H]-Riboflavin (30 Ci/mmol, 99% purity; American Radiolabelled Chemicals, 
USA) was measured by removing the medium and pre-incubating the cells with 200 
μl of incubation buffer at pH 7.4 (see below for recipe) for 10 min at 37°C. After 
removal of the buffer, 200 μl of incubation buffer with either 5 nM or 10 nM final 
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concentration of [
3
H]-Riboflavin was added per well. Control wells (no added [
3
H]-
Riboflavin) were used in parallel. The cells were incubated for either 2.5 min or 30 
min at 37°C, followed by two washes of the monolayers with 1 ml ice-cold 
incubation buffer to quench uptake. 500 μl of 0.5 M sodium hydroxide (NaOH) was 
added to solubilise the cells; half the wells were neutralised with 2.5 M hydrochloric 
acid (HCl). Success of the lysis was verified under a light microscope. Radioactive 
content of 300 μl aliquots of samples and standards of known radioactive content 
was assessed by liquid scintillation counting on a Packard Tri-Carb scintillation 
counter using QuantaSmart software (PerkinElmer) with 3 min assay time per vial.  
In previous studies of [
3
H]-Riboflavin uptake in SLC52A1 or SLC52A2-mutant 
HEK293 cells, cells were incubated with either 5 nM or 10 nM [
3
H]-Riboflavin for 1 
min (Foley et al., 2014; Haack et al., 2012; Ho et al., 2010), but riboflavin 
concentration in the culture medium was not specified in these studies. Another 
study using SLC52A2-mutant fibroblasts had grown cells for 24 h in growth medium 
containing 0.4 nM riboflavin and incubated cells with 5 nM [
3
H]-Riboflavin for a 
maximum of 30 min (Ciccolella et al., 2013). Despite the similar protocol used in 
this PhD work and the longer incubation time trialled, the [
3
H]-Riboflavin uptake 
assay could not be successfully optimized within the timeframe of this PhD. 
Decreasing the amount of riboflavin in the growth medium, increasing the amount of 
added [
3
H]-Riboflavin from 5 nM to 10 nM, and neutralising with HCl had no 
substantive effect on [
3
H]-Riboflavin uptake. Possible issues include insufficient 
number of cells, inappropriate culturing conditions (length of time and riboflavin 
concentration), inappropriate incubation time or [
3
H]-Riboflavin concentration. 
Although the pH of the buffer may affect uptake, it was verified before each assay, 
and uptake via RFVT1 and RFVT2 is known to be pH-independent (Yamamoto et 
al., 2009; Yao et al., 2010). The lower concentration of riboflavin (0.4 nM) in the 
culture medium compared to the 3.1 nM riboflavin medium used in other 
experiments in this PhD was trialled in order to increase levels of radioactivity 
detected and accuracy. Indeed, evidence from animal and in vitro studies of 
riboflavin deficiency suggests that some cells increase transport rates of riboflavin 
when grown in low riboflavin conditions as a compensatory mechanism (Section 
7.1.5) (Camporeale & Zempleni, 2003; Kumar et al., 1998; Said & Ma, 1994a; Said 
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& Mohammed, 2006). Although cells did take up some [
3
H]-Riboflavin since dpm 
values in wells with added [
3
H]-Riboflavin were somewhat higher than in the control 
wells, the dpm values were not sufficiently higher than basal levels to allow for 
accurate determination of [
3
H]-Riboflavin uptake. 
Western blot optimisation: Endogenous RFVT2 protein levels in fibroblasts 
To measure the expression levels of endogenous RFVT2 protein, both pellet and 
supernatant fractions of the cell lysates were used as RFVT2 expression has been 
identified in various cellular locations (Subramanian, Subramanya, et al., 2011; Yao 
et al., 2010; Section 6.1.3). A whole-cell sample was also used for comparison. For 
the supernatant fraction, the protein concentration was assayed as described in 
Section 2.2.7 and the sample was prepared as described in Section 2.2.22. Pellet and 
whole cell fractions were sonicated and samples were prepared in 4X SDS buffer so 
as to be representative of the supernatant fraction. The Western blot was performed 
as described in Section 2.2.22 with the following primary antibodies: rabbit 
polyclonal anti-RFVT2 (1:1,000; Sigma) and goat polyclonal anti-RFVT2 (D-13) 
(1:200; Santa Cruz Biotechnology). A donkey anti-goat IgG-HRP secondary 
antibody (1:5,000; Santa Cruz Biotechnology) was used with the Santa Cruz 
Biotechnology primary antibody. Thorough optimisation of the RFVT2 antibodies 
was carried out, with modifications in amount of protein loaded, transfer time, 
blocking agent and time, antibody concentration and incubation time, as well as 
developing time. It should be noted that this experiment was also trialled in SH-
SY5Y cells, in the event that fibroblasts did not express sufficient amounts of 
RFVT2 to be detected by Western blot. However, no bands appeared at the expected 
molecular weight (46 kilodaltons) either in the pellet, supernatant or whole-cell 
lysate fractions for any of the primary antibodies or cell types used, suggesting that 
these antibodies are not appropriate for use in this study. Unfortunately, the number 
and quality of the commercially available antibodies for RFVT2 was very limited. 
 
 
 366 
Preparation of SLC52A2-mutant SH-SY5Y cells  
Cell line and cell culture: 
Please refer to Sections 2.3.1 and 2.3.2 for a description of the SH-SY5Y cell line 
and culturing conditions. 
Description of pCMV6-SLC52A2-myc-DDK plasmid: 
Full-length C-terminal Myc-DDK-tagged SLC52A2 cDNA (GenBank accession 
number NM_024531) in a pCMV6 entry plasmid (RC202512) was obtained from 
Origene. The myc-DDK tag is attached to the C-terminal of the protein and the open-
reading frame is flanked by a polyA signal at the 3’ end. The expression of SLC52A2 
is driven by a CMV promoter. A kanamycin resistance gene is the antibiotic 
selection marker for Escherichia coli and a neomycin (G-418) resistance gene 
provides antibiotic selection in mammalian cells (Figure II-1). 
 
Figure II-1: Vector map for the pCMV6-SLC52A2-myc-DDK plasmid (reproduced 
from Origene website). 
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Quality control of pCMV6-SLC52A2-myc-DDK plasmid: 
The entire SLC52A2 open reading frame of the pCMV6-SLC52A2-myc-DDK 
plasmid described above was sequenced by the UCL DNA sequencing service and 
was confirmed to be free of mutations (see Appendix VII Table VII-6 for sequences 
of pCMV6 vector primers). A restriction digest was performed for further quality 
control. The digest reaction contained: 2 μl 10X restriction enzyme buffer 3 (NEB), 2 
μl 10X BSA, 0.5 μl restriction enzyme SalI or DraIII (20 U; NEB), 300 ng plasmid 
DNA, made up to 20 μl final volume with dH2O. The reaction was mixed and 
incubated at 37°C for 2 h. 10 μl of the digested samples were loaded onto a 1% w/v 
agarose gel with 1 Kb DNA ladder (NEB). Uncut samples were run alongside the 
digested samples for comparison. As expected, three bands of the expected size were 
obtained when using the DraIII restriction enzyme, and two bands of the correct size 
were obtained when using SalI. 
Preparation of empty vector: 
An empty pCMV6 vector was prepared from the pCMV6-SLC52A2-myc-DDK 
plasmid. The digest reaction contained 5 μl 10X restriction enzyme buffer 3 (NEB), 
5 μl 10X BSA, 1 μg plasmid DNA, 2.5 μl each of XhoI and SalI restriction enzymes 
(20 U) (NEB), made up to 50 μl with dH2O. The reaction was incubated for 3 h at 
37°C. 50 μl of the digest was mixed with 10 μl 5X loading dye (Qiagen) and loaded 
onto a 1% w v agarose gel with 10 μl of 1 Kb ladder (NEB). Samples were 
electrophoresed for 1 h at 60 V and visualized under a UV transilluminator. The 
band corresponding to the empty vector (4.9 Kb) was excised from the agarose gel 
with a sharp scalpel and the DNA was extracted using the QIAquick gel extraction 
kit (Qiagen). DNA purity and concentration were determined as described in Section 
2.1.5. Vector ligation was performed using 1.5 μl ligase buffer, 1.5 μl T4 ligase, 100 
ng DNA, made up to 15 μl in dH2O. The reaction was left to incubate for 2 h at room 
temperature. 
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Site-directed mutagenesis of pCMV6-SLC52A2-myc-DDK plasmid: 
Primers for mutagenesis of the pCMV6-SLC52A2-myc-DDK plasmid for selected 
SLC52A2 mutations (c.92G>C (p.Trp31Ser), c.700C>T (p.Gln234Stop), c.916G>A 
(p.Gly306Arg), c.935T>C (p.Leu312Pro), c.1016T>C (p.Leu339Pro), and 
c.1258G>A (p.Ala420Thr)) were designed using the QuikChange primer design 
program (Agilent Technologies) (see Appendix VII Table VII-7 for mutagenesis 
primer sequences). Mutagenesis primers, two complimentary oligonucleotides 
containing the desired mutation with unmodified nucleotide sequence on either side, 
were synthesized by Sigma. It was thereafter noted that, as the myc tag is located 
downstream of the p.Ala420Thr stop mutation, the myc tag could not be expressed in 
cells transfected with this mutant plasmid. Rather, a truncated cDNA sequence 
should have been introduced into the pCMV6 entry vector. 
SLC52A2 mutations were introduced by site-directed mutagenesis using the 
Stratagene QuikChange II XL Site-Directed Mutagenesis Kit (Agilent 
Technologies). Briefly, 5 μl of 10X reaction buffer, 10 ng plasmid DNA, 125 ng of 
forward primer, 125 ng of reverse primer, 1 μl dNTP mix, 3 μl QuikSolution, made 
up to 50 μl with dH2O and 1 μl of PfuUltra High Fidelity DNA polymerase (2.5 
U μl) was mixed in a thin-walled PCR tube. PCR thermalcycling conditions were as 
follows: 1 min at 95 °C, followed by 18 cycles of 50 s at 95°C, 50 s at 60°C and 6 
min at 68°C before a final 7 min elongation stage at 68°C. The reactions were placed 
on ice for 2 min. 1 μl (10 U μl) of DpnI restriction enzyme (NEB) was then added to 
the mutagenesis reactions and incubated at 37°C for 1 h to digest the parental DNA. 
Transformation of chemically competent cells: 
A 50 μl vial of One Shot Top 10 chemically competent Escherichia coli cells (Life 
Technologies) was thawed on ice. 5 μl of the mutagenesis reaction (or 50 ng of DNA 
for the empty and WT plasmids) was incubated in one vial of competent cells on ice 
for 30 min before being heat-shocked at 42°C for 30 s. The vial of competent cells 
was placed on ice for 2 min and 350 μl of pre-warmed SOC medium (Life 
Technologies) was added aseptically. The vial was placed in an incubator at 37°C 
and shaken at 225 rpm for 1 h. 100 μl ali uots were pipetted onto pre-warmed 
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selective agar plates (25 μg ml kanamycin) and spread throughout the plate. The 
plates were then inverted and incubated overnight at 37°C. The following day, single 
colonies were picked aseptically and inoculated into a tube containing 2 ml of LB 
broth with 25 μg ml kanamycin. These starter cultures were grown for 7 h on a 
shaking (225 rpm) incubator at 37°C. 300 μl of starter culture was aseptically added 
to a 500 ml flask containing 150 ml of LB broth (1:500 dilution) with 25 μg ml 
kanamycin and grown overnight at 37°C in a shaking (225 rpm) incubator. Glycerol 
stocks of all clones were prepared by mixing 500 μl of the overnight culture with 500 
μl glycerol at 50% v/v and freezing at -80°C. Overnight cultures were harvested by 
centrifugation at 4°C at 3,000 rpm for 20 min; the pellet was frozen at -80°C until 
needed for the Maxiprep. 
Maxiprep isolation of plasmid DNA: 
To obtain high-quality plasmid DNA for mammalian cell transfection, DNA for the 
empty, WT and the mutant pCMV6-SLC52A2-myc-DDK plasmids was purified from 
the cell pellets obtained from the overnight bacterial cultures using the Qiagen 
Plasmid Maxi kit (Qiagen) as per the manufacturer’s instructions. Plasmid DNA 
purity and concentration were determined as described in Section 2.1.5. The entire 
SLC52A2 open-reading frame was sequenced by the UCL DNA sequencing service 
(see Appendix VII Table VII-6 for primer sequences) to confirm insertion of the 
correct mutations and absence of additional mutations which may have arisen during 
the mutagenesis and transformation procedures.  
To verify that the empty vector was indeed empty following the Maxiprep above, 
enzyme digests of the WT pCMV6-SLC52A2-myc-DDK plasmid and the empty 
vector were performed using 2 μl of restriction enzyme buffer 4 (NEB), 2 μl of 10X 
BSA, 300 ng plasmid DNA, 0.5 μl XmaI restriction enzyme (20 U; NEB), made up 
to 20 μl in dH2O. The reaction was incubated at 37°C for 2 h. 10 μl of the digested 
samples were loaded with 2 μl 5X loading dye (Qiagen) onto a 1% w/v agarose gel 
with 1 Kb DNA ladder (NEB). Two bands of the expected sizes were obtained, 
confirming that the empty vector did not contain the SLC52A2 open reading frame. 
The empty vector was also confirmed to be empty by sequencing as described above. 
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Stable transfection of pCMV6-SLC52A2-myc-DDK plasmids: 
SH-SY5Y cells were stably transfected with the empty pCMV6 vector and the 
pCMV6-SLC52A2-myc-DDK vectors containing SLC52A2
WT
, SLC52A2
92G>C
, 
SLC52A2
700C>T
, SLC52A2
916G>A
, SLC52A2
935T>C
, SLC52A2
1016T>C
, and 
SLC52A2
1258G>A
. The night before transfection, cells were plated at approximately 
50% confluence in 6-well plates and incubated under normal conditions. The 
transfection procedure was performed as described in Section 2.3.7. The SH-SY5Y 
cells were maintained in selective medium containing 700 μg/ml G-418 antibiotic 
(PAA Laboratories- GE Healthcare) from 48 h after transfection to eliminate cells 
not expressing the vector. 
Recipes 
LB agar: 35 g of LB agar powder (Sigma) dissolved in 1 L dH2O, followed by 
autoclaving. 
LB broth: 20 g of LB broth powder (Sigma) dissolved in 1 L dH2O, followed by 
autoclaving. 
Orange G loading dye: 60% glycerol, 40% dH2O, teaspoon of orange G powder 
(Sigma). 
Agarose gel: 75 ml 1X TBE, 1 g agarose powder (Roche), 2 μl of 10 mg/ml ethidium 
bromide (Promega). 
10X TBE (for 1 L; pH to 8.3): 121.1 g Tris (Sigma), 61.8 g anhydrous boric acid 
(Merck-Millipore), 7.4 g EDTA (VWR), made up with dH2O. 
Fibroblast freezing medium: 20% DMSO (Sigma), 80% FBS. 
Western blot lysis buffer: 50 mM Tris (pH 7.4), 0.1 mM ethylene glycol tetraacetic 
acid (EGTA) (pH 7.4), 1 mM EDTA (pH 7.4), 1% Triton X-100 neat (Sigma), 92 
mg/ml sucrose, 0.1% β-mercaptoethanol, and 100 μl/ml each of 10X Complete 
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EDTA-free protease inhibitor cocktail tablets (Roche) and PhosSTOP phosphatase 
inhibitor cocktail tablets (Roche). 
Western blot running buffer: 100 ml 20X NuPAGE MES SDS running buffer (Life 
Technologies) in 1,900 ml dH2O. 
Western blot Tris transfer buffer: 20% methanol, 10% Tris-glycine electroblotting 
buffer 10X (National Diagnostics, USA), 70% dH2O.  
PBS Tween: 2 PBS tablets (Life Technologies), 1 ml Tween 20 (for electrophoresis, 
Sigma) dissolved in 1 L of dH2O. 
Incubation buffer for [
3
H]-Riboflavin uptake assay (from Ciccolella et al., 2013): 145 
mM NaCl, 3 mM KCl, 1 mM CaCl2, 0.5 mM MgCl2, 5 mM D-glucose, 5 mM 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), dissolved in dH2O, pH to 
7.4 and sterile-filtered. 
Glucose-free HBSS: 1.26 mM anhydrous CaCl2, 0.493 mM MgCl2 x 6H2O, 0.407 
mM MgSO4 x 7H2O, 5.33 mM KCl, 0.441 mM KH2PO4, 4.17 mM NaHCO3, 137.93 
mM NaCl, 0.338 mM Na2HPO4, 5.56 mM 2-deoxy-D-glucose (Sigma), dissolved in 
dH2O, pH to 7.35-7.4. 
CNB medium (for 200 ml): 191.1 ml 1X Neurobasal Medium (Gibco), 4 ml 50X B-
27 serum-free supplement (Gibco), 2 μl of 10 μg/ml brain-derived neurotrophic 
factor (Alomone labs, Israel), 2 μl of 10 μg/ml glial cell line-derived neurotrophic 
factor (Alomone labs), 20 μl of 5 μg/ml ciliary neurotrophic factor (Alomone labs), 
500 μl of 200 mM glutamine, 100 μl 0.05% β-mercaptoethanol (Gibco), 4 ml heat-
inactivated horse serum (Sigma), 2 ml P/S (Life Technologies). 
TMRM RM for mixed ventral horn cultures: 156 mM NaCl, 10 mM HEPES 
(Thermo Fisher Scientific), 10 mM D-glucose, 3 mM KCl, 2 mM MgSO4, 2 mM 
CaCl2, 1.25 mM KHPO4, dissolved in dH2O and pH to 7.35 with NaOH. 
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APPENDIX III  
Table III-1: Sequences of primers used to amplify the human PMP22, EGR2, 
LITAF, GJB1, and NEFL genes. All GJB1 primers have M13 tails. 
Gene Ensembl transcript Exon Direction Primer sequence (5' to 3')
Annealing 
temperature
PCR protocol
Amplicon 
length (bp)
PMP22 ENST00000312280 2 forward aaaagcaaaagatgttcc
PMP22 ENST00000312280 2 reverse actgtctgcaaataacac
PMP22 ENST00000312280 3 forward tgtgcatgtggaacttctcc
PMP22 ENST00000312280 3 reverse caacgacattctggcttgtg
PMP22 ENST00000312280 4 forward cttctgcttctgctgcctgt
PMP22 ENST00000312280 4 reverse catccagtggggagactcat
PMP22 ENST00000312280 5 forward tcaattctggacctggaagc 
PMP22 ENST00000312280 5 reverse gggattttgggctagctctt
EGR2 ENST00000242480 1 forward aagtgtggagggcaaaagga
EGR2 ENST00000242480 1 reverse agtcagcaccgtccacctg
EGR2 ENST00000242480 2-1 forward ttggactttgccacagctc
EGR2 ENST00000242480 2-1 reverse atcattgggaagagacctgg
EGR2 ENST00000242480 2-2 forward aggagacctctaccaggacc
EGR2 ENST00000242480 2-2 reverse gatatgggtggtgaggtgg
EGR2 ENST00000242480 2-3 forward ccaacagacccagcaagac
EGR2 ENST00000242480 2-3 reverse cagtgctagctccaccaaag
LITAF ENST00000339430 2 forward cagaaagaaaattgaagacttaggtg
LITAF ENST00000339430 2 reverse tggaacgtactggcacttca
LITAF ENST00000339430 3 forward actggtgttccttccccttt
LITAF ENST00000339430 3 reverse cctgaatgtcaagcatggtg
LITAF ENST00000339430 4 forward cctcttcttctaaggtcattgg
LITAF ENST00000339430 4 reverse tggagaggtgagaccacca
GJB1 ENST00000361726 2-1 forward tgggacacaagtgctctgtg
GJB1 ENST00000361726 2-1 reverse actcttccaagagccagtag
GJB1 ENST00000361726 2-2 forward gaggtcaagtcaagtgagtg
GJB1 ENST00000361726 2-2 reverse ttcacctcctccaggtgtag
GJB1 ENST00000361726 2-3 forward ctgcagctcatcctagtttc
GJB1 ENST00000361726 2-3 reverse atgtctttcagggagccatc
GJB1 ENST00000361726 2-4 forward aggtggtgtacctcatcatc
GJB1 ENST00000361726 2-4 reverse ccatctcttgtacccagtgg
NEFL ENST00000221169 1-1 forward cacacagccatccatcctc
NEFL ENST00000221169 1-1 reverse atggctcggagtgcttctg
NEFL ENST00000221169 1-2 forward ctccagctctggatcgttg
NEFL ENST00000221169 1-2 reverse gatctgcgcgtactggatc
NEFL ENST00000221169 1-3 forward tgaagaggaggtgctgagc
NEFL ENST00000221169 1-3 reverse gccaagccctatccctaag
NEFL ENST00000221169 2 forward acaggaagttattctaggagag
NEFL ENST00000221169 2 reverse ttcttggaagaagccaaa
NEFL ENST00000221169 3-1 forward tttctggtctccatcaaa
NEFL ENST00000221169 3-1 reverse caatggtttcctccacttcg
NEFL ENST00000221169 3-2 forward agagctcccaggtctttgg
NEFL ENST00000221169 3-2 reverse ttcagagtagatgccttaggaa
NEFL ENST00000221169 4 forward tcatggcaagctttgtctgt
NEFL ENST00000221169 4 reverse tcacatagaatctggaactcaa
556
633
412
350
419
402
402
571
521
551
524
493
403
630
634
591
425
432
Roche
60-50°C
60-50°C
60-50°C
60-50°C
60-50°C
60-50°C
55-52°C
Roche
Roche
Roche
Roche
Roche
Roche
Roche
Roche
Roche
Roche
58°C
58°C
58°C
58°C
62-52°C Roche
65-60°C Qiagen
62-52°C Roche
Roche
Roche
Roche
Roche
65-60°C
65-60°C
65-60°C
65-60°C
388Roche62-52°C
406Roche65-60°C
52°C Qiagen 461
65-60°C Roche 397
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Table III-2: Sequences of primers used to amplify the canine PMP22, MPZ, and 
MFN2 genes. 
Gene Ensembl transcript Exon Direction Primer sequence (5' to 3')
Annealing 
temperature
PCR protocol
Amplicon 
length (bp)
PMP22 ENSCAFT00000028432 1 forward ctccgctgagcaccactc
PMP22 ENSCAFT00000028432 1 reverse catgaatctgctcgggtttt
PMP22 ENSCAFT00000028432 2 forward aggctggctagatgagtgga
PMP22 ENSCAFT00000028432 2 reverse gactttggagccgtgtcttc
PMP22 ENSCAFT00000028432 3 forward gccagctcttcctaacctga
PMP22 ENSCAFT00000028432 3 reverse ggaccttccttccagactcc
PMP22 ENSCAFT00000028432 4 forward agattgggcgatatggtctg
PMP22 ENSCAFT00000028432 4 reverse ctggtttccttcctcccttt
MPZ ENSCAFT00000020580 1 forward ggttactggctcaggacagc
MPZ ENSCAFT00000020580 1 reverse tttcctaccatgcgacaaca
MPZ ENSCAFT00000020580 2-1 forward tcagttagcccggacagagt
MPZ ENSCAFT00000020580 2-1 reverse ctccccgtactcaccgagat
MPZ ENSCAFT00000020580 2-2 forward cctttctgcttgcagtgct
MPZ ENSCAFT00000020580 2-2 reverse gtcccccagtgtccctctat
MPZ ENSCAFT00000020580 3 forward ctgaggctagacccacaagc
MPZ ENSCAFT00000020580 3 reverse taggaggggagggaagagaa
MPZ ENSCAFT00000020580 4 forward gtgaggggctctgggaata
MPZ ENSCAFT00000020580 4 reverse gcagagagggagccagact
MPZ ENSCAFT00000020580 5 forward gaggctcaggtaaggggagt
MPZ ENSCAFT00000020580 5 reverse agccccttggacttcttttc
MPZ ENSCAFT00000020580 6 forward aaggggaaattgcacaagg
MPZ ENSCAFT00000020580 6 reverse gttcttgaggctggttctgc
MFN2 ENSCAFT00000026136 2 forward tgctgacccaggtctagtc
MFN2 ENSCAFT00000026136 2 reverse ggtgacaacctatctggg
MFN2 ENSCAFT00000026136 3 forward gtagggatccagcctttg
MFN2 ENSCAFT00000026136 3 reverse cctggtaagaggttaatatc
MFN2 ENSCAFT00000026136 4 forward gagactttgggcttcgag
MFN2 ENSCAFT00000026136 4 reverse cctggttggtctaagctc
MFN2 ENSCAFT00000026136 5 forward gtgtgaaatggaagaaggg
MFN2 ENSCAFT00000026136 5 reverse cagtctaagcaatgacagg
MFN2 ENSCAFT00000026136 6-7 forward tttgtactcctttgcctg
MFN2 ENSCAFT00000026136 6-7 reverse tggtgaactcagtcatagg
MFN2 ENSCAFT00000026136 8 forward ttagaagaaaggcacagg
MFN2 ENSCAFT00000026136 8 reverse ctgcctcactctcagaac
MFN2 ENSCAFT00000026136 9-10 forward ctgtctgcttagctttgg
MFN2 ENSCAFT00000026136 9-10 reverse gatgaggcgatcacttc
MFN2 ENSCAFT00000026136 11 forward gtgtgaaactgctgaggc
MFN2 ENSCAFT00000026136 11 reverse cttctggaaggctgagag
MFN2 ENSCAFT00000026136 12 forward ctcagggaaacttgtgcg
MFN2 ENSCAFT00000026136 12 reverse ccctgaatcactgtcctg
MFN2 ENSCAFT00000026136 13 forward ttccttgtcccttggctc
MFN2 ENSCAFT00000026136 13 reverse actaactcgttgtcaaagg
MFN2 ENSCAFT00000026136 14 forward ctgacgtggcttctcctcat
MFN2 ENSCAFT00000026136 14 reverse gggtgcctcagtcagctaag
MFN2 ENSCAFT00000026136 15 forward tttgggaattgaagagcc
MFN2 ENSCAFT00000026136 15 reverse actgagccaaagcaggag
MFN2 ENSCAFT00000026136 16 forward aactagggctcttgggaagg
MFN2 ENSCAFT00000026136 16 reverse ccaacccaggacataaggtg
MFN2 ENSCAFT00000026136 17 forward gaagtttctgcggaactgg
MFN2 ENSCAFT00000026136 17 reverse cccaagacagacaagcag
MFN2 ENSCAFT00000026136 18 forward tcacgggagcttagaatag
MFN2 ENSCAFT00000026136 18 reverse tcaaaacggtatgagacg
348
300
295
451
330
366
311
332
329
367
516
320
476
55°C Roche
55°C Roche
492
55°C Roche
65-60°C Qiagen 495
55°C Roche
55°C Roche
60°C Roche
55°C Roche
55°C Roche
55°C Roche
55°C Roche
55°C Roche
55°C Roche
Qiagen
60°C
65-60°C
55°C Roche
55°C Roche
60-50°C
60°C Roche
60°C Roche
Roche
275
457
366
390
418
60°C Roche
Qiagen
Roche
60-50°C
318
300
431
423
476
319
Roche
Roche
Roche
Qiagen
60-50°C
65-60°C
60°C
60°C
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Table III-3: Sequences of primers used to amplify the 391 bp-long cDNA region of 
interest in PMP22 for the small duplication and deletion identified in the Greek 
CMT1 cohort. *An 18 bp oligonucleotide was tagged to this primer. 
Gene Position Direction Primer sequence (5' to 3')
PMP22 exon 4 forward cctgtcgatcatcttcagca
PMP22 3' UTR reverse gggattttgggctagctctt*
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Table III-4: Variants identified in the UK CMT1 cohort along with pathogenicity predictions. 
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Table III-5: Variants identified in the Greek CMT1 cohort along with pathogenicity predictions. 
 
† parents of proband are asymptomatic with normal NCS, mother carries c.1352G>T; ‡ parents of proband are asymptomatic with normal NCS, 
father carries c.1352G>A. 
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Table III-6: Variants identified in the Yakutsk CMT1 cohort along with pathogenicity predictions. 
Gene Exon
Nucleotide 
substitution
Heterozygous/
Homozygous
Amino acid 
change
Frequency in our 
Russian CMT1 
cohort
dbSNP ID (1000 
Genomes MAF)
NHLBI 
EVS 
MAF
Polyphen-2 
prediction
SIFT 
prediction
Conservation 
across species
Literature 
References
Pathogenicity
PMP22 No variants identified
EGR2 2 c.627A>G homozygous p.Pro209Pro 2/54 (3.70%) rs224083 (0.013) 0.018 - - - - unlikely
EGR2 2 c.1086A>C both p.Arg362Arg
7/54 het. (13.0%); 
1/54 hom. (1.85%)
rs45602133 (0.065) 0.04 - - -
 Choi et al., 2004; 
Timmerman et al., 
1999
unlikely
GJB1 2 c.839G>C hemizygous p.Cys280Ser 1/10 (10%) - - benign
not 
tolerated
partially 
conserved
- likely
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APPENDIX IV  
Table IV-1: Primer sequences for PMP22 exon 4 (obtained from Kim et al., 2003) 
and housekeeping gene ACTBL2 for confirmation of the Chr17p11.2 duplication in 
CMT1A cases using SYBR
 
Green I chemistry.  
Gene Ensembl transcript Exon Direction Primer sequence (5' to 3')
Amplicon 
length (bp)
PMP22 ENST00000312280 4 forward tctgtccaggccaccatga
PMP22 ENST00000312280 4 reverse gaagagttggcagaagaacagga
ACTBL2 ENST00000423391 1 forward ttgagtccagtgggatccat
ACTBL2 ENST00000423391 1 reverse catggtgctccctccagata
75
110
 
Table IV-2: Sequences of primers used to amplify the PMP22 upstream promoter 
region and non-coding exon 1A.  
Gene Ensembl transcript Fragment Direction
Primer sequence (5' 
to 3')
Annealing 
temperature
PCR 
protocol
Amplicon 
length (bp)
PMP22 ENST00000312280 fragment 1 forward aggcaggtaacagggagtc
PMP22 ENST00000312280 fragment 1 reverse tcttgtaaagcataggcacac
PMP22 ENST00000312280 fragment 2 forward gcttcagttacagggagcacc
PMP22 ENST00000312280 fragment 2 reverse acatcacccagaggcacagtt
62-52°C Roche 744
62-52°C Roche 215
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Table IV-3: Phenotypes of the 187 CMT1A patients who passed the quality control 
measures in the Immunochip association study. Scores in bold were excluded from 
the mild versus severe CMT1A, mild CMT1A versus controls and severe CMT1A 
versus controls analyses. 
Gender AAE CMTES
Age-corrected 
CMTES
F 22 6 -0.364267
F 42 8 -1.477967
F 15 8 2.725528
M 41 9 -0.322282
M 57 9 -2.813242
M 15 5 -0.274472
M 46 2 -8.100707
F 20 1 -5.052897
M 55 12 0.498128
M 14 7 1.881213
M 14 3 -2.118787
F 27 0 -7.142692
F 8 5 0.815323
M 80 15 -0.393997
F 30 2 -5.609747
M 15 12 6.725528
F 56 13 1.342443
F 16 3 -2.430157
F 66 13 -0.214407
M 23 9 2.480048
M 24 10 3.324363
M 56 17 5.342443
M 45 11 1.054978
M 23 6 -0.519952
F 48 13 2.587923
M 39 5 -4.010912
F 62 14 1.408333
F 64 17 4.096963
F 73 20 5.695798
F 52 13 1.965183
M 42 10 0.522033
F 40 14 4.833403
M 36 9 0.456143
M 58 10 -1.968927
M 17 9 3.414158
M 44 7 -2.789337
F 33 8 -0.076802
M 18 2 -3.741527
F 14 9 3.881213
F 54 18 6.653813
M 56 15 3.342443  
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Gender AAE CMTES
Age-corrected 
CMTES
F 57 17 5.186758
F 59 14 1.875388
M 49 8 -2.567762
M 60 17 4.719703
F 63 11 -1.747352
F 64 9 -3.903037
F 43 4 -5.633652
F 46 14 3.899293
F 28 11 3.701623
M 54 8 -3.346187
F 47 8 -2.256392
F 56 10 -1.657557
F 58 13 1.031073
M 40 3 -6.166597
F 62 8 -4.591667
F 54 15 3.653813
F 17 10 4.414158
F 56 9 -2.657557
F 43 11 1.366348
F 65 22 8.941278
M 60 10 -2.280297
F 65 11 -2.058722
F 31 8 0.234568
F 30 9 1.390253
F 42 9 -0.477967
F 56 10 -1.657557
F 62 13 0.408333
M 38 8 -0.855227
F 47 11 0.743608
F 62 13 0.408333
M 34 4 -4.232487
F 27 9 1.857308
F 40 7 -2.166597
F 41 4 -5.322282
M 43 11 1.366348
M 55 14 2.498128
M 48 1 -9.412077
M 56 17 5.342443
F 54 6 -5.346187
F 53 11 -0.190502  
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Gender AAE CMTES
Age-corrected 
CMTES
F 56 8 -3.657557
M 47 12 1.743608
F 35 9 0.611828
F 73 14 -0.304202
F 63 9 -3.747352
F 49 9 -1.567762
M 56 12 0.342443
F 45 10 0.054978
M 32 9 1.078883
F 66 15 1.785593
F 33 7 -1.076802
M 15 4 -1.274472
M 54 10 -1.346187
F 29 11 3.545938
M 45 3 -6.945022
F 37 11 2.300458
M 64 17 4.096963
M 9 2 -2.340362
F 68 3 -10.525777
M 42 12 2.522033
M 8 5 0.815323
F 48 8 -2.412077
M N/A 3 N/A
F 40 10 0.833403
F N/A 7 N/A
F 11 3 -1.651732
M 45 2 -7.945022
M 70 19 5.162853
F 62 15 2.408333
M 53 19 7.809498
F 58 2 -9.968927
M 74 8 -6.459887
M 30 7 -0.609747
F 37 14 5.300458
M 61 19 6.564018
M 58 25 13.031073
F 63 6 -6.747352
M 39 13 3.989088
M 67 19 5.629908
F 10 12 7.503953
M 66 17 3.785593  
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Gender AAE CMTES
Age-corrected 
CMTES
F 64 5 -7.903037
F 42 5 -4.477967
M 73 13 -1.304202
M 25 10 3.168678
M 5 4 0.282378
M 44 1 -8.789337
M 6 2 -1.873307
F 55 16 4.498128
M 48 13 2.587923
F 42 3 -6.477967
M 55 8 -3.501872
F 38 16 7.144773
F 27 6 -1.142692
M 22 8 1.635733
F 49 14 3.432238
F 29 14 6.545938
M 36 9 0.456143
M 64 16 3.096963
M 18 10 4.258473
M 71 16 2.007168
M 72 15 0.851483
M 58 6 -5.968927
F 61 12 -0.435982
M 57 15 3.186758
M 63 13 0.252648
F 56 14 2.342443
M 43 11 1.366348
M 63 23 10.252648
F 53 5 -6.190502
F 51 11 0.120868
F 50 8 -2.723447
M 57 11 -0.813242
F 40 5 -4.166597
F 53 19 7.809498
F 22 4 -2.364267
F 46 4 -6.100707
F 48 13 2.587923
M 41 10 0.677718
F 22 14 7.635733
F 54 10 -1.346187
M 32 7 -0.921117  
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Gender AAE CMTES
Age-corrected 
CMTES
F 41 6 -3.322282
M 78 7 -8.082627
F 22 19 12.635733
F 37 17 8.300458
M 68 15 1.474223
F 53 7 -4.190502
M 24 8 1.324363
F 55 12 0.498128
M 70 11 -2.837147
M 60 15 2.719703
M 56 15 3.342443
F 40 10 0.833403
M 20 9 2.947103
F 56 7 -4.657557
F 39 11 1.989088
F 47 10 -0.256392
M 55 21 9.498128
F 36 8 -0.543857
M 48 8 -2.412077
M 42 12 2.522033
F 30 12 4.390253
F 29 14 6.545938
M 60 18 5.719703
M 54 19 7.653813  
Command lines used in gPLINK for Immunochip file conversion and quality control: 
1) To create a BED file set for combined control and CMT1A/CIDP data using 
“generate fileset”  “standard input”  “select PED and MAP files” (“allow no 
sex” option is used to ignore gender): 
“working directory”  --map “MAP file with data" --ped "PED file with data" --
allow-no-sex --make-bed --out "name of output file" –gplink 
2) To create file with controls only: 
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“working directory” --keep “Text file with list of control IDs” –bfile “BED file 
created in step 1” --allow-no-sex --make-bed --out "name of output file" –gplink 
3) To apply HWE threshold in BED file with control data: 
“working directory” --hwe 0.001 --bfile "BED file with control data created in 
step 2" --allow-no-sex --make-bed --out “name of output file" –gplink 
4) To create a list of SNPs found in the control BED file (after filtering using HWE 
threshold) using “create plink command”: 
“working directory”  --bfile "BED file with filtered control data created in step 
3" -–allow-no-sex --write-snplist --out "name of output file" –gplink 
5) To exclude CMT1A samples which failed the “per individual”  uality control 
measures: 
“working directory” --remove “Text file with list of IDs to exclude” –bfile “BED 
file created in step 1” --allow-no-sex --make-bed --out "name of output file" –
gplink 
6) To keep only SNPs which passed HWE test in the control dataset (list created in 
step 4) in the combined controls/CMT1A/CIDP BED file: 
“working directory”  --extract "SNP list created in step 4"  --bfile " BED file 
created in step 5" --allow-no-sex --make-bed --out "name of output file" --
gplink  
7) To perform further “per SNP” and “per individual”  uality control measures in 
controls, CIDP and CMT1A (all three combined) including removal of all markers 
with a very low MAF (MAF<0.01), exclusion of SNPs with a genotype rate below 
90%, and removal of all individuals with more than 10% missing genotypes: 
 385 
“working directory”  --maf 0.01 --geno 0.1 --mind 0.1 --bfile "BED file created 
in step 6" --allow-no-sex --make-bed --out "name of output file" –gplink 
8) Using FAM file updated in step 7, modify file as appropriate for association 
analyses: in fourth column, label cases (or severe cases) as “2”, controls (or mild 
cases) as “1” and samples to exclude as “-9”. 
Command lines used in gPLINK for Immunochip allelic association analyses: 
9) To perform allelic association test on entire chip with 95% CI, QQ plot option and 
100,000 permutations: 
“working directory” --bfile "BED file modified in step 8" --assoc --ci 0.95 --
mperm 100000 --adjust --allow-no-sex --qq-plot --out "name of output file" –
gplink 
10) To select for HLA region: 
“working directory” --chr  6 --from-kb 25900 --to-kb 33500  --bfile "BED file 
modified in step 8" --allow-no-sex --make-bed --out "name of output file" --
gplink 
11) To perform allelic association test on HLA region with 95% CI, QQ plot option 
and 100,000 permutations: 
“working directory” --bfile "BED file modified in step 10" --assoc --ci 0.95 --
mperm 100000 --adjust --allow-no-sex --qq-plot --out "name of output file" –
gplink 
12) To extract SNPs in LD in HLA region: 
“working directory” --bfile "BED file modified in step 10" --indep 50 5 2 --
allow-no-sex --out "name of output file" –gplink 
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13) To keep only pruned in SNPs (SNPs not in LD): 
“working directory” --extract "file with prune.in extension created in step 12"  -
-bfile "BED file modified in step 10" --allow-no-sex --make-bed --out "name of 
output file" --gplink 
14) To perform allelic association test on pruned HLA region with 95% CI, QQ plot 
option and 100,000 permutations: 
“working directory” --bfile "BED file created in step 13" --assoc --ci 0.95 --
mperm 100000 --adjust --allow-no-sex --qq-plot --out "name of output file" –
gplink 
Code used in R software package for QQ plot creation: 
data=read.table("file with .adjusted extension from association analyses in gPLINK", 
header=TRUE) 
data$QQ=-log(data$QQ, 10) 
data$UNADJ=-log(data$UNADJ,10) 
p <- ggplot(data) +geom_point(aes(x=data$QQ,y=data$UNADJ),alpha=.5) + 
  xlab("expected-logP values") + ylab("observed -logP values") + 
  labs(title=file) + 
  geom_abline(slope = 1, intercept = 0, color="red",size=1) 
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Table IV-4: Results of remaining allelic association analyses on the Immunochip. 
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Figure IV-1: QQ plots generated for further quality control of Immunochip allelic association analyses. 
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Figure IV-2: SNP cluster plots and call rates of all top hits (SNPs) in the 
Immunochip allelic association analyses (from GenomeStudio). Dots in red, purple 
and blue represent the three possible genotypes; dots in grey represent individuals 
excluded by quality control measures; dots in black represent a SNP which did not fit 
in any of the three genotype clusters in an individual (genotype was not called for 
this SNP for this individual). 
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APPENDIX V  
Table V-1: Transcript references used for primer design, as well as primer sequences 
and PCR cycling conditions for MFF primers.  
Gene Ensembl transcript Exon Direction Primer sequence (5' to 3')
Annealing 
temperature
PCR protocol
Amplicon 
length (bp)
MFF ENST00000353339 3 forward ttcaaatccaaaagtcattttacg
MFF ENST00000353339 3 reverse ccgccaatacaaaagctgat
MFF ENST00000353339 4 forward tgagaagtttcctttcgctctt
MFF ENST00000353339 4 reverse tgcattttccaactccttttc
MFF ENST00000353339 5 forward tgggtggtataattcaaaagca
MFF ENST00000353339 5 reverse aagctttcatgacatattgctaaaga
MFF ENST00000353339 6 forward gcaattcttggttgcctttt
MFF ENST00000353339 6 reverse gaccaacaaaatggccaga
MFF ENST00000353339 7 forward gggtatgagagcaggagcac
MFF ENST00000353339 7 reverse tttgagaaatcctgaaacagagg
MFF ENST00000353339 8 forward ggaaaggggcaagaacacta
MFF ENST00000353339 8 reverse gctgtttcaaatcattgcatct
MFF ENST00000353339 9 forward ggaggacacatgagacaagga
MFF ENST00000353339 9 reverse tcgaggaaagctgtagaaacaa
MFF ENST00000353339 10 forward tgtagacagttgtcattttaagctttt
MFF ENST00000353339 10 reverse tttgatagtcccacaggagagaa
MFF ENST00000353339 11 forward caaatgaaactttccatgtttgt
MFF ENST00000353339 11 reverse tggcatacaatgcagagaca
394
398
400
356
389
357
65-60°C Roche
65-60°C Roche
65-60°C Roche
65-60°C Roche
65-60°C Roche
65-60°C Roche
65-60°C Roche 399
65-60°C Roche
65-60°C Roche
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Table V-2: Coverage in neuropathy genes in individuals II-1 and II-3 of CMT 
family IS (only genes with at least one poorly covered exon are shown). 
Gene Poorly covered exon(s)
PMP22 exon 2
MPZ exon 1
NEFL exon 1
NDRG1 exon 16
PRX exons 5 and 7
FIG4 exon 1
CTDP1 exon 8
GARS exon 1
DNM2 exons 1 and 21
DYNC1H1 exon 1
LRSAM1 exons 10, 16, and 25
SPTLC2 exon 1
LMNA exon 1
MTMR13 exon 1
IGHMBP2 exons 1 and 9 to 11
PDK3 exon 12
SEPT9 exons 1, 7, 9
DNMT1 poor coverage throughout
HSP27 exon 1
KIF1A poor coverage throughout
KIF5A exons 12, 14, 16, 21, 24, 26 a nd 28  
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Table V-3: Coverage in neuropathy genes in individual II-1 of family AD (only 
genes with at least one poorly covered exon are shown).  
Gene Poorly covered exon(s)
PMP22 exon 2
NEFL exon 1
EGR2 exon 3
NDRG1 exon 16
PRX poor coverage throughout
FIG4 exon 1
CTDP1 exon 8
TRPV4 exon 11
GARS exon 1
DNM2 exons 1 and 21
DYNC1H1 exon 1
LRSAM1 exons 16 and 25
SPTLC1 exon 1
SPTLC2 exon 1
HARS exon 1
LMNA poor coverage throughout
MTMR13 exon 1
IGHMBP2 poor coverage throughout
PDK3 exon 1
MARS exon 1
SEPT9 poor coverage throughout
DNMT1 poor coverage throughout
HSP27 exon 1
KIF1A poor coverage throughout  
Table V-4: Variants identified in MFF candidate gene in CMT2/dHMN/HSP 
patients. 
Gene
Nucleotide 
substitution Amino acid change dbSNP ID 1000 Genomes MAF
MFF c.19A>T p.Ser7Cys rs3211097 0.196
MFF c.363G>A p.Thr121Thr rs11557342 0.074
MFF c.921A>G p.Leu307Leu rs74713223 0.147  
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APPENDIX VI  
Table VI-1: Reported pathogenic mutations found in the homozygous or compound 
heterozygous state in SLC52A1, SLC52A2 and SLC52A3 (adapted from Bosch et al., 
2012). *c.106G>A and c.1237T>C were found in the cis configuration; only the 
c.106G>A change was predicted to be pathogenic. **considered unlikely to be 
pathogenic and/or found in unaffected individuals. ***found in the heterozygous 
state; no other mutation found in gene. ****c.1127A>G and c.1203instT were found 
in the cis configuration. 
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Table VI-2: Polymorphisms reported in SLC52A1, SLC52A2, and SLC52A3 in the 
UCL HEX, EVS, dbSNP and 1000 Genomes databases.   
Gene dbSNP ID Position Alleles Type
Amino acid 
change
HEX genotype 
count
EVS 
MAF (%)
dbSNP/1000 
Genomes MAF
SLC52A1 rs200539588 4936262 C/A non-synonymous C446F N/A N/A 0.001
SLC52A1 rs377601117 4936272 C/A non-synonymous V443L N/A 0.0077 N/A
SLC52A1 rs148979394 4936278 C/G non-synonymous D441H N/A 0.0846 0.002
SLC52A1 rs72822610 4936336 A/T synonymous L421L
AA=130/AT=4
9/TT=3
14.1 0.115
SLC52A1 rs148131990 4936339 C/T synonymous L420L N/A N/A 0.001
SLC52A1 rs202032568 4936345 G/A synonymous G418G N/A N/A 0.001
SLC52A1 rs147687964 4936358 G/A non-synonymous A414V N/A 0.0077 N/A
SLC52A1 rs142353672 4936359 C/T non-synonymous A414T N/A 0.0077 N/A
SLC52A1 rs112874988 4936370 G/T non-synonymous A410E N/A 0.0538 0.001
SLC52A1 rs148063153 4936376 A/G non-synonymous L408S N/A 0.077 N/A
SLC52A1 rs373765126 4936382 G/A non-synonymous P406L N/A 0.0154 N/A
SLC52A1 rs377522935 4936403 A/G non-synonymous L399P N/A 0.0077 N/A
SLC52A1 rs187609896 4936443 G/C non-synonymous L386V N/A N/A 0.002
SLC52A1 rs201578619 4936457 G/A non-synonymous S381L N/A N/A 0.002
SLC52A1 rs370773962 4936460 A/G non-synonymous L380P N/A 0.077 N/A
SLC52A1 N/A 4936468 C/T splice variant N/A N/A N/A N/A
SLC52A1 rs192857700 4936572 G/A non-synonymous A373V N/A N/A N/A
SLC52A1 rs140906879 4936585 C/T non-synonymous V369M N/A 0.077 N/A
SLC52A1 rs200594561 4936587 A/G non-synonymous L368P N/A N/A 0.002
SLC52A1 N/A 4936597 N/A frameshift C365Afs*28 N/A 0.0479 N/A
SLC52A1 N/A 4936627 N/A frameshift Y355Tfs*2 N/A 0.1678 N/A
SLC52A1 rs375892458 4936667 C/T synonymous G341G N/A 0.0077 N/A
SLC52A1 rs150164483 4936784 C/T non-synonymous V334M N/A 0.0231 0.001
SLC52A1 rs374646797 4936785 G/A synonymous G333G N/A 0.0077 N/A
SLC52A1 rs184838357 4936793 C/G non-synonymous A331P N/A N/A 0.001
SLC52A1 rs200412989 4936813 T/G non-synonymous N324T N/A N/A 0.001
SLC52A1 rs140073463 4936818 G/A synonymous A322A N/A N/A 0.001
SLC52A1 rs9897165 4936855 C/T non-synonymous R310H N/A 0.8458 0.006
SLC52A1 rs141719111 4936861 T/C non-synonymous Y308C N/A 0.0538 N/A
SLC52A1 rs2304445 4936898 C/T non-synonymous V296M
CC=132/CT=4
4/TT=6
15.44 0.268
SLC52A1 rs367746302 4936899 G/A synonymous G295G N/A 0.0077 N/A
SLC52A1 N/A 4936934 N/A insertion
L283_G284 
insL
N/A 0.008 N/A
SLC52A1 rs137917213 4936969 T/A non-synonymous H272L N/A 0.0308 N/A
SLC52A1 rs346821 4936972 G/A non-synonymous A271V
GG=24/GA=75
/AA=83
31.1779 0.445
SLC52A1 rs371915134 4936980 G/A synonymous D268D N/A 0.0077 N/A
SLC52A1 rs143848711 4936984 G/A non-synonymous P267L N/A 0.0077 N/A
SLC52A1 rs200049864 4937013 C/T synonymous P257P N/A N/A 0.001
SLC52A1 rs199704379 4937014 G/A non-synonymous P257L N/A 0.0077 N/A
SLC52A1 rs148611457 4937029 G/A non-synonymous P252L N/A 0.0154 N/A
SLC52A1 rs369106349 4937051 T/C non-synonymous K245E N/A 0.0077 N/A
SLC52A1 rs142480426 4937067 T/C synonymous G239G N/A 0.0077 N/A
SLC52A1 rs150901297 4937075 A/G non-synonymous S237P N/A 0.0154 N/A
SLC52A1 rs373793198 4937105 C/T non-synonymous G227R N/A 0.0077 N/A
SLC52A1 rs377338075 4937149 C/T non-synonymous R212Q N/A 0.0077 N/A
SLC52A1 rs370188723 4937150 G/A non-synonymous R212W N/A 0.0077 N/A
SLC52A1 rs373142659 4937151 G/A synonymous F211F N/A 0.0077 N/A
SLC52A1 rs376918815 4937153 A/G non-synonymous F211L N/A 0.0077 N/A
SLC52A1 rs139373407 4937156 C/T non-synonymous A210T N/A 0.0384 0.001
SLC52A1 rs145524474 4937169 G/C synonymous V205V N/A 0.0154 N/A
SLC52A1 N/A 4937196 N/A frameshift F196Sfs*5 N/A 0.016 N/A  
 406 
SLC52A1 rs200459465 4937203 C/T non-synonymous S194N N/A N/A 0.001
SLC52A1 rs147698089 4937222 G/A non-synonymous P188S N/A 0.0077 N/A
SLC52A1 rs142091289 4937231 G/A non-synonymous L185F N/A N/A 0.001
SLC52A1 rs144716094 4937274 G/A synonymous L170L N/A 0.1538 0.001
SLC52A1 rs201198708 4937279 G/A non-synonymous R169C N/A N/A 0.001
SLC52A1 rs374197009 4937311 G/A non-synonymous P158L N/A 0.0077 N/A
SLC52A1 rs368344539 4937331 C/G non-synonymous Q151H N/A 0.0154 N/A
SLC52A1 rs370325558 4937349 C/T synonymous R145R N/A 0.0077 N/A
SLC52A1 rs374174324 4937350 C/T non-synonymous R145Q N/A 0.0077 N/A
SLC52A1 rs56126318 4937351 G/T synonymous R145R
GG=157/GT=2
4/TT=1
6.3125 0.07
SLC52A1 rs200268874 4937368 A/G non-synonymous L139P N/A N/A N/A
SLC52A1 rs148924968 4937379 G/A synonymous F135F N/A 0.0077 N/A
SLC52A1 rs143199804 4937388 G/C non-synonymous F132L N/A 0.0077 N/A
SLC52A1 rs146289149 4937413 G/A non-synonymous A124V N/A 0.5382 0.009
SLC52A1 rs140348114 4937414 C/T non-synonymous A124T N/A 0.0077 N/A
SLC52A1 rs368167047 4937420 C/T non-synonymous A122T N/A 0.0077 N/A
SLC52A1 rs371340617 4937481 G/A synonymous H101H N/A 0.0077 N/A
SLC52A1 N/A 4937481 G/C non-synonymous H101Q
GG=180/GC=2
/CC=0
N/A N/A
SLC52A1 rs375943631 4937492 G/A synonymous L98L N/A 0.0077 N/A
SLC52A1 rs187721459 4937505 G/A synonymous A93A N/A 0.0077 0.001
SLC52A1 rs145407203 4937534 C/T non-synonymous V84I
CC=181/CT=1/
TT=0
N/A N/A
SLC52A1 N/A 4937539 N/A frameshift Q82Gfs*47 N/A 0.008 N/A
SLC52A1 rs376978383 4937555 C/T non-synonymous E77K N/A 0.0077 N/A
SLC52A1 rs201983129 4937565 C/T synonymous P73P N/A 0.0077 0.002
SLC52A1 rs137937212 4937566 G/A non-synonymous P73L N/A 0.0077 N/A
SLC52A1 rs346822 4937575 T/C non-synonymous Q70R
TT=0/TC=18/
CC=164
4.498 0.074
SLC52A1 rs150112294 4937576 G/A stop-gained Q70* N/A 0.0077 N/A
SLC52A1 rs201707443 4937595 C/T synonymous L63L N/A N/A 0.001
SLC52A1 rs138410039 4937617 G/A non-synonymous A56V N/A 0.1384 N/A
SLC52A1 rs200242588 4937777 G/A non-synonymous P42L N/A N/A N/A
SLC52A1 rs372498524 4937779 A/G synonymous L41L N/A 0.0077 N/A
SLC52A1 rs199742635 4937817 C/T non-synonymous G29R N/A N/A 0.001
SLC52A1 rs377033431 4937818 G/A synonymous N28N N/A 0.0077 N/A
SLC52A1 rs201477941 4937879 C/T non-synonymous R8H N/A 0.0077 0.001  
Gene dbSNP ID Position Alleles Type
Amino acid 
change
HEX genotype 
count
EVS 
MAF (%)
dbSNP/1000 
Genomes MAF
SLC52A2 rs141698844 145583036 A/G non-synonymous N28S N/A 0.0308 0.001
SLC52A2 rs200102613 145583037 T/C synonymous N28N N/A N/A 0.002
SLC52A2 rs150137023 145583309 G/C non-synonymous V53L N/A 0.0077 N/A
SLC52A2 rs372988060 145583329 C/T synonymous N59N N/A 0.0077 N/A
SLC52A2 rs201213634 145583330 C/T synonymous L60L N/A N/A 0.001
SLC52A2 rs201246554 145583344 G/C synonymous V64V N/A N/A 0.001
SLC52A2 rs111588500 145583380 C/T synonymous D76D N/A 0.123 0.002
SLC52A2 rs377110942 145583397 G/A non-synonymous R82Q N/A 0.077 N/A
SLC52A2 N/A 145583444 N/A frameshift H100Pfs*13 N/A 0.0399 N/A
SLC52A2 rs146256291 145583461 C/T synonymous A103A N/A N/A 0.002
SLC52A2 rs376031054 145583470 A/G synonymous A106A N/A 0.0077 N/A
SLC52A2 rs370812676 145583504 G/A non-synonymous A118T N/A 0.0077 N/A
SLC52A2 rs117500243 145583505 C/A non-synonymous A118D
CC=181/CA=1
/AA=0
0.3076 0.002
SLC52A2 rs74445699 145583511 T/C non-synonymous V120A N/A N/A 0.004
SLC52A2 rs146274588 145583522 G/T non-synonymous A124S N/A N/A N/A
SLC52A2 rs200753132 145583523 C/T non-synonymous A124V N/A N/A 0.001
SLC52A2 rs374071862 145583535 C/T non-synonymous S128L N/A 0.0154 N/A
SLC52A2 rs140003920 145583536 G/A synonymous S128S N/A 0.0384 N/A  
 407 
SLC52A2 rs199864300 145583562 G/A non-synonymous S137N N/A N/A N/A
SLC52A2 rs377740960 145583573 C/T non-synonymous P141S N/A 0.0077 N/A
SLC52A2 rs371376526 145583608 C/T synonymous G152G N/A 0.0077 N/A
SLC52A2 rs376026812 145583615 G/T non-synonymous A155S N/A 0.0077 N/A
SLC52A2 rs141953803 145583630 G/A non-synonymous V160M N/A 0.0154 N/A
SLC52A2 rs142879103 145583686 C/T synonymous N178N N/A 0.0077 N/A
SLC52A2 rs151081625 145583687 G/A non-synonymous G179S N/A 0.0615 0.001
SLC52A2 rs202232509 145583703 C/A non-synonymous P184Q N/A N/A 0.001
SLC52A2 rs74370046 145583707 C/T synonymous L185L N/A 0.0615 0.023
SLC52A2 rs201705744 145583720 C/T non-synonymous R190C N/A N/A 0.001
SLC52A2 rs200455766 145583750 C/T synonymous L200L N/A N/A 0.001
SLC52A2 rs187632310 145583758 C/T synonymous A202A N/A N/A 0.001
SLC52A2 rs144883729 145583765 G/A non-synonymous V205I N/A 0.0154 N/A
SLC52A2 rs367886725 145583787 A/T non-synonymous Q212L N/A 0.0077 N/A
SLC52A2 rs147954962 145583795 C/T synonymous L215L N/A 0.1 0.001
SLC52A2 rs370367859 145583802 T/A non-synonymous L217Q N/A 0.0077 N/A
SLC52A2 rs374006728 145583808 C/T non-synonymous P219L N/A 0.0077 N/A
SLC52A2 rs141909863 145583809 G/A synonymous P219P N/A 0.0077 N/A
SLC52A2 rs367852733 145583841 G/A non-synonymous G230E N/A 0.0077 N/A
SLC52A2 rs373923619 145583861 G/C non-synonymous A237P N/A 0.0077 N/A
SLC52A2 rs200533281 145583932 C/T synonymous T260T N/A N/A 0.001
SLC52A2 rs372057075 145583958 A/G non-synonymous Y269C N/A 0.0077 N/A
SLC52A2 rs375088539 145583960 C/T stop-gained Q270* N/A 0.0077 N/A
SLC52A2 rs145009003 145583974 C/A synonymous A274A N/A 0.0077 N/A
SLC52A2 rs144912258 145583976 G/A non-synonymous R275H N/A 0.0692 N/A
SLC52A2 rs368287241 145584004 C/T synonymous A284A N/A 0.0077 N/A
SLC52A2 rs372376214 145584033 T/C non-synonymous L294P N/A 0.0077 N/A
SLC52A2 rs375399467 145584040 C/T synonymous A296A N/A 0.0077 N/A
SLC52A2 rs369031014 145584048 G/C non-synonymous S299T N/A 0.0077 N/A
SLC52A2 rs149050347 145584070 G/A synonymous G306G N/A 0.0077 N/A
SLC52A2 rs143091206 145584072 G/A non-synonymous R307H N/A 0.0385 0.001
SLC52A2 rs370929795 145584100 G/A synonymous L316L N/A 0.0154 N/A
SLC52A2 rs371669411 145584131 C/G non-synonymous L327V N/A 0.0077 N/A
SLC52A2 rs148234606 145584264 T/C non-synonymous L339P N/A 0.0154 N/A
SLC52A2 rs140307485 145584265 G/C synonymous L339L N/A 0.0077 N/A
SLC52A2 rs145502954 145584287 G/A non-synonymous V347M N/A 0.1 0.001
SLC52A2 N/A 145584295 N/A frameshift G351Afs*3 N/A 0.008 N/A
SLC52A2 rs200618841 145584313 G/T synonymous A355A N/A N/A 0.001
SLC52A2 rs138107380 145584314 C/T synonymous L356L N/A 0.1076 N/A
SLC52A2 rs142697341 145584322 C/T synonymous V358V N/A 0.0308 N/A
SLC52A2 rs146292053 145584337 G/A synonymous P363P
GG=178/GA=1
/AA=1
0.2384 0.005
SLC52A2 rs138160033 145584354 C/T non-synonymous S369L N/A 0.0154 N/A
SLC52A2 rs149575570 145584361 G/A synonymous G371G N/A 0.0231 N/A
SLC52A2 rs374615555 145584362 G/T non-synonymous V372L N/A 0.0077 N/A
SLC52A2 rs200631895 145584364 G/C synonymous V372V N/A N/A 0.001
SLC52A2 rs200245353 145584366 T/G non-synonymous V373G N/A N/A 0.002
SLC52A2 rs144290224 145584370 C/T synonymous L374L N/A 0.0615 0.002
SLC52A2 rs71691497 145584373 N/A deletion N/A N/A N/A N/A
SLC52A2 rs376552382 145584490 G/A non-synonymous V385M N/A 0.0077 N/A
SLC52A2 rs148754028 145584500 A/G non-synonymous Y388C N/A 0.0461 0.001
SLC52A2 rs370533575 145584501 C/T synonymous Y388Y N/A 0.0077 N/A
SLC52A2 rs374011301 145584510 G/A synonymous V391V N/A 0.0231 N/A
SLC52A2 rs368448590 145584528 G/A synonymous L397L N/A 0.0077 N/A
SLC52A2 rs144821688 145584534 C/T synonymous G399G N/A 0.0077 N/A
SLC52A2 rs371806077 145584541 C/T non-synonymous R402W N/A 0.0077 N/A
SLC52A2 rs374612342 145584546 G/A synonymous P403P N/A 0.0077 N/A
SLC52A2 rs368749792 145584558 A/T synonymous A407A N/A 0.0077 N/A
SLC52A2 rs371456902 145584561 C/T synonymous A408A N/A 0.0077 N/A
SLC52A2 rs147518188 145584564 C/T synonymous G409G N/A 0.0154 0.001
SLC52A2 rs140177553 145584576 G/A synonymous Q413Q N/A 0.0077 N/A
SLC52A2 rs199767089 145584594 C/T synonymous G419G N/A 0.0077 0.001
SLC52A2 rs368924997 145584595 G/A non-synonymous A420T N/A 0.0077 N/A
SLC52A2 N/A 145584601 N/A frameshift A422Vfs*67 N/A 0.008 N/A
 408 
SLC52A2 rs201673476 145584614 C/T non-synonymous P426L
CC=181/CT=1/
TT=0
N/A 0.001
SLC52A2 rs184190914 145584630 C/T synonymous H431H N/A N/A 0.001
SLC52A2 rs202178971 145584631 G/A non-synonymous V432M N/A N/A 0.001
SLC52A2 rs372200881 145584644 G/A non-synonymous R436K N/A 0.0077 N/A
SLC52A2 rs189845609 145584657 A/G synonymous A440A N/A N/A 0.001
SLC52A2 rs75165898 145584658 G/T non-synonymous D441Y N/A N/A N/A  
Gene dbSNP ID Position Alleles Type
Amino acid 
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SLC52A3 rs369872639 741694 G/T non-synonymous F462L N/A 0.008 N/A
SLC52A3 rs140360713 741699 C/A non-synonymous D461Y
CC=172/CA=1
/AA=0
0.0397 0.002
SLC52A3 N/A 741706 C/A synonymous S458S
CC=172/CA=1
/AA=0
N/A N/A
SLC52A3 rs145431028 741709 G/C non-synonymous F457L N/A 0.0548 N/A
SLC52A3 rs371883183 741741 T/C non-synonymous M447V N/A 0.0078 N/A
SLC52A3 rs138169890 741760 C/T synonymous S440S N/A 0.0078 N/A
SLC52A3 rs149534355 741792 A/G synonymous L430L N/A 0.0234 N/A
SLC52A3 rs113063693 741796 G/A non-synonymous A428A N/A N/A N/A
SLC52A3 rs139137879 741802 G/A synonymous R426R N/A 0.0234 0.001
SLC52A3 rs369230517 741810 G/A non-synonymous L424F N/A 0.0078 N/A
SLC52A3 rs200665228 741815 C/G non-synonymous R422P N/A N/A 0.001
SLC52A3 rs267606687 741842 A/G non-synonymous V413A N/A N/A N/A
SLC52A3 rs910857 741847 A/G synonymous S411S
AA=24/AG=58
/GG=95
29.77 0.392
SLC52A3 rs370820845 742370 C/T non-synonymous G391D N/A 0.0077 N/A
SLC52A3 rs374085235 742426 G/A synonymous C372C N/A 0.0077 N/A
SLC52A3 rs148181353 742440 C/T non-synonymous V368M N/A 0.0077 N/A
SLC52A3 rs367957442 742459 C/G synonymous L361L N/A 0.0077 N/A
SLC52A3 rs76947760 744167 A/T non-synonymous L350M N/A 1.6992 0.018
SLC52A3 rs147369439 744168 C/T synonymous S349S
CC=181/CT=1/
TT=0
0.0769 0.002
SLC52A3 rs139542858 744206 C/T non-synonymous A337T N/A 0.0077 N/A
SLC52A3 rs376546378 744228 A/G synonymous Y329Y N/A 0.0154 N/A
SLC52A3 rs62641669 744234 C/G synonymous L327L N/A 0.1076 0.016
SLC52A3 rs368434500 744246 G/A synonymous T323T N/A 0.0077 N/A
SLC52A3 rs147508914 744261 C/T synonymous L318L N/A 0.0077 N/A
SLC52A3 rs200604650 744263 G/A synonymous L318L N/A N/A 0.001
SLC52A3 rs372400886 744269 C/T non-synonymous G316S N/A 0.0077 N/A
SLC52A3 rs139430185 744270 G/A synonymous N315N N/A 0.0308 N/A
SLC52A3 rs6054602 744279 C/T synonymous A312A N/A 0.1153 0.002
SLC52A3 rs374661714 744281 C/T non-synonymous A312T N/A 0.0077 N/A
SLC52A3 rs145194879 744287 C/T non-synonymous V310I N/A 0.0154 N/A
SLC52A3 rs201254395 744301 G/T non-synonymous T305N N/A N/A 0.001
SLC52A3 rs3746802 744308 T/C non-synonymous I303V
TT=141.TC=4
1/CC=0
9.9185 0.096
SLC52A3 rs373350870 744324 C/T synonymous P297P N/A 0.0077 N/A
SLC52A3 rs201990981 744325 G/A non-synonymous P297L N/A 0.0231 N/A
SLC52A3 rs142265627 744350 C/T non-synonymous E289K N/A 0.0692 N/A
SLC52A3 rs3746803 744382 G/A non-synonymous T278M
GG=141/GA=4
1/AA=0
9.9185 0.093
SLC52A3 rs374137295 744389 C/A non-synonymous A276S N/A 0.0077 N/A
SLC52A3 rs377559449 744401 C/G non-synonymous D272H N/A 0.0077 N/A
SLC52A3 rs111912321 744412 C/T non-synonymous R268Q N/A N/A N/A
SLC52A3 rs145498634 744413 G/T synonymous R268R N/A 0.0461 N/A
SLC52A3 rs146474751 744414 C/T synonymous P267P N/A 0.0231 N/A
SLC52A3 rs3746804 744415 G/A non-synonymous P267L
GG=108/GA=6
9/AA=5
19.61 0.213
SLC52A3 rs370499474 744419 G/A non-synonymous R266W N/A 0.0077 N/A
SLC52A3 rs150159842 744428 G/A non-synonymous H263Y N/A 0.0154 N/A  
 409 
SLC52A3 rs3746805 744450 G/A synonymous L255L
GG=43/GA=10
8/AA=31
37.52 0.323
SLC52A3 rs199909033 744453 G/T non-synonymous D254E N/A N/A 0.001
SLC52A3 rs192438170 744462 G/A synonymous S251S N/A 0.0077 0.001
SLC52A3 rs148832841 744482 G/T non-synonymous P245T N/A 0.0077 N/A
SLC52A3 rs183391382 744504 C/T synonymous A237A N/A N/A 0.001
SLC52A3 rs3746806 744510 G/A synonymous L235L N/A 1.0995 0.014
SLC52A3 rs369075038 744522 C/G non-synonymous M231I N/A 0.0077 N/A
SLC52A3 rs373044162 744527 T/G non-synonymous M230L N/A 0.0077 N/A
SLC52A3 rs143511669 744539 G/A non-synonymous L226F N/A 0.0077 N/A
SLC52A3 rs267606685 744545 A/G non-synonymous F224L N/A N/A N/A
SLC52A3 rs202130911 744569 C/T non-synonymous A216T N/A N/A 0.001
SLC52A3 rs6054605 744570 G/A synonymous P215P
GG=160/GA=2
2/AA=00
4.8901 0.135
SLC52A3 rs16992990 744615 G/A synonymous P200P
GG=177/GA=5
/AA=0
0.7388 0.021
SLC52A3 rs142019192 744618 G/A synonymous L199L N/A 0.0231 N/A
SLC52A3 rs113864305 745868 T/C non-synonymous E184G N/A N/A N/A
SLC52A3 rs150702278 745871 C/T non-synonymous R183K N/A 0.0077 N/A
SLC52A3 rs139965967 745873 C/T synonymous T182T N/A 0.0846 N/A
SLC52A3 rs201100567 745874 G/A non-synonymous T182M N/A N/A 0.001
SLC52A3 rs143641819 745894 G/A synonymous S175S N/A 0.0154 N/A
SLC52A3 rs6054614 745898 T/C non-synonymous D174G N/A 1.0918 0.008
SLC52A3 rs201479216 745905 T/C non-synonymous I172V N/A N/A 0.001
SLC52A3 rs139629967 745908 C/T non-synonymous E171K N/A 0.0077 N/A
SLC52A3 rs200356747 745912 G/A non-synonymous V169V N/A N/A 0.001
SLC52A3 rs112034541 745920 C/T non-synonymous V167I N/A 0.0154 N/A
SLC52A3 rs377618514 745921 G/A synonymous C166C N/A 0.0077 N/A
SLC52A3 rs113754514 745936 G/A synonymous S161S N/A N/A N/A
SLC52A3 rs199778195 745941 C/T non-synonymous G160S N/A N/A 0.001
SLC52A3 rs3746807 745963 G/A synonymous P152P
GG=144/GA=3
8/AA=0
10.63 0.13
SLC52A3 rs146492942 745971 G/A non-synonymous L150F N/A 0.0077 N/A
SLC52A3 rs149076913 745981 T/C synonymous G146G N/A 0.0154 0.001
SLC52A3 rs142157418 746024 C/T non-synonymous R132Q N/A 0.0077 0.001
SLC52A3 rs267606684 746025 G/A non-synonymous R132W N/A N/A N/A
SLC52A3 rs11477762 746051 G/- frameshift N/A N/A N/A N/A
SLC52A3 rs151229044 746080 G/A synonymous F113F N/A 0.0461 N/A
SLC52A3 rs140391358 746091 C/A non-synonymous V110F N/A 0.0077 N/A
SLC52A3 rs3746808 746098 G/A synonymous A107A
GG=81/GA=80
/AA=21
25.57 0.252
SLC52A3 rs370718326 746100 C/T non-synonymous A107T N/A 0.0077 N/A
SLC52A3 rs201152444 746108 T/C non-synonymous H104R N/A N/A 0.001
SLC52A3 rs137861276 746116 G/A synonymous D101D N/A 0.0154 N/A
SLC52A3 rs369152341 746125 C/G non-synonymous W98C N/A 0.0077 N/A
SLC52A3 rs142064992 746169 C/T non-synonymous V84I N/A 0.0077 N/A
SLC52A3 rs200606057 746170 G/A synonymous T83T N/A 0.0077 0.001
SLC52A3 rs34376836 746179 G/A synonymous G80G N/A 1.3872 0.011
SLC52A3 rs35655964 746197 G/C non-synonymous I74M
GG=147/GC=3
5/CC=0
6.9526 0.04
SLC52A3 rs267606683 746208 C/A stop-gained E71* N/A N/A N/A
SLC52A3 rs149622425 746216 C/G non-synonymous C68S N/A 0.0154 N/A
SLC52A3 rs144337813 746225 C/T non-synonymous R65Q N/A 0.0077 N/A
SLC52A3 rs373887707 746284 C/T synonymous T45T N/A 0.0154 N/A
SLC52A3 rs267606686 746313 C/T non-synonymous E36K N/A N/A N/A
SLC52A3 rs199861879 746322 C/G non-synonymous E33Q N/A N/A 0.001
SLC52A3 rs267606688 746337 G/T non-synonymous P28T N/A N/A N/A
SLC52A3 rs199588390 746357 T/C non-synonymous N21S N/A 0.01254 0.001
SLC52A3 rs148387972 746361 T/G non-synonymous I20L
TT=181/TG=1/
GG=0
0.0231 N/A
SLC52A3 rs142206705 746371 G/C synonymous S16S N/A 0.0077 N/A
SLC52A3 rs146302587 746382 C/G non-synonymous G13R N/A 0.0077 N/A
SLC52A3 rs201545356 746389 G/A synonymous C10C N/A N/A 0.001
SLC52A3 rs139486822 746410 G/A synonymous F3F
GG=178/GA=2
/AA=0
0.8077 0.007
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Table VI-3: Transcript references used for primer design, as well as primer 
sequences and PCR cycling conditions for SLC52A1, SLC52A2 and SLC52A3 
primers. *This primer has a common SNP (rs35655964) therefore primers were 
redesigned; primer pairs labelled exon 2-1, exon 2-2B and exon 2-3 were 
subsequently used to cover exon 2 in SLC52A3. 
Gene Ensembl transcript
Exon/primer 
pair
Direction Primer sequence (5' to 3')
Annealing 
temperature
PCR protocol
Amplicon 
length (bp)
SLC52A1 ENST00000254853 primer pair 1 forward agcatctttggacctacc
SLC52A1 ENST00000254853 primer pair 1 reverse taggaaggccacagagtg
SLC52A1 ENST00000254853 primer pair 2 forward gcctgtggtggtaaaagacc
SLC52A1 ENST00000254853 primer pair 2 reverse tagggcactgagaccctgac
SLC52A1 ENST00000254853 primer pair 3 forward ctgagtgtagtgggcacag
SLC52A1 ENST00000254853 primer pair 3 reverse accatgggctgagaacag
SLC52A1 ENST00000254853 primer pair 4 forward aggaagaagaggctttgc
SLC52A1 ENST00000254853 primer pair 4 reverse acacagacacagcacccac
SLC52A1 ENST00000254853 primer pair 5 forward gagcaagtggagacatgaag
SLC52A1 ENST00000254853 primer pair 5 reverse agcctcacgatgaagacag
SLC52A2 ENST00000329994 exon 2 forward cagttcccctggtctcacc
SLC52A2 ENST00000329994 exon 2 reverse caccctctggaagctctctg
SLC52A2 ENST00000329994 exon 3-1 forward gcaggtgtgcccaagact
SLC52A2 ENST00000329994 exon 3-1 reverse gaaaacgctcaaggaagtcg
SLC52A2 ENST00000329994 exon 3-2 forward atgctgtgcctcgaatgtc
SLC52A2 ENST00000329994 exon 3-2 reverse gctcttgcagtggtgaggac
SLC52A2 ENST00000329994 exon 3-3 forward ccaccaccatctgtacccac
SLC52A2 ENST00000329994 exon 3-3 reverse gagcgagcagaatgtcagg
SLC52A2 ENST00000329994 exon 4 forward gcttttcctgcttaccctacg
SLC52A2 ENST00000329994 exon 4 reverse gagaacacgccaagacacag
SLC52A2 ENST00000329994 exon 5 forward gtggtcctcgtggtgagc
SLC52A2 ENST00000329994 exon 5 reverse caggcactcaggcatgg
SLC52A3 ENST00000217254 exon 2-1 forward tcacaggaaggggagtaataag
SLC52A3 ENST00000217254 exon 2-1 reverse ccagcacccaggaggtc
SLC52A3 ENST00000217254 exon 2-2 forward tccgaagtgcccatcatc*
SLC52A3 ENST00000217254 exon 2-2 reverse agaaggatggaggtgagcag
SLC52A3 ENST00000217254 exon 2-2B forward ctgcaggctgatctgagaaa
SLC52A3 ENST00000217254 exon 2-2B reverse agaggccgctgagtcctt
SLC52A3 ENST00000217254 exon 2-3 forward accctgctccatcacttcc
SLC52A3 ENST00000217254 exon 2-3 reverse ataggccgaccaaagaacct
SLC52A3 ENST00000217254 exon 3-1 forward gcagtcattattgccaccttg
SLC52A3 ENST00000217254 exon 3-1 reverse aggccaccagggtatagat
SLC52A3 ENST00000217254 exon 3-2 forward accaggtcaccctccactc
SLC52A3 ENST00000217254 exon 3-2 reverse taggtgcgtttggaattctg
SLC52A3 ENST00000217254 exon 4 forward tatggagacactggccatcc
SLC52A3 ENST00000217254 exon 4 reverse cccaagctctcccaggc
SLC52A3 ENST00000217254 exon 5 forward gccctgtgagagttctttgc
SLC52A3 ENST00000217254 exon 5 reverse ggcacttgcgttcatgattc
65-60°C Roche 469
65-60°C Roche 497
65-60°C Roche 498
65-60°C Roche 508
65-60°C Roche 292
65-60°C Roche 454
65-60°C Roche 378
65-60°C Roche 387
65-60°C Roche 445
65-60°C Roche 433
65-60°C Roche 450
65-60°C Roche 626
65-60°C Roche 386
65-60°C Roche 354
65-60°C Roche 410
65-60°C Roche 579
65-60°C Roche 610
65-60°C Roche 539
65-60°C Roche 485
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Table VI-4: Primer sequences and PCR cycling conditions used to determine the 
genotype of SNPs around the p.Gly306Arg mutation in SLC52A2 in Lebanese BVVL 
families. 
dbSNP ID Direction Primer sequence (5' to 3')
Annealing 
temperature
PCR protocol
Amplicon 
length (bp)
forward atacaagagcacccgtcacc
reverse ggttttcacagctccagagg
forward gcaactttgtgagcaacgag 
reverse gctccaggtccttctcactg
forward cactcaccctctggaagctc
reverse ggatctgacttggctcttgc 
forward ccttcttgaggctgttcctg
reverse ggattgggctggtcagagta 
forward caccgctatgcccaactaat
reverse cgcactgaggagcaaacata 
forward cacctgtgacctgtgacctg
reverse ctgacacctgtgcctgtacg 
forward cgacacggtctcctcactg
reverse tcttggggaagccctactct
forward tacctccatggtgccattct
reverse ccgacccctatgtggtcat
rs2280837 65-60°C Roche 276
rs2977835, 
rs2977834 
65-60°C Roche 589
rs6599528 65-60°C Roche 555
rs1052951, 
rs1052952, 
rs1871532 
65-60°C Roche 678
rs3817681 65-60°C Roche 595
rs7016335 65-60°C Roche 743
65-60°C Roche 577rs2272666
rs4993862 65-60°C Roche 358
 
Table VI-5: Primer sequences and PCR cycling conditions used for transcriptional 
analysis of SLC52A2 cDNA. 
Gene Primer pair Direction Primer sequence (5' to 3')
Annealing 
temperature
PCR protocol
Amplicon 
length (bp)
SLC52A2 primer pair 1 forward gccctaggtgggaaaagaac
SLC52A2 primer pair 1 reverse ccttgacccaggaagaatga
SLC52A2 primer pair 2 forward agttgcattctgtggccttc
SLC52A2 primer pair 2 reverse aagcaggaaaagctctgcac
SLC52A2 primer pair 3 forward gagtcctcaccactgcaaga
SLC52A2 primer pair 3 reverse aggagaacacgccaagacac
SLC52A2 primer pair 4 forward ctctgctgggcgtgttct
SLC52A2 primer pair 4 reverse gagggaaagacaggtgttgg
SLC52A2 primer pair 5 forward cagcccccatcaacggcacc  
SLC52A2 primer pair 5 reverse acccacgacagcaccacgag 
65-60°C Roche 522
65-60°C Roche 586
Primers used to check for NMD in patient E3:
60°C (35 
cycles only)
Roche 619
65-60°C Roche 427
65-60°C Roche 357
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Figure VI-1:  Chromatograms and pedigrees (where available) of SLC52A2 
mutations in BVVL cohort. Squares indicate males, circles females, shaded shapes 
affected individuals, and shapes with dots carriers. Double bars indicate 
consanguineous unions, and arrows indicate probands (adapted from Foley et al., 
2014). 
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Figure VI-2:  Chromatograms of SLC52A3 mutations in BVVL cohort. 
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Table VI-6: Results of haplotype analysis around the SLC52A2 p.Gly306Arg mutation in Lebanese BVVL families. *obligate carriers. 
Gene Name Chr Position dbSNP ID
Unaffected 
father of 
L1*
Unaffected 
mother of 
L1*
Patient L1
Affected 
sister of 
L1
Proband 
Unaffected 
father of 
proband*
Unaffected 
sister of 
proband
Unaffected 
brother of 
proband
Affected 
cousin of 
proband
Reference 
allele
Observed 
allele
Affected Unaffected
p.Gly306Arg status Het Het Hom Hom Hom Het Het Het Hom Hom Het
Downstream of FBXL6 chr8 145574775 rs7016335 CC TC CC CC CC CC CC TC CC T C Hom Het
FBXL6 chr8 145579953 rs4993862 GG N/A GG GG GG N/A N/A N/A GG T A Hom Het
FBXL6 chr8 145580984 rs2272666 GG GA GG GG GG GG GA GA GG A G Hom Het
FBXL6 chr8 145582839 rs3817681 N/A GA GG GG GG N/A GA GA GG A G Hom Het
ADCK5 chr8 145603114 rs6599528 CC CA CC CC CC CA CA CA CC A C Hom Het
ADCK5 chr8 145618309 rs1052951 AA N/A AA AA AA GA GA GA AA G A Hom Het
ADCK5 chr8 145618312 rs1052952 AA N/A AA AA AA GA GA GA AA G A Hom Het
Downstream of ADCK5 chr8 145618597 rs1871532 AA N/A AA AA AA GA GA GA AA G A Hom Het
Downstream of ADCK5 chr8 145620296 rs2280837 GG GC GG GG GG GC GC GC GG C G Hom Het
Downstream of ADCK5 chr8 145622923 rs2977835 CC TC CC CC CC TC TC TC CC T C Hom Het
Downstream of ADCK5 chr8 145623098 rs2977834 CC TC CC CC CC TC TC TC CC T C Hom Het
Family of L1 Family described in Mégarbané et al., 2000 Australian Lebanese Families
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Table VI-7: Biochemical profiles before starting riboflavin therapy in SLC52A2 patients (from Foley et al., 2014). *no reference range (at 
laboratory where testing performed); values in bold fall outside the reference range. Carnitine species concentrations are in micromoles per litre. 
Riboflavin, FAD and FMN concentrations are in nanomoles per litre.  
Patient E1 E2 E3 E4 E5 E6 E7 A1 A2
Age at time of 
biochemical testing 
10 years 6 years 5 years 5 years 3.5 17 years 22 yrs 10 years 9 years
Riboflavin [reference 
range]
7* 8.5* 14.9* 2.9* not done not done 7.2* not done not done
FAD [reference 
range]
201 [174-471] 185 [174-471] 87.2* 253 [174-471] not done not done 311 [174-471] 267 [174-471] 253 [174-471]
FMN [reference 
range]
<4* 7.4* 4.5* 5.8* not done not done 9.9* not done not done
C0-carnitine 
[reference range]
18.3 [<52.4] normal normal 14 [17-55] normal 41 [23-75] 37.0 [<52.4] 16.8 [13-56] 25.6 [13-56]
C2-carnitine 
[reference range]
19.3  [<11.5] normal normal 10 [10-27.8] normal 20.8 [10-34.5]  14.7 [<11.5] 4.1 [2.8-22.5] 3.7 [2.8-22.5]
C4-carnitine 
[reference range]
1.72  [<0.60] normal normal 0.5  [0.11-0.49] normal 1.69 [0.43-2.44] 0.44 [<0.60] 0.35 [0.12-0.67]
0.24 [0.12-
0.67]
C5-carnitine 
[reference range]
0.34  [<0.24] normal normal 0.56 [0.08-0.35] normal 0.21 [0.1-0.53] 0.06 [<0.24] 0.37 [<0.28] 3.82 [<0.28]
C6-carnitine 
[reference range]
0.79 [<0.12] normal normal 0.19  [0.02-0.11] normal 0.23 [0.06-0.31] 0.06 [<0.12] 0.58 [<0.13] 0.31  [<0.13]
C8-carnitine 
[reference range]
1.64  [<0.24] normal normal 0.49  [0-0.18] normal 0.00 [0.04-0.2] 0.17 [<0.24] 1.31 [<0.24] 0.29  [<0.24]
C10:1-carnitine 
[reference range]
0.47 [<0.51] normal normal not done normal not done 0.16 [<0.51] 0.79 [<0.5] 0.68 [<0.5]
C10-carnitine 
[reference range]
2.15 [<0.40] normal normal 0.42  [<0.2] normal not done 0.36 [<0.40] 1.39  [<0.4] 0.61 [<0.4]
C12-carnitine 
[reference range]
1.64 [<0.22] normal normal not done normal not done 0.15 [<0.22] 0.12 [<0.62] 0.79 [<0.62]
C14:1-carnitine 
[reference range]
2.19 [<0.25] normal normal not done normal not done 0.33  [<0.25] 0.16 [<0.73] 0.11 [<0.73]
C14-carnitine 
[reference range]
0.94  [<0.12] normal normal 0.14 [0.09-0.25] normal 0.12 [0.02-0.21] 0.05 [<0.12] 0.03 [<0.34] 0.12 [<0.34]
C16-carnitine 
[reference range]
0.61 [<0.28] normal normal 0.8 [0.4-1.7] normal 0.8 [0.5-2.2] 0.09 [<0.28] 0.07 [<0.64] 0.08 [<0.64]
C18:1-carnitine 
[reference range]
1.45 [<0.40] normal normal not done normal not done 0.15 [<0.40] not done not done
C18:2-carnitine 
[reference range]
0.44 [<0.23] normal normal not done normal not done 0.04 [<0.23] not done not done
Family 1
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Patient A3 A4 A5 A6 A7 U1 U2 I1
Age at time of 
biochemical testing 
3.5 years 15 years 16 years 16 years 21 years 52 years 44 years 1.8 years
Riboflavin [reference 
range]
not done not done not done not done not done not done not done 9.8 [3.9-49.0]
FAD [reference 
range]
not done 245 [174-471] 369 [174-471] 310 [174-471] 337 [174-471] 256 [137-370] 242 [137-370] 64.4 [46.0-114.0]
FMN [reference 
range]
not done not done not done not done not done not done not done 2.5  [2.8-21.4]
C0-carnitine 
[reference range]
38.8 [13-56] 30.2 [13-56] 21.9 [13-56] 18.3 [13-56] 27.3 [13-56] not done not done 24.30 [22.30-54.80]
C2-carnitine 
[reference range]
9.5 [2.8-22.5] 11.1 [2.8-22.5] 3.1 [2.8-22.5] 3.4 [2.8-22.5] 5.1 [2.8-22.5] 8.69 [3.74-16.56] 5.70 [3.74-16.56] 4.97 [3.40-13.00]
C4-carnitine 
[reference range]
0.65 [0.12-
0.67]
0.6 [0.12-0.67] 0.1 [0.12-0.67] 0.03 [0.12-0.67] 0.28 [0.12-0.67] 0.29 [0.00-0.45] 0.46 [0.00-0.45] 0.25 [0.07-0.58]
C5-carnitine 
[reference range]
0 [<0.28] 0.31  [<0.28] 0.1 [<0.28] 0.08 [<0.28] 0.26 [<0.28] 0.15 [0.00-0.30] 0.96  [0.00-0.30] 0.13 [0.04-0.22]
C6-carnitine 
[reference range]
0.12 [<0.13] 0.27  [<0.13] 0.04 [<0.13] 0.04  [<0.13] 0.07 [<0.13] 0.21  [0.00-0.12] 0.09 [0.00-0.12] 0.14  [0.02-0.12]
C8-carnitine 
[reference range]
0.34 [<0.24] 0.7  [<0.24] 0.09 [<0.24] 0.11 [<0.24] 0.16 [<0.24] 0.40  [0.00-0.23] 0.24 [0.00-0.23] 0.25 [0.04-0.22]
C10:1-carnitine 
[reference range]
0.19 [<0.5] 0.53 [<0.5] 0.1 [<0.5] 0.13 [<0.5] 0.08 [<0.5] 0.40  [0.00-0.31] 0.25 [0.00-0.31] 0.15 [0.04-0.22]
C10-carnitine 
[reference range]
0.52 [<0.4] 0.8 [<0.4] 0.13 [<0.4] 0.16 [<0.4] 0.2 [<0.4] 0.45 [0.00-0.31] 0.29 [0.00-0.31] 0.36  [0.04-0.30]
C12-carnitine 
[reference range]
0.16 [<0.62] 0.09 [<0.62] 0.01 [<0.62] 0.03 [<0.62] 0.02 [<0.62] 0.09 [0.00-0.12] 0.06 [0.00-0.12] 0.11 [0.04-0.14]
C14:1-carnitine 
[reference range]
0.16 [<0.73] 0.18 [<0.73] 0.06 [<0.73] 0.09 [<0.73] 0.05 [<0.73] 0.17  [0.00-0.16] 0.07 [0.00-0.16] 0.20 [0.02-0.18]
C14-carnitine 
[reference range]
0.06 [<0.34] 0 [<0.34] 0 [<0.34] 0.04 [<0.34] 0.01 [<0.34] 0.06  [0.00-0.05] 0.03 [0.00-0.05] 0.06 [0.00-0.08]
C16-carnitine 
[reference range]
0.03 [<0.64] 0.11 [<0.64] 0.04 [<0.64] 0.09 [<0.64] 0.05 [<0.64] 0.09 [0.00-0.10] 0.08 [0.00-0.10] 0.11 [0.06-0.24]
C18:1-carnitine 
[reference range]
not done not done not done not done not done 0.12 [0.00-0.17] 0.08 [0.00-0.17] 0.22 [0.06-0.28]
C18:2-carnitine 
[reference range]
not done not done not done not done not done 0.08 [0.00-0.10] 0.06 [0.00-0.10] 0.08 [0.02-0.18]
Family 2 Family 3 Family 4
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Table VI-8: Neurophysiological characteristics of patients with mutations in SLC52A2 (from Foley et al., 2014). 
 
Patient E1 E2 E3 E4 E5 E6 E7 A1 A2
Age at nerve 
conduction 
testing
8 years 2 years 4 years 5 years 4 years 2 years 10 years 8 years 3 years
Sensory 
responses
absent SNAPs in 
upper limbs and 
lower limbs
low amplitude 
or absent 
SNAPs in upper 
limbs; absent in 
lower limbs
low amplitude or 
absent SNAPs in 
upper limbs; low 
amplitude 
SNAPs in lower 
limbs 
low amplitude 
SNAPs in upper 
limbs; low 
amplitude or 
absent SNAPs in 
lower limbs
normal
absent SNAPs in 
upper limbs; 
lower amplitude 
SNAPs in lower 
limbs
low amplitude 
or absent 
SNAPs in upper 
limbs; absent in 
lower limbs 
absent SNAPs in 
upper limbs and 
lower limbs
low amplitude 
SNAPs in upper 
limbs;  absent in 
lower limbs
Motor responses
low amplitude 
CMAPs in upper 
limbs and low 
amplitude or 
absent CMAPs 
in lower limbs
low amplitude 
CMAPs in 
upper limbs and 
lower limbs
absent CMAPs 
in upper limbs; 
normal in lower 
limbs
low amplitude 
CMAPs in lower 
limbs                         
(upper limbs not 
tested)
low amplitude 
or absent 
CMAPs in 
upper limbs                   
(lower limbs not 
tested)
Normal in lower 
limbs (upper 
limbs not tested)
low amplitude 
CMAPs in 
upper limbs; 
normal in lower 
limbs 
normal normal
Age at repeat 
nerve 
conduction 
testing
10 years 6 years not done not done 10 years 10 years not done 10 years 9 years
Sensory 
responses
absent SNAPs in 
upper limbs and 
lower limbs
absent SNAPs 
in upper limbs 
(lower limbs 
not tested)
not done not done
low amplitude 
SNAPs in upper 
limbs (lower 
limbs not 
tested)
absent SNAPs in 
upper limbs;  
(lower limbs not 
tested)
not done
absent SNAPs in 
upper limbs and 
lower limbs
absent SNAPs in 
upper limbs and 
lower limbs
Motor responses
low amplitude 
CMAPs in upper 
limbs                         
(lower limbs not 
tested)
absent CMAPs 
in upper limbs; 
low amplitude 
CMAPs in 
lower limbs
not done not done
low amplitude 
CMAPs in 
upper limbs    
(lower limbs not 
tested)
low amplitude 
CMAPs in upper 
limbs; (lower 
limbs not tested)  
not done normal
low amplitude 
CMAPs in upper 
limbs; normal in 
lower limbs
Family 1
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Patient A3 A4 A5 A6 A7 U1 U2 I1 L1
Age at nerve 
conduction 
testing
3 years 3 years 16 years 16 years 3 years 51 years 43 years 2 years 6 years
Sensory 
responses
absent SNAPs in 
upper limbs and 
lower limbs
low amplitude 
SNAPs in upper 
limbs; absent in 
lower limbs
absent SNAPs in 
upper limbs and 
lower limbs
absent SNAPs in 
upper limbs and 
lower limbs
absent SNAPs 
in upper limbs 
and lower limbs
low amplitude or 
absent SNAPs in 
upper limbs; 
absent in lower 
limbs
absent SNAPs 
in upper limbs;              
(lower limbs not 
tested)
low amplitude 
SNAPs in upper 
limbs; absent in 
lower limbs
low amplitude 
SNAPs in upper 
limbs and lower 
limbs
Motor responses not done normal
low amplitude or 
absent CMAPs 
in upper limbs; 
normal in lower 
limbs
low amplitude 
CMAPs in upper 
limbs; normal in 
lower limbs
normal
low amplitude 
CMAPs in upper 
limbs and lower 
limbs
low amplitude 
or absent 
CMAPs in 
upper limbs; 
(lower limbs not 
tested)
low amplitude 
CMAPs in upper 
limbs and lower 
limbs
normal
Age at repeat 
nerve 
conduction 
testing
not done 16 years not done not done not done not done not done not done not done
Sensory 
responses
not done
low amplitude 
SNAPs in upper 
limbs; absent in 
lower limbs
not done not done not done not done not done not done not done
Motor responses not done
absent CMAPs 
in upper limbs; 
normal in lower 
limbs
not done not done not done not done not done not done not done
Family 2 Family 3 Family 4
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Table VI-9: Sural nerve pathology findings in patients with SLC52A2 mutations (from Foley et al., 2014). *g ratio=axon diameter/total nerve 
fibre diameter. 
Patient E2 E3 E5 A3 I1
Sex Female Female Female Female Male
Age at nerve biopsy 2 years 4 years 4 years 3 years 2 years
Axonal loss
2+; large 
myelinated 
fibres > small 
myelinated 
fibres
2+; large 
myelinated 
fibres>small 
myelinated fibres
1+ large 
myelinated 
fibres>small 
myelinated fibres
2+ large 
myelinated 
fibres>small 
myelinated fibres
3+ large 
myelinated 
fibres>small 
myelinated fibres
Fibrosis 2+ 1+ 1+ 1+ 3+
Degeneration Mild Moderate Moderate Mild Mild
Regeneration Absent Absent Absent Absent Absent
Demyelination Absent Absent Absent Absent Absent
Endoneurial 
inflammation
0-1/Field Absent Absent Absent Absent
Epineurial inflammation
Occasional 
single cell
Absent Absent Absent Absent
Endoneurial 
macrophages
Sparse Sparse Sparse Absent Sparse
Electron microscopy
Confirms 
chronic axonal 
neuropathy
Confirms chronic 
axonal neuropathy
Confirms chronic 
axonal neuropathy
Not done
Confirms chronic 
axonal neuropathy
Teased fibres Not done
Axonal 
degeneration
Axonal 
degeneration
Not done Not done
Morphometry Not done
g ratio* normal for 
age; large 
myelinated fibre 
loss confirmed 
Not done Not done Not done
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Table VI-10: Biochemical profiles after the initiation of riboflavin therapy in SLC52A2 patients (from Foley et al., 2014). *no reference range 
(at laboratory where testing performed); values in bold fall outside the reference range. Carnitine species concentrations are in micromoles per 
litre. Riboflavin, FAD and FMN concentrations are in nanomoles per litre.  
Family 2
Patient E1 E3 E4 E7 A1 A2 A4
Riboflavin 
[reference range]
71.9* 28.4 [3.9-49.0] 24.3* 14.7* not done not done not done
FAD [reference 
range]
313 [174-471] 126.6  [46.0-114.0] 367 [174-471] 359 [174-471] 407 [174-471] 383 [174-471] 324 [174-471]
FMN [reference 
range]
68.6* 5.6 [2.8-21.4] 73.5* 31.5* not done not done not done
C0-carnitine 
[reference range]
22 [17-55] not done 37 [17.0-55.0] 50 [<52.4] 9 [13-56] 17 [13-56] 27 [13-56]
C2-carnitine 
[reference range]
16.7 [10-27.8] not done 19.7 [10-27.8] 5.2 [<11.5] 2 [2.8-22.5] 3 [2.8-22.5] 5 [2.8-22.5]
C4-carnitine 
[reference range]
0.32 [0.11-0.49] not done 0.22 [0.11-0.49] 0.39 [<0.60] not done not done not done
C5-carnitine 
[reference range]
0.15 [0.08-0.35] not done 0.17 [0.08-0.35] 0.05 [<0.24] not done not done not done
C6-carnitine 
[reference range]
0.03 [0.02-0.11] not done 0.04 [0.02-0.11] 0.03 [<0.12] <0.1 [<0.13] <0.1 [<0.13] 0.1 [<0.13]
C8-carnitine 
[reference range]
0.14 [0-0.18] not done 0.16 [0-0.18] 0.06 [<0.24] <0.1 [<0.24] <0.1 [<0.24] 0.1 [<0.24]
C10:1-carnitine 
[reference range]
not done not done not done 0.05 [<0.51] <0.1 [<0.5] <0.1 [<0.5] 0.1 [<0.5]
C10-carnitine 
[reference range]
not done not done not done 0.09 [<0.40] 0.1 [<0.4] 0.1 [<0.4] 0.2 [<0.4]
Family 1
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Patient A5 A6 A7 U1 U2 I1
Riboflavin 
[reference range]
not done not done not done not done 219.8  [6.2-39.0] not done
FAD [reference 
range]
396 [174-471] 380 [174-471] 337 [174-471] not done not done not done
FMN [reference 
range]
not done not done not done not done not done not done
C0-carnitine 
[reference range]
21 [13-56] 20 [13-56] 27 not done not done normal
C2-carnitine 
[reference range]
4 [2.8-22.5] 5 [2.8-22.5] 5 7.30 [4.04-12.19] 4.64 [4.04-12.19] not done
C4-carnitine 
[reference range]
not done not done not done 0.07 [<0.38] 0.19 [<0.38] not done
C5-carnitine 
[reference range]
not done not done not done 0.04 [<0.30] 0.35 [<0.30] normal
C6-carnitine 
[reference range]
<0.1 [<0.13] 0 [<0.13] 0.1 [<0.13] 0.02 [<0.09] 0.02 [<0.09] normal
C8-carnitine 
[reference range]
<0.1 [<0.24] 0.1 [<0.24] 0.2 [<0.24] 0.12 [<0.65] 0.04 [<0.65] normal
C10:1-carnitine 
[reference range]
<0.1 [<0.5] 0.1 [<0.5] 0.1 [<0.5] 0.11 [<0.81] 0.07 [<0.81] not done
C10-carnitine 
[reference range]
<0.1 [<0.4] 0.1 [<0.4] 0.2 [<0.4] 0.17 [<0.51] 0.05 [<0.51] not done
Family 3 Family 4
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Table VI-11: Observed responses to riboflavin therapy including treatment dose and duration for patients E1-E4, E6, E7, A1-A2, A4-A7, U1-
U2, I1 and L1. *had been started on low-dose riboflavin (3 mg kg day) at age 15 years by patient’s metabolic consultant for evidence of a 
mitochondrial disorder; riboflavin dose was increased to 300 mg/day (10 mg/kg/day) when SLC52A2 mutations were found. **unable to tolerate 
further increase in dose due to reported associated gastrointestinal symptoms. ***had been on a riboflavin dose of 50 mg/kg/day for six months 
prior to recent increase in dose up to 60 mg/kg/day.  
Patient E1 E2 E3 E4 E6* E7 A1 A2
Age at first 
symptom
1.5 years 1 year 3.5 years 1.5 years 0.6 years 2 years 8 years 3 years
Age at initiation of 
high-dose 
riboflavin therapy
10.6 years 6 years 5.4 years 5 years 17.5 years 22.4 years 10 years 9 years
Present dose of 
riboflavin
50 mg/kg/day             10 mg/kg/day 7 mg/kg/day 40 mg/kg/day 300 mg/day 1,500 mg/day 23 mg/kg/day 26 mg/kg/day
Length of time at 
present dose
12 months 15 months 15 months 11 months 13 months 2 weeks 7 months 7 months
Observed 
response(s)
able to go from 
supine to sitting 
and then standing 
independently 
(skills lost at age 
9 years);  
stronger/louder 
voice
lost to follow-
up
stable 
functioning; 
no changes 
noted
can walk 
independently; 
can jump (skill 
lost at age 4 
years); hearing 
grossly better
stable 
functioning; 
no changes 
noted
 increased 
sensation in 
legs
normalisation of both 
pure tone 
audiometry; 
normalisation of 
brainstem auditory 
evoked responses; 
fewer falls 
stable 
functioning; 
decreased 
fatigability 
reported
Family 1
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Patient A4 A5 A6 A7 U1 U2 I1 L1
Age at first 
symptom
5 years 3 years 3 years 5 years 2 years 4 years 1.3 years 3 years
Age at initiation of 
high-dose 
riboflavin therapy
15 years 16 years 16 years 21 years 52 years 44 years 1.8 years 6.5 years
Present dose of 
riboflavin
21 mg/kg/day 1,000 mg/day
1,000 
mg/day
1,000 mg/day
400 
mg/day**
800 
mg/day**
60 mg/kg/day*** 10 mg/kg/day
Length of time at 
present dose
7 months 7 months 7 months 7 months 6 months 6 months 2 months*** 13 months
Observed 
response(s)
stable 
functioning; 
decreased 
fatigability 
reported
better at 
transferring; 
stronger kick; 
significant 
decrease in 
ventilator 
pressures
stable 
functioning; 
no changes 
noted
stable 
functioning; 
no changes 
noted
stable 
functioning; 
no changes 
noted
stable 
functioning; 
no changes 
noted
improved upper limb 
and neck strength: 
antigravity shoulder 
abduction, elbow 
flexion and extension 
and neck extension; 
can walk with truncal 
support; 
stronger/louder voice; 
decreased nystagmus
less frequent 
falls
Family 3 Family 4
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Table VI-12: Clinical features of patients without mutations in SLC52A1, SLC52A2 and SLC52A3 in the cohort of patients referred for BVVL 
testing. 
 
Patient Phenotype
1
severe bulbar weakness requiring ventilation via tracheostomy; severe truncal hypotonia; no hearing loss; feeding difficulties; on riboflavin treatment; 
suspected to have MADD; respiratory and limb muscle weakness; bulbar muscle abnormalities on EMG;  reduced activities of all respiratory chain 
complexes; sent for mitochondrial DNA sequencing and previously tested for POLG mutations
2
neurogenic weakness with upper motor neuron signs; presented at 2 years of age with a collapse; intermittently noisy breathing; absent hearing; 
unresponsive and paralysed for first few days after arrest, then distal movement in hands and feet started to reappear; weakness and inexpressive 
appearance in facial expression; difficulty closing eyes; generalised hypotonia; increased reflexes in upper and lower limbs; underwent tracheostomy; 
sudden noticeable improvement in physical abilities and responsiveness within hours of starting riboflavin, followed by steading improvement with 
improved hearing; neuronopathy on electromyography; nocturnal ventilatory support; currently unable to sit unsupported although neck and trunk 
support is improving; partial antigravity movement in forelimbs; better strength in legs than arms; better distal than proximal power; no muscle wasting; 
brisk reflexes; full eye movements; BVVL with unusual features (very early onset, very sudden deterioration with weakness)
3
40-year history of progressive distal weakness and wasting; 5-year history of breathing myoclonus; swallowing abnormalities; tongue fasciculations; 
brisk reflexes in upper limbs; previously diagnosed with axonal recessive CMT2
4
perhaps odd CMT variant; axonal pattern on neurophysiology; onset at 10 years old after flu-like illness; hearing loss; at 12 years old, foot drop and 
unable to stand on heels; difficulty keeping arms up above his head; wasted, fasiculating tongue; respiratory muscle weakness; orthopnoea; condition 
has remained static
5 poor swallowing; failed hearing tests; hypotonic (sister of patient below)
6 poor swallowing; failed hearing tests; hypotonic (sister of patient above)
7
born to consanguineous parents; nasogastric tube necessary for feeding; general lethargy and unsteadiness; slow to stand up from sitting position; 
significant and progressive hearing loss; admitted to intensive care for respiratory failure and put on ventilation; bi-temporal narrowing, high arch to 
palate and micrognathia; convergent squint; muscle weakness in all four limbs; positive gowers sign; lumbar lordosis; no contractures. MRI scan of the 
head and muscle biopsy essentially normal; normal blood and CSF lactate; normal sensory and motor NCVs; SMARD1 testing negative and normal 
very long chain fatty acids; no evidence of cardiomyopathy; normal EMG; no evidence of generalised neuropathy; presently on overnight non-invasive 
ventilation; patient has shown some improvement in motor ability and has remained stable.
8 bilateral sensorineural hearing loss; bilateral progressive facial weakness; tongue and palatal weakness
9 optic atrophy; ataxia; auditory neuropathy
10
46 year old patient with onset in first few years of life with proximal leg weakness and foot drop; slowly progressive; mild facial weakness; dysarthria; 
proximal and distal weakness in the limbs; minimal changes on muscle biopsy; neurogenic EMG; son has developed rapid onset unexplained 
sensorineural hearing loss in late teens
11
clinical diagnosis of BVVL; hearing loss and progressive anterior horn cell disease with spastic hemiparesis; muscle atrophy on left side; poor appetite; 
normal reflexes; no sensory abnormalities; occasional dysarthria; no visual impairment; no facial weakness; no tongue atrophy or fasciculations; normal 
acylcarnitine profile; improvement with riboflavin treatment
12
respiratory failure at 6 years old; hearing impairment; progressive weakness; neurogenic features on muscle biopsy, EMG and NCS; normal 
mitochondrial respiratory chain enzyme activities; two younger siblings with hearing impairment passed away with chest infection
13 dysarthria; dysphagia; restricted lateral gaze   
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Patient Phenotype
14 vocal cord palsy
15 atypical CIDP; respiratory muscle weakness
16 4 year old girl with progressive sensorineural hearing loss; slurred speech; ataxia; abducens paresis (6th nerve palsy)
17
respiratory chain enzyme deficiencies; demyelinating neuropathy; predominant upper limb and bulbar involvement; severe fatigue; sweats; episodes of 
profound collapse; some symptomatic response to CoQ10
18
facial weakness and lack of facial expression; neonatal bilateral hip dislocation; hypotonia with preserved antigravity strength and delayed motor 
milestones; severe sucking and swallowing difficulty from birth; gastrostomy and fundoplication at six months of age; recurrent chest infections; 
hospitalised for the first six and a half months of life; hearing difficulties; motor neuronopathy in bulbar nuclei and anterior horn cells on EMG; trend for 
gradual improvement; normal MRC enzyme activities; normal plasma acylcarnitines; fatty acid beta oxidation studies in fibroblasts normal; negative 
POLG and APTX testing.
19 progressive ataxia; deafness; normal imaging; normal CSF; normal muscle biopsy and EMG
20 bulbospinal muscular atrophy from 18 months of age; losing ambulation at 3 years old; no hearing loss
21
rapidly progressive and slightly later-onset BVVL; rapidly progressive ataxia; motor involvement; possible autonomic involvement; early-childhood 
onset; dragging feet
22 profound motor and sensory peripheral neuropathy; early-childhood onset; MRC score of 0; requires non-invasive ventilation; no hearing impairment
23
early-onset; marked hypotonia; feeding problems at birth; severe bulbar weakness; bilateral facial weakness; hemiatrophy and fasciculations of the 
tongue; hypotrophic shoulder girdle muscles; normal legs; normal brain MRI; mild hearing loss; normal eye movements; static course 
24 hypotonia; failure to thrive; paresis of diaphragm; psychomotor retardation; myopathy
25
preexisting mild autistic spectrum disorder; acute onset of severe epilepsy at 10 years old; profound loss of skills from 10 years old with regression and 
speech loss; currently non-ambulant; jejunostomy; EMG suggestive of motor neuronopathy; cerebellar change and progressive hippocampal change on 
brain MRI; extensive neurometabolic tests inconclusive; open muscle biopsy showed unusual core-like lesions; normal respiratory chain function; 
normal genetic investigations include POLG sequencing
26 unilateral cranial neuropathy
27 early-onset BVVL; progressive muscle weakness; head lag; respiratory muscle involvement; axial weakness
28
suspected BVVL; sensory motor neuropathy and denervation on NCS and EMG, with predominant arm involvement; onset at two and a half years after 
flu-like illness; arm and hand weakness but was initially able to run at the start of her illness; no swallowing problems or ptosis; mild facial weakness; 
atrophy of the tongue with fasciculations; difficulty with large pieces of food; MRI of brain and spine normal; areflexic throughout; downgoing plantar 
response; bilateral foot drop; normal acylcarnitine profile; no response to riboflavin or CoQ10
29
familial motor neuron disease; AD inheritance; BVVL-like; 4-year history of bulbar respiratory failure; mother died in her seventies with bulbar 
respiratory failure; SOD1 genetic testing is negative
30 severe axonal CMT
31 respiratory distress syndrome; lactic acidosis
32
13 years old; undetectable riboflavin levels; bilateral sensorineural hearing loss; progressive limb weakness; progressive bulbar palsy; scoliosis; on 
riboflavin treatment
33
failure to thrive with recurrent chest infections, wheezing and vomiting; episodes of choking when eating; legs are thin distally; normal tone and power; 
EMG revealed widespread denervation of bulbar muscles and tibialis anterior; awaiting a gastrostomy; 2 years old at present; twin brother has drooling 
episodes and bulbar denervation  
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Table VI-13: Clinical features of patients without mutations in SLC52A1, SLC52A2 and SLC52A3 in the BVVL-like cohort designed by a 
database search.  
Patient Phenotype
1 developmental delay; respiratory problems
2 ataxia with pseudobulbar palsy; patient had a child with respiratory distress who died at 10 years old
3 cataracts; developmental delay; ceberellar atrophy; abnormal muscle respiratory chain enzyme activities
4 myoclonus; respiratory depression; myopathic EMG
5 rapidly progressive brainstem and cerebellar dysfunction leading to respiratory failure; dysphagia; ataxia; nystagmus
6 seizures; developmental delay; respiratory failure
7 5-year history of external ophtalmoplegia; bulbar weakness; respiratory failure
8 sudden-onset weakness; possible mitochondrial respiratory chain disorder
9 died on first day of life; lactic acidosis; respiratory failure
10 daily life-threatening episodes with disordered respiratory pattern; frequently needs resuscitation
11 neurodevelopmental delay; mitochondrial respiratory chain disorder
12 congenital foot deformity; hypotonia; respiration impaired; facial and proximal weakness
13 generalised hypotonia; respiratory insufficiency; normal EMG and MRI of the head
14 muscle respiratory chain enzyme activities indicate reduced complex II/III activity on muscle biopsy
15 weakness and atrophy of neck extensors; onset at about 55 years old; respiratory difficulty
16 twin brother died of respiratory failure
17 respiratory distress syndrome; lactic acidosis
18 acute collapse at 3 hours old; respiratory and metabolic acidosis
19 on ventilation; bilateral sensorineural deafness; developmental delay
20 congenital deafness; cognitive impairment; epilepsy; retinal pigmentation; cortical changes on MRI
21 hypotonia; respiratory infections; feeding difficulties   
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Patient Phenotype
22
affected sensory and motor pathways in distal limbs; onset at 9 years old; progressive shortness of breath; weakness of distal 
extremities; bilateral symmetrical facial weakness; tongue fasciculations; wheelchair-bound
23 generalised weakness; breathlessness on exertion; muscle pain after exertion
24 cardiorespiratory arrest at 24 hours of age; MRI suggestive of global cerebral infarction; possible neurometabolic disorder
25 hypotonia; respiratory failure; gastrostomy-fed; complex III deficiency on biopsy
26 cardiac arrest at 2 hours of age; no respiratory effort; abnormal EEG and EMG
27
signs of motor neurone atrophy on EMG; normal vision; mild hearing loss; mild swallowing difficulties; feet and lower legs most 
significantly affected; cannot walk on heels or tip toes; distal sensory loss in feet
28 bilateral sensorineural deafness; cerebral symptoms; EMG suggestive of myopathy of facial muscles
29 CMT1A-like but with severe arm involvement; respiratory dysfunction; dominant inheritance
30 breathing problems; seizures
31 progressive myalgia; exercise-induced fatigue; respiratory depression; palatal tremor
32 neuromuscular respiratory failure
33 10-year history of predominant motor neuropathy but with respiratory involvement
34
axonal sensorimotor neuropathy with worsening intercurrent respiratory infections; a mitochondrial-like underlying condition is 
suspected; normal mitochondrial respiratory chain enzyme activities
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Table VI-14: Poorly covered exons in riboflavin transporter genes and GSTZI gene in exome sequencing for families SP, MO and TB with 
BVVL and related neuropathies. 
Gene Family SP- Individual II-3 Family SP- Individual III-1 Family MO- Individual III-3 Family TB- Individual III-3 Family TB- Individual III-8
SLC52A1 None None None None None
SLC52A2 None None Exon 4 None None
SLC52A3 None None Exon 4 None None
GSTZ1 N/A N/A None N/A N/A  
Table VI-15: Variants identified in known riboflavin transporters in family SP. 
Gene Position
Reference 
allele
Observed 
allele
Amino acid 
change Type Functional change Call
1000 
Genomes 
MAF EVS MAF
CG69 
MAF dbSNP ID
Individual II-3
SLC52A1 4937575 T C p.Gln70Arg exonic nonsynonymous hom 0.93 0.952965 0.957 rs346822
SLC52A1 4936972 G A p.Ala271Val exonic nonsynonymous hom 0.55 0.687674 0.71 rs346821
Individual III-1
SLC52A1 4937575 T C p.Gln70Arg exonic nonsynonymous hom 0.93 0.952965 0.957 rs346822
SLC52A1 4936972 G A p.Ala271Val exonic nonsynonymous hom 0.55 0.687674 0.71 rs346821  
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Table VI-16: Variants identified in known riboflavin transporters and in candidate gene GSTZ1 in individual III-3 of family MO. 
Gene Position
Reference 
allele
Observed 
allele
Amino acid 
change Type Functional change Call
1000 
Genomes 
MAF EVS MAF
CG69 
MAF dbSNP ID
SLC52A1 4937575 T C p.Gln70Arg exonic nonsynonymous hom 0.93 0.952965 0.957 rs346822
SLC52A1 4936972 G A p.Ala271Val exonic nonsynonymous hom 0.55 0.687674 0.71 rs346821
SLC52A3 744415 G A p.Pro267Leu exonic nonsynonymous hom 0.21 0.198643 0.167 rs3746804
SLC52A3 744382 G A p.Thr278Met exonic nonsynonymous hom 0.09 0.098717 0.051 rs3746803
SLC52A3 744308 T C p.Ile303Val exonic nonsynonymous hom 0.1 0.098624 0.058 rs3746802
GSTZ1 77794283 T C p.Met27Thr exonic nonsynonymous het 0.87 0.841699 0.906 rs1046428
GSTZ1 77793207 G A p.Glu32Lys exonic nonsynonymous het 0.34 0.314464 0.326 rs7975  
Table VI-17: Variants identified in known riboflavin transporters in family TB. 
Gene Position
Reference 
allele
Observed 
allele
Amino acid 
change Type Functional change Call
1000 
Genomes 
MAF EVS MAF
CG69 
MAF dbSNP ID
Individual III-3
SLC52A1 4937575 T C p.Gln70Arg exonic nonsynonymous hom 0.93 0.952965 0.957 rs346822
SLC52A1 4936972 G A p.Ala271Val exonic nonsynonymous hom 0.55 0.687674 0.71 rs346821
Individual III-8
SLC52A1 4937575 T C p.Gln70Arg exonic nonsynonymous hom 0.93 0.952965 0.957 rs346822
SLC52A1 4936972 G A p.Ala271Val exonic nonsynonymous hom 0.55 0.687674 0.71 rs346821  
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APPENDIX VII  
Table VII-1: MRC complex activities for first optimisation trial of riboflavin 
concentration in fibroblast cell medium; n=1. All MRC complex activities are 
expressed as a ratio to CS activity to normalise for mitochondrial enrichment 
(Hargreaves et al., 1999). *Grown first for four days in medium with 4.7 μg L (12.6 
nM) riboflavin, followed by four days in defined medium. 
Control 
fibroblast line
Riboflavin 
concentration in 
cell medium*
MRC Complex I 
activity
MRC Complex II 
activity
C1 0.32 µg/l (0.85 nM) 0.065390563 0.084436825
C1 113 µg/l (300.6 nM) 0.282603275 0.332510125
C2 0.32 µg/l (0.85 nM) 0.186116831 0.108491589
C2 113 µg/l (300.6 nM) 0.823152088 0.296516026
C3 0.32 µg/l (0.85 nM) 0.173873657 0.157641114
C3 113 µg/l (300.6 nM) 0.663658178 0.310432895  
Table VII-2: MRC complex activities for second optimisation trial of riboflavin 
concentration in fibroblast cell medium; n=1. All MRC complex activities are 
expressed as a ratio to CS activity to normalise for mitochondrial enrichment 
(Hargreaves et al., 1999).  *Grown first for four days in medium with 4.7 μg L (12.6 
nM) riboflavin, followed by four days in defined medium. 
Control 
fibroblast line
Riboflavin 
concentration in 
cell medium*
MRC Complex I 
activity
MRC Complex II 
activity
C1 1.17 µg/l (3.1 nM) 0.477076195 0.170098895
C1 4.7 µg/l (12.6 nM) 0.576471835 0.205537864
C1 113 µg/l (300.6 nM) 0.607107195 0.253486911
C2 1.17 µg/l (3.1 nM) 0.317714591 0.184945944
C2 4.7 µg/l (12.6 nM) 0.430646317 0.104612789
C2 113 µg/l (300.6 nM) 0.674008811 0.161198371
C3 1.17 µg/l (3.1 nM) 0.665687714 0.200517542
C3 4.7 µg/l (12.6 nM) 0.604744473 0.235675835
C3 113 µg/l (300.6 nM) 0.737721086 0.239118543  
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Table VII-3: Sequences of SLC52A2 shRNA hairpins and targeted regions. 
shRNA 
clone
Clone ID
Hairpin target 
region
Hairpin sequence
1 V3LHS_356232 exon 5 cagcatctatcacgtgttcca
2 V3LHS_356235 exon 3 ccaccactgcaagagccaccaa
 
Table VII-4: Sequence of primer used for sequencing during quality control of the 
pGIPZ vector. 
Primer sequence (5' to 3')
gcattaaagcagcgtatc  
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Table VII-5: MRC complex activities for optimisation trials of riboflavin 
concentration in cell medium of shRNA-transfected SH-SY5Y cells. All MRC 
complex activities are expressed as a ratio to CS activity to normalise for 
mitochondrial enrichment (Hargreaves et al., 1999). *Riboflavin-free DMEM with 
regular FBS used (not dialysed FBS). 
Experiment 
Number
Riboflavin 
concentration 
in medium
Days in 
medium Clone
MRC 
Complex I 
activity
MRC 
Complex II 
activity
1 10 nM 8 Empty 0.23 0.132
1 10 nM 8 Scrambled 0.204 0.102
1 10 nM 8  SLC52A2-shRNA 1 0.198 0.106
1 10 nM 8  SLC52A2-shRNA 2 0.15 0.126
1 10 nM 8  SLC52A2-shRNA 1+2 0.156 0.128
1 300.6 nM 8 Empty 0.223 0.163
1 300.6 nM 8 Scrambled 0.289 0.131
1 300.6 nM 8  SLC52A2-shRNA 1 0.238 0.125
1 300.6 nM 8  SLC52A2-shRNA 2 0.193 0.103
1 300.6 nM 8  SLC52A2-shRNA 1+2 0.162 0.121
2 3.1 nM 7 Empty 0.088 0.11
2 3.1 nM 7 Scrambled 0.016 0.088
2 3.1 nM 7  SLC52A2-shRNA 1 0.037 0.111
2 3.1 nM 7  SLC52A2-shRNA 2 0.041 0.077
2 3.1 nM 7  SLC52A2-shRNA 1+2 0.051 0.064
2 300.6 nM 7 Empty 0.066 0.18
2 300.6 nM 7 Scrambled 0.07 0.188
2 300.6 nM 7  SLC52A2-shRNA 1 0.11 0.211
2 300.6 nM 7  SLC52A2-shRNA 2 0.094 0.186
2 300.6 nM 7  SLC52A2-shRNA 1+2 0.118 0.175
3 5.89 nM* 8 Scrambled 0.068 0.097
3 5.89 nM* 8  SLC52A2-shRNA 1 0.099 0.152
3 5.89 nM* 8  SLC52A2-shRNA 1+2 0.155 0.17
3 12.6 nM 4 Scrambled 0.109 0.175
3 12.6 nM 4  SLC52A2-shRNA 1 0.094 0.193
3 12.6 nM 4  SLC52A2-shRNA 1+2 0.184 0.183
3 8 nM 4 Scrambled 0.116 0.15
3 8 nM 4  SLC52A2-shRNA 1 0.144 0.155
3 8 nM 4  SLC52A2-shRNA 1+2 0.136 0.166
3 300.6 nM 4 Scrambled 0.123 0.228
3 300.6 nM 4  SLC52A2-shRNA 1 0.161 0.188
3 300.6 nM 4  SLC52A2-shRNA 1+2 0.094 0.162
4 3.1 nM 1 Empty 0.137 0.14
4 3.1 nM 1 Scrambled 0.125 0.125
4 3.1 nM 1  SLC52A2-shRNA 1 0.166 0.141
4 3.1 nM 1  SLC52A2-shRNA 2 0.236 0.155
4 3.1 nM 1  SLC52A2-shRNA 1+2 0.203 0.119
4 300.6 nM 1 Empty 0.147 0.138
4 300.6 nM 1 Scrambled 0.156 0.133
4 300.6 nM 1  SLC52A2-shRNA 1 0.141 0.143
4 300.6 nM 1  SLC52A2-shRNA 2 0.142 0.125
4 300.6 nM 1  SLC52A2-shRNA 1+2 0.179 0.149  
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Experiment 
Number
Riboflavin 
concentration 
in medium
Days in 
medium Clone
MRC 
Complex I 
activity
MRC 
Complex II 
activity
5 0.66 nM 1 Empty 0.116 0.136
5 0.66 nM 1 Scrambled 0.095 0.133
5 0.66 nM 1  SLC52A2-shRNA 1 0.132 0.129
5 0.66 nM 1  SLC52A2-shRNA 2 0.147 0.139
5 0.66 nM 1  SLC52A2-shRNA 1+2 0.18 0.106
5 3.1 nM 3 Empty 0.106 0.129
5 3.1 nM 3 Scrambled 0.103 0.114
5 3.1 nM 3  SLC52A2-shRNA 1 0.101 0.126
5 3.1 nM 3  SLC52A2-shRNA 2 0.166 0.132
5 3.1 nM 3  SLC52A2-shRNA 1+2 0.145 0.141  
Table VII-6: Sequences of primers used for sequencing during quality control of 
pCMV6-SLC52A2-myc-DDK constructs. 
 
Direction Primer sequence (5' to 3')
forward ggactttccaaaatgtcg
reverse attaggacaaggctggtggg 
 
Table VII-7: Sequences of primers used for site-directed mutagenesis of the 
pCMV6-SLC52A2-myc-DDK plasmid. 
Mutation Direction Primer sequence (5' to 3')
sense gctgcggtcaatgggatctcggtggagcta
antisense tagctccaccgagatcccattgaccgcagc
sense ggatcaggcctctaggtgggagccc
antisense gggctcccacctagaggcctgatcc
sense cttttcctgcttaccctacaggcgtctggcctaccacc
antisense ggtggtaggccagacgcctgtagggtaagcaggaaaag 
sense ctggcctaccacccggctgtggtgctg
antisense cagcaccacagccgggtggtaggccag
sense cttggcagggccgggcggcctct
antisense agaggccgcccggccctgccaag
sense ggctctctgctcggcactgttgctatgttcc
antisense ggaacatagcaacagtgccgagcagagagcc
c.92G>C (p.Trp31Ser)
c.700C>T (p.Gln234Stop)
c.916G>A (p.Gly306Arg)
c.935T>C (p.Leu312Pro)
c.1016T>C (p.Leu339Pro)
c.1258G>A (p.Ala420Thr)
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Table VII-8: Sequences of mouse Slc52a2 and Slc52a3 shRNA hairpins and 
targeted regions. 
Gene
shRNA 
clone
Clone ID
Hairpin 
target region
Hairpin sequence
Slc52a2 Slc52a2-1 V3LMM_485753 exon 3 tgtgggttcagatgtcggg
Slc52a3 Slc52a3-1 V2LMM_17940 5' UTR aggagaacctgatagatgc
Slc52a3 Slc52a3-2 V3LMM_508722 exon 2 tctccatagtgttcaaggt  
Table VII-9: Sequences of DNA primers for the mouse Slc52a2 used for cDNA 
quality control. 
Gene Ensembl transcript Exon Direction
Primer sequence (5' 
to 3')
Annealing 
temperature
PCR 
protocol
Amplicon 
length (bp)
Slc52a2 ENSMUST00000023220 5 forward cgaatctcccctctacgaca
Slc52a2 ENSMUST00000023220 5 reverse cacactggtccacacagtcc
60°C Roche 247
 
Table VII-10: Sequences of cDNA primers for the mouse Slc52a2 used for cDNA 
quality control. 
Gene Direction
Primer sequence (5' 
to 3')
Annealing 
temperature
PCR 
protocol
Amplicon 
length (bp)
Slc52a2 forward cggtgcaggctccatgaata
Slc52a2 reverse agctctacccagatcccgtt
60°C Roche 207
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APPENDIX VIII  
Supplementary study into genetic modifiers of the CMT1A phenotype (Chapter 
4) 
Introduction 
The PMP22 p.Thr118Met variant in CMT1A: disease modifier, pathogenic mutation, 
or polymorphism? 
Much debate surrounds the potential pathogenicity of the p.Thr118Met variant in 
PMP22. It has been found in both CMT1 and HNPP families, but did not always 
segregate with the phenotype. While some studies have concluded that it is a non-
pathogenic SNP, others have suggested it may act as an AR mutation or a mutation 
with reduced penetrance; it has also been postulated to either have no influence on 
the CMT1A phenotype, to cause milder CMT1A phenotypes, or to act as a partial 
loss of function mutation causing HNPP (Keckarevic-Markovic et al., 2009; 
Kochañski, 2006; Mersiyanova et al., 2000; Naef & Suter, 1999; Nelis et al., 1997; 
Niedrist et al., 2009; Roa, Garcia, Pentao, et al., 1993; Russo et al., 2011; Seeman et 
al., 1999; Shy et al., 2006; Sinkiewicz-Darol et al., 2010; Young et al., 2000). The 
p.Thr118Met variant has also been proposed to cause a severe form of CMT1 in the 
compound heterozygous state with the HNPP deletion (Roa, Garcia, Pentao, et al., 
1993). Individuals who carried only the p.Thr118Met variant in the heterozygous 
state in PMP22 were either phenotypically normal or had CMT1 or HNPP (Nelis et 
al., 1994; Niedrist et al., 2009; Roa, Garcia, Pentao, et al., 1993; Russo et al., 2011; 
Seeman et al., 1999; Shy et al., 2006). An individual homozygous for this mutation 
had an axonal neuropathy, but it remains unclear whether the neuropathy may have 
been due to another unknown mutation (Shy et al., 2006).  
The p.Thr118Met variant causes abnormal PMP22 intracellular trafficking, although 
less severely so than other PMP22 point mutations (Naef & Suter, 1999). If this 
variant indeed decreases trafficking of PMP22, it might decrease the dosage effect of 
CMT1A and cause milder disease via partial loss of function (Shy et al., 2006), or 
the two genetic defects may add up to a more severe disease (Marques et al., 2003). 
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Interestingly, this substitution is found in a CpG dinucleotide, known to be a 
hypermutable sequence, which may increase the occurrence of this mutation 
(Marques et al., 2003). Overall, it remains unknown whether the p.Thr118Met 
variant in PMP22 may modify the CMT1A phenotype. 
The PMP22 promoter region 
Given that changes in PMP22 copy number cause neuropathy, PMP22 levels must 
be tightly controlled (Li et al., 2013). The PMP22 gene has two alternatively 
transcribed promoters, promoters 1 and 2, which are developmentally and temporally 
associated with myelination, providing an additional level of transcriptional control 
(Maier et al., 2002). Both transcripts produce the same protein and differ only in 
their 5’UTR region. Promoter 1 is mostly but not exclusively expressed in the PNS, 
specifically in myelinating Schwann cells (Bosse et al., 1994; Van de Wetering et al., 
1999). All the elements needed for Schwann cell-specific expression of a reporter 
gene are reportedly located 300 bp upstream of the transcription start site in promoter 
1 (Saberan-Djoneidi et al., 2000). 
The 5’ upstream region of the nerve-specific transcript of PMP22, including 
promoter 1 and non-coding exon 1A (Figure VIII-1) contains regulatory elements 
such as a TATA box (a binding site of transcription factors or histones often found in 
tissue-specific promoters) as well as an inverted CCAAT box (needed for the 
initiation of transcription). It also possesses several potential binding sites for 
transcription factors including steroid receptors, cAMP response element-binding 
protein and nuclear factor 1 (Hai et al., 2001; Saberan-Djoneidi et al., 2000; Suter et 
al., 1994). The cAMP response element-binding protein binding sites are located at 
−1,699 bp and −1,725 bp and are responsible for silencing PMP22 promoter activity. 
Nearby these two binding sites is a region polymorphic in terms of the number of CA 
dinucleotide repeats it contains. Variability in the repeat number could affect the 
binding of transcription factors at these sites; the number of CA repeats was 
suggested to be a potential source of phenotypic variability in CMT1A (Saberan-
Djoneidi et al., 2000). The 5’ upstream region of promoter 1 also includes a “late 
myelination Schwann cell-specific element” which is responsible for gene regulation 
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during late phases of myelination during development and in remyelination 
following injury (Maier et al., 2003). 
 
Figure VIII-1: Structure of the PMP22 gene including location of promoters 1 and 2 
(P1 and P2) and non-coding exons 1A and 1B. Adapted from Hai et al. (2001). 
Promoter mutations in the GJB1 nerve-specific 5’UTR region have been associated 
with CMT1 (Houlden et al., 2004; Kabzinska et al., 2011; Murphy, Polke, et al., 
2011). One of these mutations was in a highly conserved binding site for SRY (sex 
determining region Y)-box 10 (SOX10), a regulator of myelin gene expression, and 
was found to reduce promoter activity (Houlden et al., 2004). Another GJB1 
promoter variant was located within a domain important for initiation of translation 
(Kabzinska et al., 2011). Variants in the promoter region found in conjunction with a 
disease-causing variant in the same gene may modify disease severity. A study of 
Treacher Collins syndrome, a craniofacial malformation disorder due to null 
mutations in the Treacher Collins-Franceschetti syndrome 1 (TCOF1) gene, has 
evaluated the effect on disease severity of promoter mutations in trans with the 
pathogenic mutation. This disease exhibits high intra- and interfamilial clinical 
variability as is seen in CMT1A. Several variants in the 5’UTR were identified, one 
of which decreased promoter activity by impairing DNA-binding to a transcription 
factor. Although the sample size was small, individuals with this functional promoter 
variant had a milder phenotype (Masotti et al., 2005). 
As the PMP22 promoter region is not traditionally sequenced as part of the CMT1A 
genetic diagnostic test, variants in this region have rarely been described. A recent 
study of 45 CMT1A/HNPP patients identified five SNPs in 3.6 Kb of the 5’UTR 
region of PMP22, three of which were also found in controls; the authors concluded 
that the 5’ regulatory se uence of PMP22 is highly conserved (Sinkiewicz-Darol et 
al., 2010). Furthermore, a c.-134G>A variant was found in a CMT patient with optic 
atrophy and a c.-40G>A change was described in a CMT2 patient; both variants were 
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considered to be benign polymorphisms although an effect on splicing or 
translational efficiency could not be dismissed (Numakura et al., 2002). The PMP22 
nerve-specific promoter region was also sequenced in 15 CMT1 patients and 16 
HNPP patients without Chr17p11.2 rearrangements or PMP22 point mutations to 
assess whether variants in this region may be disease-causing. The authors identified 
one variant in non-coding exon 1A in a CMT1 patient which did not co-segregate 
with disease in the family, and concluded that variants in this region were not likely 
to be an important cause of CMT1 or HNPP (Nelis et al., 1998). While variants in 
the nerve-specific promoter of PMP22 are not thought to be a common genetic cause 
of CMT1A, a SNP in the promoter region of PMP22 may modulate gene dosage by 
increasing or decreasing the effectiveness of transcription, or by affecting mRNA 
translation or mRNA stability (Nelis et al., 1998; Sinkiewicz-Darol et al., 2010). 
Increased PMP22 dosage causes decreased protein turnover, accumulation of PMP22 
and aggregate formation (Fortun et al., 2006; Notterpek et al., 1999); these processes 
may be relieved or aggravated by the effect of a promoter SNP on transcription or 
translation of PMP22 in CMT1A. A mutation in the promoter may also affect exon 
splicing and the location of the transcription start site (Nelis et al., 1998). 
Studies of CMT1A patients found non-uniform PMP22 mRNA expression in nerve 
biopsies, with both elevated and nearly normal mRNA levels in heterozygous 
CMT1A patients (Hanemann et al., 1994; Yoshikawa et al., 1994), as well as highly 
variable levels of PMP22 protein density in dermal nerve myelin from CMT1A 
patient skin biopsies (Katona et al., 2009; Li et al., 2005). There was no correlation 
between the CMTNS and PMP22 mRNA and protein levels in the dermal nerve 
myelin of CMT1A patients (Katona et al., 2009). In one of these studies, the most 
severely affected patient had the lowest PMP22 mRNA levels, and the most mildly 
affected patient had the highest PMP22 mRNA levels (Hanemann et al., 1994). 
Although this may be an incidental finding, the authors postulated that PMP22 
expression may be down-regulated as the disease progresses (Hanemann et al., 
1994). Furthermore, patients with four copies of PMP22 do not always have a more 
severe phenotype (Boerkoel et al., 1999; Kaku et al., 1993; LeGuern et al., 1997; 
Lupski et al., 1991). These studies would suggest that PMP22 levels do not 
completely determine the CMT1A phenotype. It may be that genetic modifiers of 
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CMT1A do not affect PMP22 levels per se, but rather modulate severity by affecting 
other pathways in which PMP22 is involved. However, studies on this topic are 
rather scarce and the largest study seeking to correlate PMP22 levels and CMT1A 
disease severity in humans used tissue from skin biopsies rather than nerve biopsies 
to measure PMP22 levels (Katona et al., 2009).  
Inhibiting PMP22 expression was found to alleviate disease in a CMT1A mouse 
model, suggesting a link between PMP22 levels and disease severity (Passage et al., 
2004). Admittedly, unlike humans these animals have a defined genetic background, 
therefore the possibility of genetic modifiers acting as confounding variables is 
eliminated (Katona et al., 2009). Progesterone, a known stimulator of Pmp22 
expression in cultured rat Schwann cells (Desarnaud et al., 1998) caused 
upregulation of Pmp22 mRNA levels and an increase in disease progression in a rat 
CMT1A model; a progesterone antagonist decreased Pmp22 mRNA levels and 
ameliorated the phenotype (Sereda et al., 2003). As progesterone levels increase 
significantly during pregnancy, it is perhaps not surprising that symptoms worsened 
during pregnancy in 52% of women with CMT1A (Swan et al., 2007). These studies 
suggested a relationship between PMP22 levels and disease severity in CMT1A. 
In keeping with the conflicting evidence presented here, it is undoubtedly too early to 
entirely exclude the role of PMP22 levels in modulating disease severity in CMT1A. 
Promoter SNPs in PMP22 may be a source of further alterations in gene dosage in 
CMT1A. 
The Chr17p11.2 duplication: a source of phenotypic variability? 
NAHR, introduced in Section 1.4.3, is responsible for the majority of recurrent 
rearrangements in the human genome including the CMT1A duplication (Boerkoel et 
al., 1999; Gu et al., 2008). The CMT1A duplication usually results from NAHR 
between two highly homologous low-copy repeat sequences located at the 
extremities of the duplicated region (Chance et al., 1994; Pentao et al., 1992; Reiter 
et al., 1996). In CMT1A, this event most frequently involves unequal 
interchromosomal (non-sister chromatid) exchange at meiosis, usually during 
spermatogenesis (Palau et al., 1993). CMT1A duplications may also result from non-
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recurrent mechanisms such as non-homologous end joining (NHEJ), Alu-Alu 
mediated rearrangements, and replication-based Fork Stalling and Template 
Switching (FosTeS) (Choi et al., 2011; Huang et al., 2010; Zhang et al., 2010). In 
NAHR, the two duplicated alleles are non-identical except in the rare CMT1A cases 
with intrachromosomal exchange, where recombination occurs between identical 
sister chromatids (Lopes et al., 1997). In non-recurrent mechanisms such as FosTeS, 
alleles are identical as the mechanism is replication-based (Choi et al., 2011). It is 
possible that meiotic recombination within the duplicated region may lead to 
differences in the duplicated copies of PMP22 within a family, which may account 
for a percentage of the intrafamilial variability in CMT1A (Choi et al., 2011). 
Rearrangements occurring via NAHR have fixed breakpoints and result in 
duplications of identical size in different individuals (Boerkoel et al., 1999; Gu et al., 
2008; Zhang et al., 2010). Duplications arising from non-recurrent mechanisms such 
as NHEJ or FosTeS are variable in size (Gu et al., 2008). The hotspot for 
recombination within the CMT1A-REP is common to approximately 75%-80% of 
CMT1A patients and is similar in all populations studied (Boerkoel et al., 1999; 
Chance et al., 1994; Kiyosawa & chance, 1996, Lopes et al 1996; Marques et al., 
2005; Reiter et al., 1996; Yamamoto et al., 1998). CMT1A patients with different 
breakpoints and smaller duplications which do or do not encompass PMP22 have 
been described. These duplications most likely arose from one of the non-recurrent 
mechanisms described above (Choi et al., 2011; Huang et al., 2010; Ionasescu et al., 
1993; Valentijn et al., 1993; Zhang et al., 2010). The phenotypes of the patients with 
the smaller duplications which included PMP22 were variable with a large 
intrafamilial phenotypic spectrum, but were not different from those with the typical 
duplication (Choi et al., 2011; Kanwal et al., 2011). The subgroup of patients with 
duplications located upstream of and not including PMP22 had a somewhat milder 
phenotype but there were no outstanding clinical features. These alternatively sized 
duplications would have been missed by traditional diagnostic methods (Weterman 
et al., 2010; Zhang et al., 2010). It is likely that highly conserved regulatory 
sequences located in the PMP22 upstream region are disrupted, thus affecting 
PMP22 expression, as the genes located within these smaller duplications are not 
predicted to be associated with a neuropathy phenotype (Weterman et al., 2010, 
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Zhang et al., 2010). In fact, three distal enhancers have been found which are 
approximately 100 Kb upstream of PMP22 and within the boundaries of two recently 
identified smaller duplications not containing PMP22 (Jones et al., 2012).
 
These 
upstream enhancers contain binding sites for SOX10 and EGR2, two transcription 
factors known to regulate PMP22; duplications at these sites are proposed to cause 
CMT1A by increasing enhancer activity, and thus PMP22 expression as well (Jones 
et al., 2012).  
The variable size of the duplication and different haplotypes on the Chr17p11.2 
duplicated region observed in these studies highlight the diverse origins of the 
CMT1A duplication (Lupski et al., 1991; Palau et al. 1993; Raeymaekers et al., 
1991). It is possible that variations in the size of the duplication may account for 
some of the phenotypic heterogeneity in CMT1A. 
Methods 
Sequencing of PMP22 gene and upstream promoter region, and detection of 
p.Thr118Met variant 
Patient consent, phenotypes, and DNA samples were obtained as described in 
Section 4.3.1. Sequencing of the PMP22 gene and upstream nerve-specific promoter 
region was performed to identify possible compound forms of CMT1A, to detect the 
p.Thr118Met variant, and to assess whether PMP22 SNPs in the promoter region 
may modulate the CMT1A phenotype. The PMP22 coding exons and flanking 
intronic regions, as well as the upstream promoter region and non-coding exon 1A 
were sequenced in 379 CMT1A patients (186 UK, 83 USA and 110 Brazil patients). 
PCR amplification, agarose gel electrophoresis, purification of PCR products, Sanger 
sequencing, dye removal and sequencing analysis were performed using standard 
conditions as described in Sections 2.1.9-2.1.12. Transcript references used for 
primer design, as well as primer sequences and PCR cycling conditions can be found 
in Appendix III Table III-1 and Appendix IV Table IV-2. Primers for the PMP22 
promoter/upstream and exon 1A region were designed to span from 560 bp upstream 
of the transcription start site to the end of exon 1A, including 15 bp of flanking 
intronic sequence. Although this would not cover some of the transcription factor 
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binding sites discussed previously, it encompasses the minimal region necessary for 
Schwann cell-specific expression. SNP chromosomal locations are based on Genome 
Build 37.3. In-silico analyses were performed as described in Section 2.6. 
Detection of atypical Chr17p11.2 duplications 
In the UK CMT1A cohort, atypical Chr17p11.2 duplications were detected as part of 
the routine diagnostic tests of Chr17p11.2 dosage analysis in the NHNN 
Neurogenetics Unit. The Neurogenetics laboratory at the NHNN is the main CMT 
diagnostic centre in South East England. DNA samples were obtained by referrals 
both external and internal to the Neurogenetics Unit. The P033B-2 CMT1A/HNPP 
MLPA kit (MRC-Holland, The Netherlands) was used to measure dosage of each 
PMP22 exon and other markers within the commonly duplicated 1.5 Mb region 
(total of eight probes in the duplicated segment) following the manufacturer’s 
instructions. MLPA is a highly sensitive and specific technique to assess sequence 
dosage in CMT1A (Slater et al., 2004). MLPA data was analysed using GeneMarker 
software (SoftGenetics, USA). This work was performed entirely by Dr James Polke 
from the Neurogenetics diagnostic laboratory, NHNN. 
Results 
Identifying SNPs in the PMP22 upstream promoter region 
The SNPs identified in the PMP22 promoter region and exon 1A of 379 CMT1A 
patients are summarized in Table VIII-1. Chromosome locations refer to Genome 
Build 37.3.  
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Table VIII-1: PMP22 promoter and exon 1A SNPs identified in our CMT1A cohort. 
 
All SNPs were found in the heterozygous state. Three SNPs were located in the 
upstream region of PMP22 and two in the non-coding exon 1A (Figure VIII-2).  
 
 
Figure VIII-2: Location of regulatory regions and transcription factor binding sites, 
as well as SNPs within the sequenced region of the PMP22 promoter and exon 1A 
identified in this study and in previous studies. 
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The SNP at 17:15,168,522 (rs140650630) is the only SNP found in online control 
databases. According to the 1000 Genomes database, it is not found in the European 
population but has a MAF of 0.039 in the African population. Only the SNP at 
17:15,168,708 (SNP closest to the underlined sequence in Figure VIII-2) is located in 
a known critical region of the promoter; this region is thought to contain a positive 
regulatory element (Hai et al., 2001). This SNP was found in one patient, but the 
CMTNS is not available. Also worthy of note is the SNP at 17:15,168,778 in the 
upstream region, which was found in one severe and one mild patient. The SNP at 
17:15,168,577 had been previously identified in a CMT1 patient by Nelis et al. 
(1998); however, the SNP did not segregate with disease in the family in this study. 
All SNPs were found in UK patients, except the SNPs at 17:15,168,522 and 
17:15,168,880, which were found in Brazilian CMT1A patients. No promoter/exon 
1A SNPs were found in the USA cohort. As parental DNA was not available for 
segregation analysis, phase information is not available for these variants as it is 
unknown whether the variant was inherited on the duplicated or non-duplicated 
chromosome in these patients. Whether a variant is in cis or trans with the 
duplication may influence its ability to modify PMP22 expression (Tewhey et al., 
2011). 
PMP22 sequencing and detection of the p.Thr118Met variant 
Sequencing of PMP22 identified the p.Thr118Met (c.353C>T) variant (dbSNP ID 
rs104894619) in the heterozygous state in 6 out of 379 CMT1A patients (1.58%; 2 
UK patients, 2 USA patients, 2 Brazilian patients). It was found in three mildly 
affected patients (two of which are from the same family) and one moderately 
affected patient. Interestingly, in one instance, one sibling with the variant is 
somewhat more mildly affected than her sibling who does not have this variant. The 
phenotype is not available for the other two patients carrying this variant. The MAF 
of this variant is 0.002 in the 1000 Genomes database; it occurs at a frequency of 
0.75% in the EVS database. The allele frequency of this variant was 0.019 in a study 
of 262 Swedish controls (Nelis et al., 1997) and 0.007 in 1,018 German controls 
(Young et al., 2000). However, in a study of the English population, this variant was 
not found in 220 individuals including 150 controls, 50 patients with the CMT1A 
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duplication and 20 patients with the HNPP deletion (Marques et al., 2003); another 
English study found the variant in 1 out of 176 controls (Russo et al., 2011). A Polish 
study found the p.Thr118Met variant in 1/45 (2.2%) of CMT1A/HNPP patients 
(Sinkiewicz-Darol et al., 2010). Notably, this variant was detected in 1/89 PMP22 
sequencing diagnostic tests performed by Dr James Polke in the NHNN 
Neurogenetics diagnostic laboratory. The cohort included CMT1, CMT2 and HNPP 
patients; the variant was found in an HNPP patient with recurring episodes of 
mononeuropathy (Polke et al., 2011). The variant is predicted probably damaging by 
Polyphen-2 and SIFT, and is highly conserved between species (GERP score=5.16). 
As is the case for the PMP22 promoter variants identified in this study, it is unknown 
whether the p.Thr118Met variant was inherited on the duplicated or non-duplicated 
chromosome in these patients.  
Sequencing of the PMP22 coding region did not reveal any other potentially 
pathogenic mutations in the CMT1A cohort; all variants identified other than the 
p.Thr118Met variant were found at a high frequency in controls in the 1000 
Genomes database. 
Atypical Chr17p11.2 duplications associated with CMT1A 
Between 2008 and 2012, the diagnostic laboratory has detected 200 Chr17p11.2 
duplications, 9 of which were of an atypical size; therefore, the frequency for 
atypical duplications at our diagnostic centre was 4.5% (Polke et al., 2011). All of 
these atypical duplications included all PMP22 exons and other MLPA probes within 
the Chr17p11.2 region except the two probes for the cytochrome c oxidase assembly 
homolog 10 (COX10) gene, both of which are located in COX10 exon 7 (Figure VIII-
3).  
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Figure VIII-3: Atypical CMT1A duplication shown on GeneMarker analysis, with 
dosage of control (blue) and patient (red and green) MLPA probes. A peak ratio of 1 
indicates a genomic copy number of 2. Red probes suggest a duplication (peak ratio 
> 1.25). This example shows one of the atypical Chr17p11.2 duplications found in 
our study in which all probes except the COX10 probes are duplicated (reproduced 
from Polke et al., 2011). 
All CMT1A patients with the atypical Chr17p11.2 duplication for which clinical 
information was available had a mild, typical CMT1A phenotype. The CMTNS had 
not been determined for these patients. The CMTES was available for one patient 
(CMTES=14). No data on the frequency of atypical CMT1A duplications was 
available for the Brazil and USA cohorts. 
Discussion 
The frequency of the p.Thr118Met variant identified in our CMT1A cohort (1.58%) 
was similar to the frequency reported in online control databases and studies of 
English controls. Other than the p.Thr118Met variant, there was no evidence for 
additional PMP22 point mutations which may have caused a compound phenotype in 
the CMT1A patients in this study.   
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The small number of CMT1A patients with detailed phenotypes who carried 
promoter/non-coding exon 1A variants and/or the p.Thr118Met variant precludes any 
conclusion to be drawn about the effects of these variants on disease severity in 
CMT1A. In retrospect, SNPs identified in the upstream and exon 1A region are not 
informative because it is not known which allele is duplicated for each SNP. Indeed, 
due to the nature of the duplication in CMT1A - most frequently unequal crossing-
over event between non-sister chromatids - the two duplicated alleles are usually 
non-identical. Therefore, the haplotype across the duplicated region could not be 
ascertained without the use of small families with one affected and one unaffected 
parent and at least one affected child, plus unaffected siblings if available. This part 
of the study is inconclusive but does not rule out the role of PMP22 promoter SNPs 
and the p.Thr118Met variant in modulating the CMT1A phenotype. Larger studies 
with small families and detailed phenotypes would be necessary in the future. In-
vitro functional analysis would be required to determine how the mutations identified 
in the promoter region and non-coding exon 1A may play a role in modifying the 
phenotype, if any. 
In addition to the PMP22 upstream enhancer sites, other enhancers outside the 
promoter region of PMP22 have been found to regulate PMP22 expression, 
including EGR2 and SOX10 binding sites within the largest intron of PMP22 (Jones 
et al., 2011). PMP22 is also post-transcriptionally regulated by microRNAs (Verrier 
et al., 2009). It may be advisable to sequence these binding sites as mutations in 
these regions may be a cause of CMT or HNPP, or may modify the CMT1A 
phenotype. Coding polymorphisms within the PMP22 gene may also alter mRNA 
stability and modulate the CMT1A phenotype, however again both parents would be 
needed to determine the genotype of the patients at these SNPs. 
The frequency for atypical duplications at our diagnostic centre was 4.5%. The 
patients with these atypical duplications did not have any outstanding clinical 
features; the phenotype was that of classic, mild CMT.  
COX10 is located approximately 1 Mb from PMP22. In typical Chr17p11.2 
duplications, only COX10 exons 6 and 7 are located within the duplicated region 
therefore one of the COX10 genes on the duplicated chromosome is missing its first 
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five exons and promoter region (Figure VIII-4). The COX10 exon 6 is found on both 
CMT1A-REPs however the copy on the distal CMT1A-REP is the ancestor copy 
while the proximal CMT1A-REP has a pseudo copy of COX10 exon 6 (Boerkoel et 
al., 1999; Reiter et al., 1997).  
 
Figure VIII-4: COX10 and the CMT1A duplication. Roman numerals represent 
COX10 exons. Only COX10 exons 6 and 7 are duplicated in the typical CMT1A 
duplication (adapted from Reiter et al., 1997). 
Although the exact size of the duplication was not determined, all the atypical 
duplications in our cohort did not include the last (seventh) exon of the COX10 gene. 
Patients with the typical duplication have only two normal copies of COX10 since 
the rearranged COX10 gene on the duplicated chromosome is incomplete, and thus it 
would not be expected to result in a functional COX10 protein (Reiter et al., 1997). 
Our patients with the atypical duplications not encompassing exon 7 of COX10 
would also be predicted to have two normal copies of COX10, which may explain 
why their phenotype is not dissimilar from CMT1A cases with the typical 
duplication. Most of the previously described smaller CMT1A duplications also did 
not encompass COX10 exon 7 (Choi et al., 2011; Huang et al., 2010; Zhang et al., 
2010). 
Deletions too small to include COX10 have been described in HNPP patients. The 
COX10 gene on the chromosome of HNPP patients carrying the typical deletion only 
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contains exons 1 through 6, likely resulting in a null allele of COX10. As compound 
heterozygous mutations in COX10 lead to severe COX10 deficiency phenotypes such 
as Leigh syndrome, an HNPP patient with a mutation in COX10 on the non-deleted 
chromosome is predicted to have a much more severe, if not lethal phenotype (Reiter 
et al., 1997).  
The aim of this supplementary study was to assess the potential contribution of 
selected genetic variants and genomic features in modifying the CMT1A phenotype. 
The small number of CMT1A patients with duplications of an atypical size had a 
classic CMT1A phenotype. Screening of the nerve-specific PMP22 promoter and 
5’UTR, a region which is not usually investigated in diagnostic tests, revealed very 
few rare variants. No concomitant pathogenic variants were identified in the PMP22 
coding region, and the frequency of the PMP22 p.Thr118Met variant with 
ambiguous pathogenicity was similar to that reported in control databases. Due to 
unavailability of DNA for family members, the haplotype across the duplicated 
region could not be determined for all investigations described above, therefore the 
SNPs are not informative as the duplicated allele could not be ascertained. 
Furthermore, the number of patients studied was too small to evaluate the effect of 
the variants on disease severity in CMT1A. Due to these limitations, data from this 
study cannot exclude the role of SNPs within the PMP22 promoter region and the 
p.Thr118Met variant in modulating CMT1A disease severity.  
This supplementary study highlighted some important study design features to be 
taken into consideration for future research into CMT1A phenotype modifiers. 
Future studies seeking to identify genetic modifiers of the CMT1A phenotype may 
wish to determine the haplotype across the entire Chr17p11.2 region in a large cohort 
of CMT1A patients using small families. Additionally, other CMT genes, 
neuromuscular genes, or genes encoding components of the myelin sheath may be 
investigated as potential candidate modifier genes. 
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